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ABSTRACT 
HIV/AIDS is an incurable, infectious condition that, without access and adherence to 
lifelong treatment with specific antiretroviral drugs (ARVs), leads to declining immune-
competence and death, usually within ten years of acquiring the infection. Australians 
have benefited from universal access to ARVs under patent through the national 
health care access scheme, Medicare. Since 2005 there has been a steady rise in 
notifications, dispersed across Western Australia (WA), indicating HIV infection in 
women, and men who have sex with women, against the previous trend of risk and 
transmission in men who have unprotected sex with other men. Many people 
diagnosed hold temporary visas and come to WA with their families to work or study 
and are ineligible for Medicare. This compromises their access to effective 
antiretroviral treatment by virtue of their visa status. 
Between 2007 and 2008, one hundred and seventeen people living with HIV in WA 
participated in an international, mixed methods study of health-related quality of life. 
This thesis describes and references those findings to examine, through an 
ethnographic perspective, and within the context of current epidemiology: (1) the 
experience of managing HIV in a rural or remote environment; (2) the effect of visa 
status in mediating the experience of HIV; and (3) aspects of access and adherence to 
ARVs that influence the outcome of treatment. In 2010 and 2011 data were gathered 
from interviews with thirty participants (nine women) with HIV-infection: twenty-two 
had been granted temporary work or student visas, fourteen were current business or 
student visa holders, and nineteen lived or worked in rural areas. Group data from two 
rural-based cohorts is referenced and twenty-one key informants were interviewed to 
augment context, and contribute thick description.  
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Limited access to ARVs posed by non-citizen status and/or distance from dispensing 
pharmacies was overcome largely by motivation to accept treatment and support from 
key health professionals (HPs), which resulted in high levels of adherence and 
engagement with care. However, there were differences in approaches to HIV 
supportive care between indigenous and non-indigenous cohorts with more intense 
involvement of HPs in the former group. The data showed a pattern of stigma 
characterised by persistent fear of disclosing HIV serostatus and infecting others. This 
was nuanced by the particular circumstances of individuals, for example, non-citizen 
status, and living and/or working in regional areas. In particular HIV-positive serostatus 
affected, and frequently limited, social relationships, employment and the likelihood of 
successful migration.  
These data indicate, firstly, that the immunopathological consequences of HIV 
infection can and should be avoided by policies that facilitate unfettered access to 
treatment and medical care; and secondly that the psychosocial aspects of HIV disease 
that limit the lives and livelihoods of people with HIV infection require intervention. 
 
Key Words: HIV/AIDS, Access, ART, Medication Adherence, Health-Related Quality of 
Life, Stigma, Visa Status, Rural, Employment, FIFO, Immigration, Ethnography 
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INTRODUCTION 
Successful resolution of diseases in humans caused by infectious pathogens is 
predicated largely on compliance with medical care and, more specifically, access and 
adherence to anti-infective pharmaceutical drugs. Whilst infection with the human 
immunodeficiency virus (HIV) is incurable, treatment with antiretroviral drugs (ARVs) 
can suppress levels of the virus in the blood to levels undetectable by current 
laboratory assays; prevent progression to AIDS (acquired immune deficiency 
syndrome); and transmission to the unprotected contacts of an infected person 
(Cohen et al., 2011; Cohen & Gay, 2010). However, access to potent and effective 
medicines can be limited by issues of cost and supply (Crane et al., 2007; Bangsberg, 
2008a) and many bio-psychosocial factors can threaten successful medication-taking 
behaviour, for example, side effects, depression and tenuous engagement with health 
care services (Gardner et al., 2011; Heath, Singer, O’Shaughnessy, Montaner & Hogg,  
2002; Starace et al., 2002). 
The premise of this thesis is that the path to restoration of health and well-being in HIV 
is predicated on the unique social, cultural and geographical context in which the 
person experiences the disease. This research describes the impact of HIV and 
treatment in non-citizens and people living and/or working in rural and remote areas 
in Western Australia (WA), identified as ‘priority’ populations in the 6th National HIV 
Strategy (2010). The results are referenced and interpreted against the findings of a 
WA-based study of health-related quality of life (HRQL) conducted within the WA HIV 
Cohort Study (WAHCS) over a two-year period in 2007-2008. Ethnography was chosen 
as an approach to this investigation, it being especially concerned with cultural 
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context, detailed description, and questions that demand detailed explanation (Beebe, 
2001). 
The primary aims of this thesis are to describe (1) the impact of HIV on the health of 
these groups; (2) the experience of managing HIV in a rural or remote environment; (3) 
the effect of visa status in mediating the experience of HIV; and (4) particular issues 
regarding access to ARVs and barriers to medication adherence.  
Origins and Context of the Study 
The study grew from clinical and behavioural research conducted over a number of 
years in the WAHCS (Mallal, 1998) at Royal Perth Hospital, the premier state tertiary 
institution for HIV care. However, it was also fired by a presentation from Professor 
David Wilson, later published in the journal, Lancet (D. Wilson & Halperin, 2008), which 
highlighted the importance of understanding the particular characteristics of local 
epidemics in order to formulate effective responses. Although the premise of the 
argument was based on approaches to HIV prevention, the message could be applied, 
equally, to ensuring appropriate clinical and community services are in place to 
support affected individuals in such an epidemic. This presentation seemed particularly 
relevant in light of the changing epidemiological pattern of HIV in Western Australia 
over the preceding five years (Combs & Giele, 2009). Since I had recognised that 
geographical and social contexts were important in the approach to an earlier survey 
of HIV medication adherence, and critical if we were to implement interventions, it 
was logical to look to the changing demographics of the cohort and explore gaps in our 
research program. This program had grown from the findings of the aforementioned  
survey which had given a broad perspective on factors influencing medication 
adherence in the WA context, to examining aspects of HIV infection and treatment 
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that may impact on health-related quality of life and have direct and indirect 
associations with medication adherence (Carrieri et al., 2003; William Holmes et al., 
2007; Mannheimer et al., 2005; Xianhong et al., 2011). 
Uptake and Adherence to Treatment  
Within the time frame of this study (2009 to 2012), HIV/AIDS remains a fatal infectious 
disease unless treated with potent antiretroviral drugs (ARVs) and people adhere to 
the lifelong requirements of the therapy. Access to ARVs is limited by their cost and 
supply, and medication adherence behaviour, a dynamic state, is influenced by a 
number of bio-psychosocial factors that are critical to achieve the clinical benefits of 
treatment (Abel & Painter, 2003; Altice et al., 2001; Ammassari et al., 2002; Carrieri et 
al., 2001; Chesney et al., 2000; Friedland, 2006; A. Gonzalez et al., 2011; Heath et al., 
2002;  Herrmann et al., 2008; Hill et al., 2003; Ickovics & Meade, 2002b; Li et al., 2011; 
Murphy et al., 2000; Murri et al., 2000; O'Brien et al., 2003; Ortego et al., 2010; 
Xianhong et al., 2011). 
A precondition of successful adherence is acceptance of the treatment as being 
necessary and beneficial. Predictors of acceptance include trust in the clinician and 
engagement with health care (Altice et al., 2001; Friedland, 2006). Once acceptance 
has taken place and treatment has commenced, it is widely recognised that personal, 
environmental and drug-related characteristics (Table 1) mediate behaviour by either 
promoting or detracting from medication adherence. (Ickovics & Meade, 2002a, 
2002b; Ickovics & Meisler, 1997) The personal, such as motivation, information, 
resilience and behavioural skills; environmental, such as social support and access; and 
finally the intrinsic properties of the medication such as tolerability and dosing 
schedule are influential. However, the impact of an HIV diagnosis and the lifelong 
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experience of living with the disease can mediate factors associated with adherence in 
a way that moderates the pathogenic benefits of ARVs and this appears to be 
consistent across multiple international settings (Mills et al., 2006). 
Current Epidemiology: Regional Spread  
Since the middle of the last decade there has been a steady rise in notifications 
indicating HIV infection in women, and men who have sex with women, against the 
previous trend of risk and transmission in men who have unprotected sex with other 
men (Combs & Giele, 2009). This trend is particularly apparent in WA where 57.5% of 
notifications in 2010 alone were reported as from heterosexual transmission in 
comparison with 42.2% for the period 2001-2005. In 2010 WA had its highest rate of 
HIV notification since the epidemic began in the early 1980’s (National Centre in HIV 
Epidemiology and Clinical Research, 2011). Half of the women diagnosed were from 
sub-Saharan Africa and a third were Asian-born (Kwan, Mak, & Minas, 2010). Increases 
in infections have been attributed to: migration of people from HIV-prevalent regions; 
frequency of transmission and casual sexual encounters; and decreased condom usage 
(D. Wilson & Halperin, 2008). Of relevance to health services, people with the 
infection—men and increasing numbers of women, citizens and non-citizens—are no 
longer concentrated in urban areas and are dispersed across regional WA (Figure 1), 
reflecting the general trend in population dispersal across the state over the last 10 
years (Australian Bureau of Statistics, 2011).  
People living in rural areas rely on: services from community Population Health Units, 
which have a responsibility to provide preventative medical care and contain 
outbreaks of communicable diseases; and the city-based rural outreach programs 
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which deliver clinical and supportive HIV management to patients and provide 
expertise to the regional health professionals including GPs and the Prison Service.  
 
Figure 1: Increasing number of PLWH in regional areas between 1998 and 2009 (Numbers in 2009 refer 
to HIV positive patients and HIV-negative babies born in the Pilbara as well as one HIV positive baby)  
(Data courtesy David Nolan and Allison Cain) 
The 6th National HIV Strategy (2010) identified vulnerable or ‘underserved’ populations 
with HIV infection in Western Australia as groups needing a research and funding 
focus. Despite the important and relevant qualitative research studies exploring 
Aboriginal experiences of HIV in WA; and barriers and incentives to HIV treatment 
uptake, including the influences of culture (Bonar et al., 2004; Newman et al., 2007a; 
Newman et al., 2007b; Thompson et al., 2009), little is known about the experience of 
non-Aboriginal people living with HIV infection in rural areas. Although the ‘adherence 
studies’ (Herrmann et al., 2008b) and the WA arm of the PROQOL-HIV study 
(Duracinsky et al., 2012a, 2012b) captured a representative proportion of all people 
living with HIV across the state, including those from rural and remote areas who 
travel to the clinic in Perth, it did not seek to study groups defined by geography, 
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ethnicity or residency status. It also didn’t address health care access. Arguably the rise 
of population mobility including within the country, i.e. internal migration, and the 
health issues that arise from such mobility, is an area that could be informed by 
focused qualitative research. In particular, and in light of these gaps in knowledge and 
the changing epidemiology of HIV in our region, it appears important to understand 
the features of the current local epidemic taking into consideration transmission 
dynamics (D. Wilson & Halperin, 2008), as well as the interaction of local and macro 
factors that might impact on access to services and life-saving antiretroviral 
medication. 
HIV and Migration Status in Australia 
The experience of HIV in individuals identifying themselves as belonging to culturally 
and linguistically diverse (CALD) communities in Australia, has been described by 
Henrike Körner in New South Wales in a number of publications (Körner, 2005, 2007a, 
2007b, 2007c). Her research described how themes of HIV diagnosis, access to care 
and support, and forming social relationships were ‘interwoven’ with migration status. 
Körner also strove to explicate the reasons that people from CALD communities delay 
seeking help for symptoms of HIV, and how cultural background mediated the impact 
of an HIV diagnosis. In 2009, Asante and colleagues produced a monograph of their 
periodic ‘Survey of HIV knowledge, perceptions and use of health services among 
people from culturally and linguistically diverse (CALD) backgrounds’. Shortly after, 
Chris Lemoh and colleagues (Lemoh, Baho, Grierson, Hellard, Street & Biggs, 2010) 
provided a clinical report on a group of African-Australians as part of a study 
conducted in consultation with members of the African Australian Community, the 
importance of which he highlights in an earlier publication (Lemoh, Biggs & Hellard, 
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2008). His research recommended that Victoria’s African communities address the 
possibility of exposure to HIV in Australia; and the need to better engage with public 
health services to understand and overcome obstacles to timely diagnosis of HIV. More 
recently, in Western Australia, the diverse cultural and socioeconomic backgrounds 
and HIV/AIDS knowledge and attitudes among West African immigrant women in 
Western Australia were surveyed by Drummond, Mizan and Wright (2008). They 
reported a wide cultural and socioeconomic diversity among the refugee population 
which might impact on beliefs and understandings of health issues. The findings of 
their study of 52 West African women and 100 West Australian women who acted as a 
control group, inferred that messages about HIV should be tailored to target particular 
demographic groups in WA, and take into consideration educational level, health belief 
systems and cultural norms for any given group.  
Although skilled workers and educated students from HIV-prevalent areas in Africa and 
Asia who come to WA to work or study may share belief systems and cultural norms 
with others of similar ethnicity, they also have characteristics that link them with 
others who may not share their ethnic identities, for example guest worker or student 
status as opposed to asylum-seeker, or indeed the fact that they reside in a remote 
country town rather than in a city. The distinction in visa status is significant because 
of differing ‘qualification’ for services; for example, asylum-seekers have access to 
government funded and charitable organisations by virtue of their assigned status. 
International students may have access to student centred services and supports 
through their affiliations with universities and colleges but guest workers are largely 
unsupported, must advocate on their own behalf and seek out services using their own 
personal and financial resources. In WA guest workers with non-citizen status are 
often employed in jobs in the mining and construction industries in a fly in fly out 
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(FIFO) or drive in drive out (DIDO) capacity and so become internal migrants along with 
their resident Australian fellows. Another sector which is relying more heavily on guest 
labour in Australia is health.  
HIV Diagnosis, Treatment and Care 
Since HIV testing is not a prerequisite for a Temporary Business (Long Stay) - Standard 
Business Sponsorship (Subclass 457) visa unless work in the health sector is sought, 
people may not know of their infectious status until diagnosis is made on application 
for permanent residency or a continuation of a 457 or Student Visa. Peripatetic 
lifestyle, residency status and geographic remoteness can impact on access to health 
care by limiting opportunity for continuity and follow-up which are critical for 
successful health outcomes particularly in HIV disease (Gardner et al., 2011; Giordano 
et al., 2007; Mugavero et al., 2009; Park et al., 2007). Another important and obvious 
issue for those on temporary visas is lack of Medicare cover. In instances where an 
application for permanent residency is made, a temporary Medicare card is granted 
although in some instances interim access is granted. Temporary visa holders are 
required to have private medical cover and to date this does not cover the cost of 
antiretroviral treatment. Temporary visa holders ineligible for Medicare-subsidised 
patented antiretroviral drugs must either pay full price or import from a limited range 
of generic, bioequivalent versions manufactured mainly in India. What, if any, 
difficulties arise from this and how does this impact on their overall health? Does 
limited access to services, enjoyed by citizens and Permanent Residents, result in harm 
for temporary visa holders? If so, Pollard and Savulescu (2004) argue that this practice 
is unethical. The role that Medicare access and non-standard medication distribution 
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networks play in ensuring an uninterrupted supply of antiretroviral drugs to citizens 
and non-citizens in Western Australia needs investigation. 
Contribution to the Field of HIV Social Research  
Critical to qualitative research in this area is context (Table 1), in that unique and 
dynamic socio-cultural factors can have an influence on how people engage with 
medical care as well as access and adhere to prescribed medication (Carrieri et al., 
2001; Ickovics & Meade, 2002a, 2002b; Ickovics & Meisler, 1997; Mills et al., 2006; 
Mugavero et al., 2009a; Mugavero et al., 2009b; Mugavero et al., 2009c; Murphy et al., 
2000; Nachega & Mills, 2007; O'Brien et al., 2003; Ortego et al., 2010). I acknowledge 
that our previous surveys and audits (Herrmann, et al., 2008a, 2008b, 2009, 2012) of 
factors influencing adherence, including the role of side effects, dosing schedule and 
substance use, had limitations. In particular, a survey instrument is an inadequate tool 
to glean understanding of the motivations, beliefs, values, and processes underlying 
patterns of behaviour. In order to gather rich information about how a phenomenon is 
experienced, including such issues as how HIV reverberates within the families of those 
affected, and what motivates individuals to engage with care, qualitative research 
offers pertinent methodology. The quality of life study presented in this thesis 
addresses some of these methodological shortcomings since it employed both 
quantitative and qualitative research methods. It is ethnography, however, which 
offers an appropriate theoretical platform for studying groups of people in a given 
setting in order to reach an understanding of influential factors at play. 
People and populations now move further and more rapidly than ever before between 
and within countries. An International Labour Conference Report (2009) estimated 
that there are over 90 million people working outside their countries of origin. Greater 
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population exchanges have implications for the spread of infectious disease, and 
international travel opportunities support the ebb and flow between migrant origin 
and destination locations (Gushulak & MacPherson, 2006). Of relevance to HIV is that 
prevalence rates may be higher in immigrant populations and even higher in ‘internal’ 
migrants moving from one region to another (Soskolne & Shtarkshall, 2002).  
The number of qualitative studies in the field of HIV in Western Australia is limited. 
Other than the insightful studies by Newman and colleagues, referenced in this 
introduction, I am unaware of any qualitative study of factors affecting access to HIV 
treatment, medication adherence and clinical outcomes in Western Australia in 
‘temporary visa holders’ or people living and working in rural and remote 
environments. These are vulnerable and potentially ‘underserved’ populations.  
There is intense focus on the health of people living and working in rural Australia and 
this is reflected by State and Federal Government initiatives, such as the National Rural 
and Remote Health Infrastructure Program, and Royalties for Regions. Current media 
interest in the particular mental health challenges posed by rural living; and more 
recently the growth in remote mining industry employment opportunities and the 
biopsychosocial impacts of FIFO and DIDO work practices (Joyce, Tomlin, Somerford, & 
Weeramanthri, 2012) is intense. Although I have been made aware that the WA Health 
Department via WA Country Health Service (WACHS) has recently reviewed HIV 
services in the regions, this work has not been published and there is little or no 
research about the experience of living with HIV from the perspectives of recipients of 
those services.  
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Table 1: Classical concepts shaping medication adherence behaviour: changes in Western Australia 2002-2010. 
CHARACTERISTICS YEAR 2002                Demographic profile YEAR 2010                           Demographic profile 
PERSON 
Psychosocial/support 
Health beliefs/ Intent to 
adhere 
Use of substances 
Social stability 
Social support 
Host/viral genetics 
 
Homosexual transmission  
Mostly men 
Mostly Australian citizens-Medicare eligible, English first language 
Socio-cultural norms shared by health care providers 
Pattern of substance use common 
Host genetics – largely Caucasian  
Viral genetics – Clade B  
 
Heterosexual transmission 
More women, implications for gender related issues eg fertility desires 
Increased number of visa holders - Medicare ineligible, English not first language 
Socio-cultural norms may not be shared by health care providers 
Pattern of substance use in recent referrals unknown 
Host genetics - increased African and Asian  
Viral genetics – Clade C 
DRUG  
Access  
Side effects 
Potency 
Complexity of regimen 
Duration 
 
Potent, common adverse side effects 
Twice daily (BD) and three times daily (TDS) dosing common  
Co-formulation uncommon 
Pill burden high 
AIDS prophylaxis common  
ART & HIV prophylaxis available free from the hospital/no 
copayment 
PBS listed drugs available to Medicare eligible patients  
 
Potent, tolerable  
Once daily (OD) dosing common 
Co-formulation common 
Reduced pill burden  
AIDS prophylaxis less common in treated patients (reduces pill burden) 
Not for Medicare ineligible patients  
Choice of drug limited by availability of generic bioequivalent and cost.  
ENVIRONMENT 
Work and/or child-
rearing responsibilities 
Demographic 
Patient provider 
relationships  
Access to services 
 
Approximately 50% in paid employment outside the home 
Small number living with children 
Travel for holidays 
Majority living in metropolitan area 
Workplace in metropolitan area in wide range of occupations  
HIV prevention & supportive community services geared towards 
gay men and Sex Workers 
 
Largely in paid employment  
An increase in number of people living with children 
Travel to visit country of origin  
Increase in people living, working in regional areas of WA  
Residential work, outside country of origin, male dominated workplace. 
City based services for migrants from high prevalence countries around education 
& prevention of HIV are emerging, underpinned by advice and input from CALD 
Communities.  
References: (Combs & Giele, 2009; Herrmann et al., 2008a, 2008b; Ickovics & Meisler, 1997) 
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Figure 2: Movement of people, 19
th
 Century migration vs 20
th
 Century movement (Salt, 2011)  
Illustration by Mario Lendvai and reproduced with permission 
The demography of mobile populations is becoming more diverse and Figure 2 
provides a representation of this actuality. To date, knowledge of health outcomes is 
often limited to that attached to specific groups, for example, refugee populations, 
and responses have been framed by that which is legally mandated within 
jurisdictions. However, in two papers Gushulak and MacPherson (2004, 2006) assert 
that it may be more useful to take into consideration the particular nature of the 
‘migration’ process in order to formulate adequate health responses. HIV provides an 
 13 
example of a disease which has a ‘prevalence gap’ in Australia compared with other 
regions in the world. And, in the case of long-staying mobile populations from regions 
with disparate risk environments from that of the destination country, this gap can 
complicate public health responses. Indeed, aspects of health systems that may need 
to adjust to meet the challenges will need to be driven by policies and programs that 
consider not only linguistic, cultural and gendered aspects of service delivery, but also 
address the basic human rights of non-citizens such as international skilled workers 
and students, to access health care wherever they may find themselves. Research into 
the health of mobile individuals is limited and, to date has been largely confined to the 
situation of either migrants, asylum seekers or illegal workers, within the context of 
the social determinants of health (Ahonen, Benavides & Benach, 2007). But over the 
last few years, in the context of HIV, research on the growing population of guest 
workers, international students and internal migrants, is emerging (Connell & Negin, 
2010; Elinav et al., 2012). This thesis will, in part, focus on people with HIV whose visa 
status in Australia might affect their health and quality of life.  
The potential for social research to uncover a rich source of data that can inform the 
field in HIV and be generalised to other health conditions has been recognised, 
internationally, by large funding organisations such as the National Institutes of Health 
(NIH) (2009). This research proposes to address a number of the current international 
priorities of the NIH in HIV adherence research to advance understanding of adherence 
to ART in underserved groups, for example, people with HIV residing in this country as 
temporary visitors or non-citizens, with regard to factors that lead to linkage with and 
retention in clinical care. It also considers structural factors that affect engagement 
with care and the intersections of adherence and HIV prevention.  
14 
The 6th National HIV Strategy for 2010-2013 (2010) also identified the following 
priorities: Social, behavioural and epidemiological research in prevention, diagnosis, 
treatment, care and support of people with HIV. This thesis fits the criteria of those 
research priorities and has the potential to inform the provision of targeted services.  
Research Purpose 
The purpose of this research is to describe (1) the experience of managing HIV in a 
rural or remote environment (2) the impact of HIV in people on temporary visas; and 
(3) the outcome of ARV treatment for those individuals. The work will be positioned in 
the context of a study of health-related quality of life carried out in the WAHCS in 
2007-2008 and in the environment of current service delivery. Figure 3 is a schematic 
of the populations of interest to this research. The overlap between citizens and non-
citizens represents the ‘grey area’ of access since some visas offer some citizens’ 
rights, albeit temporarily; and Permanent Residents, while lacking full citizens’ rights 
have access to Medicare and other associated benefits.  
Organisation of the Thesis 
The thesis is divided into six chapters. The first chapter comprises a literature review 
which is concerned with current knowledge pertaining to HIV disease and treatment. 
The role of medication-taking behaviour in achieving good clinical outcomes, the 
research evidence that has arisen around issues impacting on health-related quality of 
life in HIV, a summary of research literature pertaining to HIV in rural populations and 
non-citizens, and national laws that are relevant for people living with HIV, specifically 
access to antiretroviral drugs, visa requirements and migration restrictions, is 
presented. The aim of the literature review is to position the study in the current 
context as it applies to: the state of HIV clinical care in Western Australia; the 
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individual’s experience of HIV disease and treatment from the perspective of a person 
living and or working in rural or remote areas and those who hold temporary visas; and 
the policies that prescribe access to ARVs, and Australian residency. The second 
chapter, concerning the methods used in this research, explores the methodological 
considerations, specifically the principles of ethnography and the rationale for taking 
an ethnographical perspective to the issues outlined. The aims, objectives and the 
specific methods used are detailed as are the setting and context of the study. 
Pertinent ethical issues are discussed, including observations made during the course 
of the study in interactions with participants and key informants. Chapters Three, Four 
and Five contain the research findings and discussion relevant to those results. In 
Chapter Six the findings from the three results chapters are synthesized and the 
patterns that emerged from the data gathered are discussed, and conclusions drawn 
against caveats imposed by the limitations of the work. Finally, the contribution to 
current knowledge and the implications of the study findings for policy, practice and 
future research are presented.  
 
Figure 3: Schematic of population of interest, showing overlapping, 
contingent groups and the ‘grey area’ between citizens and non-citizens  
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CHAPTER ONE LITERATURE REVIEW 
Overview 
The chapter will present literature that provides background relevant to the thesis, the 
overall aim of which is to explore the experience of people living with HIV who are 
potentially challenged by factors that might influence HIV health outcomes, with a 
particular focus on the impact of HIV disease on people’s lives, and access and 
adherence to treatment. People on temporary visas and those living or working in 
regional areas of Western Australia are seen to fit this category. Factors pertaining to 
health-related quality of life in HIV have been studied in our WA setting and this data 
will be used to position the findings in context.  
In order to understand the weighty health and social implications of a diagnosis of HIV 
it is necessary to appreciate the biology of the organism, the medical treatment for the 
condition, the availability of that treatment and the context in which people live their 
lives with HIV. This approach is consistent with ethnographic theory. Therefore this 
chapter will present material relevant to: 
 The biology and treatment of HIV disease 
 Current epidemiology 
 Medication adherence theory  
 Health-related quality of life in HIV 
 The current status of HIV treatment access nationally and internationally 
 Aspects of visa status and population mobility 
 Aspects of geography that affect access to medical care and treatment in WA 
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I will highlight where this research is positioned within current knowledge of these 
topics. Reference to research conducted in the WAHCS over the last ten years that is 
pertinent to this thesis will be made.  
Search strategy 
Databases were searched for peer reviewed manuscripts on the topics of HIV disease, 
treatment access, medication adherence, migration, guest workers and rural living – in 
the context of HIV. The Scopus database was used extensively since it is the largest 
publication database with 100% Medline coverage and has a number of features that 
enable the user to make connections between research fields and identify key 
information in less well known journals. The reference lists of retrieved articles were 
scrutinised, and these provided leads to other relevant documents. The Murdoch 
University librarian accessed articles on demand if they were not available on-line. 
Likewise with texts of interest accessed from other universities but not necessarily 
cited in this work. The Royal Perth Hospital librarian sent a monthly report of an 
Ovid/Medline search for articles in English on medication adherence and antiretroviral 
drugs. This was filtered and directly imported into Endnote. Colleagues were 
consulted, and serendipitous contacts made at conferences suggested material that 
might prove useful, including a confidential report by the Australian Federation of AIDS 
organisations (AFAO) released in 2009, but not publicly distributed (I was given access 
to this in 2011); and a submission by NAPWA (2009) to the Joint Standing Committee 
on Migration Inquiry into Immigration Treatment of Disability. Graham Brown, the 
then President of AFAO sent me his unpublished West Australian-based research paper 
on “The Male Overseas Acquired HIV Social Research Study”. In addition to this 
document, two unpublished theses were shared with me by their authors and these 
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were: “Seeking asylum and living with HIV: an ethnographic study” by Lois Orton; and 
Jane Bruning’s Master’s thesis on “Stigma and women living with HIV”. Ellen ‘t hoen’s 
thesis on “The global politics of pharmaceutical monopoly power” was discovered, 
publicly available, online. Selected conference proceedings were perused, particularly 
those from the Australasian HIV/AIDS National Conferences from 2007-2011, in order 
to uncover contemporary, national research reports concerning migrants, visa holders 
and people living or working in rural areas, in the context of HIV. 
HIV and AIDS in Context 
Infection with the human immunodeficiency virus (HIV) is the precondition for 
developing acquired immunodeficiency syndrome or AIDS. AIDS occurs as a 
consequence of damage to the immune system, specifically death mediated by the 
virus, of an important subgroup of lymphocytes called CD4 T-cells. Profound 
immunodeficiency ensues resulting in vulnerability to infection which is termed 
opportunistic and includes cancer-causing (oncogenic) viruses resulting in conditions 
such as Kaposi’s sarcoma and Hodgkin’s Lymphoma. One or more clinical problems 
may occur in someone with AIDS —therefore it is referred to as a syndrome — and 
certain clinical problems are called AIDS defining because they occur at a particular 
stage of immune deficiency (Figure 4) (Crowe, Carlin, Stewart, Lucas & Hoy, 1991; P. 
Williams, Currier & Swindalls, 1999). A person infected with HIV and untreated with 
ARVs usually dies within 10 years. Unlike many other infectious diseases transmission 
of HIV occurs in a social and frequently highly charged emotional context and this has 
significant implications for how people perceive the disease and how it can be 
prevented (Bartlett, Gallant & Pham, 2009; Coates, Richter & Caceres, 2008). 
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Figure 4: CD4 T cell count (cells/µL) predicts risk of opportunistic infections and AIDS-related 
malignancies. Adapted from: Managing HIV (1999) 
The Origins of HIV 
HIV is classified as a retrovirus because of the manner in which it reproduces. 
Experimental data indicating the connection between AIDS and retroviruses was 
published in France by Luc Montagnier’s team (Barré-Sinoussi et al., 1983) and then 
researchers led by Robert Gallo in the US, published epidemiological and virological 
data that a virus which we now call HIV caused AIDS (Gallo et al., 1983). However, the 
first case of HIV-1 was thought to have occurred in Africa around 1930 (Korber et al., 
2000). Viral mapping or sequencing reveals that HIV probably arose from a number of 
zoonotic transmissions to humans from chimps endemic to central West Africa since 
these primates are susceptible to simian immunodeficiency virus (SIV) and were 
hunted for bush meat (Sharp & Hahn, 2010). A syndrome described as ‘slim disease’ 
characterised by a slow wasting illness and described by Serwadda and colleagues 
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(1985) in Ugandans, was subsequently attributed to infection with the human 
immunodeficiency virus. This wasting came to represent the physical manifestation of 
HIV/AIDS stigma. Increased population mobility was largely responsible for the initial 
spread of HIV, when transport networks between African regions expanded in concert 
with increased economic development (Lagarde et al., 2003; Perrin et al., 2003; Salit et 
al., 2005; Tatem et al., 2006). 
HIV is classified into two major types: HIV-1 and HIV-2. The latter, endemic to West 
Africa, is considered less infectious, associated with a lower viral load and slower CD4 
T-cell count decline and slower progression to AIDS, however many people are 
coinfected with HIV-1 and the prevalence of HIV-2 is low. HIV-1 is divided into subtypes 
or clades with subtype C the most common in South and East Africa followed by 
subtype A and a mixed or recombinant form (CRF) 02-AG in West and West-Central 
Africa. Subtype B is dominant in North America, Western Europe and Australia; and in 
East Europe, Central Asia: A and B; East Asia: B, C, BC, CRF 01; and in the largest 
epidemic, South Asia, subtype B and AE have been described (Bartlett et al., 2009). The 
genetic diversity of HIV and the evolution of subtypes and recombinant forms has 
grown (Easterbrook et al., 2010). How this influences the pathogenicity of the disease 
and whether this is clinically relevant has become an important issue because of the 
significant migratory ebb and flow of people across international borders.  
In WA there has been an increase in the diversity of HIV subtypes sequenced from 
people diagnosed with HIV infection demonstrating the ingress of Clade C virus into 
the local population. This represents a shift in prevalence away from Clade B as the 
dominant circulating strain, 92% in 2000 vs 61% in 2009 (Castley, Gizzarelli, 
Whidbourne, Nolan & John, 2010), and reflects the trend in European countries that 
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are also experiencing a rise in migration from HIV-prevalent areas where Clade C is the 
dominant strain (Easterbrook, et al., 2010). 
Life Cycle of the Virus 
Viruses cannot replicate independently and rely on their hosts’ intracellular processes 
to reproduce. Retroviruses such as HIV use an enzyme called reverse transcriptase to 
copy or transcript their RNA into a DNA copy thus enabling integration with human 
DNA in the CD4 T-cell nucleus (Figure 5). RNA viruses have a high mutation rate and 
naturally occurring strains replicating in the absence of any suppressive drug therapy 
are called ‘wild type’ virus. In addition, HIV has a high error rate during reverse 
transcription. These factors together mean that when wild type HIV replicates it has a 
high rate of mutation. It is estimated that every possible mutation at every position in 
the virus occurs once a day. Such genetic changes which result in altered viral proteins 
are called polymorphisms. Particular mutations which allow the virus to resist the 
action of an anti-HIV drug would thus become naturally selected if the virus is exposed 
to drugs but can still replicate, such as when the patient is partially adherent to 
antiretroviral drugs (Bangsberg, 2008b). Individuals can become infected with multiple 
strains of HIV and this is called ‘superinfection’ (Goulder & Walker, 2002), though is 
considered a rare phenomenon. 
Reproduction 
The circulating HIV particles (virions) are surrounded by an envelope which contains 
proteins that must bind to the CD4 T-cell receptors and co-receptors such as CCR5 and 
CXCR4 on the surface of the cell before the virus can enter it. On entry the virion 
releases its genetic material into the cytoplasm of the CD4 T-cell. The HIV genome 
consists of nine genes. Gag encodes the structural proteins of the virus.  Pol gives rise 
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to the expression of three enzymes essential for HIV replication: (1) reverse 
transcriptase (RT) which acts to transcribe viral RNA to DNA; (2) integrase which 
enables HIV to insert its genetic material into the host cell’s genome; and (3) protease 
which cleaves the newly produced viral proteins and repackages them into mature 
virions which are released from the CD4 T-cell cytoplasm into the lymphatic system. 
These three enzymes are the individual targets of antiretroviral drugs which, given in 
combination disrupt HIV from multiple angles optimizing the potency of the therapy 
and decreasing the opportunity for viral escape and virological failure. Importantly, 
each person differs in their response to a drug and these differences can in large part 
be attributed to an individual’s genetic makeup or ‘host genetics’.  
 
Figure 5: Lifecycle of HIV. A virion invades a CD4 T cell and provides a target for  
antiretroviral drugs (Fauci, 2003)  
Acute infection 
After infection the virus is largely concentrated in gut-associated lymphoid tissue 
(GALT) in the small bowel where the number of viral particles or copies amplifies to 
‘peak viraemia’ (Brenchley et al., 2004). At this time there is significant depletion of 
CD4 T cells (again in the gut where the majority are found) and 60-80% may be 
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destroyed in the first 17 days of infection when clinical symptoms may be apparent 
during acute retroviral syndrome. During this phase an individual is acutely infectious 
and some studies suggest that between 40 and 45% of transmissions occur in this 
phase when individuals may be unaware that they carry the virus (Wawer et al., 2005). 
More recently the Centers for Disease Control has estimated that about 21% of HIV-
infected individuals who are unaware of their HIV infection account for 54% of new 
diagnoses and that the number of transmitted infections could reduce by 30% by 
informing those unaware of their status. Preventing transmission during this highly 
infectious period of the disease clearly poses a major public health challenge 
(Campsmith, Rhodes, Hall & Green, 2010; Centers for Disease Control, 2008). 
A number of tests are performed after exposure to HIV. The most common test for HIV 
diagnosis is a serological antibody test called the enzyme linked immunosorbent assay 
or ELISA which measures antibody responses to the presence of HIV infection. Since 
antibodies may take up to six weeks post exposure to appear, newer generation 
testing kits also incorporate the direct detection of HIV viral proteins (typically p24) to 
provide a more comprehensive assessment of recently acquired HIV infection.  
Between two and twelve weeks after infection an illness called acute retroviral 
syndrome, occurs in approximately 50-80% of infected people (Figure 6). 
Seroconversion is the transition in status from HIV antibody negative to HIV antibody 
positive. This illness can manifest from mild malaise and swollen lymph nodes, through 
to gastrointestinal effects, ulceration of mucosa and neurological abnormalities.  
Although the high levels of virus in the body stimulate the production of CD4 T-cells 
these become targets for the virus and the immune system is quickly damaged. 
Cytotoxic T lymphocyte cells (CTLs) or CD8 T-cells act to kill cells infected with foreign 
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antigens and, in response to HIV antigen, become HIV-specific. They are also involved 
in ongoing immune activation by secreting pro-inflammatory cytokines that can have 
both beneficial and detrimental long term effects, and influence progression both to 
AIDS and non-AIDS illness. Important among these cytokines are the interferons alpha 
and gamma, TNF alpha and interleukin-2. This version of natural immunity governed by 
the T lymphocytes is known as cell-mediated (Kelly, 2003). More recent research has 
indicated that within the so called humoral or B cell responses to infection, neutralising 
antibodies and complement proteins may play a greater role mediating the interplay 
between the host immune system and the virus than was previously thought (Moir & 
Fauci, 2009). Unfortunately the virus evades any HIV antibodies produced by the 
human by rapidly mutating two of the viral proteins: gp120 and gp41 which would be 
the natural targets of the antibodies and this is one of the reasons that HIV is difficult 
to eradicate. Furthermore, since each generation of viruses is different from the 
former and the immune system only recognises viruses that resemble the previous 
generation the virus is able to evade detection – in effect it escapes (Fellay, 2009; C.B 
Moore et al., 2002).  
Chronic Infection 
At a round six months post infection and following the initial CD8 T-cell activation and 
CD4 T-cell decline, a transient equilibrium is reached and there is deceleration of CD4 
T-cells depletion. Thereafter, in untreated individuals, CD4 T-cell count declines by 
approximately 60 CD4 T cells/mm3 per year, although this loss is highly variable 
between individuals. However, attrition of CD4 cells and particularly the memory 
subset of these cells mean that the immune system has lost some ability to recognise, 
and fight, previously known antigens and this is what makes people, particularly 
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children, more susceptible to infections from a range of other microorganisms. A viral 
set point (Ho, 1996; Mellors et al., 1996) is reached when viral load plateaus to a 
steady state—this is also indicative of rate of progression to AIDS and comes about 
from the dynamic interaction between HIV and the host’s cell-mediated immune 
responses which are governed largely by genetic factors specifically the Human 
Leucocyte Antigens or HLA (Bartlett et al., 2009).  
Transmission event (usually occurs in a social context)  
Viral transmission   2-3 weeks Acute retroviral syndrome   2-3 weeks  
Recovery + seroconversion   2-4 weeks   Asymptomatic chronic HIV infection avg. 8 years 
Symptomatic HIV infection/AIDS   avg. 1.3 years      Death 
Figure 6: The natural stages of HIV infection. Adapted from Bartlett et al. (2009) 
Host genetics  
HLA antigens are the major determinants of recognition and differentiation of self 
from foreign pathogens and are found in nearly all nucleated cells in the body and in 
high concentrations on lymphocytes. They form part of the Major Histocompatibility 
Complex or MHC, a region found on the short arm of chromosome 6. There are more 
than 220 highly variable HLA molecules and many of them encode proteins of the 
immune system. The genes are categorised into three basic groups Class I (HLA-A, HLA-
B and HLA-C), Class II (HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and 
HLA-DRB1) and Class III. The proteins produced or expressed by the genes are 
exported from within human cells and are bound to protein fragments known as 
peptides which, in effect, mark the cell. These are displayed to CD8 T-cells and, if 
recognised as foreign, initiate a cascade of events leading to either destruction of the 
foreign cell or an inflammatory reaction with accompanying activation of cytokines, 
depending on which class of genes is activated. Alternatively, if the proteins are 
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recognised as ‘self’ then the system downregulates to prevent immune activation —
failure to do this results in autoimmune disorders. Presentation of peptides can occur 
in response to the incursion of intracellular pathogens, spontaneous genesis of 
malignant cells and also ingestion or exposure to man-made substances such as drugs 
(Delves, Martin, Burton & Roitt, 2006).  
The Class I pathway and its major genes: HLA-A, HLA-B and HLA-C play a primary role in 
mediating pathogenic viruses like HIV, and their specialisation has evolved across 
centuries, shaped by exposure to ancient epidemics such as the plague, tuberculosis 
and malaria that have impacted upon natural selection. That this has occurred 
translates to racial differences in polymorphism frequency of certain HLA alleles 
between global regions, and this has implications for the progression of infection and 
how different individuals respond to drug therapy and are susceptible to adverse side 
effects. There have been numerous studies that describe these polymorphisms and 
demonstrate that the MHC genes are the major factor modulating durable control of 
HIV infection (Pereyra et al., 2010).  
Host viral interaction 
Three of the HIV-1 genes tat, nef and vpu encode for proteins of the same name and 
all can affect host cell recognition of the virus. While tat is a viral protein mainly 
involved in the transcription of HIV from the integrated viral genome, it also  regulates 
the amount of virus presented to the HLA genes and chemokine and cytokine 
production, thus reducing immune responses against HIV. Similarly nef interferes with 
antigen presentation to CTLs and the vpu protein acts to reduce the number of CD4 T-
cells available to assist in eradicating the virus (Bartlett et al., 2009). 
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This is important because, as previously mentioned, RNA viruses mutate in order to 
avoid immune recognition and escape from cytotoxic T-cells (largely CD8) which can 
kill HIV before it has replicated. The chance of escape and the context under which it 
occurs have been described elsewhere (C.B Moore et al., 2002), however two 
important conditions are that: first, mutation can occur under selective pressure from 
drug therapy; and second, that human genetic makeup by way of polymorphisms, can 
affect protein expression in cells. Striking examples of these are the chemokine 
‘docking’ receptors which are necessary for the entry of HIV into the cells found on the 
CD4 T cell surface: CCR5 and CRCX4 are examples of these and they have been 
exploited in new drug treatments. Although polymorphisms are uncommon they may 
be nuanced in that other chemokines that can bind to these receptors can result in 
cell-mediated responses that influence the course of the infection (Dolan et al., 2007). 
In summary, the science reveals that there is a complex relationship between the 
parasitic virus and the human host’s ability to withstand the damaging effects of the 
virus on the immune system which, without treatment, are likely to be overwhelming 
within an average of ten years.  
Treatment for HIV/AIDS  
It was not until 1986, five years after the first cases of AIDS were identified in the US 
that the short term, small, placebo controlled trial sponsored by Burroughs Wellcome 
Company demonstrated the antiretroviral effectiveness and potency of azidothymidine 
or AZT (zidovudine), a drug previously tested for the treatment of cancer, at reducing 
viraemia in people with HIV/AIDS (Fischl, Richman & Grieco, 1987; McLeod & Hammer, 
1992). And it was some long years and many more deaths before protease inhibitors 
and combination antiretroviral therapy commonly referred to as highly active 
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antiretroviral therapy or HAART was introduced in the mid-1990’s (Flexner, 1998). 
Since then there has been a dramatic reduction in mortality and morbidity from 
HIV/AIDS (Hogg et al., 1997; Palella et al., 1998). The current view is that administering 
ART is preventive in the sense that it reduces the infectivity at an individual level and 
reduces rates of transmission (Cohen & Gay, 2010). Furthermore, early intervention 
with ART may prevent irrevocable immune damage and the systemic effects of 
ongoing immune activation stimulated by the presence of virus (Cohen et al., 2011). 
To date, the primary aim of ART has been to lower viral load by preventing replication 
of the virus and thereby restore immune function (Fauci, 2003), and the pathway to 
achieve this outcome is complex (Figure 7) (Friedland, 2006). The indirect effects of 
reducing viral load, especially in acute infection, are also beneficial in that: the rate and 
number of mutations can be reduced and some HIV-specific T-helper cells preserved. 
But in general, the mutable characteristics of HIV, including the propensity of the virus 
to become resistant to drugs has presented a huge challenge to researchers and a 
burden for those with the infection. As previously mentioned, a regimen is usually 
constructed from a combination of several drugs from at least two classes that act 
variously on the life cycle of the virus (Figure 5). A person who has never been exposed 
to antiretroviral treatment is said to be drug näive and therefore the initial therapy is 
termed a ‘first-line’ regimen (HIV Treatments Directory, 2008). 
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Figure 7: Therapeutic schema of the determinants of drug efficacy adapted from Friedland et al. (2006)  
The selection of a first-line regimen and consequent determinants of efficacy are 
predicated upon a number of factors. In the developed world, sensitivity of the virus to 
antiretroviral agents is tested in any individual, ex vivo to ensure that a drug treatment 
will be effective. Genetic testing may also be carried out to ensure that a person does 
not have a predisposition to drug hypersensitivity. However, access to testing and 
access to antiretroviral drugs is not universal and selection of suitable ARVs may be 
limited. Cost may be a factor even in settings where the drug is freely available if a co-
payment is required. Acceptance of the treatment and potential adverse side effects: 
including a belief in its being effective; and the ability to adhere to a lifetime of ‘pill 
taking’ and attendant medical supervision are important aspects which both the 
physician and patient must consider at the commencement of therapy. Other aspects 
include the characteristics of the drug that are influenced by its inherent 
pharmacokinetic properties (including ease of storage) as well as the individual genetic 
and viral characteristics that influence absorption and metabolism. Pre-treatment HLA-
typing and drug resistance testing is recommended to avoid prescribing either a 
potentially toxic or ineffective regimen (Hirsch et al., 2008). Pre-treatment discussion 
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between provider and patient is considered best practice (De Bruin et al., 2010; 
Harman, Amico & Johnson, 2005) in adherence management, and key to maintenance 
of optimal medication adherence.  
Antiretroviral Drugs  
The points at which drugs target particular stages of the life cycle of HIV can be 
visualised in Figure 5.   
Nucleoside reverse transcriptase inhibitors 
The first drug to be approved for the treatment of HIV in 1987 was zidovudine, 
commonly abbreviated and known as AZT (Fischl et al., 1987). Classified as a 
nucleoside analogue reverse transcriptase inhibitor (NRTI) or simply, nucleoside 
analogue, this drug and others of its class work to block the action of reverse 
transcriptase. However, before they can be used they must be converted to an active 
form of triphosphate by a process of phosphorylation. Nucleotide RT inhibitors are 
similar to nucleosides but only require one step in the process of phosphorylation to 
convert to triphosphate (HIV Treatments Directory, 2008).  
Non-nucleoside reverse transcriptase inhibitors 
The second class of antiretroviral drugs closely related to the NRTIs, are the non-
nucleoside reverse transcriptase inhibitors, or NNRTIs, these act on RT but at a 
different site from the former and they are not incorporated into the viral DNA—they 
are therefore complementary (HIV Treatments Directory, 2008). The most commonly 
prescribed and licensed in WA are efavirenz (EFV), nevirapine (NVP) and a more recent 
addition—etravirine. The half life of these drugs is long and this has implications for 
the maintenance of therapeutic drug levels, as shall be described further. Skin rash and 
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liver toxicity are the major concerns with the administration of NNRTIs, particularly 
nevirapine, and approximately 15% of people starting may develop rash within the first 
couple of months of treatment, with a smaller proportion developing a multisystem 
drug hypersensitivity syndrome that can include a systemic illness with fever, 
hepatotoxicity, and peripheral blood eosinophilia. Predisposition to this 
hypersensitivity syndrome is thought to be genetic in origin involving HLA alleles (Yuan 
et al., 2011), with an additional affect of higher CD4 T-cell counts at the time of 
commencing nevirapine. The drug is generally unsuitable for people with HIV/hepatitis 
C coinfection or other co-existing liver disease, but is used safely in pregnant women to 
prevent mother to child transmission of the infection (Sturt, Dokubo & Sint, 2010). 
Efavirenz in contrast, is not safe to use in pregnant women but, similar to nevirapine, 
appears to be influenced by host genetic factors in that more severe side effects are 
experienced by people of African descent. This seems to be as a consequence of high 
blood levels related to the metabolism of the drug (Ribaudo et al., 2006). Major side 
effects appear to affect the central nervous system and at worst cause depression, 
disorientation and psychosis however, most commonly, EFV affects sleep and dreams. 
Efavirenz can be detected in the urine as tetrahydrocannabinol, or THC, and this has 
implications for patient management.  
Protease inhibitors  
This class was introduced in the mid 1990’s and the use of protease inhibitors (PI’s) in 
combination with NRTIS’s reduced mortality in those with access to this treatment. As 
the name suggests protease inhibitors block the action of the protease enzyme during 
the assembly of virions from the larger precursor (gag, pol) polyproteins (Figure 5). 
There are ten drugs from this class licensed for use in Australia and about six of these 
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are commonly used in WA. Common side effects are gastrointestinal, but drug-induced 
dyslipidaemia is common and monitoring of fasting blood lipids is routinely carried out. 
One important characteristic of HIV protease inhibitor therapy is that low-dose 
ritonavir is commonly used to boost the effect of other protease inhibitor drugs by 
inhibiting CYP3A4 metabolism. This increases the propensity for HIV protease inhibitor 
treatment to interact with other drugs including anti-tuberculosis agents, 
contraceptives and opiate substitution therapy such as methadone (HIV Treatments 
Directory, 2008). 
Entry inhibitors 
Entry inhibitors include CCR5 and CXCR4 antagonists, and fusion inhibitors. These 
drugs act variously to block HIV from binding to either one of the two receptors on the 
CD 4 surface or the chemokine receptors CCR5 and CXCR4 (Figure 5). Again host 
genetics play a role in determining which chemokines are likely to be expressed and 
viral genetics determine the attraction or tropism of the virus to the hosts CD 4 cell 
(Ahuja et al., 2008; Swenson et al., 2011). 
Integrase inhibitors  
The second important enzyme in the life cycle of the virus is integrase (Figure 5) which 
acts to insert viral DNA into the host chromosome in the nucleus of the CD4 T cell (HIV 
Treatments Directory, 2008). Raltegravir is an example of an integrase inhibitor drug 
now in use in WA for people for initial therapy as well as with treatment-experienced 
patients (personal communication David Nolan, August 2012). 
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Potency of antiretroviral therapy  
The efficacy of the treatment relies on achieving optimal systemic and intracellular 
concentration of drug levels in the blood to suppress the virus. The ability of the body 
to absorb, distribute, metabolise and eliminate or clear the drug from the body is 
influenced by inherited genes. However, only a small number of gene variants have 
been discovered that are known to predict outcomes (Lubomirov et al., 2011). Of 
particular relevance currently is the HLA-B* 5701 allele, presence of this allele confers 
a highly predictive hypersensitivity to abacavir, a commonly prescribed NRTI (Mallal et 
al., 2002, 2008). Another common important polymorphism is G516T which is linked to 
rate of clearance of efavirenz, this change is located on the gene for cytochrome P-450 
2 B6 which influences metabolism of the drug (Ribaudo et al., 2006) More commonly, 
drug interactions and, in particular inadequate medication adherence, lead to sub-
therapeutic drug levels which can result in the emergence of drug resistance via a 
mechanism known as selective pressure (Richman, 1996).  
 
Figure 8: How drug resistance arises (Richman D, 1998) 
Drug resistance 
Mutations in the genetic material of a virus in response to a drug usually result in the 
virus becoming less sensitive or insensitive to anti-viral drugs; in effect it becomes 
‘resistant’ (Figure 8). Resistance to antiretroviral drugs may be de novo or acquired 
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following non-suppressive treatment, this is called secondary resistance. However, if it 
is transmitted between individuals it is termed primary resistance (Turner & Wainberg, 
2006). Since HIV is highly mutable, at any one time a person can have several species 
of circulating virus or quasi species, and one or more may be drug resistant. A feature 
of drug resistance is cross resistance which means a virus resistant to one drug may be 
resistant to the entire group or class of drugs. Since tests designed to pick up drug 
resistance are only sensitive to detect mutations with a frequency above 10-20% of the 
total viral population, low level drug resistance may be undetectable. Drug resistant 
viruses are not necessarily more able or ‘fit’ than drug sensitive viruses however 
replication of the resistant virus can occur over time in a treated person leading to a 
dominance of drug resistant over drug sensitive virus and someone with a viral load 
previously undetectable using current testing methods may begin to show low levels of 
viraemia which will alert the practitioner to investigate the likely causes. In effect the 
binding capacity of the drug to the virus gradually diminishes until the drug is 
ineffective and viral rebound is said to occur. As the availability of ART increases, the 
proportion of new HIV infections that involve resistant strains also tends to increase, 
which has implications for public health interventions. However resistance can be 
avoided with the careful individualization of treatment to patients, as is the standard 
in developed countries (Hirsch et al., 2008; Little et al., 2002) 
Sub-optimal antiretroviral drug levels can occur as a consequence of poor absorption 
of drugs which can in turn come about from a drug-drug interaction for competition 
with sites of metabolism in the liver or genetic differences that result in variability in 
drug metabolism. However, in any individual, by far the most common reason for sub-
optimal drug levels arises from missing doses in a regimen that is otherwise followed 
persistently (Paterson et al., 2000).  
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Adherence to and Persistence with Antiretroviral Drugs 
Adherence to medical care or treatment is a dynamic behaviour that can change over 
time. It can be defined as the extent to which a person’s behaviour, for example, 
taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with agreed recommendations from a health care provider (Haynes, Wang & Da Mota 
Gomes, 1987; World Health Organisation, 2003). Medication adherence refers 
specifically to the ability to take medication as prescribed, which means taking the 
correct dose of the intended drug at the right time and following any special 
instructions as specified, for example: take with meals. In effect adherence refers to 
the outcome of the comparison of the prescribed dosing regimen and the patient’s 
dosing history, while they remain engaged with treatment (Vrijens, Vincze, Kristanto, 
Urquhart & Burnier, 2008). This is often expressed by patient self-report or by using 
data from a electronic medication event monitoring system (MEMS) as a percentage of 
doses taken over a prescribed period of time (Lu et al., 2008). Persistence with 
medication is defined as the “continuous treatment with a prescribed medication or 
intervention without interruption beyond the therapeutic range of the treatment” (Bae, 
Guyer, Grimm & Altice., 2011). Conceptually, persistence is related to adherence 
behaviour, but it further discriminates pill taking behaviour by describing the duration 
of time that a person remains on a course of treatment. Bernard Vrijens and 
colleagues (Vrijens & Urquhart, 2005) plotted the chronology of adherence and 
persistence in four patients taking an antihypertensive drug once daily. Their findings 
are shown in Figure 9.  
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Figure 9: Chronology of adherence and or persistent pill taking behaviour as measured by electronic 
event monitoring cap technology (Vrijens, et al., 2008) 
A person is defined as persistent to a drug as long as the ‘permissible gap’ has not 
been breached and this may vary according to the constituent drugs in the regimen. 
The permissible gap is defined as the “duration between the initiation and 
discontinuation of a specified antiretroviral regimen as agreed upon by the patient and 
the health care provider” (Bae et al., 2011). Persistence differs from adherence in that 
adherence behaviour is subject to the attributes of the individual, drug or environment 
of the person executing the regimen (Ickovics & Meisler, 1997) whereas non-
persistence can be attributed to both patient or regimen factors which may be outside 
the patient’s control (Bae et al., 2011). In essence the concepts of adherence and 
persistence are interrelated but the former pertains to the quality of executing of the 
regimen whereas the latter represents disengagement from treatment and the two 
behaviours may have varied clinical and economic consequences (Vrijens et al., 2008) 
Hill, Kendall and Fernandez (2003) while not differentiating these terms, described 
patterns of adherence to ARV regimens in HIV which usually contain a combination of 
at least three drugs as:  
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 Skipping one type of medication 
 Taking medication several hours late 
 Taking medication very rarely (once a week/month) 
 Not sticking to eating or drinking restrictions 
 Adhering to a purposely modified regimen 
 Adhering to an unknowingly incorrect regimen 
 Alternating between long periods of taking and not taking medications 
The Concept of ‘Forgiveness’ 
Hill’s findings have particular relevance for people on once-daily, and including fixed-
dose combination regimens, with regard to a pharmacological concept known as 
‘forgiveness’. The ‘forgiveness’ of a drug is the difference between a medication’s post-
dose duration of beneficial action and the prescribed dosing interval. Most drugs used 
in the general population today, have plasma half lives of 12 hours or less (Osterberg, 
Urquhart & Blaschke, 2010). If dosing schedules are interrupted, concentrations of the 
drug in the blood will fall below the level considered therapeutic that would have been 
maintained by continuous dosing. Drugs that are described as ‘forgiving’ generally 
have a prolonged pharmacodynamic effect typically because the plasma half-life has 
been extended or because, as a characteristic of the drug, a receptor or enzyme is 
knocked out and regenerates slowly. As a concept, forgiveness is probably best 
understood in the way the oral contraceptive pill has been designed and marketed. 
Indeed, the contraceptive pill represents one of the first instances where written 
instructions have been prepared for consumers on what to do if they miss one or more 
pills. A group of drugs designed to treat a particular condition for example, depression 
or hypertension may have widely differing plasma half-lives so that forgiveness may be 
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very narrow, and missed doses can have an immediate clinical consequence. This 
phenomenon might also explain why different values of forgiveness result in some 
medications seeming more effective than others (Osterberg et al., 2010). In the 
management of HIV infection drug ‘forgiveness’ has important clinical implications 
(Bangsberg, 2006a; Bangsberg et al., 2003; Bangsberg, Moss & Deeks, 2004; Knobel et 
al., 2009; Parienti, 2002; Parienti et al., 2008; Pham, 2009). 
Why is Medication Adherence so Important? 
The World Health Organisation reports that adherence to long term treatments for 
chronic conditions averages about 50% in developed countries and less in least 
developed countries (World Health Organisation, 2003). In the United States between 
33% and 69% of medication-related admissions in the US are as a consequence of poor 
medication adherence which is estimated to cost the country approximately $100 
billion dollars per year (Osterberg & Blaschke, 2005). Poor adherence in clinical trials 
can result in an underestimation of treatment side effects and efficacy, although 
adherence is better in clinical trials and this is thought to be a consequence of bias in 
patient selection and the positive attention from health care providers that patients 
receive in the course of the trial. There are now organisations engaged by 
pharmaceutical companies to monitor medication adherence during drug trials. 
Monitoring adherence has now become something of an industry, for example, the 
advertisement:  
‘The future of healthcare—there’s an app for that’ 
(http://www.bain.com/publications/articles/the-future-of-healthcare.aspx, last 
accessed 17 August 2012). 
Arguably, resolution of many infectious diseases, like tuberculosis (TB) which is curable 
and malaria which is preventable, is predicated on adherence to antibiotic or antiviral 
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treatment. Sometimes this treatment may be short term but in the case of hepatitis C 
treatment can last up to 18 months. During the early years of HAART, near perfect 
medication adherence (over 95% of doses) was needed to suppress blood levels of the 
virus and prevent progression to AIDS (Paterson et al., 2000). Later, research showed 
that not all classes of drugs required the same stringency of adherence; (Bangsberg, 
2006a) and added evidence that the relationship between adherence to treatment and 
drug resistance was not linear (Bangsberg et al.,  2003, 2004, 2007). Whatever the 
adherence level required, it was evident that HAART, only 15 years old, had saved 
millions of lives (Palella et al., 1998); and treatment has subsequently been shown to 
reduce rates of transmission (Cohen & Gay, 2010), but only in those with the ability to 
access and adhere, long term, to the drugs. 
Raising the Alarm: Medication Nonadherence in HIV 
Initial concern about medication nonadherence in HIV and the risk of primary and 
secondary drug resistance arose with the advent of HAART. Physicians in New York City 
had observed an epidemic of drug resistant TB as a consequence of poor adherence to 
anti TB drugs. Since the risk factors for nonadherence were poor mental health, 
addiction to substances and unstable housing, there was a perception that these 
factors were causal and some physicians withheld treatment from AIDS-affected 
individuals who fit this demographic (Sontag & Richardson, 1997), thereby providing 
one of the earliest examples of discrimination or enacted stigma in HIV/AIDS. 
However, the relationship between antiretroviral adherence, viral suppression, and 
progression to AIDS related mortality is now well established, although the unique 
adherence-resistance relationship of ARVs (Bangsberg et al., 2004) has broad 
implications for prescribers (Figure 10). The reason for this, in part, is that unique 
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patterns of pill-taking behaviours affects NRTI, NNRTI and PI classes differently in 
terms of the consequent signature mutations (Bangsberg, 2003, 2006). Specifically, this 
has to do with drug class characteristics such as the potency of the drug, half life in 
plasma (Hardman, Limberd & Gilman et al., 2001), and site of action, for example, 
distance from target enzyme and capacity to develop cross resistance (Bangsberg et 
al., 2004). Understanding this important relationship is critical to ensure viral 
suppression and prevent rebound viraemia. Furthermore, given the difficulty of 
maintaining high levels of adherence, it is necessary to know the threshold values for 
individual drugs so as to tailor regimens to suit individual requirements including. 
These include: host genetics; concomitant medications that might interact with ART; 
and factors in the individual’s environment that may be dynamic over time, known as 
‘pharmacoecologic’. For example, patient preference for dosing schedules and side 
effects that they are willing to tolerate (Heath, Singer, O’Shaughnessy, Montaner & 
Hogg, 2002; O'Brien, Clark, Besch, Myers & Kissinger, 2003; Pavlos & Phillips, 2011; 
Pham, 2009). 
 
Figure 10: Relation between individual drug classes, levels of adherence and risk of resistance 
mutations. Adapted from Bangsberg, Moss & Deeks (2004)   
Abbreviations: PI = protease inhibitors; NNRTI = non-nucleoside reverse transcriptase inhibitors. 
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The Pharmacokinetics of Commonly Prescribed Antiretroviral Drugs  
People with variable access to ART or who choose to interrupt their treatment, for 
whatever reason, are particularly vulnerable to the effects of non-persistence arising 
from the less than therapeutic exposure to the drugs  (The Strategies for Management 
of Antiretroviral Therapy (SMART) Study Group, 2006) and this effect is cumulative 
(Knobel et al., 2009). Some specific examples follow. Nevirapine (NVP), an NNRTI, 
remains detectable one week after discontinuance whereas abacavir and lamivudine, 
drugs which are commonly used in combination with NVP, have serum half lives of 1.5 
hours and 6 hours, respectively. The intracellular concentration of the active 
metabolite of abacavir becomes undetectable within 72 hours of the last dose. (Bae et 
al., 2011; Mackie et al., 2004; Mirochnick et al., 1998; Johnson, Moore, Yuen Bye & 
Pakes, 1999; Kumar et al., 1999). Therefore, if this combination is ceased together then 
an extended period of monotherapy (under NVP) results and resistance to nevirapine 
(which has a low genetic barrier to resistance) can ensue (Richman et al., 1994). 
Efavirenz, another commonly used NNRTI has a serum half life of 40 - 55 hours and can 
remain at a therapeutic level for 21 days after it is ceased. However, although 
efavirenz and nevirapine can continue to suppress HIV if they are stopped or missed 
for a short time they are more likely to develop resistance when they are stopped for 
longer periods. The ‘permissible gap’ for a NNRTI is estimated to be between 2 and 7 
days for an efavirenz containing regimen (Bangsberg et al., 2003; Bangsberg et al., 
2004; Parienti et al., 2008; Ribaudo et al., 2006). In contrast, ritonavir boosted PI 
regimens have a high genetic barrier for resistance so that even at a lower serum 
concentration, potency is maintained and the occurrence of resistance mutations less 
common (Swindells et al., 2006). Thus giving rise to the concept discussed earlier that 
such a regimen is ‘forgiving’.  
 45 
Non-persistence with medication can arise from factors intrinsic or extrinsic to the 
patient or regimen. Intrinsic factors include: pill burden, adverse side effects, 
underlying resistance and cost of the drug. Extrinsic factors are those that might 
influence the practitioner to alter the regimen including: findings from clinical trials, 
treatment guidelines, and choice predicated by regional access to particular 
treatments (Bae et al., 2011).  
Measurement of Adherence  
No single method for measuring adherence has been widely accepted (Nachega et al., 
2011), however, methods for measuring both adherence and persistence can be 
summarised as:  
 Directly observed therapy (DOT) (Lucas, Flexner & Moore, 2002; Ford, Nachega, 
Engel & Mills, 2009) 
 Medication event monitoring system (MEMS Cap) (Figure 9) (Bangsberg, 2001) 
 Patient recall, with or without a validated questionnaire (Morisky, Green & 
Levine, 1986; Chesney et al., 2000; Wagner, 2004) 
 Pharmacy refill data, which does not discriminate patient persistence but is 
useful to indicate whether a regimen persists (Figure 11) and in Australian 
settings was found to correlate with viral load and self-reported adherence 
(Fairley et al., 2005; Herrmann et al., 2008) 
 Medical record review which should indicate record of side effects or other 
reasons for difficulties with adherence or patient-initiated treatment 
interruptions, and start and stop dates of regimens  
 Database search (Andrade, Kahler, Frech & Chan, 2006; Vrijens et al., 2008) 
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The Challenge of Persisting with Lifelong HIV Treatment  
Bae and colleagues (2011), in an editorial review, commented that patient 
nonpersistence to ART in HIV had been insufficiently addressed given its association 
with adverse clinical outcomes. They went on to report a series of studies beginning 
from 2002 (Hogg et al., 2002) that showed that intermittent use of ART, from gaps 
exceeding 48 hours onwards, resulted in drug resistance and increased mortality.  
Significantly, the authors 
differentiate between patient 
and regimen persistence or 
durability, which has 
increased in recent years 
alongside the development of 
fixed-dose co-formulations 
(FDCs) and is associated with 
the greatest likelihood of 
sustained virological suppression (Willig et al., 2008). Klein et al (Klein, Willemot, 
Murphy & Lalonde, 2004). The authors report that NNRTI-based initial or ‘first-line’ 
regimes were more likely to be durable than PI-based combinations. Should first 
regimens fail, salvage regimens, although improved over recent years, may not be as 
successful as the initial combination, be associated with a more complicated dosing 
schedule, and be less tolerable and therefore influence likely successful adherence and 
persistence. Regimen persistence is a particular issue in resource poor settings where 
ART choices are limited, stock outs are not an uncommon occurrence and food 
insecurity prevalent (Bae et al., 2011; Nachega et al., 2011; Weiser et al., 2010). For 
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Figure 11: Adherence correlates with pharmacy refill data 
(Designed by Bethy McKinnon) 
 47 
people who may move from region to region and across jurisdictions and health 
services, such as temporary visa holders, and non-citizens in general, the challenges 
are evident. While the influence of medical insurance coverage on adherence to ART 
has been reported and although there have been some studies in migrants, asylum 
seekers, and illegal immigrants there has been less research on the circumstances of 
temporary visa holders with HIV and none to date in Western Australia. 
 
Figure 12: Schematic of fundamental domains which  
encompass factors influencing adherence to medication.  
(Ickovics & Meisler, 1997; Ickovics & Meade, 2002a, 2002b) 
Factors that Influence Adherence to and Persistence with ART  
Medication adherence behaviour is complex and dynamic (Carrieri et al., 2001; Ickovics 
& Meade, 2002a; Ickovics & Meisler, 1997). Although certain characteristics have 
predicted adherence in some studies, particularly relating to substance use and 
psychiatric illness  (Golin, Liu, et al., 2002; Paterson, et al., 2000; Wagner, 2004) as well 
as past history of non-adherence (Wilson, Doxanakis, & Fairley, 2004), some clinicians 
and researchers prefer to think in terms of patterns and correlates of medication non-
adherence (Atkinson & Petrozzino, 2009; Beusterien et al., 2008b; Fumaz et al., 2008; 
J. S. Gonzalez, Batchelder, et al., 2011; Gordillo et al., 1999; Heath, et al., 2002; M. O. 
Johnson et al., 2005; Murphy et al., 2000; O'Brien et al., 2003; Spire et al., 2002). This 
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requires a focus on identifying ‘potential barriers’ to achieving good adherence and 
developing interventions tailored to individuals, treatment settings and patient 
providers as well as an awareness of current best practice guidelines (De Bruin et al., 
2010; Fairley et al., 2003; Harman et al., 2005; Sidat, Fairley & Grierson, 2007).  
Adherence is conceptualized as pertaining to aspects of (a) the individual, (b) the 
treatment regimen, (c) the patient–provider relationship, (d) the clinical setting, and 
(e) the disease (Ickovics & Meisler, 1997). Figure 12 provides a simple schema. 
This paradigm has been widely accepted but assumes unfettered access to ART. 
Striking reasons for medication nonadherence and patient nonpersistence are drug 
dosing schedules, pill burden and side effects such as diarrhoea and fatigue. These are 
frequently cited physiological ‘de- motivators’ that result in reduced adherence and 
self-cessation of treatment without any reference to health care providers (Atkinson & 
Petrozzino, 2009; Heath et al., 2002; Murphy et al., 2000). A range of idiosyncratic 
psychosocial and behavioural factors also contribute to episodes of missed medication. 
These include younger age, substance use, sleep disturbance, depression, non-
disclosure of HIV status (Glass et al., 2006; Golin et al., 2002a; A. Gonzalez et al., 2011; 
J. S. Gonzalez et al., 2011; Gordillo, del  Amo, Soriano & Gonzalez-Lahoz, 1999; 
Herrmann et al., 2008b; Phillips et al., 2005), fear of stigmatization and notions of self-
punishment or reward (Safren et al., 2001). 
Indeed the presence of physical and psychological symptoms has been demonstrated 
as strongly predictive of viral rebound in those with previously suppressed infection 
(Lampe et al., 2010). Personal health literacy and numeracy are also important 
components of successful medication management (Kalichman et al., 2008; Waldrop-
Valverde, Jones  et al., 2010), although this finding is not universal (Paasche-Orlow et 
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al., 2006), and neurocognitive functioning plays a significant role (Waldrop-Valverde, et 
al., 2010). 
The role of environing conditions 
Clinic-related factors which influence attendance have in turn been associated with 
improved adherence within cohorts. It is now widely accepted that institutions 
delivering HIV clinical services should support a standard of care that incorporates a 
minimum of interventions to support acceptance of treatment; and long-term 
maintenance of medication adherence. The standard of care should be measurable 
and comparable between settings (De Bruin et al., 2010; Harman et al., 2005). In the 
Royal Perth Hospital outpatient hospital setting adherence care is based on research 
conducted in that context (Herrmann et al., 2008b) and is conceptualised by Figure 13. 
However, disease-specific dimensions of HIV related to treatment side effects, and less 
tangible constructs, such as stigma, in the absence of immunopathology, can interact 
with context-specific factors. These dimensions can affect the health and well-being of 
people by interfering with the appropriate use of health services (Weiss, Ramakrishna 
& Somma, 2006) by way of delaying HIV testing; delaying or preventing the acceptance 
of treatment; and threatening adherence (Sayles, Ryan, Silver, Sarkisian & 
Cunningham, 2007) and persistence with treatment. Finally, engagement with health 
care providers and long-term medical management can be threatened. 
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Figure 13: Schematic of adherence management (Herrmann et al., 2008b) 
Health-related Quality of Life  
The psychosocial and physical effects of HIV/AIDS and treatment affect health-related 
quality of life, despite the effectiveness and potency of antiretroviral drugs in 
ameliorating the condition. Adverse side effects, pill burden, inhospitable dosing 
schedules and psychosocial effects of the disease make diligent adherence and 
persistence with the treatment challenging. Despite some normalisation of quality of 
life indicators in patients with poor health pre-HAART (Carrieri  et al., 2003), in general, 
common side effects such as nausea, diarrhoea and peripheral neuropathy, and 
disease-related symptoms distressed and limited the lifestyles of people, particularly 
around relationships and employment, and this had socially detrimental outcomes 
(Ammassari et al., 2002; Blaschke, 2008; Chesney et al., 2000; Duran et al., 2001; 
Eriksson, Bratt & Nordstom, 2005; Fumaz et al., 2002; Harmon,  Barroso, Pence,  
Leserman, & Salahuddin, 2008; Maticka-Tyndale, Adam & Cohen, 2002; Mocroft et al., 
2001; Murphy  et al., 2000; Murri  et al., 2000; O'Brien  et al., 2003; Trotta et al., 2002; 
K.J Wilson et al., 2004).  
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Shortly after the advent of HAART, it became apparent that medication adherence and 
drug resistance were important issues in the successful management of HIV infection 
and, as the search for tolerable but potent ARVs continued, measuring health-related 
quality of life (HRQL), and understanding its relationship with medication adherence 
became a major focus for interdisciplinary research. However, many HRQL measures 
used in HIV research up until recently were developed either before, or in the early 
HAART era, including the MOS-HIV, FAHI, HOPES, HAT-QOL, AIDS-HAQ, and the MQOL-
HIV (Cella, McCain, Peterman, Mo & Wolen, 1996; Ganz et al., 1993; W. C. Holmes & 
Shea, 1998; Smith, Avis, Mayer & Swislow, 1997; Wu, Revicki, Jacobson & Malitz, 1997; 
Wu et al., 1991). On this basis these measures could be construed as not attuned to 
the impact of contemporary treatments, not sensitive enough to detect HRQL changes 
in HIV, or to account for the long-term experience of living with HIV. Indeed, some 
critics of general HRQL measures recommended that they be abandoned altogether, 
citing that they lack the specificity and diagnostic utility of conceptually discrete scales 
(Cummins, Lau & Stokes, 2004). That a contemporary, global HRQL measure was 
needed was also indicated by the steep increase in access to ART in low and middle-
income countries (UNAIDS, 2009). It became evident that such a measure should be 
equally useful and valid in those regions, as well as the higher income countries.  
To address this need, a team from the Patient Reported Outcomes Unit (PRO) at the 
Hôpital de Saint-Louis in Paris in collaboration with institutions internationally, 
developed the PROQOL-HIV health-related quality of life questionnaire with the 
participation of PLWH across 11 countries, including patients from Royal Perth Hospital 
in Western Australia. Two manuscripts, published recently, describe the international 
study and can be found in an appendix to this thesis. The preliminary data gathered in 
2007-2008, in the developmental phase, informed the direction of the thesis and is 
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therefore discussed, in brief, to provide background information. The data was 
presented at national and international conferences (Duracinsky et al., 2008; 
Herrmann et al., 2009b) prior to publication in 2012.  
The development of the PROQOL-HIV study followed a 4-stage process (1) 
development of a conceptual model and item generation; (2) development of source 
questionnaires; (3) linguistic validation and (4) psychometric validation. In phase 1, 
thematic analysis of semi-directed interviews with 152 patients across nine countries 
was used to develop a questionnaire item bank from which a pilot questionnaire was 
constructed. There were 11 underlying themes that emerged to represent a 
conceptual model of HIV-specific HRQL and these were: general health perception, 
social relationships, emotions, energy/fatigue, sleep, cognitive functioning, physical 
and daily activity, coping, future, symptoms and treatment. Seven issues in particular, 
subsumed into the main themes, were important to participants but not represented 
in any existing QOL instrument and these were: fear of infecting others, concerns for 
the future, satisfaction with care, self-esteem problems, sleep problems, work 
disruption and treatment issues (Duracinsky et al., 2012). As expected, differing 
epidemiological patterns of HIV transmission and inter-country, socio-cultural and 
linguistic differences moderated the themes and subsequently influenced the item 
construction.  
Across country thematic comparisons  
The idea of general health was widely understood as important for quality of life and 
people considered even small changes in their general health as important to them. 
Nuances were related to areas such as physical activities, social relationships and 
treatment. Although the ability to work was important for people in all countries, 
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physical activity was often centred on sports in developed countries and around work, 
chores and the ability to walk long distances in developing countries – leisure was not 
a concept well understood in low income countries. Work was also linked to social 
status, the ability to pay for treatment and the availability of resources and services in 
low and middle income countries.  
Issues of energy and fatigue appeared more evident in people in low income countries 
perhaps because the disease is often diagnosed at a later stage. The ability to drive a 
car was cited as important for Australians, and international travel was mentioned as 
another important activity. The former was sometimes restricted by lack of 
concentration and the latter around restrictive HIV-focused international laws. It was 
notable that blood spills were concerning to Australians who often visualised 
themselves involved in a car accident, or some other situation that involved exposing 
others (unwittingly) to their blood. 
Social relationships by way of family life were important in the USA, Senegal, China and 
India. In Western Australia, it was evident that friendship could be as important as 
family. While social stigma was felt universally, for participants in Senegal, India, China, 
Thailand and Cambodia, it extended to involving the family in the aura of 
discrimination which ensued from disclosure. In general, psychological burden was 
observed to be heavier in Asia but most participants described negative self 
perceptions and emotions, for example: shame, guilt, inferiority, embarrassment, 
sadness, anxiety, irritability and stress. However religious and/or spiritual beliefs were 
beneficial to coping and described by participants in Australia, Brazil, the USA, Thailand 
and Senegal. Significantly, there were distinctions between religion and spirituality in 
that religions were seen to impose constraints or boundaries on behaviour.  
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Symptoms and side effects were another key quality of life issue but, while universally 
felt, adverse effects of treatment received more attention from the higher income 
countries (France, the USA, Australia, Brazil) where access to ARVs was less of an issue. 
In India, Thailand, Cambodia, China and Senegal treatment was viewed as lifesaving 
and lack of access to ARVs was feared. It is also the case that in these countries there 
was less criticism of health care providers. There were general concerns around 
medication related to the stress around managing good adherence but, in addition to 
this, there was the perceived need to take medication privately to protect from 
exposing their HIV status.  
Finally there were three other issues that were frequent points of discussion for 
participants and these were: satisfaction with health care services; financial and 
employment problems; and worries about conceiving and raising children. This last 
topic came up more frequently in Thailand and Cambodia. 
Health-related Quality of Life and Adherence  
A number of studies have found a relationship between ART medication adherence 
and HRQL or HIV-AIDS specific quality of life either directly or indirectly (William 
Holmes  et al., 2007; Mannheimer et al., 2005). It was often the case that adherence 
was associated with toxicity to early HAART regimens and lipodystrophy was a good 
example of this (Guaraldi  et al., 2003; Guaraldi  et al., 2008). Figure 14 is a vignette of 
how one man manages his ART regimen. I carried out this assessment in 2005 when 
the man participated in an earlier study (Herrmann et al., 2008b). It was notable that 
despite the detrimental effects (self-reported) on the patient’s lifestyle of what is a 
disruptive dosing schedule, and a marginal immunological response to the treatment, 
the patient showed reluctance to switch to a simpler, more tolerable regimen. In a 
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post script to this narrative, the patient went on to improve adherence to his 
IDV/d4T/3TC regimen and developed nephrolithiasis (kidney stones) as an adverse 
effect of indinavir. As a consequence he was motivated to accept a change of 
treatment to a BD regimen in 2006. This led to an improvement in his ability to 
manage the regimen and he achieved an undetectable viral load for the first time in 
eight years.  
 
Figure 14: The impact of treatment regimen and lifestyle on medication adherence 
Despite some studies reporting increased drug toxicity with better adherence in the 
early HAART era, health-related quality of life dimensions in people with HIV while 
dynamic, also have a co-dependent relationship with medication adherence by way of 
(1) improved clinical outcomes and (2) increased tolerability of ART (Carrieri et al., 
2003; J. S. Gonzalez et al., 2011; Mannheimer et al., 2005; Swindells et al., 1999; T. E. 
Wilson et al., 2002).  
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However, it remains difficult to tease out the effects of ART on HRQL since there may 
be ‘noise’ from other influential biopsychosocial factors affecting PLWH concurrently: 
including experience of stigma and discrimination, depression, and relationship issues 
(J. S. Gonzalez  et al., 2011). There is a sound case for an instrument that can account 
for the emotional and social effects of treatment beyond objective observation of side 
effects. In addition, focused interventions could be informed by research that 
examines the potential mechanisms connecting adherence with depression (J. S. 
Gonzalez et al., 2011). By exploring and addressing, where possible, common aspects 
of HIV that have traditionally been associated with diminished HRQL in PLWH, a 
secondary benefit in improving or sustaining medication adherence may ensue. 
Qualitative research methods support this approach. 
In Australia the publication of The HIV Futures Surveys, the latest of which is ‘Futures 
6’ (Grierson et al., 2009) funded by the Commonwealth Department of Health & 
Ageing at intervals since 2004; and activities of the Australasian Society of HIV 
Medicine (ASHM) as well as NAPWA, AFAO and other national HIV organisations, gives 
a profile to issues that impact on the quality of life of people living with HIV, among 
other useful information. However, the population represented in the latest Futures 6 
Survey (2009) while national, may not be reflective of the WA demographic of PLWH 
or reflect the priority populations identified in the 6th National HIV Strategy 
(Government of Australia, 2010), particularly with regard to mobile populations. 
Therefore, a study that reflects the contemporary issues for PLWH in Australia, 
regardless of their ethnicity or citizenship status, is timely. 
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Medication Adherence in the WA HIV Cohort 
The concern about sub-optimal adherence to ART in the USA and Europe (Bangsberg et 
al., 1997;  Bangsberg  et al., 2001; Carrieri et al., 2001; Chesney et al., 1999; Paterson 
et al., 2000) was also shared by those in the field of HIV clinical management in 
Australia (Fairley, et al., 2003). At Royal Perth Hospital, ART and AIDS prophylaxis is 
dispensed free from the hospital pharmacy to those with Medicare access, with no 
concomitant copayment, although this is likely to change in the near future to bring 
ARVs in line with other drugs dispensed by hospital pharmacies. The results of the 
study of medication adherence in the APROCO cohort (Carrieri et al. 2001) were 
sufficient to alert health care providers that similar, sub-optimal adherence levels were 
likely contributing in the WA HIV cohort to: poor viral suppression or viral rebound, 
drug resistance, AIDS-associated or defining illnesses such as cryptococcal meningitis, 
and premature death (personal communication (nd), Professor Martyn French). 
Furthermore, it was recognised that sub-optimal adherence could confound the 
validity of toxicity and therapeutic outcome data (Ickovics & Meisler, 1997; Urquhart, 
1991), and impact on the quality of longitudinal data retained in the HIV Cohort 
Database since 1983 when the first cases of HIV were identified in WA (Mallal, 1998). 
The RPH Immunology Department had a long history of conducting clinical 
observational and basic science research, and participating in clinical trials, so aside 
from the deleterious health effects of poor adherence on the patient there was a 
perceived threat to data integrity. Therefore, implementing a program of assessment 
and improvement of adherence was imperative. After obtaining Royal Perth Hospital 
Ethics Committee approval we began the research in September of 2002.  
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Conceptual framework 
The theoretical underpinning of the program was based on the assumptions that: 
adherence is a complex and dynamic behaviour fluctuating across the disease 
continuum for any individual; therefore interventions to improve adherence should be 
supported by a maintenance program and lastly; that evidence-based research should 
be embedded in clinical practice to facilitate maintenance and evaluation of feasible 
and effective programs of care. Because many of the bio-psychosocial factors 
impacting on adherence identified in the literature fell within the domain of nursing, 
social work, psychology and dietetics, a multi-disciplinary, multi-component approach 
to adherence care was undertaken (Figure 13). This approach appeared to be a good 
‘fit’ with the management of patients at that time. Our findings and recommendations 
are detailed in an article published in the Internal Medicine Journal in 2008 (Herrmann, 
McKinnon, John, Hyland et al., 2008) but preliminary findings were presented at 
national conferences in 2003-4 (Herrmann et al., 2003, 2004). 
Summary of original findings 
The original survey identified reasons for missing medication and these reasons can be 
seen as the antecedent contexts. We grouped these into four categories or contexts: 
‘forgot’, ‘circumstance’, ‘psychosocial’ and ‘regimen’ issues. These findings were 
similar to those seen in the French and US studies. We found that diminishing 
adherence correlated with younger age and substance use which could primarily be 
attributed to reasons of unplanned circumstance. Perceived stress and indicators of 
depression were particularly associated with missing medication for psychosocial and 
regimen related reasons. Ongoing monitoring of adherence was facilitated by the 
derivation of medication scores based on self-reported adherence at routine 
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consultations with the physician. This measure was found to correlate with viral 
suppression and restoration of CD4 T-cells and indicated an improvement in adherence 
over the period of observation. We later went on to examine the role of once daily 
dosing and side effects in medication adherence and conduct a review of substance 
use (Herrmann et al., 2008a, 2012) to further characterise our cohort. However, the 
limitations of the early studies and the audits that followed became evident with the 
passing of time, primarily because of newer treatments and the changing epidemiology 
of the epidemic as outlined in the introduction to this thesis. Of the 162 patients with 
complete data who participated in the first survey, 140 were men, 135 identified as 
Caucasian, six Aboriginal and 21 (unidentified), most were living in the metropolitan 
area and only 18 were listed with the Rural and Remote HIV service and travelled to 
attend the clinic. Transmission of HIV was primarily between men having sex with men 
(MSM, 106/140). Should the survey be repeated today the demographic would be 
quite different. So in summary, the survey reflected the WA epidemic in 2002 - 
Caucasian men who were infected by other men and living mainly in the metropolitan 
area. Therefore, arguably, findings of the earlier study cannot be fully generalised to 
the current demographic of the WA HIV Cohort although at the time the demographic 
was seen to be representational and the sampling method sound. Most notably, the 
cohort reflected a population with unfettered access to free antiretroviral drugs and a 
low proportion of people living and working in regional areas. 
The Critical Role of Antiretroviral Drug Access  
AIDS Activism Influenced Drug Access  
The HIV/AIDS epidemic has been characterised by civilian activism, so much so that 
biology and sociology are said to have converged and shaped the global epidemic 
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(Ford, Wilson, Chaves, Lotrovska & Kijtiwatchakul, 2007; Killen, 2008; Nguyen, Ako, 
Niamba, Sylla & Tiendrebeogo, 2007). The juxtaposition of drug discovery and 
advocacy for access to treatment created a momentum for change in the way 
experimental drugs are regulated. In the USA an alliance between the Food and Drug 
Administration (FDA), the Department of Health and Human Services (DHHS) and the 
Burroughs Wellcome Company resulted in an unprecedented access program known 
as ‘treatment IND’ which effectively accelerated access to zidovudine as a 
monotherapy for HIV. At the same time, social activists were demanding the inclusion 
of women, children and ethnic minorities who were generally considered to be under 
represented in clinical trials. This social activism encouraged by research ethicists gave 
impetus to the creation of the AIDS Clinical Trial Group (ACTG) in 1987, a national 
multicentre clinical trials network under the governance of the National Institute for 
Allergy and Infectious Diseases (NIAID) (Killen, 2008). Internationally, concern over 
limited access to ARVs spilled over in 2000 at the 13th International AIDS Conference in 
Durban, driven by: the clinical evidence that ART could prevent deaths from AIDS; and 
a law suit filed in 1998 brought by 41 pharmaceutical companies against the South 
African Government which sought to amend the Medicines Act to make medicines 
more available to its citizens ('t Hoen, 2009). Even up to five years after HAART became 
the standard of care in developed countries, less than 8,000 HIV infected people in Sub 
Saharan Africa received treatment due to the high cost of drugs under patent 
protection and, subsequently the difficulty accessing cheaper generic, bioequivalent 
alternatives, the first of which was made in India in 2001 (Satyanarayana & Srivastava, 
2010).  
Today a global network of scientists, civilians and activists, many of whom are affected 
by or infected with HIV underpins a drug development program that has seen, in the 
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last decade, the licensing of more than 30 antiretroviral drugs under patent, and 
around 30 generic formulations, produced mainly in India followed by Brazil and 
Thailand (Satyanarayana & Srivastava, 2010). Sovereign government and activist 
responses to the high cost of first-line ARVs, estimated to be >10,000 US dollars per 
patient per year in 2000 have resulted in falls in prices to 87 US dollars in 2010 
(Satyanarayana & Srivastava, 2010). However, the prices between countries vary 
significantly depending on the success of negotiations between governments and 
pharmaceutical companies and the complexity of other trade agreements between 
those countries ('t Hoen, 2009; Ford et al., 2007).  
Access to Medication: the Socio-Political Context and TRIPS 
India was able to become a major producer and exporter of generic drugs and their 
component substances because the Indian government did not introduce patent 
protection until 2005 (‘t Hoen, 2009), and had challenged the 1994 international trade 
agreement constructed by the World Trade Organisation (WTO). This mandated 
Governments who were signatory, to issue exclusive intellectual property rights to 
inventors of new technological products. The agreement was called: Agreement on 
Trade Related Aspects of Intellectual Property Rights (TRIPS) ('t Hoen, 2009). 
The TRIPS agreement mandates the lowest level of protection that each government 
has to give to the intellectual property of the other WTO members ('t Hoen, 2009). 
Prior to the agreement between the WTO and signatories to the agreement, medicines 
and food could be excluded from patenting however since the TRIPS Agreement all 
forms of technology including medicines, now defined as medical products, are 
included; and the life of patents or patent terms, were standardised to a time frame of 
usually 20 years ('t Hoen, 2009).  
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A basic premise behind patenting is that exclusive licenses offer incentives to 
individuals that foster innovation and the enhancement of the quality of human life 
(World Intellectual Property Organisation, 2010). An expectation of the TRIPS 
Agreement was that the higher levels of Intellectual Property (IP) protection afforded 
by patents would result in an exchange of Research and Development (R & D) with 
developing countries but this was not realised (The National Institute for Health Care 
Management Research and Educational Foundation (NIHCM), 2002). A second more 
immediate and unresolved issue was how to export products manufactured in one 
country, under a compulsory license to a country in need of the product but lacking 
the capacity to produce it themselves. These and other unresolved concerns led to the 
Fourth WTO Ministerial Conference held in Qatar (2001) which adopted the 
Declaration on TRIPS and Public Health, later known as the ‘Doha Declaration’, which 
affirmed the sovereign right of governments to protect public health. Therefore 
governments, who are WTO members, can legally make exception to patent licensing 
and also use a WTO dispute settlement system when intellectual property rights are 
contentious between members.  
One important component of the Doha Declaration was the enabling of TRIPS 
flexibilities which allowed the least developed countries to defer granting or enforcing 
pharmaceutical product patents up to 2016. This is significant because it then 
facilitated negotiation on prices between governments and pharmaceutical companies 
which resulted in huge price reductions. A later amendment which came to be known 
as the August 30th decision, was taken by the WTO in 2003 which established an export 
process between those countries manufacturing generics and those in need of them 
but with no domestic production capacity. Over 60 developing countries have 
exploited these so-called TRIPS flexibilities (‘t Hoen, 2009) with India the most 
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successful player (Satyanarayana & Srivastava, 2010). Although the administrative 
processes required to invoke the TRIPS waiver are a disincentive to its use, China, 
Canada, Norway and the European Union have all sought to access changes to TRIPS 
allowed by the August 30th decision to their advantage.  
Among the sovereign measures available to governments are the use of compulsory 
licensing and parallel importation. In her thesis on “The global politics of 
pharmaceutical monopoly power”, ‘t Hoen (2009, p. xvi) defines these succinctly: 
1. Compulsory licensing enables a ‘competent government authority’ to 
license the use of a patented invention to a third-party or government 
agency without the consent of the patent-holder against a payment of 
‘adequate remuneration’.  
2. Parallel imports are cross-border trade in a patented product, without the 
permission of the manufacturer or publisher. Parallel imports take place 
when there are significant price differences for the same good in different 
markets. 
Delivery of Antiretroviral Drugs to the People 
The mechanisms of delivery of drugs to individuals world-wide varies between 
countries who supply patented ART to citizens for a price, to those that offer free 
universal access to patented drugs for their citizens. Middle income countries such as 
India, Brazil and Thailand manufacture and supply generic drugs either under universal 
access schemes or via regional projects to their own citizens and those of other 
countries (Ford et al., 2007; Satyanarayana & Srivastava, 2010; ‘t hoen, Berger, Calmy 
& Moon, 2011). The Clinton Health Access Initiative and the President’s Emergency 
Plan for AIDS Relief (PEPFAR) began distributing ARVs in 2005 and by 2008 most of 
these were generic, purchased from India, at an estimated cost saving to the donors of 
64 
approximately 323 million USD (Figure 15) (C. B. Holmes et al., 2010; Waning, 
Diedrichsen & Moon, 2010). 
 
Figure 15: Countries with highest purchase volumes (donor funded) from India of generic ARVs: 
Tanzania, Nigeria, Ethiopia, Mozambique, Zambia, Namibia, Congo, Kenya, and Cameroon (Waning et 
al., 2010) 
The rights of non-citizens 
The right of access to ARVs for non-citizens varies between countries. The Netherlands, 
Belgium and Italy are among the few countries to offer free medical care, including 
ARVs, to all immigrants whether or not their status is legal (Elinav et al., 2012; C. B. 
Holmes et al., 2010; Pollard & Savulescu, 2004; Romero-Ortuno, 2004; Waning et al., 
2010). In the least developed countries access to usually generic drugs manufactured 
in India is via patchy philanthropic governance although in South Africa, arguably 
hardest hit by the epidemic, coverage is almost complete. But in many of the least 
developed countries ‘stock-outs’ are common, supply chains tenuous and, in regions 
like Papua New Guinea, inhospitable topography limits access to essential drugs (Ford 
et al., 2007; Satyanarayana & Srivastava, 2010; ‘t hoen et al., 2011). It is also the case 
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that people move within countries for largely economic reasons (internal migration) 
and in regions where coverage is patchy access to ARVs will be compromised by 
population mobility.  
The need for more antiretroviral drugs is pressing  
Although over 10 million people with HIV are currently identified as in need of 
treatment under the current guidelines for commencement of first-line ART, only 5 
million are receiving it, although this represents a more than twelve-fold increase in 
access in the last eight years and particular gains over the last three years (WHO et al., 
2010). By 2010, Rwanda, Botswana and Namibia achieved between 76 and 88% 
treatment coverage among adults. But another eleven countries (Cameroon, Côte 
d’Ivoire, Ghana, India, Indonesia, Mozambique, South Africa, Ukraine, United Republic 
of Tanzania, Viet Nam and Zimbabwe) reported treatment to less than 40% of people 
in need. Significantly for the Asia Pacific region, Indonesia, like the Ukraine reported 
that less than 20% of adults were receiving ART (UNAIDS, 2010). Furthermore, since 
worldwide ARV coverage reaches only about 10% of children eligible under treatment 
guidelines, there is a pressing need to develop suitable, affordable and accessible 
drugs (Satyanarayana & Srivastava, 2010). Importantly, access to second-line 
treatment is rare in low and middle income countries since these drugs are expensive 
and require supply chain management and complex clinical monitoring (Ford et al., 
2007). The World Health Organisation (World Health Organisation, 2005) estimates 
that in Thailand alone, second-line therapy for a quarter of all patients will take up 
three quarters of the budget, and the total budget for ART should prices remain at 
current levels, will arrive at 500 million USD per year by 2020 ('t Hoen, 2009; Ford et 
al., 2007). 
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India, the pharmacy of the modern world 
India continues a strong and independent stand rejecting patent applications (2009) 
for tenofovir, a commonly used (and often in co-formulation) first-line NRTI, and 
darunavir a PI. The governments of other countries who also reject licensing these 
drugs and therefore avoid patent infringement, are then able to import the generics 
from India (Reuters 2009). The cost of all four of the fixed-dose coformulated generic 
drugs approved as first-line regimens by the World Health Organisation in 2009 is 
cheaper purchased from India (Waning et al., 2010). The country has also succeeded in 
limiting the number of patents issued by establishing criteria that must be met before 
a patent licence is granted. For generic drugs released between 1995 and 2005 
licensing was automatic. However, authorisation for the production and export of 
generic drugs is a separate process for each new order and there is evidence that the 
sector is moving towards the export of generic ARVs that are already off patent to 
countries that are relatively affluent (‘t Hoen, 2009) because this is more fiscally 
attractive. In addition, since 2005, for each new drug, India is compelled under the 
TRIPS Agreement to subject these to 20 year patent terms ('t Hoen, 2009). According 
to Satyanarayana & Srivastava (2010) India’s capability is under threat and ‘t Hoen 
(2011) cites Oakeshott (2009) as stating fears of a ‘treatment timebomb’. 
The international community redoubles efforts 
UNITAID was established in 2006 and is closely associated with organisations such as 
the Clinton Health Access Initiative (CHAI). UNITAID supports existing efforts to achieve 
the some of the United Nations Millenium Development Goals by establishing a stable 
drug purchasing facility. Funded by a tax on airline tickets, UNITAID negotiates with 
large pharmaceutical companies to facilitate the reduction in costs by, in part, 
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supporting ‘tiered pricing’, which is based on using the average income per head – 
obviously less in developing countries (www.avert.org/generic.htm). Another 
international initiative established The Global Price Reporting Mechanism in 2005; this 
website provides regional and country specific information on ARV prices 
(http://www.who.int/hiv/amds/gprm/en/). Therefore, low income countries are 
assisted, in an administrative way, with ordering large shipments of largely donor 
funded or subsidised ARVs. 
However, currently the most viable mechanism to promote universal affordable access 
to ARVs is the Medicines Patent Pool. Supported by UNITAID, this scheme aims to 
improve access to patents by creating a repository that can be accessed to enable 
competitive generic manufacture in exchange for royalty payments to the original 
patent holders. It is thought that this strategy will facilitate the production of FDCs, 
which has been hampered by the complexities of patenting law, and paediatric 
formulations ('t Hoen, 2009; Satyanarayana & Srivastava, 2010). Importantly the 
scheme will support India in the production of affordable, generic second-line drugs 
(Oakeshott, 2009). 
In summary, although the Doha Declaration created an environment in which the least 
developed countries could manoeuvre within the TRIPS flexibilities, middle income 
countries in Latin America and Asia are under increasing pressure from pharmaceutical 
companies to comply rigidly because of their growing market potential as purchasers 
of medicines in general. Furthermore, the capacity of these countries to manufacture 
generic medicines and supply their own demands as well as that of Africa, and 
countries that lack manufacturing capability, is under threat. Improving access to ART 
will require addressing international regulatory issues, financial remuneration, 
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strengthening procurement and supply chains to prevent stock outs, and 
pharmacovigilance to ensure quality products ('t Hoen, 2009).  
Australia’s position with regard to the importation of drugs  
In Australia, the Therapeutic Goods Administration (TGA) is the body which regulates 
pharmaceutical goods and medical devices, including the importation of drugs for 
personal use under the Personal Import Scheme. People with HIV, ineligible for the 
universal health access scheme, Medicare, but needing anti-retroviral treatment can 
import generic medicines from overseas via internet vendors provided they have a 
script written by a doctor with authority to prescribe Section 100 pharmaceuticals. A 
Canadian-based company: AIDS Drugs Online www.aids-drugs-online.com is the 
recommended internet vendor listed on the NAPWA website. In theory ARVs can be 
purchased in Australia if a prescription is dispensed but only patented drugs are 
available and these are costly. The range of generic drugs available from internet 
vendors is limited to approximately 15 drugs including didanosine, stavudine and 
zidovudine, which are unlikely to be prescribed in Australia, and seven fixed-dose 
combinations. This is in contrast with the antiretroviral drugs available for prescription 
to Medicare eligible individuals which number over 25. The generic drugs available for 
legal import are usually older drugs manufactured in countries such as India that were 
able to evade the constraints of TRIPS until 2005. Although, stavudine (also known as 
d4T) was removed from the World Health Organisation’s guidelines for ART 2009 
because the evidence of its toxicity was unarguable, and replaced with tenofovir.  
People importing generic drugs via internet vendors can and do face logistical 
problems relating to delay of shipments and confiscation by customs in the absence of 
a prescription accompanying the package. Some medications can be received through 
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Australia Post but others use reliable couriers. Unfortunately and perhaps relating to 
the regulations surrounding the import and export of generic drugs, previously reliable 
providers may become unreliable, and access may be discontinued. Interruptions to 
treatment of this nature have been shown to result in virological rebound on NNRTI 
therapy (Parienti et al., 2008) and are associated with increased morbidity and 
mortality.  
In order to optimise treatment success and avoid treatment interruptions it is 
necessary for the HIV infected person to engage with continuous medical care. This 
requires a lifestyle commitment to attending medical centres, as well as accessing and 
accepting drug treatments available at a given location. This ability favours those in 
geographical proximity to treatment, and those with citizens’ rights. The ability of 
people who live in remote locations, lack citizens’ rights or lead a peripatetic lifestyle, 
to engage with HIV care, access and adhere to medication is compromised.  
Migration, Mobility and HIV 
Before the 20th Century, lack of legal and administrative restriction facilitated the 
movement of people across borders and, historically,  a migrant was someone who left 
one country and settled permanently in another (Williamson, 2006). Current migrants 
or mobile populations are made up of a number of subgroups, such as refugees and 
asylum seekers fleeing their countries because of civil strife or environmental 
catastrophe; temporary migrants such as guest workers (a term originally coined by 
the Germans – Gasterbeiter); or international students and complex groups of irregular 
or illegal migrants, including those who have arrived through smuggling or human 
trafficking. These groups are subject to differing national and international restrictions 
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upon their movements and their rights as non-citizens, including their access to health 
services.  
Therefore, the migration pattern of the ‘modern migrant’ may be something quite 
different from this idea of a person or family setting off from one country and settling 
in another and it is this ‘pattern’ that has wide ranging implications for health,  not 
only for the destination country but for the country of origin, and countries transited 
through to that destination (Gushulak & MacPherson, 2004).  
In many countries migrants, driven by economic hardship or aspirations for a better 
life, work legally and illegally receiving lower rates of pay. Arguably, societal 
protections in health are reduced for migrants. Non-citizens may lack the protections 
afforded to citizens, for example, in terms of workers compensation/union 
representation, and access to subsidised health care (Ahonen et al., 2007; Sousa et al., 
2010). The ‘migrant’ encapsulates health impacts from their country of origin, the 
travel phase or transitioning country and the country of destination. For example, the 
prevalence of endemic disease, access to and awareness of care as well as cultural 
attitudes to health and illness are likely to be different in another country (Bhopal & 
Rafnsson, 2012). A migrant carries attitudes and expectations to the destination 
country (Gushulak & MacPherson, 2004).  If one accepts this view then it follows that, 
in the case of HIV, people are going to bring their experience, knowledge and attitudes 
to HIV to a destination country; and that these will need to be identified and 
acknowledged in the health setting. Furthermore, Kesby et al, (2003, pp1588) assert 
the necessity of exploring, ‘discourses, practices and material conditions that create 
particular subject positions, structure the relationships between individuals and frame 
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the possible limits of decision-making within particular communities’. These authors 
refer to the need to understand the ‘social embeddedness’ of HIV in Africa.   
Forcible displacement in the example of refugees can impact on health in a number of 
ways. Refugees may be subject to irregular movement resulting in environmental 
exposures such as to extremes of weather; and exposure to coercion and violence such 
as rape. However, people can also find themselves ‘between’ countries which can 
affect their engagement with health care resulting in inadequate or absent 
vaccination, and for people with chronic illness dislocation from services can have a 
most detrimental effect (Gushulak & McPherson, 2004).  
The legal status, economic status, personal behaviour and cultural practices or beliefs 
of an individual and their family members on arrival, within the context of the host 
country’s social and environmental ecology, can also have a health impact (Ahonen, 
2007). In particular, the meaning attributed to certain illness, for example, in some 
cultures it is unacceptable to talk about death. This can make fraught communication 
between health care providers and their patients when talking about cancers, for 
example. HIV is associated with behaviours that are taboo in some cultures and this 
may make people feel deeply ashamed and reluctant to seek help if they suspect they 
are ill. That this is the case has been demonstrated in studies that show fear prevents 
people, especially people of migrant status, seeking help (Burns et al., 2007; Adler et 
al., 2009). It is a challenge for migrants of all categories to ‘read’ the culture of the 
destination or ‘guest’ country. Finally, return travel can have consequences for health 
of migrants, particularly when situations have grown worse in the country of origin and 
when, for example, children born in the guest country are taken to a place where their 
immunity leaves them vulnerable to diseases (Gushulak & McPherson, 2004). 
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Migrant groups tend to have a higher labour participation and, importantly, migrations 
tend to self select young adults as it is they who may stand to gain most from 
migration (Williamson, 2006).  Economic migrants in their young to middle years, often 
fall into the age group where HIV is most prevalent.  
Foreign workers tend to be stigmatised because it may be perceived that they displace 
a local workers. As a group, migrant workers are fearful of antagonising the local 
population and drawing negative attention to themselves. The idea of foreigners 
introducing contagion has been used to vilify immigrants in the past. As such HIV 
would increase the likelihood of stigmatisation especially for people working illegally 
(Ahonen et al., 2007; J. Anderson, 2008; Bhopal & Rafnsson 2012).  
In 2010 the United Nations Development Programme (UNDP) published jointly with 
the Secretariat of the Pacific Community, a report which provided an assessment of 
migration and mobility as key drivers of the distribution and spread of HIV in the 
Pacific. The authors of the report note that in the Pacific region appropriate 
interventional responses to address the vulnerabilities created by population mobility 
have yet to be developed. The report specifically recognises workers engaged in 
‘circular migration’, which as the expression suggests, are those people who return at 
some stage to their country of origin. These people are commonly working in mining 
and construction, transport, plantations, the military and seafaring occupations 
(Connell & Negin, 2010).  
While populous countries like China (Scheineson, 2009) have large numbers of internal 
migrants, most of whom leave their homes to find work elsewhere in the country, it is 
estimated that there are over 200 million international migrants. These migrants could 
constitute the world’s fifth most populous country. An International Labour 
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Organisation Report in 2004 (Gushulak & MacPherson, 2006) estimated that there 
were 90 million people working outside their country of origin. Historically, labour 
migration rates were higher than population migration rates and were driven, 
typically, by young adult males (Williamson, 2006). Current access to international 
travel opportunities supports population exchanges, and the number of international 
journeys in 2004 exceeded 760 million. However, in the present day, legal, 
administrative and health requirements shape migration and, significantly, people with 
HIV may be subject to the HIV-related restrictions on entry, stay, and residence of a 
large number of countries (Figure 16). In fact, 52 countries, territories and areas 
impose some sort of restriction on the entry, stay and residence of people living with 
HIV based on their serostatus, including Australia, despite evidence to suggest that 
restrictions do not protect public health (UNAIDS, 2008). While 124 countries have no 
specific restrictions, 22 deport individuals once their HIV positive serostatus is 
discovered (UNAIDS, 2010).  
 
Figure 16: Countries, territories that have some form of HIV-related restriction on entry, stay or 
residence, retrieved from “Mapping progress towards universal access” (UNAIDS, 2010). 
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Immigration and HIV in Australia  
In 1985 The Human Rights Commission reviewed the Migration Act of 1958 (Cth). In 
their report they stated that permitting ‘same sex’ migration, i.e. the permanent entry 
into Australia of an interdependent couple of the same gender, was likely to increase 
the threat of AIDS. In 1989 the Australian Government introduced the requirement 
that all applicants for permanent residency aged 15 years and over be screened for HIV 
infection (Department of Immigration & Citizenship, 2010c, cited by Szaraz, 2005). At 
the time of writing, successful immigration is contingent on satisfying the Health 
Requirement (Department of Immigration & Citizenship, 2010b) under the Schedule 4 
of the Migration Regulations 1994 (Cth). This involves a series of health tests and an 
assessment of the likely implications of those results for current Australian health 
standards. The Australian Government, through a decision maker in the Department of 
Immigration and Citizenship, who takes advice from the Medical Officer of the 
Commonwealth (MOC) (Department of Immigration & Citizenship, 2008), assesses 
whether the applicant satisfies the Requirement and can waive the Requirement at 
their discretion. Between 2007 and 2009, 205,940 permanent resident visas were 
issued; and 1532 temporary visa applications were refused on health grounds. A 
subset of these (244 applications for the waiver), were refused on the basis of undue 
expense to the Australian economy, and people with HIV were the most highly 
represented in this subset, according to the National Association of People Living with 
HIV/AIDS (NAPWA) (2009). Although 59 people with HIV infection were granted 
waivers of the Requirement in the financial year 2009-10 (Australian Immigration 
News, 2010) this was thought to be because of the intrinsic value of their skills 
category. Should a visa application be refused by the Department of Immigration and 
Citizenship (DIAC), the Migration Review Tribunal (MRT), can be accessed to consider 
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new evidence in support of an application to stay in Australia but time limits apply and 
these are purportedly inflexible (Turner Coulson Immigration Lawyers, 2011).  
The primary health condition of concern to the Australian Government is tuberculosis, 
recognised by the World Health Organisation as a global public health issue (DIAC, 
2010a, 2010b, 2010c, 2010d) in contrast to HIV/AIDS, which is not considered to be a 
public health risk of the same order. In theory, applicants (with HIV infection) for 
permanent entry are considered for assessment on the same basis as others with pre-
existing conditions, as it is the economic cost of the ‘condition’, in terms of public 
expenditure, which is of overriding concern to the government. This consideration of 
cost is also extended to the ‘availability’ of health services so that no Australian citizen 
or permanent resident is displaced or prejudiced by a non-resident and is widely 
inclusive of clinical and community services (DIAC, 2008). Examples of this might be 
access to surgery and radiotherapy for cancer treatment. The term condition is also 
broad, extending itself to physical, mental and health ailments, intellectual disabilities 
and blood-borne infections such as hepatitis B, C and HIV (Szaraz, 2005). Significant 
cost is defined as 50% above the average per capita health care and community 
services cost for Australians over a five year period (DIAC, 2008). A person is assessed 
against these criteria, regardless of their ability to pay for these services and regardless 
of whether they will access them in any case. Someone with HIV, at minimum, would 
access health care for monitoring of immune status, specifically CD4 T-cell count and 
detection of virus, and review of any efficacy and toxicity related to antiretroviral drug 
treatment. The current assessment policy however, includes a ‘lifetime’ estimate of 
medicines, hospitalisations and end-of-life care. This is currently estimated at 
$240,000. Therefore, people with HIV applying for residency cannot meet the 
Requirement and rely on the award of the Health Waiver. This option is open to: 
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partners, fiancé(e)s, including same-sex and de facto relationships; dependent children 
of an Australian Permanent Resident; refugee and humanitarian visas granted 
overseas; and temporary humanitarian stays. But it is not open to student visa holders 
(Forbes & Godwin, 2011). 
Australian HIV/AIDS Organisations Action on Behalf of Immigrants with HIV 
The National Association of People Living with HIV/AIDS is the peak body representing 
organisations of HIV positive people in Australia. Along with partner organisations such 
as the Australian Federation of AIDS Organisations (AFAO) and the National Ethnic 
Disability Alliance (NEDA), NAPWA submitted their viewpoint and recommendations 
(National Association of People Living With HIV/AIDS (NAPWA), 2009) to the Joint 
Standing Committee on Migration Inquiry into Immigration Treatment of Disability in 
October 2009. Among their recommendations were the following: 
1. The Health Requirement should be removed for diseases or conditions that do 
not present as a serious public health threat 
2. Generic estimates of cost should not be used as a basis for assessments 
3. Costs should be relevant to the applicant 
4. For those seeking visas on humanitarian grounds – applications should not be 
denied on the basis of failing a health test 
Major stressors have been identified in those seeking permanent residency in 
Australia, some of which are in common with the migrant experience in general: 
 The uncertainty of successful migration: uncertainty concerning legal status, 
threat of deportation, financial uncertainty, and language proficiency  
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And these intersect with HIV specific factors: 
 The immediate effects on health, treatment success, implications for the future, 
stigma within communities and stigma from the host population  
The influence of the health environment of country of origin can compound these 
uncertainties since in the experience of many CALD communities, HIV is highly 
stigmatized and presently, without treatment, a terminal infection (Körner, 2005). 
More recently the experience of African-born Australian residents living with HIV in 
Victoria has been described, including their experiences of migration HIV screening. 
Most found the migration screening ‘coercive’ and a major barrier to accessing 
information, as was concern about the stigma attached to HIV from within African 
communities (Lemoh, 2010a; Lemoh, et al.,2010b).  
Applications for Temporary Visas for Work or Study 
Visa application is a universal condition of entry to Australia for work, study or holiday 
and there are currently over 100 different categories which carry varying entitlements 
to health, social services and the right to access employment (DIAC, 2010g). When 
there is a demand for skilled workers that cannot be met by Australian residents, 
employers recruit workers from overseas often through third party agencies. The most 
commonly used program to sponsor overseas workers to fill skilled positions on a 
temporary basis is the Subclass 457 Visa or more formally, the Temporary Business 
Long Stay Subclass 457 Visa (DIAC, 2010g). This visa allows the successful, business-
sponsored applicant to live and work—with or without their immediate family— in 
Australia for up to four years. After two years an employer can nominate the recipient 
for permanent residency. For lower skilled positions in regional areas, special 
conditions can be accessed by employers to meet the demand for labour. 
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Current statistics on temporary entrants 
In December 2010 there were just over one million temporary entrants in Australia 
including tourists and those on business, and these numbers were swelled by over 
500,000 New Zealanders. There were nearly 300,000 students, while slightly less than 
that number were temporary residents of which just over 100,000 were 457 visa 
holders. Of the 457 visa holders 11, 037 (10%) were from sub-Saharan Africa and 3000 
(30%) were in Western Australia. The guest workers typically support the resource 
industry labour market which is largely structured around fly in fly out or drive in drive 
out workers. Of the just over 20,000 (21 078) category 457 visa holders working in WA 
at the end of 2010, around 5000 worked in the mining, construction and 
manufacturing industries in comparison with the other states where most of the 
business visa entrants were working in the health sector. In 2009, of all states after 
New South Wales, WA had the highest number of 457 visa holders (Department of 
Immigration and Citizenship, 2010d). 
Health cover for temporary visa holders 
Unlike refugees and asylum seekers, applicants for temporary visas are required to 
take out private health insurance since they are not eligible to access the Medicare 
system or drugs listed on the Pharmaceutical Benefits Scheme (PBS), in contrast with 
applicants for permanent residency who may be awarded interim access. Indeed, an 
important and obvious issue for 457 visa holders and for those on student visas 
(Subclass 572, 573,574) is lack of Medicare cover which is universal for Australian and 
New Zealand citizens and residents of countries that have reciprocal health care 
agreements with the Australian Government, specifically those from the United 
Kingdom, Sweden, Finland, Norway, the Netherlands and Malta (Department of 
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Immigration & Citizenship). Employers of temporary workers can offer to take 
responsibility for their employees’ health costs but this is at the employer’s discretion. 
Furthermore it is the conditions attached to a particular visa which will determine the 
DIAC assessments of application for waiver of the Health Requirement and, in the case 
of 457 applications, the employer must sign to undertake responsibility for health 
costs should the waiver be granted. With regard to worker’s compensation, subclass 
457 visa holders are subject to the same legislation and obligations and therefore 
protection, as all other employees of Australian employers operating in Australian 
workplaces. However, if a visa holder is sponsored offshore or the employer company 
is based in another country, it is very difficult for regulatory bodies such as 
Occupational Health and Safety to follow up on breaches of the legislation, making 
workers vulnerable in the case of work place injury (DIAC, 457 Integrity Review, 2008).  
Temporary Visa Holders and HIV in Australia  
Unlike people seeking permanent entry to Australia, including migrants, refugees or 
asylum seekers from those same regions, it is not a condition of 457 visa or student 
visa access to be screened for HIV infection unless the intention is to work or study as 
a doctor, dentist, nurse or paramedic (Department of Immigration and Citizenship, 
2010b, 2010d), and this clause includes pregnant women. In effect, health checks for 
those seeking a temporary visa depend on the type of employment, prevalence of TB 
in country of origin and length of stay in Australia. However, if a student is found to be 
HIV seropositive there is no Health Waiver that can be applied to that visa category 
under the Migration Regulations 1994 (Cth).  
In Australia, people with HIV from CALD Communities; including new migrants, 
refugees and those on temporary visas, face issues that may dramatically impact on 
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their well-being. In 2003, 30% of new notifications were in people born in non-English 
speaking countries; and many of these were late presentations (Körner et al., 2005, 
Körner 2007b). These data are similar to those observed in other settings 
internationally (Burns & Fenton, 2006; Burns, 2001; Burns et al., 2007; Fakoya, 
Reynolds, Caswell & Shiripinda, 2008; Staehelin et al., 2003); and were later supported 
by Lemoh’s observations (2010), again in Australia. Of concern is the disparate level of 
knowledge about HIV/AIDS among populations living in WA in whom HIV prevalence is 
comparatively higher than the background population (Drummond, et al., 2008).  
Summary 
In Western Australia there has been an increase in notifications of HIV acquired in 
countries with a high prevalence of the infection, against the national trends, and 
these cases are distributed across regional WA. There is also an increase in citizens 
living and or working in rural areas where access to treatment and HIV services may be 
challenged by distance and lack of familiarity with health care services. Testing for HIV 
in those applying for work or student visas is not current practice and diagnosis is often 
made when an application for residency status is lodged. This means that there may be 
a burden of undiagnosed HIV infection in visa holders working or studying in WA. 
Compounding this may be low levels of knowledge about HIV transmission and 
treatment, and as yet unknown health beliefs that may impact significantly on how 
people access and respond to medical care. Stigma associated with the disease 
impacts on health-related quality of life for people with HIV universally, and may be 
particularly difficult for people living in rural areas, complicating the process for non-
citizens. Access to appropriate antiretroviral drugs is compromised since temporary 
visa holders are not eligible for Medicare and private health insurance does not cover 
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costs of ART. The influence that this has on medication adherence and persistence and 
resultant clinical outcomes is not known. Finally, the experience in other countries 
indicates that care is more complex in migrants however, whether this is the case in 
temporary visa holders with HIV in the WA health system has yet to be established. 
Migration is an outstanding feature of human history and evolution and has been 
recorded since the biblical era. People and populations now move further and more 
rapidly than ever before between and within countries. This movement has 
implications for the spread of infectious diseases. HIV prevalence rates are higher in 
immigrant populations and even higher in ‘internal’ migrants moving from one region 
to another (Soskolne & Shtarkshall, 2002). Australian studies of rural resident and 
immigrant populations with HIV infection are limited, despite the topical subjects of 
immigration and workforce mobility. To date, there is no published study that has 
focused on the impact of HIV on people whose access to care and treatment may be 
compromised by lack of citizens’ rights and/or distance from HIV services, in Western 
Australia. This work will address these gaps in the literature and contribute to an 
understanding of these issues from the personal perspectives of individuals who find 
themselves, by virtue of circumstance, in such situations.  
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CHAPTER TWO METHODS 
Activities only make sense when you know what they are a response to, what 
phenomena provide inputs and necessary conditions for the thing you want to 
understand.  
(Becker, 1998, p. 44) 
Introduction 
The primary methodological approach to achieving the aims of this thesis is qualitative 
and I have chosen ethnography as a theoretical framework. In this chapter I will justify 
that choice, consider the ethical issues that arise from the research, and detail the 
qualitative, quantitative, clinical audit and biological methods that were employed. 
This section will also include a description of the research setting and will draw on 
background given by key informants. Since the study was conducted primarily at the 
Royal Perth Hospital, the description of the setting is focused on that hospital and the 
services of other teaching hospitals are not detailed. 
The specific methods, and study design used to frame and gather the data on health-
related quality of life in the WA HIV Cohort in Chapter Three are presented in a journal 
format within the chapter as they were prepared for submission. My contribution is 
detailed at the beginning of this thesis. Chapter Three provides an explanatory rather 
than a predictive approach to understanding the relationship between HRQL and 
physical, social and psychological distress in this particular context. The data set the 
scene and provide a real and relevant setting for the subsequent observations 
concerning people living or working in rural areas; and those people whose visa status 
complicates their experience of HIV in Western Australia.   The detailed methodology 
of the larger international study was published in two manuscripts early in 2012 and 
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these manuscripts (which I co-authored) are included as appendices to this thesis. 
Findings of the international study relevant to the background of this thesis are 
outlined in the literature review, although it was the preliminary data gathered in 
2007-2008, and the preceding adherence studies, which gave direction to the 
contemporary studies in rural living and temporary visa holders.  
Methodological Considerations 
Qualitative Research 
Qualitative research is a scientific approach that uses observation, interviews and 
verbal exchanges as methods to gather in depth information to describe and explain 
complex social issues (Sankar, Golin, Simoni, Luborsky & Pearson, 2006). Qualitative 
methods such as phenomenology and grounded theory have been employed usefully 
to describe sexual practices, reveal cognitive representations of illness behaviour in 
HIV/AIDS, and illuminate adherence behaviour generally and in the context of 
uncertainty of attribution related to treatment side effects and illness ideology 
(Anderson & Spencer, 2002; Crane et al., 2006; Lewis, Colbert, Erlen, & Meyers, 2006; 
Sankar et al., 2006; Sidat et al., 2007; Vervoort, Borleffs, Hoepelman & Grypdonck,  
2007; H. S. Wilson, Hutchinson & Holzemer, 2002). Although the value of early 
quantitative research, including survey methods, into HIV medication adherence is not 
disputed, without qualitative research in the field, a limited understanding of the 
behaviour would have resulted in potentially ineffective interventions. For example, 
the research of Hill and her colleagues (2003) who, not long after the use of HAART 
became widespread in regions with access to the drugs, interviewed 78 PLWH and 
identified nine distinct, non-exclusive and unstable patterns of adherence which, 
respondents reported, had different causes and consequences.  This study offered rich 
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behavioural description which assisted practitioners to develop interventions to 
improve medication adherence behaviour. Later Beusterien, Davis, Flood, Howard and 
Jordan (2008) developed a conceptual framework for adherence based on data from 
focus groups using qualitative methods that could be translated, feasibly, into clinical 
practice. Qualitative research can allow the study of people in their social milieu, and 
some qualitative enquiries are in themselves interventions, for example the method of 
cooperative inquiry whereby participants develop and explicate the investigation and 
formulate agreed interventions as part of the process (Heron, 1996). 
Ethnography  
Ethnography has been defined most simply as ‘a holistic approach to the study of 
cultural systems’ (Whitehead, 2004), but Bruce Berg (2009) notes that the opinions of 
social scientists vary with regard to how it is both conceptualised and applied.  Most 
however, seem to agree that it is an approach to research that is especially concerned 
with description and with research questions that demand explanation and prediction 
(Miles & Huberman, 1994). While not synonymous with qualitative research (Troman 
et al., 2006), it can involve both quantitative and qualitative research methods. More 
than a method, ethnography has epistemological and ontological properties 
(Whitehead, 2004). The focus of ethnography is on the description of the local 
particularities and the individual’s perspective and interpretations of their world (Miles 
& Huberman, 1995) including socio‑cultural contexts, processes, and meanings within 
those contexts and cultural systems (Whitehead, 2004). Ethnography can be the study 
of an intact social group or an individual or individuals within the group. In 1987 
Wolcott wrote that extensive reference to cultural groups and culture help 
differentiate ethnography from other qualitative research (Wolcott, 1987). However, 
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the use of ethnography as a theoretical perspective in the study of culture in health 
systems is more recent. As Long, Hunter and van der Geest (2008, p. 71) wrote in the 
journal Anthropology and Medicine: “It was not until post-colonialism moved the 
anthropological focus from the exotic of the Other to shine a light on the exotic of the 
Self that hospitals became of interest to anthropologists.” 
Despite the acknowledged contribution of qualitative methods in behavioural research 
it is argued that qualitative methods to date have been under utilised in the field of 
medication adherence in HIV (Sankar et al., 2006), and that ethnography, in particular, 
offers a valid and useful research approach to the field, being especially concerned 
with description and in questions that demand explanation and prediction (Beebe, 
2001). Observations by ethnographers of the physical and social environments of 
intravenous drug users have assisted with understanding the epidemiology of AIDS and 
designing interventions (Sankar et al., 2006), and are considered to be well fitted to 
research in a clinic setting as well as in the community. Ethnographic studies in sub-
Saharan Africa explicating patient perspectives have also been reported (Merten et al., 
2010; Mitchell, Kelly, Potgieter & Moon, 2009; Nachega et al., 2006; Nguyen et al., 
2007; Penn, Watermeyer & Evans, 2011), and ethnographic principles incorporated 
into patient-based cross cultural curriculum frameworks to educate health 
practitioners (Carrillo, Green & Betancourt, 1999). 
Ethnography arose from social anthropology at a time when communities were 
studied with the aim of exploring shared (within those communities) cultural beliefs 
and practices, which were often presumed static. Shifts in attitude away from the idea 
of ethnographers as neutral observers and the notion of social coherence as a 
dominant feature of cultures, has led ethnography to become a powerful research 
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approach incorporating a range of methods and an explicit acknowledgement of the 
role and influence of the ethnographer as data gatherer in the fabric of the research 
outcome (Savage, 2000). Therefore, within ethnography is the explicit recognition of 
the potentially positive and negative interaction that an ethnographer can have within 
the setting.  In effect, ethnography is currently viewed as a constructivist 
epistemology, in that meaning is constructed from the outcomes of interactions 
between, and within individuals and their environments (Whitehead, 2004). Another 
key aspect of ethnographic research which emerged in the 1970s, is the concept of the 
researcher as participant observer rather than an ‘observer of participants’ (Tedlock, 
1991). In effect, the researcher is both participant and observer, although Gitte Wind 
(2008) proposes that ‘negotiated interactive observation’ may be a more appropriate 
way to describe ethnographic fieldwork that is conducted in hospital settings. 
Notwithstanding, the influence of the ethnographer in the fabric of the research 
outcome is aligned with the idea that the researcher is a primary research instrument 
and such an instrument is generally calibrated to avoid or account for bias in a 
scientific study. Accordingly, the practice of including field notes becomes an essential 
part of the study methodology.  
Relevant features of ethnography include the consideration and involvement of 
information from key informants.  Geoffrey Walford (2009) cites (Bryman, 2002) to 
explain further features: the interaction of the researcher with the participants and 
with the environment in which the research takes place; the high value assigned to the 
participants’ verbatim concerning the meanings and attributions that arise within 
discourse; and the consequent internal validity of the study. In this study I have applied 
the concepts expounded by Becker (1998, p. 44) so that rather than viewing 
participants as analytic units that are fixed entities immune to context and situational 
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variations, I have posited adherence behaviour as an activity within the illness 
experience. Accordingly, I have focused the analysis on the circumstances in which the 
participants found themselves with their attendant and critical antecedents and 
connections such as access to medication, citizen status and psychosocial aspects of 
HIV infection that may influence health outcomes. In concordance with that stance, I 
also hold the understanding that culture is a constantly shifting and multifaceted 
construct with many attributes (Sands, Bourjolly & Roer-Strier, 2007). 
Methodological issues arising from concepts of ethnicity and race  
A culture that arises from shared activities and a sense of identity or belonging to a 
common origin in language, religion, race and or ancestry, underpins the concept of 
ethnicity, however, Ragin & Hein (1993, p. 255) remind us that: 
...ethnicity is profoundly contextual (it takes many forms, depending on 
associated conditions) and deeply interactive (it is closely entwined with 
political and economic institutions, events, and processes). 
In contrast Howard Becker (1998, p. 2) cites his teacher and mentor Everett Hughes 
(1971, 1984, p. 153-4) as stating: 
An ethnic group is not one because of the degree of measurable or observable 
difference from other groups; it is an ethnic group, on the contrary, because the 
people in and the people out of it know that it is one; because both the ins and 
the outs talk, feel, and act as if it were a separate group.  
As is often the case literature can illuminate ideas. A character in Teju Cole’s recent 
novel ‘Open City’ (2011, p. 118) says (of communitarianism): 
White is a race, he said, black is a race, but Spanish is a language. Christianity is 
a religion, Islam is a religion, but Jewishness is an ethnicity. It makes no sense. 
Sunni is a religion, Shiite is a religion, Kurd is a tribe, you see?  
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The terms race and ethnicity are often used interchangeably and although intertwined, 
race is sometimes viewed as a variant of culture. But ethnicity tends to be socially 
situated (Ragin & Hein 1993) and race, biologically or ancestrally (Salzman & Rice, 
2011). Both are relevant in the context of HIV disease since HIV is a biological 
condition, socially situated, and influenced by host genetic factors. Stanfield and 
Dennis (1993) assert that data collected in ethnographic research, and pertaining to 
race and ethnicity, are often presumptive and confounded by a priori ideological and 
cultural biases. Furthermore, it has been argued that racial and ethnic issues in the 
social sciences are embedded in societal folk beliefs and can impede or confound 
research studies, particularly qualitative, which rely on the researcher as the data 
collection instrument. As a researcher, I acknowledge the potential influence of social 
and cultural stereotypes of ethnicity and race derived from historical influences and 
my own personal experience as confounding biases in this research.  
If ethnicity is accepted as deeply contextual and interactive, the methodological 
consequences are considerable. It then becomes illogical (because it weakens the 
research design) to group and compare cases based on race or ethnicity which it 
follows could then be used, erroneously, to predict or assign those constructs. 
Therefore, I sought to overcome this by focusing on the circumstances in which the 
participants found themselves; and by describing commonalities; highlighting points of 
difference; and setting the limits on generalisations that could be made.  
Another issue for the social scientist is that discourse is constrained by the 
conservative style imposed by the discipline. Stanfield and Dennis (1993) argue that 
some of the most compelling and influential accounts of issues arising from the 
concept of race can be found in the field of literature. I sought to overcome this 
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methodological challenge by using qualitative methods to facilitate the participants’ 
voices while I grappled with data validity and reliability, or credibility and dependability 
respectively; and by (Bloomberg & Volpe, 2008; Stanfield & Dennis, 1993) using a 
combination of research methods to achieve data triangulation. 
Notwithstanding the preceding comments, a cultural competency framework was 
referenced to query the participants’ social context, socio-cultural beliefs and 
behaviours. This method of questioning was developed to assist physicians to avoid 
socio-cultural stereotyping and improve their ability to understand, communicate and 
deliver clinical care to patients from diverse backgrounds. This is in contrast to learning 
presumed cultural characteristics of certain ethnic groups (Carrillo et al. 1999). 
However, in a research setting it should be recognised that the researcher’s questions 
are often responses to observations made in the field, and by the participants, so that 
the construction of meaning arises from both etic and emic sources. To explain this 
further, emic understanding is based on the categories local people use for 
compartmentalising their reality and identifying the terms that they use for these 
categories—an insider perspective. Etic understanding, however, is based on the 
categories used by the researchers or outsiders to divide up perceived reality, in effect 
an outsider perspective (Beebe, 2001).  
Research Problem, Purpose and Aims 
Research problem 
People with HIV residing in WA on temporary visa status or living and /or working in 
rural areas face issues that may dramatically impact on their experience of living with 
HIV and managing the condition at a number of biopsychosocial levels, including 
health-related quality of life. Temporary visa holders are not eligible for Medicare or 
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drugs listed on the PBS and must import generic treatments from internet vendors at 
commercial rates. In addition, evidence in migrants and people living in rural 
environments suggests that these groups are heavily affected by the stigma 
surrounding HIV/AIDS at a structural and personal level.  
Research purpose 
The purpose of this research is to describe (1) the experience of managing HIV in a 
rural or remote environment; (2) the impact of HIV in people on temporary visas; and 
(3) the outcome of ARV treatment for those individuals. Specific topics of access and 
adherence to ART are given prominence; the research positioned in the context of 
current service delivery and health provider perspective; and referenced to a study of 
health-related quality of life in PLWH carried out in the WAHCS in 2007-2008. 
Research goal 
I hope that this research will achieve a greater understanding of factors that are 
impacting and potentially disadvantaging PLWH in Western Australia, from their 
perspective, particularly those factors that are unjust or unfair, and that will lead to 
appropriately targeted interventions. A secondary objective is to delineate pathways of 
therapeutic care, again from a patient perspective, and contribute this information to 
an evidence based practice framework.  
Research questions 
1. What factors influence HIV health outcomes in the current Western Australian 
epidemic and in terms of barriers and facilitators to clinical care and treatment? 
2. Do visa status, or rural remote living/working status influence access and uptake 
of antiretroviral drugs and clinical outcomes of treatment? 
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The Research Setting: HIV Services in Western Australia 
Funding 
Under the National HIV/AIDS strategy there is dedicated funding for the provision of 
services for HIV prevention, education and clinical services. Since 1996, funding for 
HIV/AIDS has been State and Territory specific under the Public Health Outcomes 
Funding Agreements, and because the Commonwealth government enters into 
individual negotiations, service provision between states varies. Although patients with 
HIV in Australia can choose to have their HIV care managed in a variety of health care 
facilities, including public or private hospitals, a sexual health clinic, or at a private HIV 
S100 prescribing GP practice, opportunities are limited, since most services developed 
became HIV-specific. In Western Australia, these are primarily public hospital-based 
funded by the WA Health Department.  
Non-Government sector services: The West Australian AIDS Council 
The Western Australian AIDS Council (WAAC) is a community based, not-for-profit 
organisation incorporated in 1985 in response to the HIV/AIDS epidemic in WA. The 
primary objectives of the organisation are (1) the prevention of HIV, and education of 
people at risk of acquiring HIV; and (2) the provision of care and support to people 
living with HIV. The Council receives State, Federal and Local government funding as 
well as sponsorship from local non-government organisations like Lotterywest and 
Healthway.  
The WA HIV Cohort Study 
The WA HIV Cohort Study (WAHCS) was established in 1983 (Mallal, 1998) as a long-
term clinical observational study of HIV infected people in Western Australia. The 
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majority of HIV infected individuals in WA, approximately 80%, receive specialist care 
from a team of immunologists and infectious disease physicians at RPH. The service 
incorporates a Rural and Remote HIV Program delivering outreach care state-wide. A 
similar service model operates from Fremantle Hospital with approximately 120 
outpatients and at Sir Charles Gairdner Hospital with 20-30. The remaining patients are 
followed up by GPs qualified to prescribe S100 antiretroviral drugs. At RPH 
comprehensive demographic, clinical and laboratory data are collected at the patient’s 
first presentation, and updated at subsequent physician reviews. Laboratory results 
are downloaded and linked with treatment and other relevant patient information 
(adherence, nicotine use, weight, blood pressure). This information is entered into a 
database after the patients’ clinic visits and contributes to individualised patient 
management plans. Patient support nurses, a social worker, clinical psychologist and 
dietitian as well as immunologists, infectious disease and sexual health physicians, 
provide a multidisciplinary HIV service to PLWH attending Royal Perth Hospital.  
At the time of writing approximately 10% of patients in the WA HIV Cohort held 
temporary visas and were ineligible to receive Medicare and access the PBS. This 
represents a steady increase in number since 2002 (Combs & Giele, 2009). An audit in 
May 2011 reported that 48% of the patients ineligible for Medicare were 457 visa 
holders (30 primary applicants, 10 spouses), the majority from Eastern Africa and 
employed in the mining industry. Another 20% were spouses of Australian residents, 
primarily women from South-East Asia who are progressing through application for 
permanent residency; a further 16% were student visa holders. Most patients were 
based in the metropolitan area and 32% lived in the regions. Many were diagnosed 
during health screening for continuation of visas and applications for residency 
(Williams, L. K., Foley & Cain, 2011).  
96 
Shifts in epidemiology have influenced clinic core activities  
According to the anecdotal narratives of staff working in the clinic, an increased and 
varied workload has arisen as a consequence of this emergent epidemiological pattern. 
Temporary visa holders seek ongoing education, counselling and support from medical 
and allied health staff. First, they seek to alleviate their distress around the diagnosis 
of HIV since, in addition to the fear of illness and death experienced by many people 
diagnosed with HIV, visa holders are concerned that they will be deported. Secondly, 
there is fear that employment may be terminated; and thirdly, there is concern about 
preventing HIV status being disclosed to extended families or local communities. 
Following this phase further assistance is sought as medical personnel are called upon 
to support and provide documentation for visa applications and continuations. In 
addition to pre-treatment medication education provided routinely to all patients, 
nurses teach Medicare ineligible patients how to procure generic antiretroviral drugs 
using links to vendors of generic drugs on the internet. They also prepare letters 
seeking compassionate access to largely unaffordable patented medicines until generic 
supplies are established; or when generic ARVs are unsuitable for a particular patient 
because of resistance or hypersensitivity. Staff also note that since temporary visa 
holders tend not to access the WA AIDS Council which traditionally offers education, 
low cost counselling and support to HIV positive individuals, as will be demonstrated in 
this study, this role is borne largely by the outpatient service. Furthermore, people 
with temporary visas, (particularly category 457) are often likely to be living or working 
in rural areas and distance can potentially increase the complexity of their care. The 
perceived need for confidentiality of those working in the mining and health sectors 
may further complicate health service delivery.  
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Section 100 pharmaceutical prescribing authority 
This centralisation of HIV care in Western Australia has been shaped by the way 
antiretroviral drugs are classified or scheduled by the Pharmaceutical Benefits Scheme 
(PBS) as Section 100 (S100) pharmaceuticals. This scheduling means that medical 
practitioners must receive training and accreditation through the Australasian Society 
of HIV Medicine in order to become prescribers of ARVs. Since there are currently only 
two S100 prescribers aside from the Perth Teaching Hospital HIV Physicians and both 
are Perth based GPs, there are no physicians certified to prescribe ART outside the 
metropolitan area. To compound the difficulties, ART is only dispensed by pharmacies 
at Royal Perth and Fremantle Hospitals. This is in stark contrast to the other Australian 
states where, in 2009, New South Wales listed 103 prescribers; Victoria 36; 
Queensland 25; South Australia 20. WA was more akin to the Northern Territory (3); 
and Tasmania with just one authorised prescriber (McLean & Savage, 2009a).  
Services to PLWH in Regional Western Australia 
The Western Australian Rural and Remote HIV Program at RPH was established in 1998 
in response to the increase in number of HIV infected people living and/or working in 
country areas. Approximately 30-35% of PLWH in WA live and work in rural areas 
including many migrants and those on Long Stay Business (457) visas (32% of all visa 
holders), although they may return to their country of origin periodically. The 
enrolment in 2009 was 198 patients although the number accessing the program since 
its inception is 274. Three Immunologists, and an Infectious Diseases Physician 
participate in this service as part of their substantive positions and a Clinical Nurse 
Specialist (1.0 FTE) holds a dedicated position. The person in this role liaises with 
regional health professionals state-wide and also provides a clinical point of contact for 
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people with HIV infection through the Department of Justice (Prisons) and in the 
management of pregnancy. Outreach clinics to two regional areas in the North- West 
and the Goldfields have been held ad hoc about twice a year since 1998 and 2005, 
respectively and, more recently, a clinic was held in Broome in liaison with the Public 
Health Physician in that centre. The role of the Rural Remote Nurse is to support 
patients, their partners/families and health professionals, coordinate bloods, and 
dispatch antiretroviral medication from Perth to patients. Although the service is 
delivered in selected regional areas many patients take the opportunity to come to the 
city for business or recreational reasons. Others prefer to access the service in Perth to 
avoid inadvertent disclosure of HIV serostatus in their rural communities, and some 
simply prefer to see the health care providers in person. Approximately half of the 
rural cohort, about 100 people, see a doctor in their region and attend the service at 
RPH about once a year. The main regional centres are Kalgoorlie-Boulder and two 
North-West Towns but there are established shared care relationships with GPs in the 
Great Southern region although these are not S100 prescribers.  
Accessing the Research Setting  
Before beginning my PhD candidature I had worked in the field of HIV for 12 years as a 
researcher and research coordinator in a group of clinician immunologists and 
scientists. My first research project in 1997 was a study of lipodystrophy, a serious 
drug-induced adverse effect of what was thought to be protease inhibitors. This study 
was my introduction to field of HIV, the world of ARVs and their impact on the lives of 
PLWH. It was carried out in a university research facility situated alongside RPH but my 
subsequent research was conducted in the Immunology Outpatient Clinic at RPH. My 
experience in lipodystrophy, which was a focus of our group, led to an interest in 
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medication adherence which, by then, had become a primary concern in HIV clinical 
care. In 2002 I formed an ‘adherence’ working party with allied health professionals in 
the Department of Immunology, and a number of studies related to medication 
adherence followed.  
It was the findings of the 2007-2008 study on health-related quality of life (PROQOL-
HIV) which led me to believe that we needed to extend our understanding of people 
with HIV/AIDS from backgrounds other than the, largely Caucasian male, city-based 
demographic I had studied previously. I had informal discussions with a clinical 
immunologist about her perceptions of the difficulties facing migrants from Asian 
backgrounds and people working in the mining industry. From my association with the 
working party and attendance in the clinic conducting other research activities, I was 
aware there had not been any rigorous research involving non-indigenous rural-based 
patients. Therefore, conversations with my hospital-based colleagues and supervisors 
assisted the development of the proposal, informed the study design and shaped my 
approach to the interview material. In addition, the data from the PROQOL-HIV study 
provided me with access to contemporaneous and relevant sociocultural data to use as 
a reference point for the studies in regional and mobile populations. This long 
association with the service at RPH and the natural progression of the research meant 
that my hospital-based colleagues, many of whom were co-authors on collaborative 
research activities, were familiar with my presence in the clinic so there was a degree 
of trust and rapport which facilitated the acceptance of my PhD proposal.  
My primary supervisor was also a hospital-based HIV Physician, as were three 
members of my supervisory committee. However, in order to access the RPH site, I 
circulated my research proposal to the Heads of Department, the Rural and Remote 
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Service and the Clinical Nurse Specialists. I met with them subsequently to seek their 
individual approval, and advice with regard to the proposal. Contact was also made 
with the Head of the Infectious Diseases Department at Fremantle Hospital and senior 
nursing staff to gauge their interest in offering clients attending the clinics 
participation in the study. The proposal was also sent to Public Health Physicians in the 
North-West and Goldfields’ regions.  
Engaging with the community and GIPA principles  
The term GIPA refers to the Greater Involvement of People with HIV/AIDS, and derives 
from a principle embedded in the Paris AIDS Summit Declaration of 1994 where 
leaders of 42 nations met to determine how they could effectively respond to the AIDS 
crisis. The underlying principle is that PLWH should have a central and active role in 
developing policies to address the issues related to the epidemic. This principle is 
based on the idea that HIV-positive people have a unique perspective of their 
experience:  
Positive people can perform valuable functions. They can be very powerful AIDS 
educators, counsellors, and policy makers. Their involvement in the response 
also builds up the morale of other positive people. The essential link between 
protecting human rights and promoting public health suggests that a greater 
pool of positive activists must be encouraged. 
(Asia Pacific Network of People Living with HIV/AIDS, 2004)  
Although there had been representation of migrants and refugees via non-government 
organisations (NGOs), at the time of the study, there was no formal representation for 
temporary visa holders as a community. However, the HIV service providers had 
assigned temporary visa holders a ‘virtual’ group status based on their ineligibility for 
Medicare, despite their heterogeneity in gender, country of origin, ethnicity, mode of 
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transmission, and employment or student status. More commonly they held Long Stay 
Business Visa and were categorised by workers in the field as ‘457s’ rather than the 
more ‘wordy’ temporary visa holders. According to Salzman and Rice, (2011) 
temporary visa holders might be represented as a contingent group i.e. only called into 
existence and action in response to certain circumstances or contingencies. Therefore, 
it could be argued that there was no formal support or community representation for 
visa holders as a recognised group or community. Notwithstanding these limitations, I 
recognised the WA AIDS Council (WAAC) as a potential and legitimate stakeholder in 
this research and accordingly, the proposal with an invitation for comment and 
participation was sent to the Director, who circulated it within the organisation. I also 
contacted the Migrant Resource Centre (on the recommendation of Professor Peter 
Drummond at Murdoch University) which had been funded by the Department of 
Health to employ a Youth Worker for a Sexually Transmitted Infections awareness and 
prevention program who was subsequently interviewed. She had initiated HIV 
educational sessions for men (HIV status unknown) in the African Community in 
partnership with WAAC. A number of other stakeholders were interviewed, including a 
worker with the Integrated Humanitarian Settlement Strategy Scheme in WA and the 
President of the Australian Federation of AIDS Organisations (AFAO), who 
subsequently (in February 2011), authorised my access to a confidential report on the 
subject. In addition, the results of my investigation in the temporary visa holders were 
presented at the annual conference of the Australasian Society for HIV Medicine 
(ASHM) in September 2011, thus offering any party who believed they had a stake in 
the outcome of the study to comment or contact the researcher. And finally, an 
executive summary of a detailed report on temporary visa holders was sent shortly 
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after that to WAAC, AFAO and NAPWA. No response was received from those 
organisations.  
Engaging with other communities 
With the principles of community engagement in mind, in October 2010 I took the 
opportunity to attend a Community Consultation Forum on the topic of “Living with 
cancer in the country” convened by The Cancer Council of WA, a team of researchers 
from the University of Western Australia and the WA Department of Health. I declared 
my interest as a PhD student conducting a research study which involved people in 
regional areas, without disclosing my interest in HIV to the participants (although I did 
so to the convener). I therefore attended as an observer. This level of participation 
enabled me to reflect on the commonalities and differences between the experiences 
of cancer vs HIV/AIDS in rural areas and gave me access to a wider variety of views 
than I was to have from a rural HIV ‘community’ which could be argued does not exist. 
Data Collection 
Interviews with Key Informants  
I contacted the informant/stakeholders identified in Table 2 by email to invite their 
participation and attached a copy of the research proposal. If they agreed, then a face 
to face, informal interview was arranged and conducted at their venue of choice, most 
commonly the workplace. This ensured that people were given the opportunity to be 
met on their own terms and within an environment in which they were comfortable, 
their own ‘territory’ in effect. For this reason, I went to Kalgoorlie-Boulder and a 
North-West Town to interview regional staff in these towns and to the offices of the 
non-clinical participants. I travelled to Kalgoorlie by train for the first visit in May 2010, 
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a seven hour journey one-way. I wanted to experience the journey as would a local 
making the trip to and from Perth for medical care.  As it happened, I struck up a 
conversation with a fellow passenger, a New Zealander who, with her husband, had 
been attracted by the work available in the Goldfields. That journey and the return a 
day later gave me a sense of the distances to be traversed and a snapshot of the 
demographic (including people with evident mental health problems) using the train as 
a mode of transport (since air travel is significantly more expensive). The next visit to 
Kalgoorlie-Boulder was in August 2010 when I flew from Perth, a one hour flight. In 
September I travelled to the North-West Town, a two hour journey by air. 
I asked those interviewed for advice as to other informants who could be approached 
to ensure the adequate representation of people who felt they had a stake in the 
research. The interval between the participants receiving the proposal, and discussions 
with me ensured that by the time the interviews took place the participants had had 
ample time to consider their participation. Some of the interviews with clinical 
personnel were rescheduled up to four times.  
Table 2: Sampling frame of key informants and stakeholders/constituents 
Key constituency Roles Organisation 
*Clinical  Immunology Consultant 
Clinical nurses (3) 
Psychologist 
Social Workers (2) 
Dietitian 
Pharmacist 
Perth Teaching Hospital 
Public Health Public Health Physicians (2) 
Public Health Nurses (2) 
Aboriginal Health Care Worker 
Secretary 
Kalgoorlie Boulder  
North-West Town 
Population Health Units 
Health Promotion/Prevention Executive Director 
CALD Counsellor 
Treatments Officer 
WA AIDS Council 
Migrant Health  Migrant Health Workers  IHSS and Migrant Health Unit 
Health Policy  President   Australian Federation of AIDS Organisations 
*The Study was approved by the Fremantle Hospital Ethics Committee but no participants were recruited 
at that centre. 
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The interview questions were topic based and framed by the occupation of the 
informant, but access to medication and engagement with care were consistent 
themes. More generally, roles within organisations, specific patient or client-centred 
responsibilities and relationships with other members of their team and/or other HIV 
service providers were explored. Participants were advised that the information they 
gave would not be shared with any other informants but should they wish to discuss 
their interviews with others that was acceptable to the researcher. The interviews 
lasted between 40 and 80 minutes, were recorded, transcribed verbatim and returned 
to the interviewees for verification and additional comment, none were forthcoming. 
Recruitment of ‘Patient’ Participants  
Eligibility Criteria 
People were eligible for inclusion in my research if: (1) they had HIV-infection and lived 
or worked in a regional area; (2) may have been at some stage, ineligible for Medicare; 
and (3) were eligible to give written consent. Since the research focus was not based 
on any particular ethnic group (including Aboriginal and Torres Strait Islander people) 
or gender, no one was excluded or included on the basis of ethnic background, or 
minority status. In 2009 there were approximately 50 patients on temporary visas 
distributed across both metropolitan and country areas attending the Ambulatory HIV 
Services at RPH at intervals of 3-6 months. Of the approximately 168 adults enrolled in 
the Rural and Remote Service (RRS) around 25 were classified as ‘fly in fly out’ workers 
and 19 lived overseas or ‘offshore’. However, I subsequently discovered that many 
FIFO workers were not listed with the service and during my candidature their status 
as enrolled in the RRS was revised. 
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Method of recruitment  
There are four outpatient clinics held each week at RPH to care for PLWH. I knew from 
experience that these clinics were extremely busy and that there were no rooms 
available for dedicated research purposes. I was also advised that one of these clinics 
was too busy to accommodate my research activity at all. However, rooms in an 
adjacent clinic were frequently unoccupied and the regular clinic staff and clerks 
helped me secure peripatetic accommodation that would normally remain disused at 
those times. Therefore, during the data collection phase between April 2010 and 
October 2011, I attended at least two of the four clinics held each week at RPH in 
order to recruit participants.  
I reviewed the clinic lists prospectively and then sought advice from the Consultant or 
Clinical Nurse supervising that particular clinic as to the potential eligibility of patients 
on the list for that day.  If it was thought that a patient might be eligible, I accessed the 
case notes during the clinic to confirm the fact.  For each case reviewed I sought advice 
from the Clinical Nurse as to whether there might be some reason which might make 
an approach by a researcher, at that time, inappropriate, and this was sometimes the 
case. For example, it happened that some patients (potential participants) were 
recently diagnosed or undergoing a personal crisis. Subsequently, patients were 
introduced to me by the Nurse or Consultant Immunologist. I then explained the study 
and provided an information sheet. At this stage I endeavoured to establish rapport 
and trust so that participants understood the purpose of the study and my role in it. 
Many patients who cited being busy or being unlikely to return to the clinic for some 
months asked if they could do the interview straight away. However, to ensure that 
the patient had time to consider the implications of their participation and potentially 
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discuss the study with a person(s) that they cared about, I explained why that was not 
possible (with regard to the condition for informed consent) and a follow-up 
appointment was made either then, or by phone subsequently. Written informed 
consent was obtained at the next appointment. A second issue here is that from an 
ethical perspective, the participant exercises choice, and separating the interview from 
the initial encounter maximises the likelihood of freedom of choice (Morse et al., 
2008).  
The pre-arranged interviews were held either in the outpatient clinic, often during the 
lunch break between the morning and afternoon clinics; a research office elsewhere in 
the hospital; at the participants’ homes (two participants); by phone (two regional 
participants); and at a regional Population Health Unit (three participants).  
At the beginning of 2011, I became concerned that I was not reaching sufficient 
numbers of rural-based or offshore workers. After discussions with my supervisor I 
sought a project amendment from the two ethics committees. This would allow the 
RRN nurses at RPH and Fremantle Hospital to send an email to clients who did not 
attend the hospital-based clinics, and with whom they had established patterns of 
electronic communication, to offer the clients information about the study and my 
email contact details. However, the nurses subsequently declined to do this. 
Outcome of recruitment 
Between April 2010 and October 2011 I met with over 45 people including the three 
seen at Kalgoorlie-Boulder Population Health Unit. Three patients declined to 
participate, one citing that he feared jeopardising his visa application in some way, 
another felt too busy with work and family commitments, and a third refused after 
discussion with her husband. Another 12 patients expressed interest and spoke freely 
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with me at our initial encounters however, for reasons related to their busy lives or 
work away, follow-up appointments proved too challenging. Two patients (both FIFO 
workers) agreed to field notes as one was not clear about when he would be able to 
return to the clinic and the other said that it would be difficult since he was a sole 
parent on his ‘off weeks’. Therefore, the data used for analysis was gathered from 
interviews with 30 participants (9 women) with HIV-infection: 22 had been granted 
temporary work or student visas, fourteen were current business or student visa 
holders, and nineteen lived or worked in rural areas. The other participants lived or 
worked in the metropolitan area. Interview data from nine participants was used in 
Chapters’ Four and Five, with the focus on Chapter Four related to issues of 
geographical remoteness; and in Chapter Five, were pertaining to visa status.  Group 
data from the two rural-based cohorts was obtained from the WA HIV Cohort Study 
clinical records at RPH.  
Interviews with ‘Patient’ Participants  
The face to face interviews were of 40 to 90 minutes duration. The participants were 
again briefed on the aims of the research and assured of confidentiality. I had 
prepared a list of questions which were submitted to the ethics committees as part of 
the original submission. The questions were largely open-ended and participants were 
invited to qualify their responses (e.g. could you describe to me...? Would you like to 
say more about that?), and because I wanted the participants to ‘own’ the interview as 
much as possible, the questions became more of a cue to me to indicate whether we 
had covered the subject matter relevant to the research problem than a systematic, 
structured interview . The interview schedule was therefore based on broad topics and 
themes (Table 3) which had emerged from the PROQOL-HIV study, and informed by 
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the cross-cultural approach described by Carrillo and colleagues (Carrillo, et al. 1999) 
and was revised in December 2012 following the early analysis. Participants were free 
to direct the interview time so that the issues important to them were articulated, 
however, I ensured that access to treatment and adherence to medication were 
thoroughly addressed in the conversations. All interviews from consenting participants 
were recorded using a digital recorder and transcribed verbatim by a professional 
secretary with extensive experience in the process and in managing confidential 
material. All identifying features were removed from the transcripts. Field notes and 
observations prompted by the interviews were retained in a separate electronic file.  
Table 3: Evolution of themes derived from the PROQOL-HIV Study. Seven issues important to 
participants not covered by any single existing HIV HRQL instrument: These issues were subsumed 
within 11 broader underlying themes  
Themes revealed by PROQOL analysis                        Broad underlying themes 
Fear of infecting others General health perception 
Concerns for the future Social relationships 
Satisfaction with care Emotions 
Self esteem problems Energy (fatigue) 
Sleep problems Sleep 
Work disruption Cognitive functioning 
Treatment issues Physical and daily activity 
 Coping 
 The future 
 Symptoms 
 Treatment 
Language considerations  
Most of the participants used English competently or fluently. English language 
competency is also a requirement attached to 457 and student visa status. Three 
South-East Asian women had limited English but were able to communicate with the 
researcher given sufficient time during the interviews. Two were accompanied by their 
husbands and one had an interpreter present, this participant’s English improved upon 
subsequent clinic visits as she was attending English language classes. I gave written 
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information about HIV/AIDS to the women in their language. To account for potentially 
low literacy, most questionnaires were administered by interview.  
Use of Diverse Forms of Data: The Reflective Diary and Field Notes 
In social science, data triangulation is a metaphor for the use of data from different 
sources. In this research I have aimed to achieve perspective by positioning reference 
data from the PROQOL-HIV study, interviews with key informants, a mix of clinical and 
fixed demographic data and finally my own observations recorded between August 
2010 and October 2011. I also present two small case studies, one of which appears in 
the literature review and the other appears in Chapter Four. The information for these 
came from case notes, electronic records from the Cohort Study database and 
interviews with the participants themselves. 
Keeping the project goal in mind I took opportunities, particularly while I was waiting 
for long periods in the Outpatient Clinic during recruitment opportunities (the ‘field’), 
to interact with staff, and record observations and discussions. As time passed I could 
see that these notes became valuable in providing context and detail to the research 
issues and useful reference data when I came to discuss the findings. I also planned 
and scoped a focus group on the topic of health literacy with nursing staff from three 
hospitals but did not achieve the participation necessary to make the activity feasible. 
Clinical Data  
Socio-demographic characteristics 
I recorded socio-demographic characteristics including: country of birth; visa status; 
professional activity; level of studies; marital status; ethnic identity; year of diagnosis, 
mode of transmission; and place of infection if known. Use of alcohol, nicotine and 
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other drugs were assessed using the questionnaire adapted by Chesney and colleagues 
(2000) and used in previously in our unit (Herrmann et al., 2008b, 2012). 
Biological markers 
Plasma HIV RNA levels were determined using a polymerase chain reaction assay with 
a lower limit of detection of 40 copies/mL. The Taqman 48 assay which detects virus in 
the range of 40-10,000,000 copies/mL was used for testing since 2007. The kit used for 
the assay includes primers which detect A, B, C, D, E, F and G HIV subtypes. Where the 
information was available, the HIV subtype (or clade) was recorded. The HIV RNA level 
was dichotomized as detectable (copies/mL) or not. The CD4 T-cell lymphocyte count 
was measured using the current standard flow cytometry using Trucount Tubes 
(Becton Dickinson) and recorded as the absolute number (mm3) and the percentage 
(%) of total lymphocytes.  
Antiretroviral Medication History, Access and Adherence to Treatment 
History and recent changes (within the last 3 months), in anti-retroviral therapy, 
current AIDS prophylaxis, and treatment of co-morbidities, was collected from the 
participants’ medical records and cross referenced with participant self-report. 
Symptoms and side effects were assessed, in all the studies, using a modified version 
of an HIV symptom index (Justice et al., 2001), adjusted to include questions sensitive 
to side effects of current drugs. A history of AIDS diagnosis, depression, self-reported 
and clinically diagnosed, and other co-morbidities were collected and verified using the 
patients’ medical records. Use of complementary therapy, pill burden and dose 
scheduling was also confirmed with the participant. The way in which the participants 
accessed ART and the cost of the medication was recorded. Adherence to ART was 
assessed by self-report using the Adult AIDS Clinical Trial Group Adherence 
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Instruments (Chesney et al., 2000), and discussed with the participants within the 
interview, except in the second stage of the PROQOL Study, where it was assessed by 
asking the participant if they had missed doses of medication in the two weeks 
preceding their visit.  
Data Analysis  
Once identifying features were removed from the transcripts they were imported into 
NVivo 8 (QSR International Pty Ltd). I used the software to create broad categories 
(free nodes) into which I put selected text from the transcripts. I coded nearly all the 
verbatim and included positive and negative responses within the same coding node, 
for example, comments concerning the topic future included concerns about the future 
but also optimistic statements. This approach allowed me to assess balances and 
trends within the participants’ responses. I later coded from the free nodes into a 
more hierarchical structure (tree nodes).Table 4 provides more detail. I conceptualised 
the impact of HIV as emotional, social and physical but also coded for eight other 
topics: access to and experience of health services, prior experience of illness; personal 
history, which allowed the participants to share information about themselves; 
thoughts and feelings about the future; moderators of HIV impacts; use of alcohol and 
other drugs; attitudes to the future; and treatment related impacts. Because of 
interrelationships between the themes some verbatim appears in more than one 
node. 
An interim analysis of the text at the end of 2010 provided key data to refine the 
questionnaire schedule and informed the focus of the latter data collection which 
started in early 2011. I then began refining the coding e.g. from stigma as a broad 
subcategory of emotional and social impacts into ‘stigma manifestations’. I also 
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considered how people perceived that having HIV infection limited their lives now and 
in the future. The themes of access and adherence became intertwined with aspects of 
stigma but also the functional constraints posed by non-citizen status.  
In addition to the qualitative software, I used simple pen and paper data summary 
tables in order to do a close and textual analysis of the transcripts and field notes 
(Bloomberg & Volpe, 2008) which helped in recording frequencies. Some of this was 
later transcribed to Excel to be collated with the clinical data. The NVivo program was 
also useful as a project management tool and linked the ethics committee submission, 
assessment tools and project proposal. Demographic, symptom, adherence and clinical 
outcome data was entered into Excel version 7 and summarised.  
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Table 4: Topics and themes drawn from the interviews. Themes incorporate positive and negative utterances e.g. continuity of care or lack of. 
TOPICS THEMES TOPICS THEMES 
Emotional impact of HIV Social impact of HIV 
Experience of diagnosis 
Diagnosis adjustment 
Feelings about HIV 
Shock & distress  
Confusion 
Constraints of the disease 
Leading a ‘normal’ life 
Visa & immigration issues 
HIV in home country 
Employment 
Impact on relationships & family 
Employment health screening 
Health cover and cost 
Partner impact/Physical intimacy/ 
Childbearing/rearing 
Limited opportunities, e.g. work & 
relationships 
Stress 
Confidentiality concerns  
General stress & due to HIV 
HIV in rural area/heightened disclosure  
Confidentiality concerns  
Personal histories Reason for being in Australia 
Work/workplace issues 
Cultural/diff epidemiology  
Travel to country of origin 
Stigma  
Cultural nuances  
Enacted/actual 
Perceived/anticipated 
Internalised 
Fear 
Fear of testing  
Fear disclosure/discrimination/shame 
Fear transmitting HIV 
Future/health/residency 
Health services/Access & experiences 
Clinic, Medical and Nursing 
RR services 
WA AIDS Council  
Other health services e.g dentist/GP 
HIV education/websites 
Ease of contact/People care/don’t care  
Assistance to access drugs 
Engagement /Convenience 
Continuity of care 
Education, use of internet 
Use of non-clinical services 
Moderators Treatment related impacts 
Support 
 
HIV Knowledge 
 
 
Alcohol & other drugs 
 
Physical impact of HIV 
 
Appetite 
General health 
Health Beliefs 
Sleep 
Coping/adjustment  
Partner/spiritual 
Positive thinking 
Previous experience of HIV in home country 
 
Use and impact on adherence  
 
 
 
Belief in healthy lifestyle 
Access medication 
Adherence/missed doses 
Treatment interruption  
 
Adverse side effects 
Beliefs about medication 
Beneficial effects of treatment 
Complementary therapy 
Facilitators of adherence 
HIV treatment experience 
Managing medication at work 
Organisation 
Secrecy 
Frustration 
Determination, motivation, access 
Concern if have to leave country 
 
 
 
 
 
 
Patterns of secrecy  
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Sample size or How Many Interviews Are Enough?  
Guidelines for the size of non-probabilistic samples in qualitative research usually rely 
on the concept of data saturation i.e. the situation in which the data has been heard 
before. Guest and colleagues (Guest, Bunce & Johnson, 2006) used data from in-depth 
interviews conducted with sixty women from two West African countries to document 
the degree of data saturation and variability observed during their thematic analysis, 
and to demonstrate how to apply the concept of saturation. They found that 
saturation occurred within the first twelve interviews. A different approach is adopted 
by Howard Becker who discusses aspects of sampling at length, arguing that the aim of 
theoretical sampling (Glaser & Strauss, 1967) is to capture and describe variety and 
exceptions, in contrast with probabilistic random sampling which aims to reduce data 
to its common features (Becker, 1998). Nixon’s assessment is that if the qualitative 
research is focused on a homogeneous population then ten individual interviews is 
enough (Nixon & Wild, 2010), yet the issue arises in the definition of homogenous. The 
essential feature of the participants with whom I researched was that they were not an 
homogenous or easily definable group. The information on hand when I prepared the 
research proposal (at the end of 2009) indicated that there were approximately 198 
active patients registered with the Rural and Remote Service, 25 were fly in fly out 
workers, 19 held visas, and 19 were living or working offshore. Approximately 50 
patients attending the Immunology Outpatient Clinic at RPH were on temporary visas. 
After considering the feasibility of the project, I aimed to interview 40-60 patients with 
the goal of describing the issues important for people living and/or working in rural 
areas and those on temporary visas, while theorising that there would be three 
‘contingent’ groups, termed loosely as: rural, FIFO, and temporary visa holders.  
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Validity or issues of trustworthiness 
In qualitative research, data validity and reliability undergo a semantic change to 
become credibility, dependability, and transferability, respectively (Bloomberg & 
Volpe, 2008). These are the criteria for evaluating the trustworthiness of qualitative 
research. In this setting I have sought to represent the reality of the persons involved 
in my research and I have done this, in part by using multiple methods of data 
collection and providing an auditable trail of data. On completion of my field diary I 
kept a notebook of observations made during the data analysis and thesis writing 
phase. I also prepared three peer reviewed publications during the course of the 
candidature which required me to scrutinise details of my work repetitively. One of my 
supervisors cross checked the interpretation and analysis of several interviews. In 
addition, my long immersion in the field facilitated my understanding of the context in 
which the participants of the study are involved.  
It is generally understood that in qualitative research by comparison with quantitative 
research, ‘generalisability’ is limited.  Transferability, in this sense, relates to how 
useful the data is to another researcher or setting. For example, if the data is richly 
described it can offer a vicarious experience to a reader, thereby allowing them the 
opportunity to expand and develop new theories that can be used in relation to other 
research avenues (Bloomberg & Volpe, 2008). Whether or not this is achieved in this 
thesis will be expounded in the final chapter and judged by the reader. 
Ethical Considerations 
In the first ethics committee submission to RPH and Murdoch University, I indentified 
ethical issues that might arise in the course of the research and how I proposed to 
manage these risks. The relevant issues were: (1) consent, privacy, confidentiality; (2) 
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potential harm related to distress arising from the interview process which is of 
particular import in qualitative research; and (3) people in potentially dependant or 
unequal relationships, including visa holders and health professionals. Both 
committees gave approval conditional to receiving clarification on a number of points. 
These were related, primarily to: the security of the study data; the involvement of 
visa holders; the implications of asking people to reveal illicit substance use; and issues 
of consent. The study was subsequently submitted to the Fremantle Hospital Ethics 
Committee and was approved. Finally approval for protocol amendment was sought 
(and later approved) to seek more efficient access to ‘hard to reach’ but potentially 
eligible participants.   
Particular issues conducting research in PLWH 
Writing in the Oxford Textbook of Clinical Research Ethics, John Killen (2008) observes 
that the HIV/AIDS epidemic has had a profound impact on almost every aspect of 
research ethics. This revolution in ethics played out in community advocacy as access 
to care and treatments for the social communities most affected by HIV/AIDS was 
sought. Killen notes that as a consequence of community activism, the concepts of 
autonomy and justice have been broadened by recognising the important role that 
humans with life-threatening diseases play in assessing the potential harms or benefits 
of their participation in research as opposed to this decision being made by others with 
no personal ‘stake’.  
An overriding concern when conducting research in the field of HIV/AIDS is to protect 
the privacy of the participant and take prescribed steps to avoid harm (the principle of 
maleficence) in the form of unauthorised, inadvertent disclosure of the participant’s 
HIV serostatus to others. Of course, protecting the privacy of participants in any 
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research setting is a prime concern. However, it is generally the case in mainstream 
research that given ethics committee project approvals, participants can be feasibly 
and inoffensively contacted by post, telephone or newspaper advertisement. However, 
in HIV research these practices can lead to inadvertent disclosure of HIV serostatus 
which can occur in a number of ways for example, by leaving messages on answering 
machines that reveal the nature of the inquiry or by sending documentation through 
the post that contain content with explicit reference to HIV or HIV/AIDS. This may be 
opened by neighbours if incorrectly addressed or by people living with the person who 
may unaware of their serostatus. The consequences of inadvertent disclosure of HIV 
serostatus for an individual can be distressing and result in real or perceived 
stigmatisation of that person. However, one of the downsides of this vigilance is that a 
health care worker can reinforce the stigma attached to the condition by implying that 
the patient has something of which to be ashamed. Careful communication is required 
to avoid this situation, especially around decisions made concerning to whom and 
when the decision is made to disclose HIV serostatus.  
Similar issues around ensuring confidentiality can also constrain how educational 
material is disseminated. It is standard practice to use brochures to inform and 
educate patients about health disorders and drug treatments. Frequently people with 
HIV are reluctant to retain hard copy material (and this was also the case for people 
with cancer who may or may not have told family members about their cancer 
diagnosis) that may be viewed by visitors to their homes. Even those patients who are 
unconcerned about privacy at home may be reluctant to carry material on their 
persons away from the unit. This has practical implications for how patients are 
educated about HIV/AIDS on a number of levels, including how they interact with the 
health care system. This study was not designed to be an educative intervention, 
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however, wherever possible I took the opportunity to correct any knowledge deficits 
that I uncovered and used educational material during the interview, for example, the 
pill identification chart and graphic representation of the virus and targets for ART. I 
also assessed participants’ access to particular HIV/AIDS websites and directed them to 
those appropriate to their needs. In this way I dealt with the ethical dilemma that can 
arise when conducting research when a problem is uncovered: should the researcher 
act when they discover a deficit that may influence an outcome for a participant? In 
this way I also ‘gave something back’ to the participants.  
The particular sensitivities around HIV disease complicated my access to patients in the 
regions. Traditionally clinicians act as advocates for their patients, and this is explicit in 
nursing codes of professional conduct. In research, this behaviour can be construed as 
functional ‘gate-keeping’. I had expected that my credentials as a qualified, 
experienced researcher in HIV over a ten-year period and my widely circulated, 
ethically approved proposal, would overcome some of the initial barriers to conducting 
the PhD research project. However, the extreme concerns of the Public Health 
Physicians and the Rural and Remote Clinical Nurse Specialist around privacy 
considerations, limited access to patients in regional areas. Just before this thesis was 
submitted I was asked by the Mid-West PHP responsible for the North-West Cohort to 
suppress the name of the town out of which the cohort is managed. Since all the 
patients in the cohort were Aboriginal it was necessary to obtain approval from the 
Western Australian Aboriginal Health Information and Ethics Committee (WAAHIEC) in 
order to invite Aboriginal people, as a targeted group, to participate in any research 
studies. However, this was not part of my proposal and I would not be offering 
participation to this population. I visited the Goldfields twice; at the first visit I 
interviewed the Public Health Physician and the Public Health Nurse. The PHP 
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informed me of his confidentiality concerns and suggested that I attend the next 
outreach clinic and recruit patients by the invitation of the Rural and Remote Nurse  
during the clinic, which is what happened. All of these negotiations involved lengthy 
communications over weeks. Just before this thesis was submitted for examination, I 
sent Part 1 of Chapter Four to the Public Health Physicians from both the regions that I 
visited, as a courtesy and in order to invite their comments.  Other than the request 
from the PHP to suppress the name of the North-West ‘Town’, both were happy to 
approve the presentation of the data. 
The preceding comments and observations are drawn from my field notes and 
correspondence with providers. They serve to illustrate the realities of conducting 
research in populations assigned as vulnerable, and the current context for conducting 
qualitative research in Western Australia and they are not in any way a reflection of 
personal resentment.  
Summary 
In this chapter I have delivered a comprehensive description of how I conducted the 
research, the rationale behind those decisions and their theoretical bases, and some of 
the methodological aspects pertaining to qualitative research in general and 
ethnography in particular. I have described the social context of the research and 
pertinent details that contribute to context and the principle of thick description.  
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CHAPTER THREE HEALTH-RELATED QUALITY OF LIFE  
Introduction  
This study was reported in a manuscript submitted to the journal Health and Quality of 
Life Outcomes under the title of: “HIV-related stigma and physical symptoms have a 
pervasive influence on health-related quality of life in Australians with HIV infection”. 
The manuscript is under revision, following the receipt of reviewers’ comments. The 
study outcomes are discussed in this section of the thesis but further explicated and 
placed in context in Chapter Six. I have acknowledged the contribution of co-authors in 
the preliminary section of this thesis. 
Background 
Antiretroviral therapy (ART) has slowed progression of HIV infection to AIDS, and 
significantly reduced morbidity and mortality in people with HIV who have access to 
the treatment (Palella et al., 1998). However, symptomatic HIV infection, effects of 
treatment, stigma and other psychosocial features of the condition continue to exert a 
considerable influence on health-related quality of life (HRQL) (Abboud, Noureddine, 
Huijer, Dejong & Mokhbat, 2010; Bouhnik et al., 2008; Jia et al., 2007; Logie & Gadalla, 
2009; Protopopescu et al., 2007; Xianhong, et al., 2011). Measures to assess the effect 
of ART on health status and wellbeing were introduced in 1991 (Wu et al., 1991). 
Underpinning these measures was the hypothesis that adverse symptoms would 
impact on respondents’ perception of their Physical, Social and Mental Health 
functioning and quality of life. This pragmatic perspective of HRQL shifted in the mid-
nineties when the World Health Organization broadened the concept to encompass 
‘an individual’s perceptions of their position in life in the context of the culture and 
values systems in which they live and in relation to their goals, expectations, standards 
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and concerns’ (1995). A priority for long-term clinical management of HIV, and a critical 
endpoint, is to improve quality of life indicators. Increased tolerability of ART, reduced 
pill burden and dosing frequency have been positive influences on quality of life 
facilitated by medication adherence (Mannheimer et al., 2005). However, these and 
other disease-specific dimensions of HIV such as stigma and treatment idiosyncrasies 
can impact on individual and public health and may not be captured using the current 
instruments. A new Patient-Reported Outcomes (PRO) questionnaire to measure the 
HRQL in people living with HIV was developed in eight countries; and later validated in 
our centre and others (Duracinsky et al., 2012a, 2012b). The aim of the study was to 
enhance understanding of the major factors impacting health-related quality of life in 
our cohort. By focusing on this local perspective, the work provides an explanatory 
rather than predictive approach to understanding the relationship between HRQL and 
physical, social and psychological distress, including HIV-related stigma, on a specific 
sample in a particular context. Here I present the results from the Australian arm of 
the PROQOL-HIV Study: a summary of themes from in-depth interviews (Stage One); 
the results of the psychometric testing (Stage Two); and present the factors most 
relevant in influencing HRQL in the WA HIV Cohort.   
Specific Methods 
Study design and setting 
Semi-structured interviews with fifteen patients and survey data from 102 (out of 106 
administered) respondents were analysed. It had been determined that fifteen 
interviews were sufficient for a within-country analysis based on the research of others 
into qualitative data saturation [24]; and the sample size for a within-country analysis 
of the PROQOL-HIV questionnaire had been powered for 100 patients. This figure 
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considered the number of conceptual dimensions needed to ensure a final factor 
model with reliable factor loadings in exploratory factor analysis (Duracinsky et al., 
2012a; Guest et al., 2006). Patients with HIV infection, over the age of 18 years and 
able to give informed consent, were eligible for inclusion in the study. Patients were 
recruited during scheduled clinic visits to the Immunology Clinic at Royal Perth 
Hospital, a tertiary ambulatory facility.  The fifteen interviewees were informed about 
the study by the unit social worker and patients subsequently contacted the 
researcher to arrange an appointment at an agreed venue. These participants were 
chosen to reflect a mix of age, gender and mode of HIV transmission. Recruitment for 
the survey phase was conducted at consecutive clinics from June to October 2008. 
Patients with sufficient time before their appointment with the physician were invited 
to complete the survey. Of 109 patients approached two patients declined to 
participate and data from five surveys were not included in the final analysis because 
they were incomplete. The study was approved by the Royal Perth Hospital Ethics 
Committee (2007/115). 
Interviews Stage One 
The two interviewers, this author and a Clinical Psychologist, reviewed the English 
version of the interview guide for fluency and use of the Australian vernacular.  We 
then conducted semi-directed interviews of 60 to 120 minutes duration which were 
recorded and transcribed verbatim.  The interview guide comprised 107 questions of 
which the first five were open-ended seeking participants’ experiences of the impact of 
HIV on their daily lives and their quality of life in general. The latter 102 questions were 
categorised into topics of self and body care, daily activities, physical activities, health 
perception, energy/fatigue, cognitive functioning, social relationships, emotions and 
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treatment. Participants were invited to qualify their responses. Hard copies of the 
transcripts were printed and patient interview data were examined by the two 
interviewers, independently, and several themes were identified and discussed.  I 
subsequently imported the transcripts into the NVivo 8 qualitative software 
programme (QSR International Pty Ltd) where the verbatim was catalogued under 
theme headings called nodes. Analysis in NVivo facilitated the exploration of recurring 
themes and concepts, and drew attention to commonalities and variation between the 
verbatim of the interviewees. 
Questionnaires administered in Stage Two 
Two HRQL instruments were administered: (1) the 70 item pilot PROQOL questionnaire 
and (2) the Medical Outcomes Study HIV-Health Survey (MOS-HIV) (Wu et al., 1997; 
Wu et al., 1991), together with an HIV symptom index modified to include common 
side effects of current regimens (Justice et al., 2001). Psychometric analysis of the pilot 
PROQOL-HIV questionnaire across all participating cohorts arrived at an eight-factor 
solution, based on 39 items, explaining 60% of the variance in HRQL. The eight sub-
scales were identified as follows: Physical health and symptoms (PHS), emotional 
distress (ED), treatment impact (TI), health concerns (HC), body change (BC), intimate 
relationships (IR), social relationships (SR) and stigma (ST). Each Likert item score 
(range 0-4 points) was summed and expressed as a final score on a 0-100 scale where 
each item contributed equally, and with higher values indicating better HRQL. The 
main properties including the validity and reliability of the questionnaire are described 
in the publications found in the appendix, but briefly, the score’s reliability was 
assessed using Cronbach’s alpha (0.936, 95% CI = 0.929-0.943) and the intra-class 
correlation coefficient (ICC) was assessed in 34 participants (ICC=95%, 95% CI=0.701-
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0.959). Analysis was conducted on the 8 subscale scores corresponding to the 8 factors 
of the final solution, and two composite scores derived by averaging over the subscales 
with and without the treatment impact domain (termed the global 8-factor and 7-
factor scores respectively). The two main composite scores derived from the MOS-HIV 
SF36 were also assessed within this study: the physical health summary (PHS) and the 
mental health summary (MHS).  
Clinical measures 
Plasma HIV RNA levels were determined using a polymerase chain reaction assay with 
a lower limit of detection of 40 copies/ml (Roche). The CD4+T cell lymphocyte count 
(mm3) was measured by flow cytometry using Trucount Tubes (Becton Dickinson). A 
history of HIV/AIDS diagnosis, co-morbidities, current anti-retroviral therapy, AIDS 
prophylaxis, and other treatments were collected and verified against the participants’ 
medical records. Adherence to ART was measured as the number of self-reported 
missed doses in the two weeks preceding the study visit. This was concordant with the 
standard clinic practice of recording level of adherence, longitudinally, for all PLWH 
attending the clinic (Herrmann et al., 2008b) and work published by others (Gao & 
Nau, 2000; Lu et al., 2008).  
Analysis 
Sociodemographic, biomedical and psychometric data obtained from the PROQOL 
participants were compared across treatment groups using Fisher or Kruskal-Wallis 
tests as appropriate. PROQOL composite and subscale scores, and MOS-HIV composite 
scores, were analysed within a linear regression framework, with model R2 values 
utilized to obtain the percent of score variability explained by inclusion of specified 
variable sets. Pearson correlations were calculated, with Fisher’s z transformation used 
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for calculation of 95% confidence intervals. Analyses were undertaken using TIBCO 
Spotfire S+ 8.2 for Windows (TIBCO Software Inc., Palo Alto, CA). 
Results 
Results of Interviews (Stage One) 
Clinical and demographic data 
Most of the 15 interviewees were Caucasian men, three were South-East Asian and 
two identified as being of Aboriginal ancestry. The median year of HIV diagnosis was 
2001, and the mean (± SD) age was 41yrs (±10.5); CD4 T-cell count 542 copies/ml 
(±332.2), and percent lymphocyte count 25.5% (±9.7) (Table 5). Of the 3/15 
participants who had a detectable viral load, two were not on current ART and one had 
a history of poor adherence. Symptoms were frequently reported (1-20 symptoms/31) 
at an average of eight symptoms per person. The most common were gastrointestinal 
(11 patients) followed by sleep difficulties (10), fatigue (10), and skin dry/itching (9). 
Eight participants smoked and eleven reported current use of alcohol. Seven lived 
alone, five in a couple, two with family members and two with children. Six 
participants were in paid employment and two were students. All completed school to 
at least age fifteen and six were tertiary educated. Co-morbidities were described by 
4/15 (26%): hepatitis C (HCV) (2 participants); pulmonary hypertension (1); Type 2 
diabetes (1); and chronic back pain (1); and four (26%) reported current depression, 
two were treated. Three participants had lipodystrophy attributed to previous 
treatment with thymidine analogue nucleoside reverse transcriptase inhibitors.  
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Interview Verbatim: Aspects of Living with HIV 
Quotes illustrating four dimensions of living with HIV are presented in Table 6: (1) 
emotional/social, (2) physical, (3) impact of treatment and (4) understanding of quality 
of life. Most participants perceived HRQL as having HIV or non-HIV influences. For 
some it involved feeling happy, and having supportive networks of family and/or 
friends, a satisfactory income and access to potent and effective treatments. The 
participants who experienced lower HRQL described co-morbidities, a high frequency 
of stigma fears, adverse symptoms and were more likely to be receiving disability 
pensions.  
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Table 5: Characteristics of the 15 interviewees who participated in Stage One of the PRO-QOL HIV Study 
Patient Age (yrs) Gender 
m/f/o 
Transmission 
mode 
Year  CDC CD4 
count 
CD4 (%) Viral Load 
(log) 
HAART* Duration (mths) 
1 48 m msm 1985 C 1295 35 <40 3TC/AZT/ABC 109 
2 31 m msm 2004 A 600 30 <40 3TC/AZT/EFV 42 
3 41 f unknown 1987 B 330 22 <40 FTC/TDF/LPV/RTV 180 
4 66 m hetero 1997 C 540 20 <40 3TC/DDI/RTV/ATV 114 
5 28 f hetero 1994 C <6 <6% 4.8 no current HAART 156 
6 36 m msm 2003 A 392 28 1.84 3TC/AZT/NVP 33 
7 55 m msm 1988 A 612 34 <40 3TC/ ABC/ LPV/RTV 78 
8 47 m msm 2002 A 416 26 <40 3TC/ ABC/ LPV/RTV 36 
9 45 m msm 2001 C 784 28 <40 3TC/TDF/NVP 72 
10 38 m msm 2006 A 340 17 <40 3TC/AZT/EFV 9 
11 26 f hetero 1998 A 1127 49 <40 3TC/AZT/EFV 72 
12 32 f IDU 2001 A 384 32 3.92 no current HAART 72 
13 44 m msm 1986 C 336 21 2.16 3TC/AZT/ABC 156 
14 37 m msm 2005 A 690 30 <40 3TC/ABC/RTV/ATV  26 
15 42 m msm 2002 C 280 20 <40 3TC/AZT/EFV 63 
Abbreviations: msm=men who have sex with men, hetero=heterosexual, IDU=intravenous drug use. HAART=highly active antiretroviral therapy; 
3TC=lamivudine, FTC=emtricitabine, AZT=zidovudine, ABC=abacavir, TDF=tenofovir, DDI=didanosine, NVP=nevirapine, EFV=efavirenz, LPV=lopinavir, 
RTV= ritonavir, ATV=atazanavir; 8/13 patients on a BD regimen, mean number of pills = 3.4, median=3. CDC = stage at first presentation 
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Emotional and social impact 
Feelings of social stigma triggered by HIV were associated with fear and anxiety in 11 
out of the 15 interviewees despite a degree of self-reported adjustment to living with 
HIV. A fear of transmitting HIV inadvertently or in a situation where one was powerless 
to protect others, for example during a car accident, was intense for some individuals. 
A minor cut while preparing food resulted in interviewees repeating the food 
preparation from the beginning. One participant abandoned a profession in catering 
because of this concern. There was an aversion to disclosing HIV sero-status in any 
circumstance and a fear of being ‘outed’ by the appearance of ill health or being seen 
attending the hospital clinic. Anxiety about disclosure to employers, sexual partners 
and parents and for two of the women, their children, was considered most stressful. 
Some perceived career options to be limited. Attitudes of others featured strongly; 
stigma related to disease but also sexual identity, for example a heterosexual man 
feared homophobia. HIV impacted on work opportunities for those with ill health and 
choice of work generally. Feelings of sadness, shame and inferiority were common. 
The greatest restrictions for over half of participants were around sexuality: reduced 
spontaneity and avoidance of sexual intercourse. The legal and moral requirement to 
disclose to prospective partners and, potentially, employers weighed heavily. 
Restrictions to travel opportunities were perceived, compounded by concerns over 
travelling with medication, disclosing HIV sero-status on entry to some countries, and 
fear of becoming ill while holidaying. Some withdrew by degrees from social activities. 
The loneliness of chronic illness was described by one participant who perceived that 
friendships had fallen away since illness has altered his appearance and relationships 
132 
with health care providers were tense because of his inability to ‘get well’ despite their 
‘efforts’.  
Physical impact 
With regard to physical activity, some participants were limited by disability related to 
co-morbidity, whilst in others symptoms of pain and/or fatigue limited activity and 
affected motivation, resulting in feelings of social isolation. Activity that might result in 
transmission of HIV was avoided by interviewees and some had given up pleasurable 
body contact sports which they perceived might lead them to spill blood.  
Impact of treatment 
The interviewees who started ART pre-2000 described effects of pill burden, frequent 
dosing and residual side effects. One developed immune restoration syndrome and a 
disfiguring skin condition, not necessarily related. His experience of high-dose steroids 
and frequent changes of ART were debilitating and he felt unable to work or maintain 
an intimate relationship. Another interviewee had a long-standing history of non-
adherence to ART and was hospitalised with severe immunodeficiency. This 
respondent took medication secretly, as did others. However, the majority viewed ART 
positively, as improving their health despite the effects of long term toxicities. 
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Table 6: Interviews: themes emerging from narratives (N=15) 
EMOTIONAL AND SOCIAL IMPACT 
The fact that (it’s, a) it’s a scary thing for people that don’t have it and a scary thing for people that do have it, it’s 
just a terrifying thing… (woman, 28yrs).  
What disturbs me most about HIV is even though there is a lot of information out there, there are a lot of people 
that still are quite ignorant and they’re still quite fearful of HIV (man, 31yrs). 
That my mother will find out...(man, 42yrs). 
I am scared that I tell them and then it will be different. They would treat me differently (woman, 28yrs).  
I’m afraid of dying...getting sick and not being able to take care of my children. I’m afraid of my children finding out 
like that’s probably my biggest fear in this world is when my children find out (woman, 32 yrs). 
Oh massively restricted in the sexual sense (woman, 26yrs).  
The fear that something may happen to me and I’m in a car accident....and someone tries to help me and I’m 
bleeding profusely and I pass it on to them (woman, 32yrs). 
Sometimes if I’m cooking… silly thoughts of cutting myself (man, 37 yrs). 
When they talk about people there is a disgust in the way they talk there’s disgust and it really deeply hurts because 
I have HIV and I don’t think that I’m disgusting (woman, 28yrs).  
Sometimes it’s really difficult... like can be very isolating. Sometimes I feel like no one really understands and it’s very 
secretive as well like no one really knows, I don’t want people knowing (woman, 32 yrs).  
...the friends that I did have put distance between us…. Separated themselves from me because it’s all got a bit hard 
or whatever (man, 47yrs). 
That fear of possibly infecting him. I think the guilt eventually killed it (man, 42 yrs). 
PHYSICAL IMPACT 
I went straight back to work as soon as I could- (work) was just a very lucky distraction to have (man, 38yrs). 
I get tired very quick but don’t generally stop me doing anything I want to do...my problem is not wanting to do 
anything...it’s the motivation I don’t have (woman, 41yrs).  
Tired and exhausted both (man, 66yrs). 
I might have three or four bad days in a row and I have to ring up and take it off work and there’s no employer… 
they can’t put up with that for too long (man, 47yrs). 
...any sort of activity that involves danger, all the risk of you know getting cut or something like that I just don’t do 
(woman, 32yrs). 
IMPACT OF TREATMENT 
I look at them making me sick, making me vomit like just want to vomit already just looking at them (woman, 28yrs).  
The drugs, the drugs are great. I can’t complain I haven’t had any side effects (man, 55yrs). 
None… problem is just taking them in front of people (man, 37yrs). 
I never had a eight hour sleep… there was not such a thing as an eight hour sleep (man, 44yrs). 
PERCEPTIONS OF QUALITY OF LIFE 
The way you do to get to do the things you like to do, like what kind of barriers do you face like - do you have the 
support networks and all that sort of stuff (man, 66 yrs).  
... means enjoying yourself, being happy… feeling good within yourself and about the people around you. I don’t 
have that any more (man, 47 yrs).  
I think within the realms of HIV itself, I would think that my health is good… um… but within the realm of the general 
population, I would say that my health is quite bad…(man, 42yrs). 
Since my medication my life’s actually been enhanced (man, 37 yrs). 
I’ve got the best drugs, good treatment at the hospital - I can still work (man, 38yrs). 
It’s been up and down but it’s now it’s pretty good according to all the numbers and results and things, I’m pretty 
well normal...(woman, 41 yrs). 
I realised it’s all psychological really (woman, 32yrs). 
I suppose for two thirds of my life, because ... I have been living with HIV for a third of my life, I lived a quality of life 
where I didn’t have to think about everything I just did what I wanted to do basically within ones responsibilities and 
obligations. Now through HIV my quality of life has changed in that now everything I do has to be considered (man, 
45yrs). 
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Results of the Psychometric Testing of HRQL (Stage Two) 
Sociodemographic and clinical attributes 
Data were collected from 102 participants (15% female) aged between 24 and 71. 
Socio-demographic characteristics can be found in Table 7. Transmission was mainly 
through sexual contact (94%) and nearly 40% of participants lived alone. All but two 
participants reached at least secondary school level, and 80% were employed. The 
most common co-morbidity was depression (24%), followed by HCV (17%), psychiatric 
disorder (5%), cardiovascular disease (3%) and hepatitis B (2%). Of the participants 
with depression, 30% had Hepatitis C. Most participants were treated with ART 
(87/102), two participants had stopped previous treatment, and 13 were naive to ART. 
Amongst treated participants, 76% reported 100% adherence over the last two weeks, 
and of the 47% on a protease inhibitor (PI) based regimen, 56% were taking ART once 
daily compared with 83% of those on a non-nucleoside reverse-transcriptase inhibitor 
(NNRTI) regimen. An undetectable viral load was recorded in 85% of patients and the 
average CD4 T-cell count was 26%.   
Health-related quality of life outcomes  
Health-related quality of life outcomes were assessed in terms of both the global 
PROQOL score and the 8-subscale scores. The global 7-factor score had an observed 
mean (SE) of 60.62 (2.01), with mean subscale scores ranging from 43.32 (ST) to 72.55 
(SR). Restricting to the treated participants only, scores were slightly higher across all 
domains except the physical health score, with the highest subscale being that 
measuring treatment impact. Inclusion of this latter domain resulted in an increase of 
the global mean from 61.66 (2.21) for the 7-factor score, to 64.07 (2.06) for the 8-
factor score. On average, participants scored higher on the MOS Physical Health Scale 
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(mean (SE) = 52.5 (1.2)) than the Mental Health Scale (48.0 (0.9)) (p<0.001, paired t-
test).  
Univariate regression analyses of demographic associations with the PROQOL global 
and subscale scores are presented in Table 8, with covariates grouped according to 
indication of sociodemographic, treatment, biological and clinical factors. Of 
sociodemographic factors considered, the most discerning was professional activity, 
with patients who were unemployed or on sickness benefits reporting consistently 
lower HRQL across the domains. Those living alone were significantly more impacted 
by difficulties with intimate relationships compared with those living with others 
(p=0.006), whereas older age (>45yrs) was associated with higher HRQL scores in this 
domain. Worry over HIV and other health outcomes, for example test results and 
catching other infections, was less common in Caucasians (p=0.003) and older patients 
(p=0.02), However, those recently diagnosed (<2 years) were more likely to express 
health concerns (p=0.001) and, with lower scores in the stigma domain, indicate fear 
of disclosing their HIV status and infecting others (p=0.02). Duration of ART was 
considered as a treatment-related factor.  
Participants not on treatment had significantly lower HC and ST scores (p<0.01) than 
those treated. Accordingly, having a detectable viral load correlated with increased 
health concerns and treatment impact on HRQL. In contrast, those receiving protease 
inhibitor-based ART who, on average, had been on therapy for 3 years longer than 
participants receiving NNRTI-based therapy, appeared less affected by issues of 
stigmatization. A small number of participants infected via IDU (mean = 12 years ago) 
reflected this trend since they scored most highly in this domain. However, PI regimens 
per se, having a higher daily pill burden and inducing more treatment-related 
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symptoms, were associated with both worse PHS scores and greater treatment impact 
on total HRQL. Negatively impacting on HRQL across many of the subscale scores were 
clinical factors: suffering from depression, another comorbidity or sexual dysfunction 
and frequency of experienced symptoms. The number of symptoms, in particular, was 
highly predictive of reduced HRQL across all domains except stigma. Symptoms were 
more prevalent amongst participants receiving PI regimens (mean (SE) number = 8 
(0.85)) compared with those on NNRTI regimens (5.48 (0.80), p=0.005, Mann-Whitney 
test) but were not confined to participants receiving ART. Symptoms of malaise, 
particularly, were common across all three groups, as were insomnia and skin 
problems. Reflecting the observed consistent effect across most of the subscales, the 
clinical variables were also strongly associated with lower global PROQOL scores (Table 
8). When considered together in multivariable models, these clinical factors explained 
over 30% of the variability in the global scores, contrasting with about 20% for the 
sociodemographic factors alone, 10% for the treatment factors and about 5% for the 
biological parameters.  
After accounting for the clinical predictors, the contribution of the sociodemographic 
variables to observed score variability reduced to 12%, whereas that of the treatment 
factors and biological parameters dropped to 6% and 2.5%, respectively, in sequential 
models. The additional contribution of behavioural indicators such as smoking and 
alcohol consumption was negligible. With quality of life being a global concept, a total 
of 55% of the PROQOL score variation could be explained by the combined covariate 
sets. This compares with 75% and 70% of the variation in the MOS HIV PHS and MHS 
scores, respectively, each of which could attribute over 50% to the clinical outcomes 
alone.  
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Correlations between the composite scores and the PROQOL subscale scores are 
presented in Table 9 (restricting to treated patients only). Whilst the global PROQOL 
correlated most strongly with the subscale encompassing emotional distress (R [95%C] 
= 0.86 [0.79-0.91]), both MOS HIV composites correlated particularly strongly with the 
physical health and symptom subscale (MOS-MHS: R [95%CI] = 0.80 [0.71-0.87]; MOS-
PHS: R [95%CI] = 0.85 [0.78-0.90]). Conversely, the stigma subscale, which recorded 
the lowest mean of all the subscales, had the lowest correlation with the MOS scores 
(MOS-MHS: R [95%CI] = 0.25 [0.04-0.44]; MOS-PHS: R [95%CI] = 0.09 [-0.13-0.30]), 
unsurprisingly, since MOS-HIV does not purport to measure stigma. 
The stigma subscale of the PROQOL instrument is comprised of items pertaining to fear 
of disclosure of HIV status and transmitting the infection. There was a strong 
correlation between having a high frequency of these two fears (p=0.0001), with 33% 
of participants reporting that fears of both disclosure and infecting others were 
often/always on their mind. These participants had consistently lower scores spread 
across subscales other than the stigma domain, particularly in the areas of emotional 
distress (p=0.02), intimate relations (p=0.0007), social relationships (p=0.04) and 
health concerns (p<0.0001). Whilst there appeared to be some attenuation of 
stigmatization with time, a substantial proportion of participants with these issues 
frequently on their mind had been on treatment for some time: 50% for at least 3 
years and 25% for more than 7 years. 
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Table 7: Characteristics of participants (n=102) who took part in the PRO-QOL psychometric testing 
Variables ALL Not on Rx NNRTI PI p-value 
 N = 102 N = 15 N = 46 N = 41  
Female 15 (14.7%) 4 (26.7%) 7 (15.2%) 4 (9.8%) p=0.3 
Age 46 (37-53.8) 41 (32.5-49.5) 48 (37-56.5) 45 (40-53) p=0.4 
Transmission     p=0.08 
Heterosexual/other 42 (41.2%) 10 (66.7%) 21 (45.7%) 11 (26.8%)  
IDU 6 (5.9%) 0 (0%) 3 (6.5%) 3 (7.3%)  
MSM 54 (52.9%) 5 (33.3%) 22 (47.8%) 27 (65.9%)  
Married 34 (33.3%) 5 (33.3%) 17 (37%) 12 (29.3%) p=0.7 
Caucasian 80 (78.4%) 9 (60%) 37 (80.4%) 34 (82.9%) p=0.2 
Living alone 40 (39.2%) 8 (53.3%) 16 (34.8%) 16 (39%) p=0.5 
Post-secondary 37 (36.3%) 6 (40%) 17 (37%) 14 (34.1%) p=0.9 
Unemployed/sickness benefits 18 (17.6%) 2 (13.3%) 3 (6.5%) 13 (31.7%) p=0.007 
Smoker ≥ 2 cigarettes/day 41 (40.2%) 4 (26.7%) 19 (41.3%) 18 (43.9%) p=0.0002 
Alcohol ≥ 2 glasses/day 15 (14.7%) 1 (6.7%) 7 (15.2%) 7 (17.1%) p=0.5 
Diagnosed < 2 years 16 (15.7%) 8 (53.3%) 6 (13%) 2 (4.9%) p=0.7 
Time since diagnosis (years) 7.3 (2.9-15.6) 1.5 (0.8-3.8) 6.8 (3.2-11.9) 13.2 (6.2-18.9) p<0.0001 
Body mass index 24.3 (22-28) 23.6 (22-28) 25.4 (23-28) 23.9 (22-27) p=0.5 
CD4 T-cells 530 (376-733) 546 (512-695) 591 (386-853) 455 (323-638) p=0.1 
Undetectable VL 77 (75.5%) 2 (13.3%) 43 (93.5%) 32 (78%) p<0.0001 
Time on ART (years) 4.2 (0.8-11.8) - 4.4 (2.1-9.9) 10.7 (3.2-13.6) p<0.0001 
On non-ART medication 38 (37.3%) 3 (20%) 15 (32.6%) 20 (48.8%) p=0.1 
ART pill burden (tablets/day) 3 (2-5) - 2.5 (2-3) 4 (3-5) p<0.0001 
Non-adherent to ART 18 (17.6%) - 7 (15.2%) 11 (26.8%) p=0.2 
Depressive 26 (25.5%) 3 (20%) 8 (17.4%) 15 (36.6%) p=0.1 
Other comorbidity 56 (54.9%) 8 (53.3%) 20 (43.5%) 28 (68.3%) p=0.07 
Sexual dysfunction 25 (24.5%) 4 (26.7%) 9 (19.6%) 12 (29.3%) p=0.5 
Number symptoms (total) 5 (2-10) 4 (1-10.5) 5 (1-8) 8 (5-12) p=0.01 
For categorical variables, values are N(%) and the p-value corresponds to a Fisher exact test of equal proportions 
across treatment groups; for continuous variables, values are median (interquartile range) with the p-values 
reflecting differences across the treatment groups as assessed by a Kruskal-Wallis test. 
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Table 8: Linear regression estimates of univariate predictors of mean (SE) increase/reduction (+/-) in PROQOL subscale and global scores (body of table), together with the percent 
of the score variances explained by fitting joint models of covariates blocks as grouped according to indication of sociodemographic, treatment, biomedical or clinical factors 
(R
2
×100).  
 Emotional 
Distress 
Health 
Concerns 
Social 
Relationships 
Intimate 
Relationships 
Stigma 
Body 
Changes 
Phys. Health 
& Symptoms 
Treatment 
Impact 
GLOBAL  
7-factor 8Q-factor 
All patients: Mean (SE) 64.89 (2.63) 54.90 (2.64) 72.55 (2.58) 51.63 (2.98) 43.32 (3.10) 66.48 (2.58) 71.36 (2.14) - 60.62 (2.01) - 
Treated patients: Mean (SE)  65.16 (2.88) 57.69 (2.80) 73.41 (2.79) 52.01 (3.17) 46.66 (3.40) 66.52 (2.73) 71.05 (2.27) 81.08 (1.63) 61.66 (2.21) 64.07 (2.06) 
Sociodemographic factors           
Male gender +8.18 (7.43) +13.56 (7.36) +2.01 (7.33) -9.81 (8.41) +9.77 (8.71) +4.18 (7.32) +3.09 (6.05) +7.36 (4.86) +4.29 (5.67) +4.50 (6.18) 
Transmission (ref: 
heterosexual/unknown) 
          
IDU +11.61 (11.65) +14.29 (11.65) -0.89 (11.49) +2.28 (13.14) +27.39 (13.43)* +1.64 (11.49) +1.29 (9.48) +3.46 (6.77) +8.51 (8.89) +7.60 (8.57) 
MSM +3.51 (5.49) +3.17 (5.49) -2.28 (5.42) -8.60 (6.19) +8.41 (6.36) +2.56 (5.42) -3.01 (4.47) +4.34 (3.46) +0.82 (4.21) +2.20 (4.41) 
Caucasian race +11.38 (6.33) +18.93 (6.16)** +4.84 (6.29) -2.75 (7.29) +5.98 (7.52) +10.87 (6.22) +4.29 (5.20) +11.34 (4.04)** +7.52 (4.84) +9.16 (5.23) 
Age  >45 years +9.04 (5.22) +12.21 (5.16)* +8.24 (5.13) +12.32 (5.87)* +11.00 (6.13) +5.18 (5.17) +6.27 (4.25) +9.25 (3.12)** +9.02 (3.95)* +9.23 (4.02)* 
Living alone -0.33 (5.42) -2.15 (5.42) -11.91 (5.18)* -16.74 (5.91)** -6.87 (6.36) -2.18 (5.32) -6.44 (4.35) +2.82 (3.38) -7.05 (4.1) -4.23 (4.29) 
Diagnosed <2 years -0.98 (7.27) -22.96 (6.91)** -2.65 (7.13) -3.79 (8.24) -18.98 (8.32)* +4.54 (7.13) +6.54 (5.86) -7.04 (5.61) -5.34 (5.52) -3.04 (7.12) 
Unemployed/sickness benefits -23.14 (6.54)*** -5.95 (6.92) -20.63 (6.49)** -16.88 (7.69)* -2.01 (8.14) -25.92 (6.3)*** -27.45 (4.91)*** -10.32 (4.07)* -17.32 (4.99)*** -16.34 (5.01)** 
Post-secondary education +8.44 (5.44) +3.18 (5.5) -0.4 (5.4) -0.8 (6.24) -0.65 (6.47) +3.03 (5.39) +8.22 (4.39) -0.92 (3.42) +3.2 (4.19) +2.17 (4.31) 
Substance use over previous 
2 weeks 
          
Tobacco +1.1 (5.4) +1.49 (5.4) -8.65 (5.22) +6.95 (6.08) +1.75 (6.37) -4.62 (5.28) -7.68 (4.31) -0.81 (3.31) -1.69 (4.13) -1.09 (4.2) 
Alcohol -3.29 (7.46) +10.37 (7.41) -0.06 (7.33) +0.04 (8.47) -0.96 (8.76) +4.12 (7.32) +1.92 (6.06) +3.18 (4.44) +1.88 (5.69) +3.57 (5.6) 
Proportion of variance explained 
by sociodemographic factors 
18.01% 22.49% 19.64% 20.7% 18.74% 20.69% 32.63% 20.6% 22.61% 21.22% 
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 Emotional 
Distress 
Health 
Concerns 
Social 
Relationships 
Intimate 
Relationships 
Stigma 
Body 
Changes 
Phys. Health 
& Symptoms 
Treatment 
Impact 
GLOBAL  
Treatment factors           
On ART +1.82 (7.47) +18.94 (7.24)* +5.92 (7.31) +2.57 (8.47) +22.49 (8.46)** +0.27 (7.33) -2.08 (6.06) - +7.00 (5.65) - 
Current ART (ref: NNRTI)           
none -3.79 (7.96) -19.27 (7.74)* -7.50 (7.80) -6.44 (8.98) -15.00 (8.80) -2.09 (7.82) -2.99 (6.30) - -7.95 (6.04) - 
PI -4.16 (5.75) -0.70 (5.59) -3.35 (5.63) -8.23 (6.48) +15.71 (6.37)* -3.86 (5.65) -10.76 (4.55)* -9.93 (3.10)** -1.99 (4.37) -2.97 (4.13) 
Time on HAART (per year)
 †
 +0.23 (0.5) +1.38 (0.47)** -0.07 (0.49) -0.04 (0.56) +1.44 (0.57)* -0 (0.48) -0.12 (0.4) +0.36 (0.28) +0.43 (0.38) +0.42 (0.36) 
ART pill burden (per tablet/day)
 †
 -2.78 (2) -0.68 (1.96) -2.06 (1.94) -3.74 (2.18) +3.06 (2.36) -2.12 (1.9) -3.06 (1.55) -3.36 (1.08)** -1.56 (1.54) -1.78 (1.43) 
ART non-adherent
†
 -2.48 (7.16) +2.13 (6.96) -3.26 (6.93) -7.21 (7.84) -2.8 (8.4) -1.57 (6.79) -6.58 (5.58) -9.22 (3.91)* -2.95 (5.46) -3.72 (5.07) 
On non-ART medication -8.00 (5.41) -2.57 (5.47) -6.05 (5.34) -6.45 (6.17) +8.08 (6.38) -11.07 (5.26)* -12.39 (4.26)** -1.19 (3.34) -5.35 (4.14) -4.61 (4.18) 
Proportion of variance explained by 
treatment factors 
8.33% 20.27% 4.02% 5.39% 17.01% 6.51% 14.28% 26.55% 10.18% 10.18% 
Biological factors           
Body mass index (per unit) -0.01 (0.58) -0.35 (0.58) -0.29 (0.57) +0.20 (0.66) +0.02 (0.68) +0.08 (0.57) -0.18 (0.47) +0.16 (0.35) -0.07 (0.44) -0.01 (0.44) 
CD4 count (per 100 T cells) +0.25 (0.82) +1.50 (0.81) +0.30 (0.81) +1.90 (0.91)* +0.22 (0.97) +0.80 (0.80) +0.42 (0.66) +0.88 (0.47) +0.81 (0.62) +0.84 (0.60) 
Detectable viral load -9.13 (6.08) -17.09 (5.92)** -10 (5.95) -6.36 (6.94) -13.05 (7.10) -5.94 (6.01) -0.87 (4.99) -10.52 (4.61)* -8.79 (4.6) -10.96 (5.86) 
Proportion of variance explained by 
biological factors 
2.99% 11.15% 3.31% 4.57% 3.47% 2.07% 2.49% 10.00% 4.80% 5.51% 
Clinical factors           
Depressive -27.84 (5.41)*** -11.26 (5.95) -19.64 (5.63)*** -20.76 (6.51)** +4.91 (7.12) -17.22 (5.69)** -24.26 (4.27)*** -6.49 (3.67) -16.48 (4.29)*** -16.42 (4.29)*** 
Other comorbidity -10.5 (5.21)* +0.27 (5.32) -3.97 (5.2) -3.95 (6.02) +9.49 (6.2) -7.59 (5.16) -8.61 (4.23)* -3.35 (3.27) -3.35 (4.06) -4.35 (4.14) 
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 Emotional 
Distress 
Health 
Concerns 
Social 
Relationships 
Intimate 
Relationships 
Stigma 
Body 
Changes 
Phys. Health 
& Symptoms 
Treatment 
Impact 
GLOBAL  
Symptoms            
Sexual dysfunction -26.02 (5.57)*** -22.06 (5.75)*** -6.69 (6.00) -23.14 (6.58)*** -12.38 (7.11) -14.88 (5.85)* -23.6 (4.40)*** -7.86 (3.73)* -18.29 (4.31)*** -16.03 (4.49)*** 
Gastrointestinal (per number) -6.73 (1.53)*** -3.99 (1.63)* -4.2 (1.59)** -5.38 (1.82)** -0.31 (1.97) -5.63 (1.54)*** -8.57 (1.05)*** -3.3 (0.94)*** -4.95 (1.18)*** -5.06 (1.15)*** 
Malaise (per number) -8.11 (1.58)*** -4.75 (1.71)** -6.44 (1.62)*** -4.28 (1.97)* +0.17 (2.09) -8.29 (1.53)*** -9.18 (1.11)*** -2.21 (1.12) -5.95 (1.22)*** -5.84 (1.3)*** 
Morphological (per number) -4.71 (1.36)*** -2.2 (1.42) -2.75 (1.38)* -5.29 (1.54)*** -1.04 (1.68) -4.81 (1.33)*** -4.97 (1.05)*** -1.76 (0.84)* -3.65 (1.03)*** -3.66 (1.01)*** 
Other (per number) -8.39 (2.5)** -4.6 (2.6) -5.32 (2.53)* -4.34 (2.96) -0.8 (3.15) -11.06 (2.34)*** -9.17 (1.93)*** -2.48 (1.58) -6.71 (1.93)*** -7.01 (1.91)*** 
Proportion of variance explained by 
clinical factors 
37.25% 19.37% 19.68% 21.82% 6.7% 29.97% 62.04% 14.2% 31.92% 33.31% 
           
Proportion of variance explained by 
all factors 
63.64% 49.81% 37.24% 46.31% 33.07% 41.26% 75.36% 47.83% 53.01% 55.4% 
P-values: ***<0.001<**<0.01<*<0.05. †Analysis restricted to treated patients only. 
Table 9: Pearson correlations (95% CI) of PROQOL subscale scores with the global PROQOL 8-factor score and the MOS Mental health and Physical Health Scales. Scores are 
obtained from patients receiving anti-retroviral therapy: N = 87 (PROQOL), N = 85 (MOS).  
 Emotional 
Distress 
Health 
Concerns 
Social 
Relationships 
Intimate 
Relationships 
Stigma Body 
Changes 
Physical Health 
& Symptoms 
Treatment 
Impact 
PROQOL 0.86 (0.79-0.9) 0.84 (0.77-0.89) 0.74 (0.63-0.83) 0.81 (0.72-0.87) 0.62 (0.47-0.73) 0.77 (0.67-0.84) 0.73 (0.61-0.81) 0.63 (0.48-0.74) 
MOS MHS 0.72 (0.60-0.81) 0.67 (0.54-0.78) 0.49 (0.31-0.64) 0.50 (0.33-0.65) 0.25 (0.04-0.44) 0.57 (0.40-0.70) 0.80 (0.71-0.87) 0.45 (0.27-0.61) 
MOS PHS 0.48 (0.30-0.63) 0.45 (0.26-0.6) 0.42 (0.22-0.58) 0.36 (0.16-0.53) 0.09 (-0.13-0.30) 0.55 (0.38-0.68) 0.85 (0.78-0.9) 0.38 (0.18-0.55) 
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Discussion 
We have gathered data on health-related quality of life in our cohort using qualitative 
and quantitative methods, validated instruments and the new PROQOL HIV patient 
report outcomes measure. This is the largest study of HRQL in Western Australia since 
the HIV epidemic began thirty years ago. The results from these surveys, supported by 
the interview material, demonstrate that HIV disease influences HRQL across the 
spectrum of biological, social and psychological domains that comprise the complex 
continuum of measures of health (I. B. Wilson & Cleary, 1995). In particular, people 
reporting unemployment, depression, and a higher frequency of symptoms, especially 
those impacting negatively on sexual expression, scored a poorer quality of life overall, 
independently of other factors and regardless of ART status. Interview respondents 
struggling with romantic relationships described feelings of loss around cessation of 
sexual practices relinquished to prevent transmission; opportunities to engage in 
sexual activity without the burden of disclosure; fear of rejection and the potential for 
transmission despite use of safer sex strategies. Accordingly, the novel instrument 
captured dimensions of stigma, by way of an individual’s fear of disclosing their HIV 
serostatus and/or transmitting the infection that clearly results in emotional distress. 
Therefore, although the widely used HIV/AIDS-Targeted Quality of Life Instrument 
(HAT-QOL) has a dimension for disclosure concerns (W. C. Holmes & Shea, 1997, 1998), 
the PROQOL–HIV goes a step further and juxtaposes anxiety about transmitting the 
infection with fear of disclosure.  
The survey showed that feelings of stigma were heightened in those more recently 
diagnosed in contrast with those who had a longer history of HIV infection, including 
those infected via IDU who might be expected to experience compound or layered 
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stigma related to their membership of another marginalised group (Goffman, 1963). 
However, in the interview group those perceptions of stigma appeared to have 
persisted over time for the majority, and particularly by way of effects on relationships 
and employment opportunities, as has been found in other studies (Bouhnik, et al., 
2008; Logie & Gadalla, 2009; Rongkavilit et al., 2010).  Holzemer and colleagues (2009) 
showed that stigma had a negative impact upon quality of life independently of HIV-
related symptoms and severity of illness. More recently Hutton, Misajohn and Collins 
(2012), using the personal well-being index (PWI-A), reported that stigma impacted on 
subjective wellbeing in PLWH in Australia and the USA. While disclosure fears have 
been reported in a number of studies (Anglewicz & Chintsanya, 2011; Bouillon et al., 
2007; Hosseinzadeh & Bazargan-Hejazi, 2011; Kalichman et al., 2007; Körner, 2007c; 
Logie & Gadalla, 2009; Nachega et al., 2012; Rongkavilit et al., 2010; Wolitski, Pals, 
Kidder, Courtenay-Quirk & Holtgrave, 2008) we could not find evidence in the 
literature to confirm that transmission anxiety per se is a cofactor in HIV-related 
depression, or studies of interventions targeted to reduce transmission fears and lower 
anxiety. However, there have been interventions aimed to increase coping and reduce 
stress in PLWH, and contagion fears have been addressed in educational interventions 
with uninfected individuals (Brown, Macintyre & Trujillo, 2003). Courtenay-Quirk, 
Wolitski, Parsons and Gomez (2006) found that HIV/AIDS stigma in a community of 
HIV-positive men who have sex with men was associated with increased levels of 
anxiety, loneliness, depressive symptoms, suicidal ideation and avoidant coping 
strategies. Winnie Mak (2007) however, in a meta-analysis, explored the relationship 
between stigma (not specific to any condition) and mental health and found 
‘meaningful patterns’ between the constructs but no strong moderators. She 
acknowledged that this may be due to limitations in her study, and the diversity of 
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measurement instruments used in the studies included in the analysis, among other 
factors.  
It is concerning in this sample, that the fear of infecting others, which in some 
individuals results in irrational behaviour, will likely not be uncovered in the course of 
most clinical consultations, and may be linked to depression which we note was 
prominent in our cohort in direct comparison with others in the larger study. Since 
stigma may be nuanced by its various associations with sex, death and ethnicity 
(Goffman, 1963), and deeply internalised (Herek, 2002), it could be examined by 
assessing the limits that people place upon their lives as a result of the anxiety. 
Furthermore, it was observed that the intensity of disclosure fear is proportional to the 
fear of infecting others, which, while it seems to be attenuated by duration of 
infection, persists for a large proportion, although some people perceived stigma but 
attributed it as a problem of ‘others’.  
A number of demographic factors contributed to a diminished perception of HRQL 
among the respondents to the interviews and the questionnaires. Notably people 
living alone cited restricted intimate and/or social relationships, although whether this 
was as a result of self withdrawal or inhibition with regard to disclosing HIV status, or 
some other reason, is not clear. Older age and longer duration of HIV were associated 
with an improvement in HRQL, as observed by others (Tsevat et al., 2009). In 
particular, older Caucasians were less troubled by health concerns related to regular 
CD4 and viral load monitoring and progression of the disease, perhaps reflecting their 
adjustment to diagnosis, better knowledge of the disease and/or greater confidence in 
the treatment, reinforced by successful treatment outcomes. However, 
unemployment and disability resulted in diminished HRQL regardless of age and the 
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interviews revealed a picture of social isolation and physical discomfort not necessarily 
directly attributable to HIV disease.  
People on PIs reported more symptoms, especially gastrointestinal, and more tablets 
overall compared with those on NNRTI regimens. This translated into greater 
treatment impact, but not into reduced HQRL overall, most likely because of 
improvements in overall physical health and perhaps psychosocial adjustments 
associated with the longer average duration of ART and time since diagnosis. The level 
of adherence in our patients was higher than in the other cohorts in the international 
study, perhaps reflecting once daily dosing (Juday, Gupta, Grimm, Wagner & Kim, 
2011) and our standard of adherence support (Herrmann et al., 2008b) but we did not 
find a direct relationship between adherence and global HRQL. However, non-
adherence to ART remained predictive of lower treatment impact scores over and 
above treatment choice and viral load but with some abrogation, once account was 
taken of the number of gastrointestinal symptoms, although this was not statistically 
significant. This finding suggests that the benefits of treatment were not perceived by 
non-adherent participants.  
This study consolidates the utility of the new PROQOL-HIV instrument which had been 
powered to show significant site-specific effects of covariates on HRQL domains. The 
total HRQL scores from the test PROQOL-HIV and the MOS-HIV in the Australian group 
were similar to France, USA, Thailand and Brazil but higher than in the Chinese cohort 
in the larger study. Briongos-Figuero and colleagues (2011) demonstrated comparable 
total MOS-HIV scores in a Spanish cohort which matched the Australian for age, but 
encompassed more women, IVDU transmission and HCV coinfection. Carrieri and 
colleagues (2003), proposed that influential dimensions impacting HRQL may be 
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missing from the MOS-HIV and showed that ART initiation was associated with general 
improvement in HRQL moderated by immunodeficiency, time since diagnosis, 
increased age, side effects and choice of regimen. In our study the combined covariate 
sets explained 75% of the variation in the MOS-HIV PHS and 70% of the MHS but 55% 
in the PROQOL score variation suggesting this score may incorporate facets additional 
to just health-related components. This finding concurs with I. B Wilson and Cleary’s 
(1995) conceptual model suggesting that total HRQL is substantially impacted by some 
hard-to-measure factors relating to personality, which may contribute to resilience and 
coping (A. Armstrong, Galligan & Critchley, 2011; Frain, Berven, Chan & Tschopp, 
2008). It is likely that MOS-HIV with a greater focus on general physical and mental 
health correlates better with symptoms and clinical factors emanating from non-HIV 
comorbidities. In contrast, PROQOL-HIV is measuring concepts of quality of life that are 
specifically related to HIV and is assessing additional information from a patient 
perspective that cannot be adequately inferred from the usual sociodemographic or 
biological variables. 
There were limitations to our study. Cross-sectional design is less robust than 
longitudinal measurement where responses are measured over time; however, the 
qualitative component strengthens the internal validity of the study. The closed-ended 
format of the questionnaires did not accommodate explanations, but the questions 
were derived from the themes gathered in the interviews where respondents qualified 
their responses to semi-directive questions freely. There are, potentially, factors not 
accounted for that influence quality of life; some of these may relate to idiosyncrasies 
in personality. However, the interview data captured aspects of acceptance, 
adaptation and coping in a number of respondents which reflected their experience of 
living with HIV. 
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The development of PROQOL-HIV, has allowed the measurement of dimensions not 
assessed in the past. Application in this local setting has demonstrated that the 
instrument will provide a useful tool in cohort analysis to assess health-related quality 
of life in general, and those that result from treatment interventions in particular. 
Inclusion of a stigma domain adds further utility since it is evident that stigma is a 
persistent feature of HIV-infection and may result in emotional harm, especially in 
those less resilient.  The multiple nuances of stigma should be disentangled in future 
research in order to develop suitable interventions. In conclusion, disease-specific 
HRQL instruments can bring additional information to the classical criteria for 
evaluating clinical outcomes and should be part of studies evaluating health policy and 
treatment strategies (Chassany, Sagnier, Marquis, Fullerton & Aaronson, 2002).  
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CHAPTER FOUR PEOPLE IN RURAL AND REMOTE ENVIRONMENTS 
Background 
In the first twenty years of the HIV epidemic in Western Australia (WA) HIV infection 
was largely confined to high risk groups, namely men who have sex with other men 
(MSM) and people who inject drugs (IVDU), within a relatively static local population. 
Since 2002, however, there has been a steady rise of HIV notifications to the WA 
Department of Health among women and heterosexual men, against the previous 
trend of risk and transmission in MSM (Combs & Giele, 2009). Geography, population 
mobility and the idiosyncrasies of health care provision across the state have also 
served to shape the epidemic and influence health outcomes. The rise in numbers of 
people living and/or working in remote areas (see Figure 1 in the Introduction) who 
are both citizens and non-citizens, has added to the complexity of managing HIV; and 
for the person affected may present numerous personal challenges including living in a 
small community and  distance from specialist HIV care .  
 
Figure 17: Map of designated regions  
URL: http://www.ruralhealthwest.com.au/go/about-us/wa-regions 
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These changes in the social and ethnic diversity of the current epidemic in this state 
have not yet been described in peer reviewed publications on the subject of living with 
HIV in country areas or on rural HIV services in WA, although there have been 
conference presentations and reports in recent years related to models of care and 
workforce planning for example (Cain et al., 2008; McLean & Savage, 2009). More 
recently, a WA Department of Health-initiated evaluation of HIV management in rural 
and remote areas was carried out in 2010, but is not publically available. Researchers 
(Bonar et al., 2004; Newman et al., 2007a; Newman et al., 2007b; S. C. Thompson et 
al., 2009) have published Western Australian studies giving valuable, firsthand 
accounts of the complex attitudes of Aboriginal people towards HIV and usage of anti-
retroviral drugs, however the experience of non-indigenous people living with HIV in 
rural WA has not been described to my knowledge. Since linkage and engagement with 
HIV services is a critical factor in determining health outcomes in PLWH, this chapter is 
divided into two parts focusing on: Part One (a) the perspectives of health care 
providers on delivering care to people with HIV in the North-West and Goldfields 
(Kalgoorlie-Boulder) regions; and (b) a brief description of those cohorts. Part Two 
contains the results of interviews with 19 ‘patient’ participants who either reside or 
work in rural areas, detailing their experience of living with HIV, and accessing care and 
treatment. Three of these participants were from the Kalgoorlie-Boulder region, the 
rest were dispersed across Western Australia. Interview data from nine participants 
used in Chapter Four will also be accessed in Chapter Five since Chapter Four is 
concerned with issues of geographical remoteness; and Chapter Five, with visa status.  
Themes emerging from the participants’ narratives are discussed at the end of the 
chapter but will be explored further in Chapter Six. 
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A Tale of Two Cohorts: The North-West and Goldfields HIV-Outbreaks 
The introduction of effective combination antiretroviral drugs in the mid-nineties 
resulted in fewer deaths from AIDS, and a growing but clinically stable population of 
(N=~1700) individuals is currently linked with a simple network of state-wide clinical 
services provided by either RPH, Fremantle or Sir Charles Gairdner Hospitals, their 
rural outreach services (RR Service) and in cooperation with the WA Country Health 
Service. There is one small but growing cohort (N=~32 in mid 2010) of Aboriginal 
people dispersed over the North-West (NW) of the state and about 15-16 of them are 
followed up by staff at the Gascoyne Population Health Unit. A second, more 
epidemiologically diverse cohort of ~30 patients is engaged with the Goldfields 
Population Health Unit in Kalgoorlie-Boulder (K-B). Both the ‘North West Town’ and 
Kalgoorlie-Boulder are within the Yamatji region of Aboriginal people. An arrangement 
with the Rural and Remote Service at Royal Perth Hospital has created the ‘shared care 
model’ described in Chapter Two. In both of these cohorts, HIV was acquired largely 
through unprotected sexual contact between men and women, but the K-B cohort is 
representative of a divergent epidemic reflecting international population movement 
from high prevalence to low prevalence areas driven by travel and work opportunities.  
The Service Model  
The current service model seeks to deliver optimal care state-wide. Central to 
successful management of HIV is the provision of ART. In addition, HIV education, 
medication adherence counselling and psychological support are hallmarks of effective 
HIV care, although access to these and in particular to specialist services, is limited in 
country areas. Since the emergence of HIV in Australia 30 years ago, controlling the 
epidemic ‘in the bush’ has been an overriding and sometimes very public (Date, 1992), 
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concern for health care providers because drivers of HIV transmission, such as rates of 
sexually transmitted infections (STIs) and drug and alcohol use, are higher in rural 
areas (Wright et al., 2005). However, despite continued high rates of STIs, rates of HIV 
transmission, particularly among Aboriginal people remain low (National Centre in HIV 
Epidemiology and Clinical Research, 2011). In the North-West region this is largely 
attributed to a swift response to the original outbreak and uninterrupted, intensive 
health care provision to affected individuals now known as the ‘North-West Cohort’. 
Nonetheless, there are increasing numbers of non-indigenous Australians with HIV 
infection residing and working in regional areas, together with a growing number of 
infections in non-citizens or temporary guest workers which have been contracted 
outside Australia. Some in this group are based in Perth or in Kalgoorlie-Boulder and 
travel to work on mine sites in remote locations. It is notable that some FIFO workers 
traverse the country from centres on the east coast of Australia. Table 11 provides a 
demographic ‘snapshot’ of the Kalgoorlie-Boulder region. 
Attainment of treatment goals are challenged in Aboriginal Communities  
The goal of administering ART is to reduce the level of virus in individuals to a point at 
which it is considered undetectable using current tests. Reducing the viral ‘load’ 
stimulates immune recovery and moderates the risk of HIV transmission. However 
failure of medication usage to treat many acute and chronic conditions in Aboriginal 
communities has led to poor health outcomes and unnecessary mortality from all 
causes. While HIV medication adherence rates have improved over the last ten years in 
the metropolitan area (Herrmann et al., 2008b) likely through improved, more 
tolerable drug treatments and supportive, educative measures, there is, purportedly a 
dissonance between Aboriginal cultures and belief systems and Western medical 
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culture (McConnel, 2003). This has resulted in poor adherence to ART and other 
medicines in Aboriginal people infected with HIV despite some successes in the North-
West Cohort over the years. Health providers’ early concern over adherence issues has 
been a factor underpinning the provision of funds and the deployment of health 
workers to rural areas, and has shaped the way that HIV care is delivered.  
Methods Specific to this Chapter 
Interviews with Health Care Providers (Key Informants) 
Semi-directed interviews lasting between 50-60 minutes were conducted at Royal 
Perth Hospital with the Rural and Remote Clinical Nurse Specialist and an HIV Physician 
with a long-term association with the rural outreach service. Much of the information 
from these interviews provided contextual data for the methods section (Chapter 3) of 
the thesis. Health providers in Kalgoorlie-Boulder and the ‘North West Town’ were also 
interviewed in those towns in May and September 2010, respectively. Interviewees 
(Goldfields) were: the Public Health Physician (PHP) and the Senior Public Health 
Nurse, Population Health, WA Country Health Service. In the North-West Town: the 
Public Health Physician of the Gascoyne Population Health Unit, the Public Health 
Nurse, the Aboriginal Health Worker and the Unit’s Secretary. The NW PHP was 
interviewed alone and the three other staff members as a group. In Kalgoorlie-Boulder 
and Perth the interviews were conducted one on one. The interviews began with a 
request for informants to describe: their roles; background relevant to their cohorts; 
particular challenges managing and administering HIV clinical care; engagement with 
patients; ensuring follow-up and achieving good clinical outcomes. Patterns of 
communications within the RR Service were also explored. Questions were open-
ended, conducted in a conversational manner and informants were encouraged to 
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express professional opinion. The interviews were recorded, transcribed and sent to 
the interviewees for further feedback.  
Interviews with Participants  
Interviews with 16 patients enrolled in the Rural and Remote Service and those who 
identified as working in remote areas were conducted at Royal Perth Hospital in Perth. 
Three more patients were seen in the Population Health Unit in Kalgoorlie-Boulder 
(total N=19) at an outreach clinic held in August 2010. One of those patients had been 
interviewed in the RPH clinic prior to the Kalgoorlie outreach clinic and was followed 
up subsequently, again at RPH. Semi-directed interviews lasted between 40-130 
minutes and were recorded and transcribed. Questions were open-ended and based 
on the broad themes that emerged from the PROQOL-HIV study and gaps in previous 
research in the same centre. Patients were encouraged to speak freely about issues 
important to them but questions relating to ART access and experience of taking 
medication were explicit.  
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Part One 
Clinical Data 
The WA HIV Cohort database was accessed to audit clinical data and present group 
statistics for the cohorts in the North-West Town and the Goldfields in mid 2010. This 
data can be found in Table 10.  
Table 10: Group statistics for cohorts in the North-West Town and the Goldfields (audit data mid-2010) 
Variable Kalgoorlie-Boulder n=22 (%) NW Town n= 12 (%) 
Age in years (mean (SD); range) 39.6 (9.1); 28-66 35.8 (4.1); 29-44 
Gender f/m 9f/13m 10f/2m 
Ethnicity    
African 9 (40.9) 0 
Caucasian 6 (27.3) 0 
Asian 3 (13.6) 0 
Aboriginal 3 (13.6) 12 (100) 
Unknown 1 (4.54) 0 
Have children  ~11 (50.0) ~7 (31.8) 
Visa status   
Temporary 9 (40.9) 0 
Permanent residents 12 (54.5) 12 (100) 
Unknown 1 (4.54) 0 
Probable place of infection   
Australia 4 (18.2) 12 (100) 
Overseas 17 (77.2) 0 
Unknown 1 (4.54) 0 
Years since diagnosis (mean (SD); median) 6.3(7.0);3 13.4 (2.8);15 
   
*Treatment status   
On ART 15 (68.7) 8 (66.7) 
Generic ARVs 5 (33.3) 0 
Viral load detectable/no of treated patients 6/15 (40.0) 7/8 (87.5) 
CD4 T Cell count mm
3 
(%)         Mean (SD) 520.7 (230.2); 24.6 (8.1) 652.5 (384.2); 22.9 (12.4) 
*Unknown for two patients  
Within the Kalgoorlie group it was documented that fifteen patients taking ARVs 
reported complete adherence in the month before their clinic visit. One patient was 
receiving directly observed treatment (DOT), and two had assistance filling either 
calendar boxes or Webster-Pak®. Eleven patients had their treatment scheduled once 
daily. Two patients had reported interruptions to their treatment, another reported 
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missing doses. Thirteen patients were married or partnered although there were two 
patients whose status was unknown, and eleven had children whose HIV status was 
not available.  
For the North-West cohort adherence monitoring data was not available in the 
database, but six of the eight patients treated with ART had detectable virus. Five were 
taking their ARVs once daily but had concomitant medications that were scheduled BD. 
Seven of the patients in the group were known to have children. 
Access to Anti-Retroviral Drugs in Regional Areas 
For the North-West cohort antiretroviral drugs are prescribed by the RPH-based 
Immunologist who reviews the patients’ clinical results either during a clinical case 
review teleconference between the PHP and Population Health Unit team, or directly 
during the outreach clinic when the hospital-based team travel to the North-West 
Town to see patients, once or twice a year. These clinics have not always been 
successful as oftentimes Aboriginal clients have not kept appointments with the 
hospital specialists (personal communication, Martyn French, 7 June 2011). This 
potential discontinuity in care between client, the North-West providers and the RPH 
specialist service is mitigated in part, by the teleconferences and by the quick 
turnaround time for feedback to questions directed to the RPH service by email or 
telephone and triaged by the RR Nurse coordinator. It has meant that: “If there’s any 
queries (sic) in between then we just send an email and then within hours we get a 
response so it’s extremely responsive support” (Public Health Nurse, North-West 
Town). This serves to augment local care with specialist input. The Schedule 100 drugs 
prescribed by HIV specialist physicians are couriered to the Population Health Units in 
the North-West Town or Kalgoorlie-Boulder and are then taken to a local pharmacy for 
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individualised calendar (Webster-Pak®) packing with any other prescribed drugs. This 
practice serves to promote safe and uninterrupted use of medicines but also to 
disguise ARVs so that clients can avoid family or friends becoming aware of their HIV 
status.  
In the Goldfields nearly half of the cohort is ineligible for Medicare and PBS subsidised, 
patented antiretroviral drugs. Five patients are importing generic bioequivalent drugs 
purchased from internet vendors which sent to their homes. Unlike communication 
practices with the North-West, teleconferencing is less common, clinics are more usual 
and fewer patients have their medication prepared in calendar or ‘dosette’ packing. 
Table 12 contains an extract of my field notes taken during the outreach clinic 
conducted at Kalgoorlie- Boulder in August 2010. 
Interviews with Key Informants 
The North-West cohort: ‘containing’ an epidemic  
Incidental testing for blood borne viruses led to the first diagnosis of HIV in an 
Aboriginal man from the North-West in 1994 when he was being treated for a trauma 
injury at RPH. After screening approximately 300 people in the NW, some of them four 
or five times, twenty five were found to be positive for HIV. More females than males 
were found to have the infection, two were non-indigenous and one was Medicare 
ineligible. The size of the current cohort engaged with the Gascoyne PHU numbers 15-
16 patients.  
The view of the PHP as to why there was not more extensive transmission of the virus 
is that a large proportion of infections were in women and the virus transmits less 
efficiently from female to male. However, she added that patients also underwent STI 
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and HIV screening every three months and infections were treated so that conditions 
that favoured HIV transmission (other STI coinfection, and lack of awareness of HIV 
serostatus) were reduced. She also noted that there was a reduction in sexual activity 
although there were “some women who continued to put themselves at risk” and 
others “who were also putting others at risk on a regular basis” by failing to have 
protected sex. In addition, two of the four men infected were “extremely sexually 
active, extremely” and both of them, due to ongoing risky sexual behaviour, were 
required to go on case management in the local town. This took the form of a curfew 
preventing them from going out at night and placing them under the supervision of the 
PHP who visited every day up to three times in 24 hours. The alternative was to 
exercise the provision under Public Health Act and send one of the men to Perth, to an 
isolation unit (which to the PHP’s knowledge has never been used). She noted that 
“that was considered too expensive actually, more than anything else.” Evidence that 
there was ongoing unprotected sexual intercourse was confirmed by rates of other 
STI’s and that sixteen babies had been born since the epidemic started in the region. 
The imperative to test, diagnose, treat, assess and monitor people with HIV in the 
North-West led to the establishment of the Rural and Remote HIV Service at RPH, 
funded through WA Country Health. However, Federal Government concern over an 
(long feared) outbreak of HIV in Aboriginal people living in rural areas prompted the 
funding, independent of the WA Country Health budget, of extra staff, including two 
dedicated Aboriginal support workers and a non-Aboriginal case manager to assist in 
containing the epidemic. This funding arrangement represents one of the many points 
of difference between the NW and Goldfields cohorts. 
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Kalgoorlie-Boulder: the ‘divergent’ epidemic  
The impetus for an outreach clinic in Kalgoorlie-Boulder (K-B) arose in part from the 
successful shared care model in the North-West. Previously people from the Goldfields 
diagnosed with HIV would travel to Perth, seven hours by train, although their 
immediate health needs were met by GPs in liaison with RPH and the Population 
Health Unit in Kalgoorlie-Boulder. The establishment of an outreach clinic meant that 
trips to Perth could be avoided, translating into a cost saving for both the health 
budget (via the Patient Assisted Travel Scheme) and the patient in terms of time away 
from work, family and child care responsibilities. The funding for the outreach clinic 
comes from Rural Health West which is the organisation responsible for the 
recruitment and retention of a rural health workforce. This organisation supports fares 
and accommodation for the medical specialist but not the RPH nurse who is the 
primary HIV clinical contact for patients and medical staff across the regions. As well as 
offering patients support, queries from GPs and other health professionals are triaged 
by the nurse directing them, expediently, to appropriate specialist advice at RPH.  
The Kalgoorlie-Boulder Population Health Unit is directed by a Public Health Physician. 
Like the Unit in the North-West Town, the core purpose of the organisation is to 
prevent the spread of infectious diseases in the community. Infections classified as 
Notifiable under the Health Act of 1911 (WA), for example, sexually transmitted 
infections, like chlamydia, and blood borne viruses such as HIV or hepatitis C, are 
recorded in the Western Australian Notifiable Infectious Disease Database (WANIDD). 
In addition, the organisation is responsible for sexual health promotion and prevention 
of infectious diseases (by way of, for example, vaccination programmes), and injuries 
from alcohol and other drugs. There is also liaison with community health, school 
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nursing and environmental health services, an example of which is the recent lead 
contamination of water supplies in the Esperance area. Although there are several 
sexual health nurses, at the time of my visit to the region in 2010, the responsibility for 
HIV management has fallen upon one Senior Public Health Nurse.  
Table 11: Kalgoorlie-Boulder and the surrounding region 
The Goldfields area covers almost a third of WA's total land mass and is the largest region in WA. Its 
population is around 59,000, with an estimated 8% of the population being of Aboriginal descent, 
compared to 3% for Western Australia as a whole. There are 17 Aboriginal communities within the 
region. Although just over half the population in the Goldfields lives in Kalgoorlie-Boulder, the transport 
hub for the region, a significant number of workers fly in from Perth and the east coast to work on 
remote mining sites (FIFO). The East-West (Indian Pacific) railway passes through the town and the 
airport hosts regular flights in and out of Perth, 595 kilometres west south-west, and more recently, 
Melbourne, to service the demand for FIFO workers. The town supports administrative organisations 
that underpin the activities of the pastoral and mining industries; and government agencies including 
health and education; in addition to retail, recreation and tourism businesses. In the south, Esperance is 
the major population centre of approximately 13,000 people. Its port is one of the busiest in WA since it 
supports the agricultural, fishing and mining industries of the entire region (City of Kalgoorlie-Boulder, 
http://www.ckb.wa.gov.au/). 
The Public Health Physician characterises the Goldfields regional HIV epidemic thus:  
We’ve got all sorts of people Australian, non-indigenous Australians who 
contracted it one way or another either through, either they’re men accepting 
men or they got it abroad or something and they vary from being again you 
know dream patients to people who I need to put a bit of effort into. There are 
people on 457 visas who are on the whole, as a group they need more resources 
because for all various reasons around Medicare access, confidentiality, not 
wanting anybody to know, they tend to use us a bit more you know particularly 
a lot of them use me as their GP because I don’t cost anything, they don’t know 
how little I know but they come to me. And then we do have some indigenous 
clients and they, I think there will be other places where they have indigenous 
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clients who do not cause any issues but we, ours, cause issues and cause us to 
be, to struggle. 
With regard to the ‘457’ ‘contingent’ group, the PHP noted that HIV infection was 
often diagnosed in a temporary visa holder following treatment for a different, major 
illness. This has resulted in the need to alert the regional medical community to risk 
factors other than MSM contact, such as travel and place of birth, when patients 
presented at their practices with constitutional symptoms indicative of HIV infection.  
The K-B team also describe challenges with the small number of Aboriginal people with 
HIV infection in their region that are echoed by the NW staff. In particular, they speak 
of the social support needs of the patients that are necessary to augment their 
medication adherence. According to the PHP, the region lacks allied health staff and 
the one social worker at the local hospital is busy dealing with inpatients. The 
Aboriginal Health Service, although providing other non-HIV care, does not support 
HIV medication adherence in clients so the PHN K-B has extended her role as she 
comments here:  
...the team provides a huge social work type role which we shouldn’t be doing. 
But in order to make sure [the patient] takes medication we have to do that and 
we’ve been sort of sucked in over the years into providing more and more of 
that and people are, there’s nobody else would do it. 
Although the treatment as prevention approach is now adopted as a strategy to reduce 
transmission of infection at a population level, clinicians and particularly those working 
in public health are ‘vocationally’ motivated to support any measure that underpins 
critical medication adherence behaviour in individuals. Therefore, HIV management 
has been shaped by this context. The PHN explains: 
There are a large number of people who live the same, exactly the same life as 
[the patient] does who nobody gives a stuff about, the only reason that we care 
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at all about this *patient+ is that she’s/he’s a public health problem you know 
otherwise no one would care. So it’s not, I mean it’s just an indictment on the 
system rather than, and it’s just we got, we feel obliged to make sure *the 
patient] remains as low a public health risk as possible. 
This comment underscores the responsibility placed on public health providers to 
contain infectious disease. The transmission pattern of HIV disease is intrinsically 
challenging to track since approximately 40% of transmissions occur when people are 
unaware of their serostatus. Furthermore, the disease can remain asymptomatic for 
many years before constitutional symptoms of deteriorating immunity occur. The 
tension for providers responsible for communicable disease management is clear. The 
K-B physician further explains the importance of drug treatment:  
..we’ve got some people that we think are misbehaving from all categories, well 
I mean every category I’ve talked about. The non-indigenous Australians, the 
indigenous Australians, the people born overseas...and it scares the hell out of 
me ‘cause I don’t know what I don’t know and what’s going to pop up. The only 
saving grace is all the people we know about are, were, maintaining either on 
therapy or pre-therapy where we’re maintaining low viral loads on pretty much 
all of them.  
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Table 12: The Kalgoorlie-Boulder Outreach Clinic: Dosettes in the dust 
On 7 August 2010 I flew into Kalgoorlie on a busy 6am flight from Perth in the wake of 
the Diggers and Dealers conference held in the town earlier that week; and on the same flight 
as government ministers in full election ‘mode’. My companions were the Rural and Remote 
Nurse Coordinator (RRN) and a pharmaceutical company representative who was sponsoring 
the dinner at the restaurant where an educational talk was to be given that evening to GPs and 
other health providers. These talks, given after each outreach clinic by the visiting specialist, 
are a condition of ongoing funding for the service by Rural Health West. 
 
In Perth, the RRN had collated clinical information from the WAHCS on the patients 
with appointments and assembled equipment such as Dictaphones, stethoscopes, 
ophthalmoscopes. The Infectious Diseases Physician or ‘Indie Doctor’ had travelled up the day 
before and spent some hours at the Population Health Unit downloading results of blood tests 
from a computer linked with the PathWest Laboratory in Perth, so that they would be available 
for the two clinics. To avoid local gossip when travelling in country areas, the nurse tells me she 
deals with casual enquiries by curious locals by trying not to look like a medical professional 
and has in the past said that she is a midwife to deflect interest in the real reason the team is in 
town – to deliver care to people with HIV infection. We don’t look like a medical team although 
the nurse is somewhat ‘outed’ at security by the guard who wants to know of what use is the 
ophthalmoscope.  
 
The ‘Indie Doctor’ had a long day ahead of him when he picked us up at the airport at 
7am. Patients were local but some had travelled from other towns in the region, one patient 
had driven for three hours. The appointments were made by the RRN in person working out of 
the Perth office, by phone or email. Some of the working people took advantage of the 
opportunity to attend a clinic on the Saturday morning. The preparation ensured that each 
patient had a recent blood test (HIV RNA quantitation, CD4 T-Cell count, and any other tests 
indicated by the patients’ GP or from previous clinical encounters). Pre-populated blood forms 
were posted to patients who attend the PathWest collection Centre in Kalgoorlie-Boulder for 
phlebotomy. The blood sample was couriered to the PathWest RPH laboratory in Perth. HIV 
monitoring in the regions creates tensions for the patients and the staff since the blood does 
not always arrive at the lab within the four hour window required for a reliable assay. 
Furthermore, all of the patients are concerned to ensure their HIV serostatus is not known by 
non-medical staff. Apparently, in the recent past, phlebotomists have inadvertently disclosed 
clients HIV serostatus causing them to become angry, embarrassed and distressed. 
 
To maintain patients’ privacy during the clinic, appointments in the long sprawling 
building were staggered and by using one door as a dedicated entry and another as an exit so 
people were less likely to encounter each other. I was provided with a small private room in 
which to conduct interviews with patients. The nurse attended each clinical consultation and 
frequently walked with the patients as they left the building chatting informally. At the end of 
the clinic a team case meeting took place and each patient’s medical care was reviewed.  
 
At the evening presentation the Indie Doctor—mindful of the demographic of the 
current epidemic in WA—focused his presentation on communicable diseases commonly 
presenting in travellers, temporary visa holders and migrants/refugees, which, he noted, could 
make diagnosis challenging. The talk was well received and the gathering gave an opportunity 
for local health workers to meet and discuss common professional interests with their 
colleagues from the city as well as catch up with local news. 
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Managing HIV in the North-West: Engaging with PLHV  
In 1998, a major challenge for the Gascoyne PHU was how to ensure the ongoing 
engagement with patients necessary to implement successful HIV treatment and 
prevention strategies and avoid morbidity and deaths from AIDS. The PHP described 
the public health imperatives of the time: 
[What was] really critical in terms of reducing ongoing transmission was two 
different mechanisms of contact: One which is all supportive which is us 
[including the Aboriginal health workers], and another which is more of the 
policeman thing which is, you know, making sure they know their rights and 
responsibilities. 
Separating the two roles prevented confusion in clients. Today the service employs a 
senior public health nurse and an Aboriginal health worker but the team includes the 
unit secretary whose continuity of employment over ten years, knowledge of the 
workings of the local community and pragmatic approach to problem solving has 
extended her role beyond that of office administration, to offer wide-ranging support 
for clients and health workers and particularly when there was staff upheaval: 
If other people were busy and somebody needed to be brought back (home) I 
was quite happy to take them back home or on the way home pick up their 
medication from Amcal [the local chemist] and all those sort of things which 
today we are still doing. So I wasn’t only just sitting at my desk I became really 
quite closely involved with our clients.... Many, many times there was just the 
two of us like ‘the period’ that people had left and weren’t replaced was a very 
difficult period, but I suppose, for me, I just became more and more involved. I 
have had long periods when I was just the only one here so I, when I got phone 
calls or people came, I had to help them to get what they needed and I sort of 
loved that...  
(Secretary) 
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All the interviewees described their service as having good engagement with the 
clients and a collegiate relationship with doctors and local hospital staff who are likely 
to manage the HIV-infected clients’ comorbidities, such as diabetes and renal disease. 
It was noted that a period of staff stability at the local hospital has underpinned 
efficient co-management between the PHU and hospital doctors and allowed the 
hospital doctors time to establish trusting relationships with the clients.  
Adherence to Antiretroviral Drugs 
Engagement with health care providers: trust and continuity of care 
Central to promoting uptake, adherence to and persistence with treatment is the 
therapeutic relationship between the patient and the provider. Recurrent themes 
throughout all of the informants’ interviews were related to the importance of 
establishing and maintaining relationships in order to ensure engagement and 
retention in medical care. The Rural Nurse Coordinator puts it this way: 
Engagement, building rapport, building relationships because the most 
important aspect is when you first —I think— see a new client with HIV, ‘cause 
if they don’t like you they’re not going to come back.  
Trust was a word that was frequently used by all the informants, particularly in relation 
to the maintenance of confidentiality within communities. The Aboriginal Health 
Worker put it this way: “and it is the trust where you don’t open your mouth.” 
Fear of disclosing HIV status and of family ‘finding out’ is particularly strong within the 
Aboriginal community. Health care workers go to great lengths to protect against 
inadvertent disclosure of their clients HIV status to other members of their family and 
since family (kinship) ties can be complex to non-indigenous outsiders this can be 
difficult and lead to some complex management practices. Employing Aboriginal 
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health care workers helps to ensure that kinship issues that might affect HIV 
management are taken into consideration. Providers have acknowledged that if they 
are recognised as trustworthy a closer engagement with clients ensues, represented by 
regular clinical contact and better medication adherence in the clients. Although the 
benefits of this relationship have been recognised in people of all backgrounds, it is 
acknowledged to be particularly pertinent in Aboriginal communities. In the past lack 
of trust in local hospital staff fuelled by a perception of discrimination led to some 
clients in the North-West Cohort disengaging altogether. The secretary explained: 
“Some of our girls have discharged themselves because of treatment from nursing staff 
in hospitals, the sick ones.” 
Because of the need for close engagement between provider and patient, continuity of 
care and stable staffing levels are critical, since it takes time to establish trust between 
client and health care provider. The Public Health Nurse provides an example:  
...there had been a period where over the last sort of two years there was a bit 
of an instability of staff and we found that some of the clients were disengaged 
because they didn’t have the same person that they were coming to 
see...knowing they were seeing the same person made a huge difference to the 
engagement of the clients and them coming to the clinic. We did have one 
particular client who hadn’t had any blood tests for two years and then once 
she knew that I was the nurse here we started to reengage and then she 
actually came on track with her three monthly bloods and now we have great 
continuity of care with her. 
The NW Public Health Physician states this more bluntly: “We’ve got a hundred percent 
contact with our clients [now], which had dropped down to about fifteen percent 
contact when the staffing dropped here.” Threats to continuity of care are likely in the 
regions where doctors staffing the local hospitals don’t stay long : The PHP explains: 
“it’s going to be complicated for them, for our lot, to actually re-engage with another 
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doctor and go through that whole process of basically letting them know about their 
[HIV] status.” 
Therefore, the intensity of the engagement, the number of staff and the extended 
roles they have had to play are justified according to the PHP: 
M’s been here ten years you know. She doesn’t do a normal secretarial job at 
all, she knows them (the clients) and drops off medicine sometimes, picks them 
up, all sorts of stuff... And like I say, we’ve been criticised for this level of care 
but I think we’re showing results because of it. I’m not sure it’s that realistic 
everywhere and we do have way more staff (than they do in the Goldfields) you 
know, just to look after the cohort. I mean we had five staff at one point looking 
after twenty-three people, you know, how fair is that or how equal is that? Well 
I would argue it’s extremely, exactly the right response and it’s because of that 
response that we’ve managed to contain the epidemic. 
 
Cultural dissonance: the concept of ‘Health’ 
In effect the barriers to medication adherence in Aboriginal people described by the 
staff are classical but also culturally nuanced. The term chaotic lifestyle, commonly 
used to describe a way of living that lacks a regular pattern of activity known to be 
conducive to consistent pill taking behaviour, is a somewhat derogatory term since 
having a chaotic lifestyle, in Western culture, implies a lack of control over one’s life 
that is negligent and in that way is morally suspect. The following quote provides a 
stark reminder of the rigour required to adhere to lifelong ART:  
The measure of satisfactory adherence is a dosing history that includes timely 
initiation of dosing plus punctual and persistent execution of the dosing regimen 
throughout the specified duration of treatment 
 (Blaschke et al., 2012)  
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There is also a Western view of health as centrally important, together with longevity, 
exemplified by the expressions “you can’t buy good health” and “take care of your 
health”. Aboriginal culture could be said to be dissonant with Western medical culture 
which embodies the concept of the centrality of health (McConnel, 2003).  
The PHP in the Goldfields had this to say about how culture influences medication 
taking behaviour in Aboriginal people: 
...we’re (white Australians) pretty bloody selfish, we want to be well and happy 
and cheerful and whatever but and if we get a sniffle we go to the doctor. A 
number of Indigenous people have other priorities, either their own priority, 
which might be trying to find somewhere to sleep at night or familial or 
community responsibilities that take precedence over their own health. So they 
don’t take the (tablets) long term and (say something like) if I don’t take my 
tablets I’m going to die. It’s like “oh I haven’t got my tablets with me, I can’t, 
I’ve got other things to do. I can’t go and get anymore. I’ve lost them” 
whatever, so it’s yeah they have other priorities. Taking their HIV medication 
may not be very high on the list. Indeed going to see a doctor is not often high 
on the list ..., which is part of the reason for all the disparities anyway —is that 
they just have different things to do. 
The NW PH nurse comments similarly: 
But I still think that it impacts on their lives in relation to their lifestyles and it’s 
really hard for them to get into lifestyles particularly when they do like to travel 
and they do like to be transient and their families are very important to them so 
they do tend to put their families first before themselves which can have an 
impact on medication compliance. 
Talking with Aboriginal people about medication adherence without sounding like ‘the 
pill police’ (my expression) taps into these cultural nuances: “Well we do it much more 
in the sense of we care about you and you’re going to get ill and you know if you get ill 
you’re not going to get the chance to see your kids grow up” (NW PHP). 
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Motivators to accept antiretroviral treatment 
Uptake or acceptance of treatment has been recognised as the first barrier to 
adherence since treatment cannot be effective if it is refused. Newman and colleagues 
(2007b) asked Aboriginal people living in the regions what motivated them to accept 
antiretroviral treatment and found that pregnancy was a major driver. Aboriginal 
women continue to report excellent medication adherence during pregnancy, and at 
the time of my visit in September 2010 there had been no HIV positive babies born in 
WA to Aboriginal women to date who were aware of their HIV status before pregnancy 
(Gilles et al., 2007; and personal communication with Allison Cain, 2011).  
Fear of death is a motivator to begin treatment as well as to improve erratic 
adherence. The NW staff members have noticed that: “...every time one dies they get 
more motivated to take their tablets for a while.” The Goldfields’ staff also noticed this 
motivation in the small number of Aboriginal people they have cared for over the 
years. But treatment interruptions and erratic dosing are still common. The NW PHP 
observes: 
... despite that we still have deaths because of non-compliance for all sorts of 
reasons really. Just making a decision they don’t want to take their meds, or not 
really, so each year we get a couple. We had one this year, we had one last 
year, and the one before. But the one [person] who died this year, [had] been 
positive since 1994, so did quite well really. 
In some treatment programs in African countries, access to treatment for an individual 
is contingent upon the nomination of a helpful friend or relative to help support 
medication adherence, and social support in general has been shown to facilitate 
medication adherence (Foster et al., 2010; Merten et al., 2010). A major challenge for 
the Aboriginal health worker and other staff has been how to break down the barriers 
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preventing Aboriginal people disclosing their HIV serostatus to each other. But 
disclosure fears remain strong in Aboriginal and rural communities in general across 
WA, as the patients in the next section will attest. 
Delivering appropriate HIV education 
HIV education to Aboriginal people in this setting is generally given verbally, in part 
because of disclosure concerns: “They don’t want to take anything home.” The nurse 
describes taking a visual approach to HIV education to ensure clients understand how 
drug resistance develops:  
I try and get them to visualize like with the virus that it’s like, I sort of say to 
them oh look it’s like a brick wall, you know if you take your medications you’re 
going to have a strong wall to stop that virus getting through but as soon as you 
don’t take your medications there’s a crack in that wall and then that virus is a 
very smart virus it can get in the crack and then it can actually develop a 
resistance. 
The fact that the virus can be quantified and ‘counted’ is also helpful and the clients 
who have regular blood tests are interested in their results and aware of changes that 
occur as a consequence of poor adherence and/or treatment persistence. The other 
members of the team say they are careful to reinforce each other’s educative 
messages.  
However, the Goldfields PHP commented that:  
There’s never been very good HIV related information for indigenous people 
because this hasn’t been, you know it’s not been perceived as a major issue 
amongst indigenous people. 
‘Supporting them in their everyday lives’ 
The service given to Aboriginal clients may seem paternalistic and it is evident that the 
Public Health personnel do ‘what it takes’ as the NW PHP states frankly:  
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We definitely put way more energy than would be considered normal it would 
be perceived by some people as being paternalistic even maybe. But they 
contact us for all sorts of reasons you know. They ring us because of a funeral 
they have to go and we’ll help them with their fares, we’ll fly them down. 
And the Aboriginal Health Worker offers support, working across team roles to 
reinforce engagement:  
...with our crew I’m just more or less the ‘in between’. I’ll pick them up for their 
transport or, you know, whatever they’ve got to do around town, if they need 
help or come in here, just do whatever they need. 
Another factor underpinning successful adherence is engagement as incentive, the PHP 
explains:  
We have become...a major incentive for them to take medication. ... you have 
to actually help them out in other ways which is what you do, you know, with 
food and transport —*it+ is bizarre isn’t it, but that’s one of the motivations. 
Travel in general is considered to present an organisational challenge to a person’s 
ability to adhere to the scheduling of medication, and Aboriginal people frequently 
travel great distances to see family, attend funerals and cultural ceremonies, at short 
notice. The NW unit has adapted to accommodate this way of life by introducing a free 
call number for people who find themselves without their ARVs, use of this initiates a 
chain of events:  
All of a sudden we’ve got to jump to attention, make sure that we have got the 
medication here, go and get to the chemist, post it out so it could be at least 
four or five or six days before they then have their medication.  
The staff remark, wryly, that by the time the medication has arrived in one rural town 
the client has moved on to another, hundreds of kilometres away. Yet social and 
professional networks between health and other services in the bush often help to 
locate people who are travelling between towns. And the attentive liaison between 
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the rural services and the service at RPH, where all the medicines are dispensed means 
that medication can be made available at short notice to avoid treatment interruption. 
On the other hand the team was very clear about the principle of autonomy and how 
their close cooperative team approach strengthened their ability to behave effectively 
to reinforce this view with clients: the term ‘united’ was frequently used. The nurse 
unpacked their comments for me:  
Yeah,  because whilst we are there to support the clients, you can’t like I said 
you can’t, they do have to maintain their own lives and they’re very, very 
capable of maintaining their own lives so you do have to be careful not to cross 
that barrier where you make them totally dependent, I, you know I think it’s 
very important. 
Barriers to medication adherence: alcohol and other drug use  
In addition to unplanned travel, another classical adherence barrier, and an important 
risk factor for HIV transmission of infection, is substance abuse. Both the NW and 
Kalgoorlie-Boulder PHUs freely administer needle and syringe packs (‘fits’) with no 
questions asked. At the time of my visit in 2010, to both centres, about 900 fits per 
month were being dispensed at the Unit in NW, although the NW PHP thought it 
important to stress in a subsequent communication with me, that IVDU drug use was 
“not an issue for our cohort” (personal communication NW PHP, 16 August 2012). In K-
B and in addition to the local Hospital vending machine and chemist, the PHP observed 
that the unit distributes: “something like between six and eight thousand needles a 
month through the door here”. This number was confirmed by the PHN the next day. 
Substance abuse clearly concerned the K-B PHP who had this to say about alcohol 
consumption in the region: 
Our rates of alcohol consumption are far in excess of state average and that’s 
not indigenous people, that’s non-indigenous people as well. We’ve got more 
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pubs than you can shake a stick at. Liquor outlets everywhere people getting, 
and I enjoy drinks I’m not a, I’m not anti-alcohol but we have shocking rates and 
this clinic is full of people who come in and say I’ve woke up, been to bed with 
someone, I’ve been drunk, worried, don’t know who he/she was, don’t know 
her/his phone number. Come back positive, no idea where to go. So there’s 
huge amounts of unprotected sex as a result of alcohol which then, as HIV 
becomes more prevalent, is going to increase our risk here. 
Despite evidence of intravenous drug use among the community and transient 
workers, mainly in the fishing industry, substance abuse in the North-West Cohort is 
usually in the form of alcohol. Alcohol affects medication adherence directly, by way of 
intoxication, which leads to missed doses and also by the belief, quite entrenched, that 
mixing alcohol and prescribed medicines is harmful (Kalichman et al., 2012). But it is 
possible for health care professionals to assist individuals to overcome the impacts of 
heavy alcohol consumption and to adhere to treatment, in part by understanding the 
patient’s pattern of alcohol consumption. The NW PHP talks about some successes: of 
patients who continue to drink heavily but adhere to ART and maintain blood levels of 
clinically undetectable virus. She reiterates the value of being non-judgmental and 
remaining engaged with the clients in the long term:  
That’s one thing I feel really strongly about, that is totally unacceptable, 
because people have preconceived ideas and they sometimes get it absolutely 
wrong. There was a perception amongst some that it [introducing ART] would 
be a waste of time, they wouldn’t take it and it’s just not been the case...So I 
think that assumptions around socioeconomic and other things that they have 
in their life can be so wrong and we become their colleagues, you know their 
friends or part of their family ironically ... then that is a major incentive for them 
to take medication. 
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Summary of Part One  
From the interviews with staff in both regions it is clear that the needs of the clients 
differ along demographic and cultural lines. Although this finding is not new it 
highlights that recognising social ecology in health care planning and delivery is 
important and directly impacts on health outcomes. The care needs of the North-West 
cohort are echoed in the small numbers of Aboriginal clients in the Goldfields region, 
and are in contrast with the growing number of Medicare-ineligible clients in K-B. 
However, the approach to patient care in both regions and overall through the Rural 
and Remote Service, is focused on remaining engaged with patients/clients to promote 
their retention in medical care and ensure treatment is delivered in a way that is 
acceptable to them. This approach is fundamental to adherence theory (M. A. 
Thompson et al., 2012).  
The need to contain the epidemic is a pressing responsibility for public health workers. 
This is particularly challenging in HIV because of the current (pharmacological) 
necessity of maintaining continuous treatment. It is evident particularly from the 
interviews with the health care providers in the NW that disruption to staffing levels 
and the quality of the interaction between health providers and the clients affects 
ongoing engagement and continuity of care so that there is a visible waxing and 
waning of the clients’ health according to the current level of service and the capability 
of the team. In practice therefore, the primary goal is to maintain engagement with 
clients: medication adherence is an outcome of that therapeutic engagement.  
The clinical management of both cohorts is complicated by the need for stringent 
vigilance around inadvertent disclosure of HIV status since all patients, regardless of 
ethnicity, fear stigmatisation and discrimination. This situation has contributed to 
 177 
patients preferring to limit their care to particular providers, and in the Goldfields 
region the PHP has become the primary provider for the temporary visa holders or 
‘457s’. The increase in temporary visa holders—essentially non-citizens with HIV in 
Kalgoorlie-Boulder presents further challenges by virtue of ineligibility for Medicare 
and subsidised medicine, leading to concerns over the implications of HIV for visa 
status; and the tensions within families and the social issues that arise from these 
tensions. The staff at RPH has developed a current body of knowledge around visa 
issues in order to advise the regional providers and provide information for those 
people willing to access the RR Service. However, there is general concern about the 
social impacts of HIV for example, within the marriages of the growing numbers of 
heterosexual couples especially since social services are limited and not evenly spread 
across the regions and, additionally, may not be suitable for the needs of a culturally 
diverse group. Finally, it is apparent that the temporary visa holders are limiting their 
contact to personnel they consider essential to their needs.  
Substance abuse, although a pressing health concern on a number of levels is a 
particularly critical issue in sexually transmissible infections and clearly concerns the 
providers responsible for public health in both regions. As a factor complicating HIV 
clinical care, it presents a barrier to successful adherence, and is a risk activity for 
transmission of HIV. Although heavy alcohol use is common in the two regions, 
intravenous drug use is clearly prevalent in Kalgoorlie-Boulder and as was described by 
the K-B PHP, is cause of considerable concern. 
Despite the great distances involved, the rural and regional providers are able to 
access seamless, city-based expertise in HIV medicine via a straightforward and 
responsive chain of communication. They are also able to facilitate access to 
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antiretroviral drugs at an individual level by interventions tailored to fit with the 
lifestyles of patients in those regions, for example those travelling frequently between 
rural towns. Medical conditions in temporary visa holders and travellers that are not 
commonly seen in resident Australians, complicate HIV care, as do social issues around 
visas that limit access to Medicare and patented ARVs. Therefore, the social 
manifestations of HIV infection clearly complicate the management of the condition at 
a number of levels: health providers recognise the importance of remaining engaged 
with patients/clients and that this engagement may need to be on their terms. In 
Figure 18 I provide a summary of the social and structural elements which promote 
engagement with care which have been shown to be critical in the successful 
management of HIV infection (Gardner, McLees, Steiner, del Rio & Burman, 2011; M. 
A. Thompson, et al., 2012) and which the findings of this study support.  
 
Figure 18: The social and structural elements that support relationships and engagement with HIV care 
The Role of HIV Support Services 
It was difficult to ascertain the role of HIV support services, specifically the Western 
Australian AIDS Council, in the regions. The NW PHP said that WAAC had, in the past, 
provided speakers for them between the years 1999–2002 and funded the purchase of 
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some ‘white goods’- a word applying generally to electrical appliances such as 
refrigerators. In her recent communication with me she said “they aren’t really 
relevant in our situation though perhaps we need to revisit that” (Personal e-mail 
communication 16th August 2012). From the perspective of personnel, the Australasian 
Society for HIV Medicine was very active in supporting staff including those within the 
rural workforce, to attend conferences and educational meetings. 
Conclusion  
In Part One of this chapter I have given the perspectives of health care providers 
working across the state of WA to deliver HIV care. Part Two will present the voices of 
PLWH either living or working in rural and remote areas in the regions of WA or in the 
case of two participants, offshore. 
Part Two: Participants Living or Working in Regional Western 
Australia 
Introduction 
This section focuses on participants who were either living in the country or working in 
remote locations. The potential mediators of the impact of HIV on the participants 
were considered in relation to their personal, social and geographical circumstances. 
Knowledge about HIV was nuanced by life experience, some people especially those 
from HIV prevalent regions, knew family or friends who had either died or were still 
living with the infection, while others had no such experience. As well as being 
ethnically diverse, the group came from a mixed educational background. The 
recorded interviews began with general questions about the circumstances leading to 
HIV testing; the immediate aftermath; and a reflection on managing chronic HIV 
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infection in a regional area or remote workplace. The mostly open-ended questions 
steered the participants to speak about: access to ARVs and HIV clinical care; managing 
HIV in the workplace; and issues of concern around confidentiality nuanced by living or 
working in a rural area. The results are presented as a narrative reflecting the flow of 
questions, beginning with the experience of receiving a diagnosis of HIV and the 
circumstances surrounding this event.  
 181 
Table 13 (a): Demographic characteristic of the participants either living or working in regions 
designated as rural and/or remote (N=19)  
Age (mean ± SD) 41.2±10.0 Median year of diagnosis 2006 
 Number (%)  Number (%) 
Female  5 (26.2) Indication for first positive HIV test  
Married/partner 13 (68.4) Illness or concern re symptoms/risk 9 (47.5) 
Children  10 (52.6) Health screening 10 (52.6) 
Sero-discordant 8 (42.1)   
    
Self-reported HIV exposure   Self-reported location of HIV exposure  
Heterosexual 10 (52.6) Country of origin  11 (57.9) 
MSM  5 (26.3) Australia 7 (36.8) 
Unknown 3 (15.8) Abroad 2 (10.5) 
IVDU 1 (5.5)   
    
Employment  Visa Status  
FIFO worker 9 (47.5) 457 long stay business visa 4 (21.0) 
Full-time other work 8 (42.1) Other 1 (5.5) 
Unemployed or home duties 2 (10.5) Permanent resident* 12 (63.1) 
  New Zealand citizen 2 (10.5) 
Abbreviations: FIFO=fly in fly out; * Four ex-visa holders 
Table 13 (b): Clinical and treatment characteristics of the participants either living or working in regions 
designated as rural and/or remote (N=19)  
Drug Regimens Number/schedule Treatment Status Number (%) 
FTC/TDF/EFV 5 (OD) ART naive 1 (5.5) 
FTC/TDF/NVP 1 (BD) On  ART 18 (94.7) 
FTC/TDF/ LPV/RTV 3 (BD) Generic ART 3 (15.8) 
3TC/AZT/ RTV/ATV 1 (BD) On patent ART 14 (73.6) 
3TC/AZT/ABC 1 (BD) Medicare ineligible 5 (26.3) 
3TC/ABC/NVP 4 (OD)   
3TC/ABC /RTV/DRV 1 (BD) Self-reported adherence 18 patients 
TDF/LPV/RTV 1 (BD) Never missed 4 (22.2) 
FTC/TDF/DRV/RTV 1 (BD) Missed > 3mths ago 7 (38.9) 
  Missed < 3 mths ago 2 (11.1) 
CD4-T cell count cps/ml  542.47± 311.72 Last month 4 (22.9) 
CD4-T cell (%) 26.11± 10.76 Average no. self-reported side effects 5/30 
Median CD4-T cell cps/ml 558   
‡Detectable viral load 6/19 (31.6) Average cost of generic ART (AUD) 177/month 
Abbreviations: OD=once daily dosing, BD=twice daily; ART=antiretroviral treatment; 3TC=lamivudine, 
FTC=emtricitabine, TDF=tenofovir, ABC=abacavir, AZT=zidovudine, EFV=efavirenz, NVP=nevirapine, 
LPV=lopinavir, RTV=ritonavir, ATV=atazanavir. ‡ One patient naive to treatment; two patients recently 
changed drugs; two patients recently recommenced.  
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Results 
Sociodemographic and Clinical and Treatment Characteristics of the 
Participants 
There were nineteen patients included in the analysis (Tables 13a and 13b). Ten (five 
women) lived and worked in rural areas and nine (all men) worked in remote regions, 
typically working for two weeks continuously, with one week off when they returned 
to their homes in the metropolitan area (FIFO). The sample was ethnically diverse: 
eight were Caucasian, six were from East Africa, two from South-East Asia, two were 
from Oceania and one was of mixed Caucasian and Aboriginal and Torres Strait 
Islander descent.  
Rural Participants  
Of the ten participants living and working in rural areas: one lived in the Wheatbelt, 
one in the Mid-West, three in the Goldfields, four in the Peel, South-West or Great 
Southern Regions. Eight of the 19 participants had Permanent Residency, but three of 
them had been on temporary visas before that. Two (both women), were on current 
temporary visas, and were therefore ineligible for Medicare—one of these was a Long 
Stay Business Visa (457) holder working in the health sector. With regards to 
employment, two worked in family businesses, one in the mining industry, one in the 
health sector, one in hospitality, one in education and two in general employment. 
Two (both women), were supported by their spouses and one had an Australian-born 
HIV negative baby. Three of the participants had children, and two of those children 
lived in other countries with family members and were receiving financial support 
from their parents in Australia. Four of the five women were married to Australians or 
New Zealanders. Two of the women were not fluent in English. Six of the participants 
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had been exposed to HIV by having unprotected sex with members of the opposite sex 
and four infections were in men who had sex with other men. Six of the rural 
participants were diagnosed during health screening.  
Fly In fly out and offshore workers 
With regard to the nine men working in remote areas, two were classified as working 
offshore (internationally) and the others worked in WA in the mining and construction 
industries, as either skilled tradespeople or skilled professionals such as engineers or 
geologists. Three of the participants were on temporary visas and two were New 
Zealand residents and therefore eligible for Medicare. Five were either married or 
partnered, and seven out of the nine had children and six were living with them. One 
working man on a temporary visa was a sole parent for two children under five years 
old. Seven of the participants were exposed to HIV by having unprotected sex with 
members of the opposite sex, and two infections were in men who had sex with other 
men and injecting drug usage was an additional transmission risk factor. Three of the 
FIFO workers were diagnosed during health screening for employment or application 
for residency, two suspected they had HIV infection and sought testing from their GPs 
and one had been diagnosed in East Africa.  
Interview Data 
The Impact of HIV Diagnosis 
Most of the nineteen participants had received their results from city-based health 
personnel in either Australia or New Zealand after pre-test discussions took place, 
although the quality of these is not known. One patient received the diagnosis in a 
Middle Eastern country and was given one month to leave voluntarily or be deported. 
Another woman received results by phone in a rural area of WA; and a WA man 
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describes being telephoned at work by his city-based GP, who gave him the results of 
the HIV test, citing “he was about as subtle as a train smash.” Those diagnosed 
through Health Services Australia, now Medibank Health Solutions, were referred to 
specialist services at RPH where they received emotional support and HIV-specific 
education from nursing personnel, sometimes prior to clinical assessment by a medical 
practitioner. 
The immediate reaction of most participants to a diagnosis of HIV was one of shock, 
even though at least three people suspected that the results of the test would be 
positive, and some other men had knowingly participated in high risk behaviours. 
However, one gay man diagnosed interstate and now living in rural WA had this to say: 
I don’t know whether it’s a self denial or whatever, I just didn’t take much 
notice. I thought oh it probably doesn’t auger well so I wasn’t shocked when I 
actually got the news from the specialist surgeon that you know I’d had HIV. 
This deeply religious man talked of communing with the Holy Spirit before being told 
of his diagnosis, indicating that he had received the news ‘spiritually’ before hearing 
the results from his doctor. Another rural gay man infected in 1991 speaks about his 
low self esteem and depression at the time he was infected saying: “I sort of set out to 
infect myself as a form of self harm.” Most reactions were primed by what people 
knew and thought they understood about the condition. People from HIV-prevalent 
regions had vicarious experience of HIV. However, a small number of people in this 
group, came from low HIV-prevalent regions, had few risk behaviours and little 
experience of the disease; for example the person infected while living in the Middle 
East said: 
I mean I thought I’m going to be dead within two or three years to be honest 
because prior to this HIV really didn’t, yeah didn’t interest me, wasn’t part of my 
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life, I didn’t know anybody who had HIV and yeah didn’t think, I wouldn’t even 
think about that illness. 
Some of the participants from regions in Africa, Asia or Oceania had seen people 
looking sick or even close to death, and assumed that they had HIV/AIDS or lost family 
members. This led to the belief that they would also die rapidly of the condition. One 
man in this group had delayed testing: 
I was reluctant to go for a test, I didn’t have the courage. But then when I was 
getting sick and sick then I finally just decided to go for an HIV test. 
Concerned about steady weight loss, a second man went to his GP: 
...after having seen some members of the family die, with my educational 
background I just went to the doctor and I said I want to be tested, what for, I 
said HIV. He said are you prepared, I said yeah then he goes ah yeah it’s alright 
because now with medication for that we can keep it under control so we will 
send you for the test. 
(African man, FIFO worker) 
Yet another African FIFO worker could not understand how he came to be infected and 
two other men were similarly mystified:  
...this came as a shock because I didn’t know where I got it and I tried to find out 
and I couldn’t think of anything of the way that I knew it was transmitted. 
Months after his diagnosis the patient continues to ruminate and perseverate, over 
what might have been the source of infection. And, possibly because of this confusion, 
he fears inadvertent, casual (so called) transmission to his family. The Australian-born 
participants’ basic knowledge of HIV was also rudimentary and often based on 
advertising campaigns going back many years (‘the Grim Reaper’). And except for one 
man who had worked for an AIDS Council as a volunteer, there was a general lack of 
awareness about improvements in drug treatments that have led to increased survival. 
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There seemed to be no difference between those who identified as gay (all 
Australians), who might have been expected to have some prior knowledge of HIV 
because of the country’s swift, high-profile response to the epidemic and ongoing 
funding for prevention, and those who were not. A gay man living in a rural area talked 
about “being knocked for six.” Another gay man put it this way:  
I was devastated, absolutely devastated. At the time my thinking was that this 
was a death sentence, that was the state of my knowledge, and yeah, I was 
devastated. 
The women also described their reactions as coloured by their prior knowledge of the 
condition: one woman living in a rural area said: “my whole life was basically thrown 
upside down” and another Asian woman travelling around Australia explained: “Just 
feel want to die or something.” The immediate threat to health was tempered by the 
quality of the pre and post-test discussion which was variable, as was seen in the case 
of the first FIFO worker. One of the Asian women’s husbands talked about receiving a 
diagnosis of HIV while visiting a remote town in WA: they were phoned with the 
results and he took the call explaining that his wife could not ‘understand’ the 
message. He talked about his perceptions of the reaction of hospital staff when they 
went for confirmatory testing:  
 ...then we went had more blood tests in [one country town], both of us, and we 
had more blood tests in [another country town], and everybody was pointing 
the bone if you know what I mean, like you know. You’re virtually dead like you 
know you’ve got HIV, you’re crap you know. 
He implies that the health care workers in the country hospitals were just as ignorant 
of HIV as they were.  
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The role of socio-cultural norms in mediating the impact of HIV 
Half of the participants were diagnosed with HIV before they developed constitutional 
signs or symptoms of HIV. But the impact of an HIV diagnosis is emotionally ‘disabling’ 
in the sense that the appraisal of HIV is mediated by deeply held socio-cultural norms 
reflective of contexts such as country of origin, rural vs city settings, gender and 
sexuality. For example, in East Africa one of the men observed that in his experience: 
So promiscuity level is a bit managed because there is a lot of cultural things 
involved and procedures given [so] traditionally, [to] approach a girl or a 
woman for sex is hard.  
He went on to explain: 
So this stigma is based upon lack of faithfulness; and marriage relations are 
highly respected; and issues like, because they either say: one, you’ve been 
promiscuous; number two: you’re a homosexual and the homosexuals are not 
accepted in the community at all, so it’s across the board that’s why there’s this 
stigma. 
A man from Oceania pointed out that the experience of being HIV-positive in a rural 
town is isolating whereas in the capital no one knows or cares: “Yes, back in the 
traditional villages yeah, people talk bad things about you. Like you know don’t want to 
be near you or talk to you or things like that yeah.” This was also true in Asia where the 
disapproval extends to the whole family and in small villages an HIV-affected family 
can stand out: “Oh people very hate that family or something. Them hate all family, not 
just one people” (woman, traveller). 
One new Australian resident who had been on a spousal visa noted that attitudes in 
the large regional town were ‘backward’ explaining: 
Remarks... I mean might have to do with K-B as well, remarks, I mean nobody 
except *partner+ knows what’s going on with me but remarks you hear from 
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colleagues about, I have a colleague in [the city] who is gay and they just make 
remarks about him and then relate AIDS and HIV to him even though he 
probably has nothing. But ahm they’re *the+ remarks about Aboriginals which 
really make my hair stand. 
Once the initial personal threat had been processed most people were concerned that 
they may have infected their spouses, partners and indirectly their children. This can 
cause considerable anxiety: “I would die if I gave it to someone, not die but you know 
be horrified if I gave it to someone” (FIFO man). Allied Health Services to support 
people with HIV are not readily available in the country regions and specialist HIV care 
is limited. People with HIV living in remote areas commonly travel long distances to the 
RPH where they have access to a social work and psychology service. Whether people 
who don’t have family support in the city do this to the same extent is not clear. 
Although the RRN offers direct telephone and e-mail communication to deliver 
emotional support to people in distress, which helps to overcome lack of access to 
supportive services in rural areas, this will not be adequate for people who need a 
specialised mental health assessment and ongoing treatment for any condition that 
might be uncovered. However, it was beyond the scope of this study to evaluate this 
service. 
Access to HIV Medical Care and Treatment: Overcoming Distance  
The FIFO group all attended the RPH Immunology Outpatient Clinic for follow-up HIV 
care, scheduling their appointments on their work-free week. However, unlike most of 
the West Australian-based workers, the two offshore workers maintained e-mail 
contact with the RRN. Another WA-based worker, diagnosed in 2004, remained 
engaged with the RRN over a seven year period, despite peripatetic living and work 
arrangements around the state and a long-standing personal need to keep his 
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diagnosis private. All of the rural dwelling participants used the e-mail link with the 
RRN, but also telephoned on occasion to request another batch of ARVs, a blood 
request form or general advice and support. One country participant put it this way: 
It’s just more efficient. I can talk to A [the RRN] via email any time if there’s a 
problem. You’ve got someone to talk to without necessarily annoying a 
professor who’s got 500 people underneath him or, has got a heavy workload 
and so, and someone who knows you and knows that you’re not overreacting, 
they understand that you wouldn’t be contacting unless it was a valid reason. 
The FIFO workers take advantage of their week free. One participant describes how he 
accesses the service: 
More often than not I just walk in there and say. ‘Cause I’ll have me break, like 
say me break started today and goes for a week, well I’ll go in there knowing 
that if I get blood test done today by the time I see the doctor in four or five 
days the blood test will be through, you know, so off I go. 
As was described in Part 1 of this chapter, rural participants can attend a regional 
pathology collection service (PathWest WA) for sample collection and subsequently 
the specimen is couriered to PathWest in Perth for analysis of CD4 T-cell count and HIV 
levels. In this study, patients reported reluctance to use the pathology centre in their 
home towns but travelled to another regional centre to avoid disclosure of their HIV 
serostatus to people they might be known to in their communities. A man spoke about 
his own uncomfortable experience in the past:  
...I think if you’d turned up for a leprosy test she probably would have been just 
as judgemental for want of a better description. I mean a double lot of gloves 
you know and sort of like taking the samples. Her body language said a lot... 
He went on to comment that times had changed and pathology staff use what are 
generally known as ‘universal precautions’ as a matter of protocol for all phlebotomy 
procedures. Universal precautions in this and many other health settings, assume that 
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bodily fluids from all persons are potentially infectious and that the same level of 
protection is required. This protects health workers from infection with blood borne 
viruses and patients from discrimination.  
Three of the ten rural participants attended the outreach clinic in the Goldfields but 
the rest attended RPH for three-four monthly appointments, some driving for up to six 
hours from regional centres and returning home the same day. One patient flies down 
from the North-West. It is a seven hour train journey one way from Kalgoorlie and one 
hour by plane.  
The cost of petrol may be reimbursed or subsidised through the Patient Assisted Travel 
Scheme, but the temporary visa holders are ineligible to access this. West Australian-
born patients often stay with family or friends and make the trip to the city an 
occasion for visiting or shopping, but the temporary visa holders usually travelled 
home the same day. One of the rural participants enjoyed seeing the allied health 
workers, in particular the clinic social worker from whom she received psychological 
and practical support: 
All the people in hospital, about ten people, right ten people here help me, help 
me, expect me, push me, hello P how are you, you look beautiful, you look more 
healthy. 
Although most participants were listed with GP only a few reported visiting them for 
other illnesses; and disclosure of HIV serostatus was a carefully considered decision in 
a country town, as this man said:  
Look partly too I think, the GPs would be very confidential and very good but I 
still feel a slight stigma attached to going to see a GP because they probably 
hear when I come to see [the medical team from RPH at the outreach clinic] 
there are no sort of manifestations of any problems or whatever so I figure I 
only go to a GP when I need to really. 
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Another woman in a country town feels similarly, her newborn baby is under the care 
of a child health nurse with whom she feels very comfortable but she is less so with 
GPs and travels to another town to ensure privacy and she knows her rights: “...it’s my 
right I don’t have to say it [disclose HIV status] if I don’t want to say it.” 
However, one man (FIFO) said that he would prefer to be under the care of a GP and 
not attend the hospital-based service at all, since he complained of discontinuity of 
care by medical registrars and a dislike of the public waiting room: 
No I just hate coming here I’d rather just have a GP. I’m worried about people 
seeing me in there that I know and stuff you know. But I’d just much rather the 
privacy of a GP, off you go, get your tablets. 
Two of the South-West participants, in particular, described ‘good’ relationships with 
GPs, and in one town, teleconferencing facilities between city and country hospital are 
used – but not for HIV care. One of these men noted that because he was from a 
country town, his hospital stay was prolonged: “I mean the only reason why they kept 
me in for three weeks was because I was country patient and they wanted to get me 
sorted out.” These men expressed satisfaction with HIV care and their views were 
representative of nearly all the participants interviewed regardless of ethnicity or 
gender.  
Antiretroviral Drugs: Access, Adherence and Persistence with Treatment 
Three of rural group attended the outreach clinic in the Goldfields and received ART 
from the Population Health Unit where it was mailed from the RPH pharmacy.  But the 
rest collected their treatment from the hospital pharmacy, apart from the three 
interviewees who received a generic supply posted to their homes by internet vendors. 
Another visa holder required drugs that were not easily accessible in generic form and 
he was granted compassionate access to patented drugs by the Director of Clinical 
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Services at RPH. The Medicare ineligible participants were more likely to access nursing 
services at RPH for assistance in maintaining an uninterrupted supply of ART. The 
offshore workers sought permission from the RPH Pharmacy to receive a longer supply 
of ARVs which are regulated to be dispensed on a three-four month script and they 
took these with them internationally. Three of the participants described treatment 
interruptions. One participant (FIFO) diagnosed and treated in Africa, came to Australia 
on a 457 Long Stay Business Visa. His supply of ARVs was interrupted for six weeks 
until he sought assistance from a GP who referred him to the service at RPH where he 
was introduced to a generic supply. Subsequent immune monitoring uncovered 
nevirapine resistance which occurs commonly after continuous treatment with the 
drug is interrupted. 
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Table 14: Case study of participant (diagnosed in 2004) living and working in a rural area 
September 2004-2006: Thirty-four year old gay-identified man living in rural area & working in family business. Diagnosed interstate &referred to RPH for care. Not ‘out’ to parents & limited friends: “You know? [its] a small 
country town so everyone talks and gossips and shit like that so it’s a bit harder I think.”  So you sort of just keep it to yourself’. Received adherence support per 2004 protocol & enrolled in RR Service. Adherence/persistence 
patchy, developed resistance to NVP, adherence complicated by secrecy of HIV serostatus & taking meds, poor health literacy, mobile lifestyle working in family businesses, side effects of Rx & helicobacter infection. Feels 
depressed & overwhelmed from time to time & finds number of pills a burden, however he eventually stabilised on ART by the end of December 2005. 
December 2006-2010: Moved interstate and slowly disengaged from care “...there’s no like interaction like you and me are talking...I think that’s why I just stopped.”  Spent one year in Africa & ceased ARV’s altogether. “I 
was just over taking tablets all the time and I just thought oh ‘cause I’m feeling so good, I’ve put on a lot of weight and, and just felt really good inside and outside and I just thought maybe I can stop.” 
April 2010-2011: Presented at a rural Public Health Unit with Kaposi’s sarcoma. Family supportive & concerned about ‘illness’ still no disclosure of serostatus to family. “She’ll look at me differently or treat me differently or I 
don’t know.  That’s the worst thing I’m worried about”. Motivation to adhere to ART is strong: I suppose if you’re thinking about going off your medication because you feel really good and stuff like that I wouldn’t, I would get 
that thought right out of your head.” Still has difficulty naming &recognising drugs, currently engaged with service providers.  
 
Abbreviations: Dx=diagnosed, Hx=history, Rx= treatment.3TC=lamivudine, ABC=abacavir, RTV=ritonavir, ATV=atazanavir, NVP=nevirapine, LPV=ritonavir, DRV=darunavir 
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Two country participants had at some stage disengaged and re-engaged from the 
service at RPH. One of those men (diagnosed in 2001) had a comprehensive knowledge 
of HIV and treatment having worked as a volunteer for WAAC and known, personally, 
many people with HIV who had died of AIDS. Despite this knowledge, while working 
for 18 months in South-East Asia he rationed his six months daily supply of ARVs taking 
them three times a week. During this time he was not engaged with the RR Service and 
did not realise that he could access medication from Australia. He took this attitude 
“And so I thought well... I’ll worry about that down the track.” The second man 
(diagnosed in 2004) who reported interruptions, left the state and enrolled with 
another service from which he slowly disengaged, he then left the country did not take 
ARVs for at least a year, when asked what he was thinking when he stopped treatment 
he said: 
Just didn’t want to [take ART]. I thought I was feeling pretty good and stuff like 
that and yeah and I thought oh maybe it’s a miracle or something like that 
yeah. I’m feeling, I don’t know I just think I was just over taking tablets all the 
time and I just thought oh ‘cause I’m feeling so good, I’ve put on a lot of weight 
and, and just felt really good inside and outside and I just thought maybe I can 
stop. 
The man reengaged with the WA health system when he presented with Kaposi’s 
sarcoma at a regional hospital in 2010. Now he talks of the deterioration in his health 
as ‘a reality check.’ A case study of this participant, juxtaposing clinical and social 
aspects of his illness experience, can be found in Table 14. Another participant who 
reported treatment interruptions described taking all his tablets, never missing a 
scheduled dose, but then waiting for his next supply to arrive. He also believed that 
the medication would continue to ‘kick in’ and suppress the virus thus demonstrating 
his lack of understanding concerning the development of drug resistance. The 
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examples above show the importance of retaining patients in clinical care; and for 
ongoing monitoring and evaluation of patients’ health and treatment literacy and 
motivation to continue with therapy.  
One of the major challenges for clinical service delivery is to support uninterrupted 
medication access to patients across the state. The coordinating role of the RRN 
underpins this effort. Despite the challenges of accessing ARVs and supporting their 
cost—particularly for those importing generic versions—nearly all patients expressed 
good motivation to take medication continuously although it was evident from the 
patients with a history of treatment interruptions that that was not always the case. 
One patient, a temporary visa holder and FIFO worker, had not yet started medication 
and expressed his reservations about whether the medications would benefit his 
health. Some others expressed concern about the long-term effects of the medication 
and a couple of people from HIV-prevalent regions wondered whether it would 
continue to work after many years: 
I’m really happy but the thing that concerns me is I’m not sure if the medicine 
I’m on might, my body might get used to it that after a while the virus start 
rejecting it. That’s the only thing that I worry about. 
However, of the 18 participants on treatment only four had missed doses in the last 
month but these were regimen-related interruptions: two of the participants recently 
changed drugs and two recently commenced. Over half reported last missing 
medication over three months ago or never. This high level of adherence may be due 
in part to a relatively low frequency of side effects (an average of five out of a possible 
30), the most common concerns being either weight loss, weight gain or in the women 
vivid dreams. 
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One rural participant’s comment encapsulated some others’ views:  
But I, I can understand how non-conform, non-compliance can affect people 
because in some ways if you’re having, if you’re having medication and you’re 
having no side effects or minimal side effects then you’re fine. It’s a very easy 
routine to get into and it’s like comfy slippers. But if you’re, every time you take 
that tablet you can feel your fingers coming dead or there’s another layer of 
skin coming off you sort of, after a while you think what’s it doing to my organs 
inside you know...And what is the side effect that’s going to show up in 10 years 
time even from a 12 week exposure to that medication. 
However, few participants articulated concern for long-term side effects.  
Another prerequisite for successful adherence is motivation to maintain the treatment 
regimen in spite of barriers that must be overcome to achieve this. Sometimes this is 
underpinned by personal experience (or antecedents) like one of the participants who 
reported a significant treatment interruption and developed an AIDS complication:  
Well like well now I know how important medication is because I got really sick 
and stuff like that, I don’t want to go through all that sort of stuff again 
anyway. 
Or as the Public Health Physician in the previous section noted, every time someone in 
the North-West Cohort dies, fear of death becomes an incentive for others to increase 
pill-taking behaviour. This may also be a motivating factor, particularly in the African 
and Asian groups since they had observed death from HIV/AIDS at close hand. 
However, another evident motivating factor is the desire to protect (sexual) partners 
and also remain well to avoid distressing family members, for example elderly parents. 
People with children and dependents are also highly motivated to remain well, 
employed and therefore financially secure. One single father, a FIFO worker said: 
“yeah I got to live, I got children to take care, I can’t like bow down to the sickness or 
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what people say to me you know.” Seven out of nine FIFO workers had children to 
support as opposed to three out of the ten rural patients. 
Adherence: supportive strategies and healthy behaviours 
All of the participants either used alarms, calendar medication boxes or had developed 
idiosyncratic routines to support continuous dosing. These strategies and the careful 
consistent ordering of generic supplies in the case of the Medicare ineligible 
participants; and close communication with the RR Service, demonstrates that patients 
are highly motivated to take treatment. In addition they show a leaning towards health 
seeking behaviour in general, particularly with regard to healthy diets and a low rate of 
tobacco use—only two out of 19 were current smokers. Three of the 19 had a history 
of intravenous drug use and five had used marijuana but none were currently using 
recreational drugs. Although only six of the 19 drank alcohol daily or weekly, four of 
the six drank five or more drinks in a session, which would be considered risky under 
the National Health and Medical Research Council (NHMRC) Guidelines for alcohol 
intake (2009), and three more participants, including two women had similar amounts 
two or three times a month. However, only one of the rural participants reported 
alcohol interfering with her capacity to adhere to ARVs in the past.  
Work in Remote Areas – Living With HIV ‘On the Job’ 
Recent publicity and a government sponsored national review of the health and social 
impacts of FIFO and DIDO work highlights current concerns about the social effects of 
living in one place and travelling to distant work places for up to one month at time, 
but most commonly for two weeks ‘on’ and one week ‘off’. A lot of this concern 
centres around the effects on the family life and relationships of the workers: 
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You’re working away from (my) family, you’re working eight hours every day for 
two weeks straight, it’s kind of stressful and it’s sort of, it’s a routine job 
whereby it’s wake up, go and eat, go to work, come back, go eat, go into a 
room for fourteen days it’s all, it’s a bit monotonous 
 (FIFO worker) 
This participant was particularly concerned about his children’s education and the 
need for him to supervise their homework since he said that in his home country in 
East Africa academic advancement was critical to improving employment prospects 
because unskilled labour was paid so poorly unlike, he observed, in Australia.  
For people with HIV, the FIFO work environment takes on other dimensions, not all of 
them negative. For example, the same ‘routinisation’ and block of work-free time can 
support adherence to medication and facilitate engagement with medical care by 
allowing time to attend hospital appointments. One participant spoke with me while 
waiting for his clinic appointment. Despite being unhappy about working away from 
home because he missed his children, he noted that regular time off means he can 
schedule and attend his hospital appointments. He also finds that the routine of FIFO 
work facilitates regular dosing, except when he has to share a room. When this 
happens he conceals his medication and takes them privately. When he returns to 
Perth on his week free he finds regular dosing more challenging since as a single father 
he is busy and preoccupied with domestic and child-centred activities in the time he 
has off work—he is also very tired. Although this participant would prefer to work in 
the city he expressed concern that return to regular work would make attending 
medical appointments difficult and this is one of the factors, for him that weighs in 
favour of the FIFO lifestyle.  
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Many of the men spoke of the Occupational Health and Safety regulations in the 
workplace as far as management of accidents and blood spills as being ‘good’ and held 
the opinion that safety regulations would not be so good in other workplaces: “In fact 
in the mines you are fairly safe working at the mines than working at a factory in the 
city there, it’s not safe.”  
However most men feared blood spills and all of them used the equipment supplied: 
They call it personal protective equipment which is your clothes, your gloves, 
long sleeves and you’ve got hard hats and you’ve got boots. So and even when 
you are working, when you are doing some certain hard work you use leather 
gloves     (FIFO, 457 visa holder)  
And they follow the protocols for safe practice in the workplace. However, some 
remain anxious and the following patient, another 457 visa holder, not yet on ART, 
spoke most expressively on this theme and was representative of others in the FIFO 
group: 
I try by all means to avoid a cut, a simple cut and if I’m cut I don’t want to be 
helped by anyone, I do it myself. If I can’t help it that’s it and to be honest with 
you I don’t feel comfortable to even go to anyone in the event that there’s a cut 
and say I need assistance. 
He notes that use of sharp implements is common in mining workplaces:  
We’ve got what we call utility knives, those are the dangerous things, avoid 
things that are sharp. Watch where you’re going, what you’re doing. So every 
time it’s in there that I don’t have to hurt myself because I was told that if I have 
any health problem, whoever I go to for treatment I must declare [to them] that 
this is my condition. So that’s very hard for me to go and tell everyone and in 
the work environment *and+ you don’t go by yourself, the health and safety 
officer will there for your or maybe your supervisors will be there with you, takes 
you and the doctor comes in, there you are declaring that. 
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One FIFO worker, who manages a large, contained offshore workplace, had this to say: 
...we protect our people as much as we can and all the work’s done in such a 
fashion or we try to do it in such a fashion that, well our motto is nobody gets 
hurt so there isn’t very often there is a blood spill thank God and you do feel 
safe in your environment. You’re probably safer in what we do than if you’re 
working in the kitchen here at home where you don’t bother about these safety 
rules and regulations that we do. 
Health care access on the mine sites in general is cited as good: “They’ve got a site 
nurse over there and yeah if you’ve got any problem call, you can just visit the site 
nurse and he or she attends to you” said one FIFO worker on a 457 visa. 
In the health sector, despite increased safety precautions and new needle and syringe 
technology to protect staff from needle stick injury, percutaneous injury does occur 
and these events can provoke high anxiety in someone with HIV:  
Yeah sometimes I think like this other day it happened that I was prickled [by 
the glass ampoule], I was in the middle of giving some morphine but then I was 
prickled so but then thank God I just told, I just told that the colleague that it 
wasn’t safe for me to give that medication because I don’t trust myself is what I 
said and they just put discarded. 
(457 visa holder) 
A small number of participants showed a less fearful appraisal of risk of transmitting 
the infection via a blood spill—this man after commenting on the fact that the 
paramedics in his industry practice adhere to safety standards, commented: 
So I don’t worry too much about you know. It’d be different if I wasn’t taking me 
tablets and me viral load was miles high and all that sort of stuff then I’d sort of 
worry. 
The workers fear transmitting the infection in a work place accident. Some of this 
anxiety may be related to not wanting others to go through what they have, as 
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expressed by a number of participants, but it appears that anxiety is associated with 
the requirement to disclose HIV serostatus if such a situation was to arise.  
I’ve got four supervisors I’m in good books with them. We chat, we laugh, we do 
everything but I don’t know when that comes what will happen but because of 
the visa issues my HR manager knows and a few managers at work knows...So 
how they would respond I’m not sure. So I don’t know.  
 (FIFO worker, 457 visa holder) 
Fear of disclosure 
Most participants anticipated negative appraisal from others, however, some cite 
examples of where they felt they had been exposed to discrimination. One FIFO 
worker described, furiously, how his HIV serostatus was disclosed by a hospital-based 
health professional to the company doctor. The clinic staff intervened with 
communication that supported his overall good health and ability to work, but not 
before the participant advocated on his own behalf and pointed out that the hospital 
worker had breached confidentiality. This participant had been working ‘up there’ for 
over seven years, mostly on contract this meant that he had to undergo regular 
medical checks and drug testing prior to their award. Since efavirenz is detected in the 
urine as a metabolite of cannabis (tetrahydrocannabinol or THC) erroneously, he had 
failed a number of tests. Subsequently he changed his medication to an alternative 
drug in the same class. This characteristic of efavirenz, a ‘first-line’ treatment for HIV 
and commonly coformulated with emtricitabine and tenofovir to the generic brand 
Viraday (Cipla Ltd) and the patented Atripla (Gilead Sciences Ltd), is a common 
problem for people working in jobs that require regular and unscheduled drug testing. 
Most employment in the mining industry involving manual labour or driving would fit 
into this category. 
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Another rural participant on a 457 work visa works in the health sector and described 
feeling anxious about disclosing her HIV status to her managers. But support from a 
family member helped her overcome this:  
So yeah it was hard for me to approach them [the management] and let them 
know but I just thought oh, but my sister was very supportive. She was like oh 
there’s many people with different diseases here so don’t be afraid just 
approach them and let them know and usually here there’s private so it’s 
nothing to worry about. 
This same participant is preoccupied with the fear of infecting another person, she 
volunteered this information: “I’m always living in fright in Australia”. When asked 
why, she said “Oh I’m just afraid maybe if I accidentally infect someone.” 
The concern expressed by the FIFO workers may in part be attributed to the 
perception that mine sites and oil rigs have a “very masculine type, homophobic type 
atmosphere”, as one man working on an offshore rig described it. All of the nineteen 
participants whether FIFO workers or not were reluctant to disclose their HIV status to 
future employers, their managers or their workmates. One man, who worked offshore, 
one month ‘on’ one month ‘off’ for an international company, was screened for HIV 
during routine professional licensing. When the doctor learned that the man would 
most certainly lose his employment, he reported his HIV status as negative after 
referring him for treatment with an HIV Physician. In his work environment, on an 
offshore oil rig there is an on-site medical doctor with whom workers are required to 
leave a list of their current medications. This participant omits ARVs from his list which 
includes medication for other chronic medical conditions. When asked what would 
happen if he included the ARVs, he said “Because I’d probably lose my job.” He clarified 
this response by saying:  
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Mmm well if it got out yeah you know, there’d be the questions asked why? Are 
you HIV positive, are you gay? And if that came out then in my type of job I 
don’t think management would consider a gay person capable of doing it 
although I’ve been doing it for 40 years. 
This man acknowledges that the rig, owned by a European company is likely is to be 
bound by anti-discrimination legislation but notes that “I’m an Australian so we’re 
more dispensable.” In effect the participant felt the need to conceal both the fact that 
he identifies as gay and that he is HIV-positive.  
This view is echoed by the respondent who had worked for a mining company in Africa 
and then was offered a position with the same company in an Eastern European 
country: 
I obtained a job in [the Eastern European country] and I had to give up on that 
job and that’s why I’m back here basically without a job because [that country] 
has a policy of no entry [for people with HIV]. 
This situation is ironical since the company publicises supportive programs for 
employees with HIV and encourages regular testing of HIV-negative employees in high 
prevalent areas. However, it was the case that this patient anticipated being 
stigmatised by his company to the extent that he refused to access free ARVs available 
from the company clinic when in Africa citing:  
I could have gone there but as I said I didn’t want the things to be on the 
company records...It’s hard to know, there’s a stated policy, there’s an un-
stated feeling do you know what I mean? And my feeling was that this was not 
going to do me any favours. 
He chose to access ART in Perth and travel abroad carrying the medication.  
Out of the nineteen participants in this group, who feared other people, particularly 
employers knowing their HIV status, there was one exception. This FIFO worker is now 
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a permanent resident of New Zealand and is aware of citizens’ rights in that country 
and that he should be able to access Australian Residency because of the relationship 
between NZ and this country. In addition to having disclosed his status to his family in 
East Africa he offers support to male friends in the workplace, sharing his knowledge 
of HIV, most of which he gets from websites and verifies with the medical staff in the 
clinic: 
What I’ve discovered if you test HIV positive there’s a period where you sort of, 
you are lost and it’s very important that you have somebody to talk to, to share 
with.  
This man is also unusual in that he has actively engaged with the WA AIDS Council, 
unlike most of the other people in this group, and reported receiving support from the 
organisation.  
Community Services for People Living with HIV/AIDS in WA 
It was not a focus of the interviews to determine if participants had accessed the WA 
AIDS Council (WAAC) but at least four people out of the nine that knew of the 
organisation had some contact. One rural participant seemed unclear whether he had 
received counselling from WAAC or from the Contact Tracing Service after he had 
received his diagnosis from the Medibank Health Solutions Unit. However, he found 
the interview frightening and distressing. A FIFO worker felt the service did not cater 
for heterosexuals and found the interview intrusive:  
I think he [she] just... if you weren’t gay didn’t want to know about you basically 
you know, that was the real impression I got...This is all bullshit aside, walk in 
there and talking to him and he *she+ asked me how I got it. I don’t like telling 
people how I got it [HIV]. It shouldn’t matter how I got it you know? 
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Three more people had heard about the organisation but did not want to use it. One 
Australian-born man feared that his privacy would be compromised:  
I think when I was first diagnosed I was told about those but because, a) 
because I was away and b) you know there’s always the thought in the back of 
my mind hey if I get in touch with these people then somebody might come back 
and try and use it against me or something you know. 
Internet access overcomes distance and privacy concerns 
Most of the participants had received standard approved HIV information in hard copy 
concerning the relevance of ‘CD4 counts’ and ‘viral loads’; how to practice safe sex and 
the importance of treatment adherence. But it was evident that the internet was used 
on an ongoing basis to access information and this practice was widespread 
throughout the group. However, participants did not seem clear about what sites they 
were visiting. Some accessed information regularly, for example the man who believed 
it was beneficial to disclose HIV serostatus while others did so less often. Private living 
facilities at the mine sites and portable ‘laptop’ computer ownership facilitated this. 
Accessing information in this way was considered an advantage for the privacy it 
afforded as well as the obvious advantage in overcoming the need to travel and 
receive information from a health care provider. In this way educated working people 
could be perceived to be advantaged over those who were not.  
Summary of Part Two 
The interviews reveal that the experience of HIV infection pervades nearly all facets of 
a person’s life. However, there are common aspects to living in rural communities 
regardless of the country and ethnicity, that nuance the social experience of HIV and 
this seems to be related to the number of people that ‘know’ you, ‘know’ your family, 
and ‘know’ that you have HIV infection. To a lesser extent there is a perception that 
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people in rural areas are less well informed (‘backward’) and that health care facilities 
outside of the main regional centres lack requisite knowledge of HIV. So people appear 
to fear gossip and ‘shunning’ from people and social groups that they know, more so 
than people that they don’t. There is an apparent desire to control who ‘knows’ and in 
this there is collusion with health care workers who shape their practices around the 
construct of confidentiality and the practice of protecting privacy beyond that applied 
to the management of other diseases.  
In a sense, the workplace also represents a small community and thus has some of the 
same social, ecological attributes of a rural community except that there is an 
expectation of conformity to certain practices that protect people with HIV and those 
around them from accidental transmission of infection, for example, the health and 
safety practices in the mining and health sectors. And there are laws which protect the 
explicit discrimination of people with HIV and ensure equal opportunity of 
employment—for Australian citizens. In this study, there were two men working 
internationally for whom a disclosure of positive HIV serostatus would result in 
exclusion from employment because of the discriminatory regulations of those 
international companies. However, for the remaining participants it was apparent that 
people feared discrimination in their places of employment rather than having 
experienced it and this is compounded for the people who are not recognised as 
Australian citizens and feel they have a lot to lose. These issues will be further explored 
in the next chapter. 
It is evident and in agreement with the verbatim of health providers, that considerable 
efforts go into overcoming structural barriers to accessing medication and this is met 
by participants’ motivation to accept their treatment. Those who interrupted their 
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regimens, particularly the man represented in the case study who developed AIDS, 
found the fear of death a great motivation, in common with other people who had 
seen members of their communities die. 
Overall, and in agreement with the reports of the health care workers, people are 
selective in their access to care and firmly engaged with the shared care network in the 
regions coordinated by the RRS in Perth. The service has to date, offered flexibility 
such that country people can attend the city-based service on an ad hoc basis while 
remaining linked to providers in the regions. This engagement is cemented by their 
need for immune monitoring and drug treatment (the bare minimum of HIV care) that 
they would not be able to access otherwise without either indirect of direct linkage to 
the Rural & Remote Service. Some of the participants appear to see the city-based 
service as a ‘safe haven’, where they can be themselves. However, it is apparent that 
services other than medical are in short supply in regional areas and that people with 
HIV may have a number of unmet social and psychological needs that are not being 
identified, in part because of their limited exposure and contingency status as ‘hard to 
reach’ populations. In addition their ability to access HIV education may be impeded by 
secrecy practices. 
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CHAPTER FIVE TEMPORARY VISA HOLDERS 
Introduction 
Migrants, guest workers and international students represent a growing, mobile 
population of ‘modern migrants’ who bring the health impact of their country of origin 
to one or more destination countries. Additionally, international travel and work 
opportunities support population exchanges and movement between migrant origins 
and destination locations. In December 2010, there were just over one million 
temporary entrants in Australia, excluding the half million or so entrants from New 
Zealand. Traditionally, public health approaches to managing the health of migrants or 
‘mobile’ groups have derived from the paradigm of quarantine; protecting the host 
population from an external threat by a process of exclusion (D. Armstrong, 2011; 
Gushulak & MacPherson, 2006). In this century, however, Western Australia 
increasingly relies on skilled workers to fill positions—particularly in the mining 
sector—and competition for enrolment of international students in universities is 
keen. Those seeking positions may come from HIV-prevalent regions in Africa, Asia and 
Oceania, and diagnosis of HIV is commonly made when people apply for visa 
extensions or permanent residency in Australia, or when people present with an AIDS-
defining illness. Thus a person who may have previously been eligible for permanent 
residency may find themselves suddenly ineligible by virtue of their inability to meet 
the Health Requirement which is enshrined in Commonwealth legislation under the 
Health Act 1958 (Cth). The nature of HIV infection with its long, largely asymptomatic 
phase and current potent and tolerable treatment, allows for a near normal lifestyle 
for infected individuals who have access to medical supervision and drugs. However, 
temporary visa status does not confer Medicare eligibility which would otherwise 
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cover the cost of antiretroviral treatment through the Pharmaceutical Benefits 
Scheme; and generic antiretroviral drugs (ARVs) are not available for prescription in 
Australia because of international trade restrictions (‘t hoen, 2009). Therefore, those in 
need must import from a limited range of generic formulations, usually first-line 
treatments from internet suppliers. The impact of an HIV diagnosis during health 
screening and/or outside one’s country of origin is therefore likely to add an extra 
dimension to the event of diagnosis; and the potential barrier to accessing ART is 
evident.  
At the time of writing this thesis, there were approximately 83 HIV-infected individuals 
(about 10% of the WA HIV Cohort) on a range of temporary visas, ineligible to receive 
Medicare, who were attending the Royal Perth hospital (RPH) Immunology Outpatient 
Clinic (L. Williams et al., 2011). In order to establish the health care needs of these 
individuals and the wider implications for health care delivery, I sought to: (1) 
understand the impact of HIV on visa holders; and the broader implications that 
temporary resident status has for infected visa holders and their families; (2) describe 
the experiences and outcomes of ART in those without Medicare access and; (3) 
identify points of difference between those holding temporary visas and those 
subsequently granted residency. The methods used in this chapter are detailed in 
Chapter Two but a summary follows to assist the reader and render the Chapter more 
complete.  
Specific Methods  
Patients and setting 
The study was conducted at RPH in Western Australia between April 2010 and October 
2011. Patients were eligible for the study if they had HIV infection; and were, currently 
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or previously, ineligible for Medicare. This status was established by accessing the case 
notes of potential participants during their  Outpatient Clinic visits. Patients were 
introduced to the researcher who explained the study and provided an information 
sheet. At this stage the researcher endeavoured to establish a rapport with 
participants to ensure that they understood the role of the researcher and felt 
confident that their private information would be protected. Written informed consent 
was obtained at a follow-up appointment. Twenty-two patients took part, three 
refused to participate.  
Semi-directed interviews with patients 
The interviews were conducted in English, which most patients spoke competently as a 
requirement attached to 457 and student visa status. Three Thai women had limited 
English but were able to communicate with the researcher when sufficient time was 
allotted. Two were accompanied by their English-speaking husbands and one had an 
interpreter present. Questions were largely open-ended and a schedule was developed 
based on broad themes which had emerged from our previous study (Chapter Three) 
and established cross-cultural approaches (Carrillo et al., 1999). Participants were 
encouraged to speak freely about issues important to them and the interviews were 
recorded and transcribed. 
Results  
A summary description of the sample can be found in Tables 15a and 15b. Semi-
directed interviews were conducted with 22 consecutive participants (10 women) 
fulfilling the study criteria. Twelve interviewees were of East African ethnicity, from 
either Zimbabwe or Kenya, seven were of varying Asian ethnicities, two were from 
Oceania and one was European, ranging in age between 23 and 43 years (mean=30.3 
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years). Ten lived in the metropolitan area, fourteen were in paid employment, six were 
fly in fly out workers, four performed home duties and one was supported by another 
family member, and two were students. Five lived in regional areas and one was a 
‘traveller’ with no fixed address. Twelve were currently ineligible for Medicare while 
two had interim access, three were New Zealand citizens and therefore eligible for 
Medicare; and five had transitioned to permanent residency. Of the sixteen married 
people, nine had hopes to increase the size of their families and—amongst the 
temporary visa holders—seven were in sero-discordant relationships. The median year 
of HIV diagnosis was 2007 and most had been exposed in their country of origin, 
except for two men infected by other men (clade B) in Australia. Eight patients 
infected overseas had clade C virus, one had the recombinant form AE and another 
clade D; the rest did not have results available.  
A common reason for HIV testing was health screening for visa or on application for 
Permanent Residency. Seven had detectable virus, of these, four were treatment 
naive, one was not on current treatment, and two had been on ART less than four 
months and the virus was barely detectable (166-224 copies/mL). Co-morbidities were: 
tuberculosis (TB), hepatitis B, uterine fibroids, haemolytic anaemia, osteoporosis, and 
dyslipidaemia (each comorbid condition was found in 1 out of 22 patients). In addition, 
depression was diagnosed and treated in one patient, and self-reported in another. 
The patient being treated for TB was naive to ART and reported good adherence to 
treatment for his tuberculosis.  
At the time of the study 19 patients had prior treatment with ART via compassionate 
access and/or generic formulation, including three women who had pregnancies 
managed with ART; 17 were on current treatment (range: 3-94 months, median = 19). 
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The average cost of imported generic ARVs was AUD$180/month. Two patients 
reported treatment interruptions of more than four days. Two patients with 
compassionate access to patented drugs experienced side effects in the early stage of 
treatment necessitating a treatment switch. Of the five patients not on treatment only 
one was likely to be eligible for interim Medicare cover. All 17 on current ART 
demonstrated high levels of adherence regardless of whether they were taking 
generics or not. Five patients reported never missing a dose, 4 people >3 months ago 
and 1 person <3 months ago). Where there was a threat of treatment interruption, 
clinic staff sought (successfully) compassionate access to meet the shortfall. Patients 
reported few side effects (5 out of 17 reported none, 11 out of 17 reported up to five 
and 1 out of 17 reported 10). The most usual side effects were fatigue, pruritis, dry 
skin and bad dreams. The most common drug combination was emtricitabine, 
tenofovir and efavirenz (9 out of 17) co-formulated as the generic Viraday.  
All of the participants spoke fluent English, except for the Thai women, two of whom 
were interviewed in the company of their husbands who they frequently looked to for 
translation, although their partners could not speak Thai. Half of the sample had 
university or college education, and the other half had finished secondary school 
and/or vocational training. Computer access was common, and participants, 
particularly the men who owned computers, accessed HIV information from the 
internet. This was independent of hard copy material received from the clinic staff. 
However, one woman avoided HIV information and thinking about HIV altogether. This 
woman received support from her husband and his family in Australia. Three of the 
other women had only disclosed to their husbands, but no other family member. But a 
fourth received support from her husband’s family and was attending English lessons. 
Her language skills developed over several meetings she had with the author and 
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consequently, not all were attended by an interpreter. The women were provided with 
written information about HIV in Thai and were directed towards internet sites 
affiliated with recognised HIV/AIDS organisations. 
Table 15 (a): Demographic characteristics of the participants (N=22) 
Age (mean ± SD) 33.4 (6.0) Median year of diagnosis 2007 
 Number (%) Indication for first positive HIV test Number (%) 
Female/male  10/12 (45.5/55.5) Illness or concern re symptoms 5 (22.7) 
Living in a couple/family 17 (72.2) Health screening 14 (63.3) 
Children  13 (59.1) HIV-positive partner 1 (4.5) 
Sero-discordant 12 (54.5) Risk exposure 2 (9.0) 
 
   
Self-reported HIV exposure   Self-reported location of HIV 
exposure 
 
Heterosexual 17 (77.2) Country of origin  19 (86.3) 
MSM  2 (9.0) Australia 2 (9.0) 
Unknown 2 (9.0) Abroad 1 (4.5) 
IVDU 1 (4.5)   
    
Living/working in metro area 10 Visa Status  
Employment  457 long stay business visa 7 (31.8) 
Student 3 (13.6) Student 3 (13.6) 
**FIFO worker 6 (27.2) Spousal 2 (9.0) 
Full-time 14 (63.3) Other 2 (9.0) 
Unemployed or home duties 4 (18.2) Permanent resident 5 (22.7) 
  New Zealand citizen* 3 (13.6) 
*All East African ethnicity; **FIFO= fly in fly out  
 
Table 15 (b): Clinical and treatment characteristics of the participants (N=22) 
Regimens Number (schedule) Access, adherence and side effects Number (%) 
FTC/TDF/EFV 9  OD ART naive 3 (13.6 ) 
FTC/TDF/NVP 1  BD No current treatment 2 ( 9.09) 
FTC/TDF/ LPV/RTV 2  BD On ART 17 (77.3) 
3TC/AZT/ RTV/ATV 1  BD Medicare ineligible  12 (54.5 ) 
3TC/AZT/ABC 1  BD Generic ART 8 (47.0) 
3TC/AZT/NVP 1  OD On patent ART* 9 (52.9) 
3TC/ABC/NVP 1  BD Self-reported adherence 5/17 never missed  
3TC/ABC /RTV/LPV 1  BD  4 missed > 3mths  
   1 < 3 mths ago 
    
CD4-T cells/mm
3 
(mean ± SD) 578.95 ± 245.45 Self-reported side effects 5 = nil 
CD4-T cell (%) 27.18 ± 9.2  11 = < 5 
Median CD4-T cells/mm
3
 623.5  1 = 10 
Viral Load‡  7/22 (6093.3 ± 9667.7) Average cost of generic ART (AUD) 180/month 
Abbreviations: OD= once daily dosing, BD=twice daily; ART=antiretroviral treatment; 3TC=lamivudine, 
FTC=emtricitabine, TDF=tenofovir, ABC= abacavir, AZT=zidovudine, EFV=efavirenz, NVP=nevirapine, LPV= 
lopinavir, RTV=ritonavir, ATV =atazanavir; *Includes one patient on a spousal visa with interim access to 
Medicare: ‡= ≥40 copies/ml.  
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Results of Interviews  
Impact of an HIV Diagnosis 
HIV is currently ineradicable but treatable, with potent antiretroviral drugs. The 
analysis of interview transcripts focuses on the impact of HIV and ART on the physical, 
social and emotional situations of people who have experienced temporary visa status 
in Western Australia. Moderating influences perceived to be related to personal, 
situational and environmental characteristics are also presented. The sample was 
characterised by diversity driven by sociocultural influences including the social 
perception of HIV in the country of origin. Therefore, there were differences between 
the Thai interviewees and the Africans, the men and the women. However, there were 
also commonalities. Since most of the recorded interviews began with general 
questions about the circumstances predicating HIV testing and the immediate 
aftermath; together with the participant’s reflection on HIV in their country of origin, 
the results are presented as a narrative reflecting the dynamic nature of the illness 
experience:  
It’s like I was prepared for it because I was sort of, ‘cause I’ve seen lots and lots 
of HIV positive people back home and I was displaying all the classic symptoms 
of being HIV positive so I was, in a way I was sort of, I had sort of prepared 
myself for it. But despite that you sort of get a shock out of that. Despite being a 
hundred percent sure that you are positive, still you get that shock. 
 (African man, NZ citizen) 
HIV testing for married people is necessarily a family affair and the family’s future 
prospects may hang on the HIV serostatus of one member. Indication for testing was, 
for most interviewees, prior to applying for permanent residency or for a temporary 
visa. Four were diagnosed in their countries of origin and one while working in the 
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Middle East who according to the law of that country, had to leave within a month of 
the diagnosis or be deported. One patient concerned about chronic weight loss 
wanted to avoid an HIV test in Australia and returned to Africa for testing, citing his 
fear of the Australian Government’s 2007 position (Stafford, 2007) that argued for the 
most stringent possible conditions to prevent people with HIV emigrating to Australia:  
...that’s when I said (to my wife) ok ...you know what? Maybe I should go. So 
we’re trying to think where should I go then? My worst fear was... if I do the test 
here we’ll be deported. 
 This interviewee received a diagnosis of AIDS in Africa; commenced ART purchased by 
a family member there and returned to Australia. Generally, interviewees diagnosed 
outside Australia received their results by telephone. However those diagnosed in 
Australia received them in person from medically qualified personnel at Medibank 
Health Solutions, a hospital-based specialist or a GP. In most cases, pre-and post-test 
discussion took place, although the quality and effectiveness of this discussion is not 
known. In the case of a diagnosis made by the doctor at Medibank Health Solutions, 
new diagnosed people were referred to RPH and seen as soon as possible, usually in 
less than two weeks but mostly within days after diagnosis —by either experienced 
nursing staff or the staff immunologist. These staff provided post-test counselling and 
immediate support to alleviate distress and initiate HIV/AIDS education. One woman 
was glad she had been tested:  
I think so it’s good to be tested. Before I used to think no, getting tested, 
knowing that you are HIV positive not a good thing. I would rather not know 
and just die without knowing. But I think knowing is a little bit better, at least 
the disease you can manage it with the medication. 
(African woman, 457 visa)  
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However, health screening for immigration or temporary visas in the country of origin 
can result in inadvertent disclosure to families and friends of applicants who fail the 
assessment. One African woman said of her 457 visa application process: 
That’s a requirement that all these countries want for us before we get visas, 
that has to be checked and it doesn’t come out clearly that you’ll be allowed to 
come, you know you’ll be stopped so all the time you always think this is, I’m 
already being told if you’re HIV you’re not coming to Australia. That’s how it 
looks... So it’s just a first barrier that you have to protect your [country] but 
yeah still it pushes you back and you think twice, you feel discriminated at that 
time, at that level you feel discriminated. But coming in I noticed they really 
don’t, they’re just trying to do what’s best for their country. 
Fear of imminent death was described by most participants regardless of cultural 
background: “I didn’t cry I was just so scared, it was just so hot, everything was hot, I 
was feeling tight, like I’m in this tight place. I’m going to... oh die you know”? (African 
woman, diagnosed with HIV in Africa). This fearful response was nuanced by the 
perception of HIV and personal experience of death in the participants’ country of 
origin:  
...there was a time when you would get into your bus —you can really see that 
when you actually get into the AIDS thing people start getting slim and their 
hair, you can really see that someone is sick 
(African man, 457 visa, diagnosed in Africa) 
And there are immediate implications for partners:  
...it was mainly the stress that was, I think, the biggest thing when I first found 
out because I mean we’re discordant my wife and I. I think my first, if anything, 
my first fear was that oh ...I think my wife, oh damn I think I’ve given her (HIV). 
(African Man, 457 visa, diagnosed in Africa) 
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Although diagnosis of HIV led to testing of partners and children this was not always 
the case: “She’s gone through a lot, yeah... she’s lost three members of her family 
through HIV so she’s not prepared to have a test.” (African Man, NZ residency, 
diagnosed in NZ). One interviewee whose wife is also positive had not tested their 
children despite his NZ residency providing him with a degree of security from 
deportation: ‘...from experience the children would be very sick. [Now] I’ve got to have 
them tested because I want to apply for Australian residence so it’s part of their 
application to process.’ Two men delayed testing for fear of a positive result while 
others, once diagnosed, were keen to avoid treatment until it was absolutely 
necessary.  
Disclosure of HIV Status: “Is she black?” 
Recruitment for this study was challenging. People on temporary visas wanted to 
confine the number of people who knew of their HIV serostatus to a minimum of those 
who needed to know; and the nursing staff were keen to ensure that patients did not 
doubt the nurses’ commitment to protecting the patients’ privacy. Patients 
approached by the clinic nurse and offered participation in the study were also 
concerned about the cultural background of the researcher. “Is she black?” asked one 
man who was keen to avoid anyone in his East African friendship group from knowing 
his serostatus. There was also concern about how information gained from the 
interviews would be used, and whether the researcher was a trustworthy person. 
Significantly, some interviewees believed that when they engaged with the health 
system, even to participate in research, it meant that they became a ‘burden’ to the 
Australian Community and that this could affect the outcome of their visa application: 
‘nothing is confidential’ (African Man, 457 visa). One patient used participation in the 
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research to his advantage and framed it as a ‘contribution’ to the community. A letter 
was prepared that he could use to advocate this stance to the Department of 
Immigration and Citizenship. This idea of being ‘a burden’ extended itself to treatment, 
so that people felt that as long as they did not need ART they were less burdensome, 
despite the fact that in the eventuality of needing treatment they would need to 
import generic ART at their own expense. The fear of disclosure of serostatus also 
stemmed from the perception of being considered contagious: 
...they write on the clause of the immigration document to say this person is a 
potential danger to the Australian community and society ...So when such 
words are mentioned you get even scared of going to the hospital or to any 
public centre and it says to go into a public place and it mentions school or 
college and probably maybe hospitals but those are public places you know so 
what I just thought is I’m only coming here because they are the ones who 
referred me to come here otherwise given a chance with the letters which I’ve 
got from the Department of Immigration and what they say about my 
condition, going to any public place should be a no go area to me.  
(African man 457 visa) 
The process of disclosure was, in general, universally stressful,  although the patterns 
varied. Six had disclosed to parents or siblings, fourteen had either not disclosed or 
only disclosed to their partners; and two of the women married to Australian men 
received emotional and social support from their husbands’ families while their own 
were unaware on their infection. One of the gay men had also not told his parents 
about his sexual orientation. A number chose not to disclose because they did not 
want to make others sad; this attitude was common among women, particularly the 
Thai women: “I don’t want to her be worried you know and she, I think she going to get 
worried and tell me to go back to Thailand” and in reference to one’s child: 
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I don’t want his to know anything about me but I just let him know a little bit 
like mummy not healthy, mummy not healthy person, one day I will sick, one 
day I will gone by then or you have to help yourself and I don’t want to carry, for 
him to carry me around thing.  
(Thai woman, Permanent Resident) 
In contrast, the European forced to leave employment in the Middle Eastern country, 
returned home to receive social support from family and access to ‘first world’ 
treatment. However, very few participants had disclosed to friends. One man, who 
often sat with his fellows from ‘Zim’ (an affectionate abbreviation for his country) and 
discussed all of the issues relating to their life in Australia, will not discuss his 
serostatus with them despite living with the infection for years in Africa.  
However, in contrast with his countrymen, another man explains his view:  
What I’ve discovered if you test HIV positive there’s a period where you sort of, 
you are lost and it’s very important that you have somebody to talk to, to share 
with. It’s sort of takes the weight off you to the person that you have told. 
(African Man NZ citizen) 
 Inadvertent disclosure by health professionals is a constant and real concern as was 
described by a FIFO worker in the previous chapter. He described a situation whereby 
a hospital doctor disclosed to his company’s doctor: “I thought I’m not going to make 
my job just because someone has divulged that information, I didn’t have any peace of 
mind.” In general there is respect for the qualifications of health professionals as 
educated people trained to protect privacy, in comparison with others in official 
positions. For example:  
You firstly are disclosing to the receptionist. And then you go and disclose to the 
dentist. I feel receptionists are not medical people. They are not trained to keep 
my information secret. 
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(African man, NZ citizen) 
Most people find the hospital clinic to be a safe haven where a small and trusted 
number of people know that they are HIV seropositive and are seen to actively protect 
their privacy. However, fear of disclosure can get in the way of gaining access to 
information and patients rely heavily on a few hospital staff to guide them to 
appropriate services and provide information on a wide range of subjects without 
divulging their HIV serostatus.  
Fear of Transmitting HIV  
Fear of transmitting the virus was common and most acute around children: “I was 
afraid to breathe near my children” (African man, 457 visa). One woman began to 
avoid association with children: “...before I not get sick, I have a lot of kid(s) too, like to 
come to play with me and then I know I get sick I don’t want to play with them I’m 
scared them gets HIV from me...”(Thai woman, spousal visa now PR). Some avoided sex 
altogether at first. One woman working in the health sector put it this way: “I’m always 
living in fright in Australia...I’m just afraid maybe if I accidentally infect someone.” 
Others were pragmatic citing that their knowledge of HIV transmission made them 
aware of what practices to avoid. This appeared to be easier for married men: “You 
know when you’re married that’s such a relief, you know that your wife knows you 
know, you know you just have to concentrate on you know using your protection and 
that’s it.” Cuts and blood spills provoked the most anxiety and this was not moderated 
in any way by HIV education. It is unclear why the fear and sense of contagion was so 
strong in some participants but these findings reflect those of the PROQOL-HIV study 
in Chapter Three. 
224 
Physical Impact of HIV  
The prevailing attitude concerning the physical impact of HIV could be best expressed 
by the following statement: “I’m not sick or anything, I’m fit for work that’s all they 
need” (articulated by one FIFO worker on a temporary visa). Indeed, at the time of 
interview all participants were physically active and/or employed, including two 
participants with severe immunodeficiency. Many expressed frustration recalling the 
situation in their country of origin—most commonly Zimbabwe—that if one was 
walking about then one was well enough to work: “Back home they say ‘look you’re 
walking aren’t you, OK so you’ve got the job just do your work OK”  (African man, 457 
visa). All of the women in the sample, except one, were either working or caring for 
children. Some patients had concerns about their weight which they seemed to see as 
a reflection of their overall health, perhaps influenced by their observation of HIV in 
others and their understanding of the importance of nutrition in the management of 
HIV:  
So it’s basically, you have to say if you want to have a strong immune system 
what do you do. You’ve got to eat a lot of foods with a lot of vitamin C and 
you’ve got to eat a lot of fruit, a lot of vegetables, green leafy vegetables. 
You’ve got to eat proteins and stuff like that. 
 (African man, 457 visa)  
Interviewees tended not to take common supplements like fish oil and appreciated the 
nutritional value of fresh food, although one man noted that ‘everybody’ in Zimbabwe 
takes ‘vitamins’.  
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Complementary Medicine and Use of Substances  
None of the patients were currently using herbal or complementary medicine, 
although most had been exposed to it in their countries of origin. One woman 
explained the use of herbs to treat conditions in Oceania:  
...but I wouldn’t trust it for the HIV thing but apart from that I’ll say I’ll trust it 
for malaria or typhoid because it’s so normal over there...You know it’s been 
practiced for generations and people know it but HIV I wouldn’t believe it if they 
say they have a herbal medicine for that.  
The African participants who considered themselves educated, spurned the idea of 
effective herbal remedies for HIV, which were commonly used in Africa, but thought 
highly of the supportive capacity of good nutrition. Healthy lifestyles were also 
esteemed in the sample. There was only one who smoked and no one was currently 
using recreational drugs. Only one participant from South-East Asia had a history of 
IDU. Heavy and/or episodic drinking was uncommon but reported by a couple of the 
men and two Thai women, however abstinence was more usual. 
Treatment and Side Effects 
Most patients held firm beliefs concerning the efficacy of the treatment and their 
ability to adhere. “The moment that I knew I was HIV positive it was in my mind that if I 
get something to help me I would adhere to that, I would stick to that” (African man, 
student visa). There was no apparent resentment about purchasing generic drugs 
although financial hardship was evident for those with families in their country of 
origin:  
I have to look after the kids, their school fees and their aunty, it’s a bit of a 
challenge...for the meantime I’m coping since I’ve got a job here and my wife is 
always assisting me with looking after the kids. 
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(African man, student visa)  
It is also necessary for all temporary visa holders to take out private health insurance. 
Most of those taking generic drugs expressed frustration that they could not achieve 
residency by declaring intent to continue purchasing ART and thereby avoid the 
perceived cost to the Australian community. Once a decision had been made to begin 
treatment and a prescription prepared, the patients were instructed on how to 
purchase generic drugs from internet providers. Access for most patients seemed 
relatively unfettered and potential shortfalls in treatment due to hold-ups by the 
Australian Customs and Quarantine Service, which are quite common, and delay in 
postage are minimised by the comprehensive instruction received from nursing staff 
prior to starting ART:  
Yeah you can always look around for the prices and they’ve got all the set prices 
and you look for the cheapest and you just go. Ever since I started here I have 
been buying from one pharmacy. As soon as you order them they will send them 
to you and maybe two weeks you’ll get it. 
(African man, 457 visa)  
One patient said: “The concern I got the website who is selling it, it’s been four 
company or three company been changing around. ‘Cause before it’s cheaper and I 
order them and all of a sudden it stop.” The first time this happened it was twelve days 
before the supply arrived and in this period nursing staff sourced an alternative supply. 
Another patient on medication since 2006 said that he had accessed three or four 
different sites which had subsequently closed without notice resulting in treatment 
interruption. In this instance he sought help from an HIV/AIDS service in Sydney to fill 
the gap until the generic supply was re-established. In another instance, when he 
moved to Perth, he ran out of ART and could not get an appointment to see a doctor 
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for some weeks. Again the same Sydney-based service sent ARVs to Perth.  This 
participant, whose family member purchases and posts drugs from within Zimbabwe, 
was constrained by supply but also hyperinflation in the economy of that country:  
So because of that you know... the prices go up every day including the meds so 
everything, literally everything would go up every day. So even the companies 
like they would tell you this quote is valid for the next seven hours.  
(African Man, 457 visa)  
For a small number of participants presenting with severe immune deficiency or during 
pregnancy, a request for compassionate access was sought from the hospital’s clinical 
director, after which patients moved onto generic supplies. One participant said “I’m 
really not the sort of person who likes to sort of feed, like leech you know off something 
like that... like there’s a system, but if you abuse the system then it’s not good” (Asian 
man, student visa). One patient’s husband purchased medication full price from the 
hospital pharmacy amounting to $1000 AUD/month rather than have his wife run the 
risk of treatment interruption which, he understood, was important: 
I just didn’t want any hold ups. I wanted to make sure she had them every day. I 
didn’t want to be sitting on the letterbox waiting for the tablets to arrive and 
she run out. I didn’t want that to happen. They told me I can buy cheaper but I 
said as long as I’ve got the money to pay for them I don’t care. 
(Husband of temporary visa holder) 
There were few reported minor side effects and concern was expressed by those who 
had experienced severe side effects. One woman was hospitalised following separate 
hypersensitivities to nevirapine and cotrimoxazole and another experienced rash and 
abnormal liver function while on nevirapine and subsequently efavirenz. These side 
effects to the commonly used generic drugs presented obstacles since alternatives 
(generic) are few and generally more expensive when they are available. The first 
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woman went onto a compassionate supply and the second stopped treatment 
altogether and returned to her country of origin. During pregnancy, taking ART is not 
always straightforward: “I like it much more better (now) because when I was pregnant 
they put me to another medicine and it was, I was too much vomiting and all this so I 
switched again so now I’m feeling very happy with this medicine.” (Oceania woman, 
461 visa).  
A number described having vivid dreams as the only side effect of the three drug 
combination (lamivudine, tenofovir and efavirenz) known as Viraday or Atripla. One 
patient describes violent nightmares: “Oh let’s say in a week I’ll say two to three times 
in a night and just very long ones and very scary ones”, from which she wakes 
screaming (Oceania woman, 461 visa). Another views them positively: “Sometimes 
they’re a bit emotional then I find myself that I’ve cried, you wake up and you’ve wet 
cheeks but it’s nothing negative it’s all like really happy tears...” (European, PR). A third 
young woman on generic drugs described the dreams and confusion as occurring only 
during early treatment: “Like I would feel dizzy, oh I would feel dizzy, I couldn’t even 
eat. Oh the dizziness was so bad and I was nauseous... I mean otherwise bad dreams 
and confusion it was only when I first started taking the medication.” Dizziness and 
mood changes were described by the young men also and a common anecdote 
concerning Atripla vs Viraday emerged during the interview with another young man 
on generic ART: 
Atripla had the side effect of a bit of a weird taste in the mouth, in the back and 
oh you would just feel so dizzy. I don’t know if dizzy’s the right word, basically 
your head going round and it would last for probably half an hour to an hour... 
But Viraday on the other hand which I’ve become a great fan of does not give 
that side effect at all. There’s not a hint of it.... So there have been no side 
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effects with Viraday at all which I find weird because this is basically the generic 
brand of Atripla. 
 (Asian man, student visa) 
Only one of the two patients on a lopinavir/ritonavir combination complained of 
diarrhoea and problems with night sweats and weight loss – this man was in the early 
phase of treatment and severely immunosuppressed. Otherwise fatigue and skin 
problems were the only other complaints. More commonly the patients expressed 
themselves in terms of feeling fortunate, such as in the following statement:  
I’m very blessed and lucky, not lucky blessed because I don’t come up with any 
issues at all. I’ve got no side effects, no nothing whatsoever and it’s sort of one 
tablet a day, I’m just doing it perfectly fine 
(African man, PR) 
However, participants naive to ART were apprehensive, possibly because they have 
not yet received the medication counselling and education which is commenced closer 
to starting drug treatment. 
Adherence to Antiretroviral Drugs 
All of the interviewees on treatment were highly motivated to take ART and this was 
evidenced by the high affirmative frequency to the questions: (1) How sure are you 
that that you will be able to take all of your medication as directed?; and (2) How sure 
are you that your body will become resistant to the medication if not taken as directed? 
Self-reported adherence over the last 30 days was excellent across all participants: “I 
just have to take my tablets to keep me going really. It’s like a fuel, how you never 
forget to fill up your car with fuel, same as me, something which I know that I have to 
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do” (African woman, NZ citizen). There was also motivation to adhere to avoid drug 
resistance:  
[If] I have to start using the other medications which going to be even more 
difficult because the price and also the number of the drugs you need to takes 
going to be completely different.  
(Asian man, student visa) 
Some feel they have to overcome some barriers to get their ART.  
I think at the end of the day sometimes I think as a patient you do want your 
meds, you know you do need them. You know [emphasis] and you have to go 
through so much red tape just to get them. 
  (African Man, 457 visa)  
One participant had started ARVs (lamivudine, stavudine and nevirapine), in Zimbabwe 
in 2006. He had taken these continuously for two years until his supply ran out three 
months after arriving in Australia to work as a FIFO worker for the mining industry. He 
attended a GP and was referred to the RPH clinic and given compassionate access to 
one month’s supply of ARVs to cover the period until a generic supply was established. 
This gap represented a six week treatment interruption. Six months later, testing 
showed NNRTI resistance and his therapy was subsequently switched to another 
generic combination. He responded well to this treatment with excellent adherence 
and no complaints of side effects. This man takes a pragmatic view of his illness and 
has pride in his ability to manage his medication despite the potential difficulty posed 
by shift work. He also keeps up to date with HIV information on the internet as do a 
number of the other participants.  
Most participants felt they needed to hide their medication and either rebottled their 
ART or kept it out of sight. One man, for example, kept his in his car. Motivation to 
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take treatment and social support overcame some potential threats to medication 
adherence posed by ‘situation’. For example, one interviewee with a new baby said:  
But just when I had bubs I, my whole attention was him and I’d fall asleep tired 
and I’d think, just three or four times I kind of forgot. But J, before I sleep J 
always reminds me, have you taken your medicine? 
 (Oceania woman, 461 visa)  
This same woman expressed great confidence in ART: “So it’s only one little bottle and 
that’s it. It’s pretty good—it’s amazing how this one little tablet can do so much for 
you.” Three of the ART naive interviewees demonstrated some misgivings about the 
efficacy of ART. As one man explained: 
...because back home in Zimbabwe we’ve had people with HIV, some of them 
they have even gone to take antiretrovirals’ but what we have noticed across 
the board of many people who’ve been taking HIV antiretroviral drugs, instead 
of them getting better they’ve been getting worse. So I don’t know whether it’s 
because it’s in Zimbabwe or it happens across the board, I really don’t know, it’s 
not something I’ve experienced so I cannot conclude and say it’s going to help, 
it’s not going to help, I’m blank with it. So that’s my position with that. 
 (African man, 457 visa) 
A Thai woman contemplating starting ART said: “The scary thing is I think when got 
somebody got very sick yeah, that scared me. Yeah like I can see when somebody got 
very sick they very like skinny and weak.” Other women believed the medication would 
stop working as they thought it inevitable that they would die of AIDS eventually, 
despite ART. Some patients were concerned about the long term side effects of ART 
and hoped one day not to continue taking it. 
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Returning to Country of Origin 
Fear of returning to country of origin was expressed by all but two of the participants 
on temporary visas. After the interviews, two participants returned to their countries 
because their temporary visas were not renewed. One returned to Africa reluctantly; 
she had not disclosed her HIV serostatus to her family and had concerns about access 
to appropriate ART. She had been switched off first-line treatment in Australia due to 
toxicity and would probably need close supervision and dose/drug adjustments. She 
said: “So yeah it depends on how react to the medicine but after the two trials here I 
know I’m very sensitive to the medicine so it’s scary” (African woman, 457 visa). She 
was not, however, prepared to risk refusal and the waste of the application fee in 
applying for residency. The main fear of participants’ concerned access to treatment, 
regardless of their country of origin: 
I will not survive. It’s really hard over there... it’s really complicated I think to get 
the medicine in, you need a lot of money for that, like way a lot of money. Cause 
people trying to rip you off and yeah and then it’s, yeah it’s harder, not every 
city got it and I’m not from a big city as well...that’s why my cousin pass away 
‘cause he can’t get access to medicine and then the pay we get over there... the 
wages over there for months is very (low), you know for one month medicine 
 (South-East Asian man, bridging visa) 
Particpants’ awareness of treatment access in their countries of origin varied widely 
and —at least in Africa—probably reflected the patchy coverage of AIDS treatment 
programs. A number of interviewees cited corruption and poor standards of 
confidentiality as threatening uninterrupted access to generic ART: “Yeah it does worry 
me because if anybody gets that disease in Zimbabwe then the only way for them is to 
die because there is no medication for that in Zimbabwe” (African man, 457 visa). Two 
patients were relatively unconcerned about returning to their country of origin but 
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needed to support their wives who were keen to stay in Australia. One of these had 
experience of unfettered access to ART in Zimbabwe in the region in which he worked 
and was sanguine about return stating: “But now with this introduction of ARVs you 
can really hardly tell now ‘cause everyone is getting normal” (African man, 457 visa). 
He felt supported by his sense of intrinsic worth with regard to being fit to work and 
had also improved his work related skills while in Australia. Another interviewee, 
whose HIV-infected spouse remains in Zimbabwe along with their son, cited that ART 
was readily available from the local hospital.  
Relationships and Support 
Sero-discordancy was common in this study (13/22 participants) so that the diagnosis 
had implications for the relationships of the interviewees in a number of ways, and not 
merely for future intimacy and child bearing. This creates tensions within relationships: 
‘[We] both felt like we killed each other and I told him killing each other would not take 
it away so it, either we continue the relationship or we just break apart’(African 
woman, 457 visa). However, supportive partnerships were common, and their 
reactions also helped to consolidate adjustment to the diagnosis:  
I felt like the world was coming down on me and I told her to, I got to a point 
where I told her to move on with her life, I’m helpless you know and she tell me, 
no she really give me a lot of support and she told me that’s not the way to go 
about it and she showed me so many things  
 (African man, now resident)  
Others have not yet adjusted. One man has yet to tell his wife who lives in another 
country, as do his children. In two other couples, the wives were fearful to be tested. 
Sero-discordancy also complicates visa applications for couples and families creating 
‘visa-discordance’ where ‘ineligibility’ lies with only one member. This in turn appears 
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to place stresses on the marriage and wider family relationships. Conversely the 
support received from families in general was a powerful moderator of HIV-related 
adversity. Two of the young women married to Australian men spoke of the broad 
range of support received from their husband’s families, including support for their 
residency and acceptance of their HIV serostatus. A number of interviewees cited a 
supportive family member in their home countries and many were comforted by their 
religious beliefs: “Yeah that keeps me going really. Yeah I trust that He will look after 
me” (African woman, NZ citizen), while recognising the (Christian) Church’s position 
that promiscuity is immoral. This led one participant to say: “No it’s like in, in religion 
they tend to sort of associate HIV with being immoral...Yes, yes they are judgmental” 
(African man, NZ citizen). The role of Buddhism in the lives of the Thai participants was 
less clear although the Temple seemed to provide a meeting place for some women 
both in Perth and in Thailand: “...but I still look after young children, the little children 
at the temple for the old people at the temple but they don’t know what happened to 
me.” And there is the role of karma and prayer:  
Yeah more, more because they can’t afford to buy the medicine [for HIV] but I 
think now the way they can fix by themselves they just think their luck or their 
bad luck but we are so pleased like we are Buddhist and we can pray.  
An African man stated in the interview:  
I don’t know if it’s Christianity or but it carries you to do good things, yeah I 
would say the right things. It might not be existing or whatever but it somehow 
carries you to do things that are human and that are right that does not offend 
the next person... 
People With and/or Wanting to Have Children 
The impact of HIV on people with children and those who would like to have children 
was considerable: “Concern is always there. Am I going to be able to have a partner or 
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have kids like normal” (South-East Asian man, bridging visa). In addition to this stress 
was the fear of passing on the infection, during conception and childbirth and 
unwittingly by some unknown (as yet) mechanism: “I’m concerned about is that 
probably the way we are told that it only is transmitted is not the way we get it...” 
(African man, 457 visa). One interviewee, naive to ART, fervently believed she would 
die young and just wanted to see her children become independent: “I don’t want to 
be sick, sick and then they have to get sick and sick to the end I really don’t want that” 
(African woman, spousal visa). A number were concerned about how they would tell 
their children and how that would affect their relationship: “...especially when they are 
young like this and I would want them to find it out from me and they are too young for 
them to handle something like that” (African woman, NZ citizen). Others were 
concerned about financial support for their children since their own ability to apply 
successfully for personal insurance may be affected by their HIV status.  
Outpatient Care: Social Support  
Like many Australian residents living with HIV, people on temporary visas and those 
that have transitioned to permanent residency are characterised by their wish to 
minimise the number of people who are aware of their HIV serostatus. Often there is 
no one outside the hospital system who knows that they are HIV seropositive. This can 
place enormous stress on people, although others adjust and are comfortable with this 
‘duality’. In addition temporary visa holders are sometimes reluctant to access hospital 
services beyond those absolutely necessary. The two key roles are the clinic nurse and 
the clinic doctor. Participants in this sample respected and relied on these positions to 
fulfil a number of ongoing functions, not only to monitoring their HIV and negotiating 
visa renewals and applications to support Health Waivers. Participants spoke about 
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being able to ‘be themselves’ and were greatly appreciative of the social support they 
received and access to the service: “It was wonderful, you can’t ask for anything more 
than that” (African man, NZ citizen). The stress of visa application described by one 
African interviewee was moderated by her clinic experience: 
Being here, getting my visa made me know that it’s possible to still come in but 
you still, you have to be strong hearted to keep on fighting but how many is 
strong hearted to keep on jumping the hurdles? So it’s possible to come in and 
they treat you right, Australia treated me right and I’m not saying it just 
because I’m being recorded. I felt easy to talk and even allowing you [the 
researcher] to come and talk to me it was easy and I’ve talked to *the nurse+ 
about this, I’ve cried in [her] office and we’ve talked you know and laughed a lot 
and you feel human again. 
For those diagnosed during screening for Permanent Residency status in WA by 
Medibank Health Solutions, the unit responsible for immigration health screening, the 
experience of diagnosis was tempered by close liaison between clinic staff and the 
unit. This is because once a diagnosis of HIV is made by the doctor the person is 
referred promptly to the RPH service. The nurse is therefore able to offer post test 
discussion and implement HIV support and education before the patient is seen by the 
hospital doctor. A typical experience is described here: 
I think it happened in one day when I phoned the Health Services Australia and 
the doctor called one of the nurses and then the nurses said to me you can 
come and see me any time. So I went to see her and then she organised for my 
blood to be taken again and fresh tests and diagnosis to be done and then they 
did it and I was still told that I’m HIV positive. So that’s how it went, it wasn’t, it 
didn’t take long, it was, it happened in a few days. 
Others described experiences akin to emotional rescue after receiving their diagnosis. 
One African man who now has residency said:  
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Since I started this medication and I learnt more about it and I know there is 
more research being done about it I’m quite positive and just the way the first 
times I came and I saw the doctors and they told me: ‘look you need not to 
worry about anything. You can live up to 70, 80 using the right medication. That 
changed my whole, my whole life and the way I looked at it. Since that time I’ve 
never stopped to wonder will I be here tomorrow or the day after because I 
know with the right medication I’ll just, I’ll be fine 
 (African Man, PR) 
Employment 
A diagnosis of HIV has immediate implications for temporary visa holders since it is not 
possible for them to meet the Health Requirement necessary for successful application 
for permanent residency and it complicates renewal of a temporary visa. Seven of the 
interviewees were on 457 work visas. Once someone on a temporary work visa knows 
that they are HIV-serostatus positive they must, by law, disclose their serostatus in the 
event that they apply for a new visa. Should the company go on to sponsor the 
applicant, a situation leading to the applicant feeling bound to that company can arise: 
“the truth is at the moment I’m locked with this company almost for life” (African man, 
457). This leads to a common perception that either a visa will not be renewed or that 
employment will not be continued. The same man explains his frustration:  
I applied for another job with another company and the Department of 
Immigration told me to go and have HIV test and they demanded $40,000 from 
that company for them to grant me the 457 visa, which the company said we 
can’t do that but that was a better paying job so my source of income is highly, 
it’s [HIV] holding me up. 
A common problem for temporary visa holders with HIV is that they find it difficult to 
access advice since to do so may require them to disclose their status. This seems to 
extend itself to the number of people who ‘know’ about them. In Western Australia 
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people may use migration agents, but may also (or instead) seek pro bono advice from 
the HIV legal centre in Sydney as there is not an equivalent organisation in WA. They 
fear and have experienced discrimination, and many feel shame; stigma is a nuanced 
and multidimensional phenomenon. For those that go onto a bridging visa, the 
conditions attached to that visa are dependent on the subcategory assigned to it and 
some may not be allowed to work. One man in this study, a young able-bodied person, 
had not worked for some years and was being supported by a family member with 
residency. 
Three of the Medicare ineligible interviewees were diagnosed in their country of origin 
during screening for work visas which, to their surprise, were granted. They were 
subsequently confused about whether it was necessary to later disclose their HIV 
serostatus and they said this caused them some anxiety. One interviewee already in 
Australia suspected that he could be seropositive and flew back to his country of origin 
for testing because he was fearful of the consequences of testing HIV seropositive in 
Australia.  
The workplace 
Interviewees commented on the perceived necessity of keeping their HIV status a 
secret from their colleagues and employers to avoid stigma on a personal level and 
discrimination on a professional level: “I haven’t talked to anyone in the company 
about these things. Yeah and I’m, I don’t want to talk to them” (Oceania man, 457 
visa). In the health sector, in Australia, it is mandatory to have an HIV test; two of the 
study participants worked in this area. Their supervisors were aware of their status, 
and the interviewees were fearful of a break in confidentiality. This was also a problem 
for an HIV seronegative spouse working in the health sector when a curious workmate 
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asked uncomfortable questions. Breaches in confidentiality have occurred and 
although the outcome is not always detrimental, the breach nonetheless results in 
emotional distress. Workers in the FIFO sector find it stressful when they are subjected 
to random drug testing. This has led to a change in prescribing practices away from 
efavirenz so that workers can keep their HIV status confidential. Most of the 
interviewees are acutely aware of the likelihood of workplace injury and, driven by 
their common, acute fear of transmitting the infection, welcome the stringent 
universal Occupational Health and Safety precautions implemented by the mining 
companies. These precautions serve to moderate anxiety related to transmission fears 
in the infected person and serve to protect others without the infection: 
Yeah but nearly everybody is trained to do with injuries and everybody is 
following the procedures, even if I get injured and blood comes out of me you’re 
not supposed to be getting infected from that because there is a medical kit, 
they have gloves in there, you need to just take your gloves put them on. So 
even if I’m getting injured, if I see someone treating me without gloves I will 
soon be telling him to put on his gloves  
(African man, NZ resident) 
Accommodation on the mine sites assures them of privacy to store their medication, 
while private accommodation combined with an internet connection, allows them to 
access information about HIV readily and confidentially: “yeah internet I would say 
that’s where I get most of the information” (African man, 457 visa). Another advantage 
of working in this situation is that on their weeks off they need not miss work to attend 
hospital appointments– a common source of stress for other PLWH.  
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Culture: Anonymity and Visibility 
The African interviewees in particular viewed themselves as protected by a degree of 
anonymity because they were separated from their extended family networks, 
however in general they felt that their skin colour made them visible in the small sea of 
white faces in the clinic waiting room “...definitely it’s a worry that people would be so 
ignorant to think that everyone from Africa has got HIV or everyone from Africa is 
poor”, said one man. Another man talked of how his homeland was regularly 
associated with crime. Although the personal attention received from clinic staff was 
appreciated, anonymity in the waiting room is desired. For example, one participant 
prefers to be referred to by number and not name, believing that this better protects 
his privacy. The Thai women also ‘noticed’ each other in the waiting room through 
their recognition of shared phenotypic ancestry. The differences in cultural norms 
between Australia and PNG were articulated by one interviewee who, in response to a 
question concerning the stigma attached to HIV said: “Yes, back in the traditional 
villages yeah, people talk bad things about you. Like you know, don’t want to be near 
you or talk to you or things like that.” In contrast with Australia, which offers 
anonymity and something more, or less: “Here it’s ok, nobody like really talks about 
you or cares about each other. Like they don’t talk about people and yeah I think its ok 
in Australia. It’s different to PNG.” This sentiment was expressed similarly by an African 
woman: 
...I’ll go to the hospital and I’m comfortable just because I know not so many 
people know me here and yeah will talk open. They’ll ask me a question I can 
tell even over the counter because I know the next person here doesn’t know 
me.  
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Other interviewees prefer to mix outside their ethnic groups, while one man prefers 
the company of other Africans to his Zimbabwean countrymen, whom he referred to 
as ‘cliquey’. In Thailand the stigma extends to the attitude of health workers:  
... if somebody know I got HIV and they try to like isolate from them. I don’t 
know even doctor and nurses, I feel like they not, they not really sincere or really 
happy to deal with them. 
 In contrast with the non-judgmental care received by this Thai woman in several 
health facilities in Australia: “I feel like that but in Australia they like, they do (treat) like 
really normal like other people you know.” The marked difference in the sample was 
the European living in rural WA who comments:  
So that really is one thing that disturbs me and I think in this point Australia is a 
little bit backwards and I think in [European country] it’s more, yeah it’s more 
proactive and people are more supportive and open about it [HIV]. Here it’s still 
very much stigmatised but that’s why I don’t tell anybody.  
A difficulty negotiating cultural nuances can arise when couples need marital 
counselling. One man spoke at length about how, in his opinion, it was not possible to 
counsel ‘across racial lines.’ He recommended that counselling be provided by 
professionals of the same culture. He also commented that in Zimbabwe men often 
married women who are not as well educated as themselves and that this had 
implications for how they viewed HIV, for example: ‘”...she has that image of people 
dying in Africa whereas I’d sort of done my homework, I’d done a lot of reading so I was 
in a better position than her.” Since a diagnosis of HIV infection can place pressure on 
relationships and complicate family dynamics the observation made by this man is 
relevant for service providers. 
Some interviewees said that, in Africa, polygamy is practiced by some communities. A 
few participants discussed promiscuity as an ‘immoral’ behaviour which they did not 
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identify with themselves. One man thought that, in fact, Australian men were the 
more promiscuous, he made this comment:  
Here I have seen people they come to work, some work mates they tell you ‘I 
know I used to be in love with so and so, I’ve moved, I’m now with so’ and [so] if 
you look at them they’ve had maybe four or five partners and you really 
wonder.  
Promiscuity was frowned upon by both men and women from East Africa. A few 
participants observed that African society is less forgiving of a promiscuous woman. 
The opportunity to access casual sex is hindered by personal codes of behaviour and 
social mores. One man explained how things were in his society:  
Even if you look at the young people they, until probably around the age of 
about 19 or so your contact with the opposite sex is very minimal and you can 
only get in contact with the people of the opposite sex probably in your twenties 
because there is culture issues and stuff like that. So promiscuity level is a bit 
managed because there is a lot of cultural things involved and procedures given 
traditionally, [to] approach a girl or a woman for sex is hard. But of course you 
get like prostitutes in the streets, they are there, but not as much as probably, 
here you don’t see them in the streets but what you witness what happens 
across the partners... 
Another man talked of differences in how Africans spend their time socialising and the 
impact of a fly in fly out employment: 
For starters you don’t have a social life here. It’s like you are sort of living in a 
society that you cannot sort of fit into. How can I put it? It’s like the way we 
spend our free time in Africa is very different from the way Australians spend 
their free time. In Africa we’ve got a set up whereby you tend to visit your 
relatives most of the time. But here [we] don’t have any relatives and I don’t 
have anybody to visit except my friends and most of the time maybe they’re at 
mines or they’re at work so we tend to have different free times. 
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Cultural attitudes towards work practices differ between Africa and Australia. This man 
comments upon the constraints placed upon work opportunities by, arguably, 
organisations designed to protect workers from harm: 
That’s what I like about people back home, as long as you’re working it’s like oh 
so he can work, you know unlike here it’s like oh no you can’t, ok look you’ve got 
this condition, ‘oh look I am sorry you can’t get in’. Back home they say ‘look 
you’re walking aren’t you, ok so you’ve got the job just do your work ok’. Here 
they start looking at all these complications, [for example] what impact it will 
have with Work Safe. 
Adaptation and the Future  
Some interviewees appeared to adjust to HIV emotionally and pragmatically, 
demonstrating self efficacy which was apparently mediated to an extent by education, 
support received (primarily from partners and hospital workers) and the passage of 
time since diagnosis. The European was the only interviewee, besides one of the 
African men with NZ citizenship, who had disclosed to a friendship group, (albeit 
outside Australia) and explained in this way: 
So I tried to find out as much as possible. Lucky there was, when I then was back 
home in Europe I had a very good clinic and very good doctors looking after me 
so I’ve been yeah I’ve read up a lot and talked to quite a few people and yeah 
learned to, learned to live with it now it’s doesn’t faze me at all to be really 
honest. 
However, this person has indicated that they do not intend to disclose to anyone in 
their regional community. An African man also referred to the benefits of 
understanding the disease: “I know how to deal with my family, like my kids, my work 
mates, my family at home, how to protect them from any exposure which is hardly 
close to zero exposure... yeah everyone is safe from me.” Satisfaction with care seemed 
to give people a ‘lift’:  
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I’m getting used to it because I’ve got really good doctors in Perth and nurses 
and I call them and I have concerns and all that worries and it’s doing pretty 
good so right now I’m, all my virus level is undetectable so I’m happy. 
The power of positive thinking crossed cultures: “I think it sort of as well your body 
works around it as well and you just tend just to grow stronger and better. So the main 
thing is acceptance I think and just keeping it very positive.” The word ‘positive’ was 
also used by the four Thai women, despite their limited English, in expressing how they 
try and view the future, knowing that they will have to continue with the infection.  
However, some use different coping mechanisms. As one young African woman says: 
But really I treat myself like I don’t have it. I don’t want to know, I know what I 
know, I know it’s bad and it’s going to be there like forever and I can’t treat it 
but really I don’t, I’m just I know I’ve got it but I treat myself like I don’t have it. I 
treat myself like normal, I don’t think about it, I don’t want to go and look about 
it yeah. So, even in my house when I got a letter like this I really want to throw it 
away I don’t keep it, it’s just me. I don’t want to look at those words and just 
see because it just reminds me about me.  
The African man who believes in the value of disclosure now supports other family 
members adjust to the impact of HIV within the extended family: “It’s sort of takes the 
weight off you to the person that you have told.” But this ‘unburdening’ from one 
person to another was precisely what the Thai women were keen to avoid since they 
wanted to avoid causing others distress. 
Discussion  
This is the first study investigating the impact of HIV infection on people holding 
temporary visas in Western Australia. The data gathered in this study illustrates that 
for people seeking to work or reside in Australia, a positive HIV test has wide-ranging 
implications, including aspects that can dictate the futures of people affected and their 
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families. For those applying for long stay business visas, once diagnosis is established it 
must be declared on application for renewal of 457 visa status. Inability to meet the 
Requirement limits access to permanent residency which might have otherwise been 
met by other attributes or those of spouses. Furthermore, Medicare ineligibility 
precludes temporary visa holders from accessing subsidised patented ARVs as would 
Australian citizens. In this study, diagnosis made during visa screening in countries of 
origin also had implications for the interviewees since they feared being exposed as 
infected in their own communities, if the visa application was refused. It was also the 
case that interviewees thought refusal was automatic and were surprised to find that 
they were successfully issued with a visa to enter Australia.  
Treatment with current antiretroviral drugs can prevent HIV transmission, disease 
progression and death from AIDS (Cohen et al., 2011; Cohen & Gay, 2010; Hogg et al., 
1997; Palella et al., 1998). However, an individual must be highly adherent and ARVs 
must be taken continuously without interruption to prevent virological failure (Hogg et 
al., 2002; Parienti et al., 2008). The clinical imperative, therefore, is to ensure access to 
potent drugs and consistent and effective medical and psychological support. Despite 
many common findings, a contrast with that of Körner’s studies (2005; 2007a, 2007c) 
was that the temporary visa holders in this study who were diagnosed in Western 
Australia, engaged with the WA health system, in spite of their lack of citizens’ rights, 
via a simple chain of clinical care delivery from screening by Medibank Health Solutions 
(previously Health Services Australia) to Specialist Tertiary HIV Services. They were also 
able to negotiate access to patented or, more commonly, generic ARVs. The 
participants’ strong motivation to take ART and their efficacy in executing the regimen 
overcame two potential barriers to adherence firstly access to ART; and secondly an 
uninterrupted supply. Private health cover and Occupational Health and Safety 
246 
Regulations in places of employment also ensured access to general medical care. The 
immediate emotional impact of HIV was also moderated by the context in which the 
news was received. In contrast with the interviewees diagnosed in Africa and the 
Middle East, timely post-test discussion attenuated distress with reassurance and 
education. Eligibility for a Long Stay Business or Student visa means that recipients are 
—at the very least—educated at a secondary school level and have English language 
skills, although these skills may only apply to the Primary Visa holder and not to their 
spouses. Proficiency in English may increase a person’s capacity to act autonomously, 
access information and manage medication and may be another point of difference 
between temporary visa holders, asylum seekers and refugees. Drummond and 
colleagues study (2008) on HIV/AIDS knowledge and attitudes among West African 
immigrant and Australian-born women in Western Australia, showed that knowledge 
of HIV and HIV prevention was linked to education. Indeed health literacy and 
numeracy together with clinical protocols for adherence monitoring and counselling, 
may be a major factor underpinning the successful medication adherence and 
persistence seen in this group (Waldrop-Valverde et al., 2009). One participant 
reflected that in East Africa men often marry women of lower educational levels than 
their own. This may be an important factor to take into consideration when providing 
HIV and treatment education and adherence support to couples, particularly since 
some researchers have found medication management may be nuanced by gender 
(Waldrop-Valverde et al., 2009).  
Interviewees also maintained high levels of medication adherence and virological 
control underpinned by adept management of potential treatment interruptions posed 
by the importation of generic ARVs. Successful health outcomes for those who were 
symptomatic at the time of diagnosis may serve as a motivator towards adherence. 
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Only one of the participants expressed concern that generic drugs might not be 
effective since he was not experiencing the same side effects that he had when taking 
a patented combination. This is in contrast with a recent study by Bulsara, McKenzie, 
Sanfilippo, Holman and Emory (2010) which found that Western Australians were 
suspicious of foreign generic manufacturers, and sceptical about generic drug 
bioequivalence. These views were echoed by the epidemiologist Andrew Grulich in an 
interview featured in the Weekend Australian in 2011 (Dayton, 2011). However, in this 
study, it was evident from the interviews and self-report questionnaires that ARVs 
were thought to be effective. From a clinical perspective, only one participant 
experienced virological failure on medication, and this was likely related to nevirapine 
resistance acquired or developed in Africa. Importantly, health screening picked up 
some infections before AIDS-defining illnesses became apparent and, since an 
estimated 40% of HIV is transmitted by those who are unaware of their status (Coates, 
Richter & Caceres, 2008), may have prevented inadvertent transmission. Lemoh and 
colleagues (2010) reported delayed diagnosis in half of the 20 African Australian 
participants of their study; and clinical and virological failure in seven and five 
respectively. Arguably in our setting, health screening identified asymptomatic HIV 
infection and prevented morbidity from delayed diagnosis seen by Lemoh and others 
(Burns et al., 2007). 
However, unmasking HIV infection in non-Australian residents meant that the patients 
in this study were burdened with the very real threat to future health and longevity 
because their HIV serostatus could prejudice their applications for residency and 
necessitate return to their countries of origin where, despite the global scaling up of 
treatment availability, especially in Southern Africa, coverage remains patchy. In South 
East Asia and Africa, corruption, cost of drugs, low wages and local turmoil can result 
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in interrupted supply of ARVs (Posse et al., 2008). The participants in this study also 
pointed out that, even if they have access to drugs, these would be first-line 
treatments effective only for those with susceptible virus. Further, participants noted 
that should side effects occur then options would become limited. Some of the 
Africans were concerned about access to nutritional food which several cited as 
necessary for someone with HIV infection to maintain their good health. 
Except for the one European, participants pointed out how important the psychosocial 
support they had received from clinic staff was for their current acceptance of the 
disease and noted that this would be lacking in their countries of origin. Indeed the 
small number of health care workers involved in their care could be said to represent a 
small island of support as, on arrival at the clinic, interviewees could be relieved of 
their secrecy. Other studies have highlighted the role of health care workers in highly 
stigmatized communities with HIV (Ruanjahn, Roberts & Monterosso, 2010). However, 
some of the participants were unsure about whether they would be viewed so 
compassionately by ‘ordinary’ Australians, their workmates, or people of similar ethnic 
backgrounds outside the health system. Given the current laws and public dialogue 
around visas and immigration their concerns are hard to dismiss (Stafford, 2007). 
These and other perceptions led them to exercise a high degree of vigilance around 
their need for confidentiality and made them reluctant to seek health services, such as 
dentistry, outside the immediate hospital environment from those who were not 
trained to protect confidentiality, such as receptionists. For those willing to proceed 
with residency applications there was a necessity to negotiate with the Department of 
Immigration and Citizenship and migration agents. Some participants also accessed pro 
bono assistance from the HIV/AIDS Legal Centre (HALC), a community legal centre in 
Sydney that specialises in HIV related legal matters. 
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In common with the participants of the studies in Chapters Three and Four, most of 
the participants in this group expressed a high level of anxiety relating to the fear of 
unwittingly transmitting HIV. For some this fear was out of proportion to the likelihood 
of the occurrence and did not seem to diminish over time. Although there are a 
number of studies that explore aspects of stigma, like non-disclosure, in relation to 
risky sexual behaviour (Adebowale, 2010; Bouhnik et al., 2008; Logie & Gadalla, 2009; 
Simbayi et al., 2007) the author could not locate any studies that described fear of 
transmitting HIV as a cofactor in depression—common in HIV (Bhatia et al., 2011; 
Valente, 2003) nor any studies of interventions to reduce transmission fears. The 
deeply rooted fears in some individuals may not be uncovered in the course of most 
consultations. This evidence suggests that the clinical encounter should include an 
assessment of ‘stigma- related limitations’ and further research is needed to reveal the 
nature of the issue and develop suitable interventions. When Goffman (1963), 
articulated stigma as a social construct, he described three manifestations of stigma 
assigned to deformity of the body including: (1) physical symptoms of disease; (2) 
taboo behaviours; and (3) racial and social ‘groups’ or tribes. For non-Australian 
residents with HIV infection the stigma attached to HIV with its associations of sex, 
death and country of origin, would likely be heightened, as some participants in this 
study feared.  
The impact of HIV was moderated by other personal and situational characteristics of 
the participants and mediated in turn by ethnic background. Family ties were strongly 
evident in all the interviewees as demonstrated by the frequency of contact with 
families in country of origin. Despite this, most families were not aware of the 
interviewees’ HIV diagnosis. Five out of twenty-two participants only disclosed to 
selected members of their immediate families—not including their partners—apart 
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from the two women who disclosed to their Australian husbands’ families. The reasons 
for this appear to concur with Körner’s study (2007c) which refers to the collectivist 
attributes of non-Anglo-Celtic cultures that emphasize the interdependence of 
families, for example, the desire to avoid causing the family distress from the burden 
of illness and the association with ‘immoral’ behaviour. The interviewees with children 
also had to consider discussing their HIV status with the children as they grew older. 
Körner also speaks of the opportunity for gay men to access an ‘alternative’ 
community allowing them an identity free of family ties. This was evident in my study 
where two men, who identified themselves as gay, spoke of their friendship and 
support from Australian gay men, some of whom were HIV-positive. However, their 
disclosure issues were complicated by their families’ reactions to their sexuality, and 
the double stigma of being gay and HIV seropositive. The South-East Asian man 
infected through intravenous drug use, cited support from one parent and a sibling; 
and his greatest ‘disclosure concern’ was how to meet someone to marry. Although 
disclosure was an issue for all but one of the participants there were some differences 
as to how intensely people internalised their diagnosis and their sense of shame. A 
pragmatic attitude was evident among some, particularly the men who viewed 
themselves as fit and strong. They considered that they should be able to be ‘like 
normal’ as with medication they would remain well. They also derived confidence from 
a sense of knowing how to protect their wives by practicing safe sex. This may well 
have something to do personal characteristics associated with recovery from stressful 
events, resilience and coping which have been reported in survivors of difficult 
circumstances (Antonovsky, 1991; Bonnano, 2004). However the sample was also 
characterised by the strong support drawn by many from spiritual sources and life 
partners. Both of which have been shown to assist people in overcoming psychological 
 251 
distress and adversity (Kohls, Sauer, Offenbacher & Giordano, 2011; Kremer & Ironson, 
2009; Makoae et al., 2008; Tsevat, 2006).  
Limitations and conclusions  
The characteristics of the people in this study reflected the requirement of the visas 
that they hold. For example, the Business Long Stay and Student Visa holders were 
English-speaking and educated to at least secondary school level. The eligibility for 
Spousal Visas differs, and only two women held these. Therefore, the findings cannot 
be generalised to refugees or asylum seekers none of whom were recruited into this 
study. However, the interview material and triangulation with clinical outcome data 
provide sound observations. Furthermore, the sample reflects the expanding Western 
Australian epidemic in people born overseas and temporary visa holders from high 
prevalence regions; which represented ten percent of the HIV cohort at Royal Perth 
Hospital at the end of 2011. This situation has implications for service delivery across 
the state (The Kirby Institute, 2011). In particular, there has been a shift in the type of 
services and support that is required as a consequence of this epidemiological pattern, 
for example, there are increased issues around pregnancy and serodiscordancy. In 
addition to standard HIV care, temporary visa holders seek support for visa 
continuations and residency applications from outpatient services. Awareness over the 
perceived cost to the Australian community, which will have a bearing on their 
applications, appears to limit how and what health services are accessed. Running 
through the interviews there is a palpable sense of frustration; some feel that the 
situation is hopeless and give up trying to stay in Australia, while others persist with 
determination by accessing migration agents and pro bono legal advice. Access to 
generic first-line ARVs and specialist HIV clinical care in Western Australia is relatively 
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unfettered and results in good health outcomes but—coupled with the need to take 
out private health insurance—is expensive. The threat of treatment interruption and 
adverse health outcomes when people leave the service to return to countries of 
origin is a pressing concern for most participants; some patients fear for their lives. 
However, the challenge of applying for permanent residency may prove too daunting 
for some people who fear refusal, fiscal disadvantage and a repetition of ‘disclosure 
anxiety’. People with either Australian or New Zealand residency feel secure in their 
Medicare and there appears to be some evidence that this moderates disclosure and 
testing concerns. It also seems apparent that people may actively avoid those from 
their own ‘cultural’ communities because of confidentiality concerns, regardless of 
their residency status. Furthermore, high visibility as ‘foreigners’ heightens anxiety 
about potential discrimination from Australians outside the health system.  
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CHAPTER SIX DISCUSSION 
‘AIDS occupies such a large part of our awareness because of what it has been taken to 
represent. It seems the very model of all the catastrophes privileged populations feel 
await them.’  
Susan Sontag (1988, p. 84)  
Introduction  
This final chapter presents a discussion of the major issues emerging from the 
preceding results and synthesises the primary observations. The research illustrates 
that while HIV infection has the potential to be a treatable chronic illness, the stigma 
attached to the condition is universal and operates within infected and non-infected 
individuals to shape how care and treatment are apportioned, accessed and delivered. 
Further, the data give clear evidence that even with universal access to the latest, 
tolerable and potent drug regimes, HIV-related impacts on individuals cannot be 
resolved through pharmacological treatments alone. Specifically, the data show that 
most participants accepted treatment, were motivated to adhere to ART, and 
overcame obstacles posed by access to achieve favourable physical health outcomes; 
even the few who, at some stage in the illness continuum, chose to stop or adapt their 
treatment regimes. Health care professionals working in the WA health system 
contributed to these outcomes by way of thoughtful and creative engagement with 
patients. They recognised the imperative to establish and maintain contact with 
patients; and overcome barriers to treatment, in order to increase the likelihood of 
continuous treatment with ARVs, which has been shown to be critical at an individual 
and population level (Cohen & Gay , 2010; Elinav et al., 2012; Gardner et al., 2011; 
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Giordano et al., 2011; Giordano, et al., 2007; Montaner et al., 2010; Rosenthal et al., 
2011; M. A. Thompson, et al., 2012). 
Despite these positive health outcomes by way of reduced morbidity, the pattern of 
stigma characterised by persistent fear of disclosing HIV serostatus and infecting 
others, was nuanced by the particular circumstances of individuals, in terms of visa 
status, or living and/or working in regional areas. In particular, HIV-positive serostatus 
affected, and frequently limited, social relationships, aspects of employment; and the 
likelihood of successful migration.   
Contribution to the field of HIV/AIDS 
The research offers a rich, contextual description of the current Western Australian 
HIV epidemic while acknowledging historical antecedents. The data are representative 
of resident Australians, international visitors and guest workers living in both 
metropolitan and regional areas. In addition, this project is positioned within the 
current framework of HIV care in the state of WA.  While the PROQOL-HIV research is 
the largest HRQL study conducted in the state to date, the subsequent narratives of 
participants who find their circumstances complicated by their visa status and and/or 
living and working in rural areas, reveal new information and understandings about the 
current epidemic that is relevant on a number of levels.   The inclusion of the 
perspectives of health care workers gained from wide consultation, give a depth of 
understanding such that the intersection between health care delivery and the 
patient/participant experience of that care is explicated.  The work presented 
represents the most comprehensive picture of the impact of HIV in WA and the clinical 
outcomes of care to date. It builds on early clinical observational research conducted 
in our cohort (Gillieatt & Mallal, 2000; Gillieatt et al., 1992; Herrmann, et al., 2008, 
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2012; Mallal, 1998), the work of Newman et al. in Aboriginal PLWH (Bonar et al., 2004; 
Newman et al., 2007a, 2007b); and the survey work of Peter Drummond and his 
colleagues (Drummond et al., 2011, 2008); and complements the national findings of 
successive HIV Futures Surveys. While this study of temporary visa holders shares 
some common observations with Körner and Lemoh’s research (Körner, 2005, 2007a, 
2007b; Lemoh, et al., 2010) in CALD communities and African Australians, respectively, 
it has a greater focus on Medicare ineligibility and how this affects access, adherence 
and attitudes to ART. It also highlights the lack of support for people who find 
themselves in the position of being diagnosed with HIV/AIDS; and how they can be 
isolated within their communities and feel threatened by their non-citizen status. 
Further, as was alluded to in Chapter Two, the system of delivering HIV care in WA 
differs markedly from the other states and this changes the context of care. Another 
important contribution of this work is to add an understanding of how PLWH manage 
HIV in work situations, particularly FIFO occupations. In the light of the current 
recruitment of overseas workers, and a growing workforce engaged with the FIFO 
work arrangement, this research is of current relevance.  
The study juxtaposes with Drummond and colleagues’ Perth-based survey concerning 
the knowledge of HIV and attitudes towards condom use in West African refugees; and 
a larger group of West Australian women matched, where possible, with the West 
African women for age and education (2008). Their findings suggested that HIV-
focused educational programs directed at emerging immigrant communities should be 
customised to their needs and cultural sensitivities.  From information shared with me 
by the migrant health worker at interview, and Professor Drummond himself (August, 
2010), it would appear that this recommendation has been acted upon. They 
subsequently published details of a study (2011) which used West African peer 
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educators to conduct a workshop on sexual health with recently settled groups of 
West African refugees. The authors found that the sexual health knowledge of 
participants increased significantly as a consequence of the intervention. Notably, the 
study was conducted in consultation with representatives of the West African 
community and was funded through the WA Department of Health Blood Borne Virus 
Program and Healthway. Both these studies, and the activities of the WA AIDS Council 
in WA (to address issues arising from the emerging heterosexual epidemic in WA); and 
AFAO and NAPWA nationally, to advocate for non-citizens, indicate a sector response 
to changing conditions (AFAO, May 2011; NAPWA, 2009; Sergeant, 2009). However, 
only one of the participants (East African and already eligible for Permanent 
Residency) in my study said that he had participated in one of the WA-based education 
sessions.  Further, the data would suggest that the temporary visa holders are averse 
to anyone from their countries of origin knowing their HIV status and they would take 
steps to avoid situations that may result in a breach of their confidentiality.  It may be 
the case however, that temporary visa holders while not eligible to access government 
funded services and networks available to migrants and refugees, may be members of 
other communities, like churches, which may link them to others with whom they 
identify socially or culturally, including education and supportive sources.  
The PROQOL-HIV Study: Findings and Concordance with the 
Subsequent Research  
The PROQOL-HIV study presented in Chapter Three serves to explicate the West 
Australian context and embed the subsequent research. In addition to fulfilling the aim 
of developing a contemporary health-related quality of life instrument to discriminate 
treatment-related impacts on HIV, the wider international study uncovered some 
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universal themes nuanced by sociocultural factors pertaining to stigma and 
discrimination. For example, the concept of so called ‘courtesy stigma’ where others 
associated with the affected person, e.g. family or partner experience discrimination 
from individuals or communities (Goffman, 1963; Rongkavilit, et al., 2010; Talley & 
Bettencourt, 2010). 
HIV/AIDS and Employment  
HIV/AIDS impacted on work opportunities for those with ill health and choice of work 
generally. The legal and moral requirement to disclose to prospective partners and, 
potentially employers, particularly in the case of the person working in the health 
sector, weighed heavily.  Even minor changes in general health were concerning for 
participants from all the countries that participated in the development of the 
PROQOL-HIV instrument, and particularly when they affected the ability to work 
(Duracinsky et al., 2012a). This became evident in the later interviews where some of 
the motivation of visa holders to access and adhere to treatment could be attributed 
to the desire to be ‘normal’, to overcome the physical effects of HIV and ‘get on’ with 
earning a living. Indeed much of the stress around HIV was associated with aspects of 
employment, being considered not fit to work or a potential hazard in the workplace. 
Secrecy about HIV seropositive status was evidently stressful. Some participants were 
afraid of xenophobia and/or homophobia which, in the case of the former is enacted 
at a structural level in Australia (Stafford, 2007); and in the case of the latter at an 
individual level, as evidenced by participants who feared being exposed to their co-
workers, erroneously or not, as attracted to other men. Some people in the PROQOL-
HIV study perceived their career options to be limited because of their fears of an 
inadvertent blood spill, for example, the participant who abandoned a profession in 
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catering because of this concern. In the wider literature on stigma Link & Phelan (2001, 
p. 363) describe how stigma (not specific to HIV) bears on the “distribution of life 
chances in such areas as earnings, housing, criminal involvement, health and life itself.” 
Stigma and Health Seeking Behaviours 
A critically important aspect to HIV/AIDS related stigma observed in this thesis, and as 
cited in other studies and stigma-related literature (Chesney & Smith, 1999; Fakoya, et 
al., 2008; Körner, 2007a; Logie & Gadalla, 2009; Link & Phelan, 2001), is how it may 
interfere with health seeking behaviours, specifically accessing testing and engaging 
with treatment and services studies which are critical for HIV prevention (Gardner et 
al., 2011; Giordano et al., 2007). This concern has been raised in Australia and Europe, 
in a number of articles and reports which explicate why people delay testing for HIV 
(Körner, 2007b) (Adler et al., 2009; Burns et al., 2007). Notably, there seem to be some 
differences related to citizen status, and not only because of fear of losing the 
possibility of citizenship, for example, some people born in HIV high-prevalence areas 
now residing in low-prevalence areas, perceive their risk of acquiring HIV to be 
reduced. And interestingly, an Australian report of survey data showed that HIV 
education did not appear to influence voluntary testing rates (Asante et al., 2009). 
At least three of the men in this study delayed testing for HIV, even though they 
suspected that they had the infection, and two of the men diagnosed in WA presented 
in an AIDS-defining category. One of the men had not had his children tested and 
another man’s wife refused to have an HIV test for fear of the result. Fear of social 
death clearly outweighed physical health considerations. Some studies have shown 
that women are more likely to perceive HIV/AIDS related stigma (Hosseinzadeh et al., 
2011). Jane Bruning’s unpublished thesis (2009), explores the impact of stigma on 
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women living in New Zealand using the method of cooperative inquiry. This innovative 
study brought about a set of actions developed and agreed upon by the participants 
that resulted in personal transformation and community consciousness-raising. A more 
recent Australian study conducted with 236 Iranian-Australians, used a survey 
instrument to explore felt or perceived stigma (stigma that is anticipated) (Berger, 
Estwing Ferrans & Lashley, 2001; Goffman, 1963; Herek, 2002) and its impact on the 
social risk associated with HIV testing and disclosure and the decision-making around 
the same (Hosseinzadeh et al., 2011) Approximately one quarter of the variance in 
those factors could be explained by respondents’ perception of HIV/AIDS related 
stigma. The result was strongly influenced by how long respondents had lived in 
Australia (time since migration). They concluded that these findings suggest that there 
are opportunities to change the social construction of HIV/AIDS associated stigma in 
that population.  In a recent global survey Nachega and colleagues (2012) showed that 
fears of disclosing HIV serostatus and the perceived outcome by way of losing family or 
friends, especially in those diagnosed less than five years, was higher in the Asia Pacific 
and Latin America in comparison with Europe, North America and Africa. However, a 
limitation of their study was the pooling of data from Australia and South Korea to 
create a composite Asia-Pacific region. The epidemics in these countries vary 
considerably according to mode of HIV acquisition, dominant religious background and 
sociodemographic makeup and this may have confounded their findings. While Korea 
did not participate in the PROQOL-HIV study, observations from the 152 interviews 
from all the countries that did, showed family discrimination was of particular concern 
in Senegal and India, and that broader issues of stigma were raised more commonly by 
participants living in Senegal, China, Cambodia, and Thailand. For participants of the 
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high-income countries (Australia, France, and United States) disclosure of HIV status 
seemed easier and more frequent (Duracinsky et al., 2012a). 
It might be considered that the temporary visa holders in this study were discriminated 
against by the requirement for HIV testing on application for Permanent Residency. 
However, discovering their HIV serostatus allowed participants to protect others from 
infection (via inadvertent transmission) and, as well, offered an opportunity to engage 
with HIV care and treatment, thus avoiding personal morbidity. There was also 
evidence to suggest that the supportive, non-judgmental environment in the specialist 
tertiary centre served to overcome stigma fears and that there was, for some 
participants, a waning of distress as time passed. 
Persistent stigma 
Of concern, the PROQOL-HIV instrument showed a clear and strong correlation, in one 
third of patients, between persistent self-reported fears of disclosing HIV serostatus 
and fear of infecting others, which significantly reduced their total HRQL score. While 
Link and Phelan in their discussion paper (2001) describe stigma as persistent, this is 
the first time, to my knowledge that this association has been described statistically. 
Furthermore, the qualitative data which contributed to the development of the pilot 
instrument revealed the difficulties of living with HIV, which was reinforced by the 
more recent interviews, in the domains of forming and maintaining intimate 
relationships, and chronic ill-health. Subsequently, the psychometric analysis 
discriminated the impact of treatment via symptomatology, pill burden and treatment 
duration. But it was concluded that emotional distress, largely due to persistent, 
stigmatising aspects of HIV infection, and poor physical health were major influences 
on HRQL in the WA HIV Cohort despite advances in tolerable and effective treatments, 
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and national antidiscrimination laws. This data supports the findings of other recent 
studies concerning the emotional and social well-being of PLWH (Hasanah et al., 2011; 
Holzemer, et al., 2009; Hosseinzadeh et al., 2011; Jia et al., 2007; Kalichman et al., 
2000; Preau et al., 2007; Rongkavilit et al., 2010) and provide clear evidence that 
interventions to alleviate emotional stress in PLWH are needed.   
Treatment Access, Adherence, Attitudes and Literacy 
In the international PROQOL-HIV psychometric analysis (Duracinsky et al., 2012b) and 
in contrast with other country cohorts, West Australian participants had the highest 
proportion of participants taking ART in a once daily regimen (71% OD and 29% BD). 
Complete adherence to treatment in the two weeks preceding the survey was reached 
by 78% of participants, suggesting a high level of adherence in a population with 
universal access to the most modern regimens for its citizens. In the subsequent 
studies in this thesis, adherence was also high, and participants overcame barriers 
posed by access. A comment made by one African student is memorable: “The 
moment that I knew I was HIV positive it was in my mind that if I get something to help 
me I would adhere to that, I would stick to that.” There was also a pragmatic attitude 
taken by the temporary visa holders, particularly the men, which indicated their 
capacity to effectively manage their medication if they were adequately resourced, in 
terms of education about HIV and access to drugs. This apparent confidence is perhaps 
reflected by their competency in other areas of their lives, for example, as skilled 
workers. 
Social context influences adherence 
Nguyen and colleagues (2007) offer some interesting data that shed light on how social 
context can influence constructs such as adherence. They write that accompanying the 
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rapid increase in access to ARVs in Africa, has been high levels of adherence which they 
cite as at least equal or superior to ‘northern contexts’. Using an ethnographic 
perspective, they examined the context of access to ARVs in three Francophone 
countries to explicate the reasons for successful adherence in the face of considerable 
structural barriers, including a cap on the number of people who could be treated. As 
an outcome of this research they were able to formulate the term: ‘therapeutic 
citizenship’ which they describe “as a set of rights and responsibilities to negotiate 
(these at times) conflicting moral economies” (Nguyen 2007, p. S31). In effect 
communities evolved a form of social triage to decide who should receive the drugs 
based on an assessment of who would most benefit the community as a whole. These 
were people who were considered the most valuable to the community and not the 
most vulnerable. This decision-making approach diverged from the aims of the donor 
organisations which aimed to give the most vulnerable (to death) and sickest, favoured 
access. The people chosen to receive ART by their communities went on to develop 
leadership in treatment literacy which benefited the wider community by way of 
sustained and robust ART programmes.  
Treatment literacy  
Treatment literacy in relation to HIV, and an associated concept, community 
preparedness, form part of a broader concept of treatment education and are defined 
by UNESCO and WHO in this way: 
Treatment education encourages people to know their HIV status, explains how 
to get access to treatment, offers information on drug regimens, offers support 
and ideas for adhering to treatment and helping others to do so, emphasises 
the importance of maintaining protective behaviours and healthy living, and 
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suggests strategies for overcoming stigma and discrimination and gender 
inequality. (UNESCO/WHO, 2005) 
In this statement can be found some of the potential barriers to successful treatment, 
therefore, conversely, a person who is HIV treatment literate will have the information 
that follows. Practically, at a minimum, people need to know how to access their drugs 
without fear of being stigmatised or discriminated, be able to identify correctly and 
unambiguously the medication they have been prescribed, understand the scheduling 
and side effect profile and know how to manage any adverse effects. While it was 
notable that the participants in my research achieved good adherence, it was apparent 
and consistent with earlier studies in our unit (Herrmann et al., 2008b) that many 
patients could not name all of the drugs correctly, were confused about co-formulation 
and brand versus generic nomenclature, and only had a superficial understanding of 
how drug resistance developed, despite a high level of literacy among the group. At 
least three of the participants had resistance to NNRTIs, which is most concerning 
since nevirapine and efavirenz are commonly used in frontline combination treatments 
for HIV. The ignorance of the patients was reinforced by the clinic staff. Quite 
frequently staff members would use the generic name for one drug in the combination 
e.g. nevirapine and then use the brand name for the co-formulation of two (or more) 
e.g. Truvada and this would be documented in the patients notes. It is possible that 
clinic personnel try and simplify what they think is complicated information for 
patients, and it is the case that some patients, despite comprehensive treatment 
information over time (e.g. the rural case study in Chapter Four) do not internalise this 
knowledge. However, treatment literacy is critical where people live mobile lifestyles 
and move between services, states or indeed have to exit the country quickly as is the 
case if a visa is discontinued.  
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Treatment literacy is related to health literacy which, in turn, is an interrelationship 
between neurocognitive functioning, reading literacy and numeracy and is affected by 
gender, language and culture (Kalichman, Benotsch, et al., 2000; J. O. Moore et al., 
2011; Waldrop-Valverde, et al., 2009,  2010). Eligibility criteria for a Long Stay Business 
or Student visa require recipients to be proficient in English, although these skills may 
only apply to the Primary Visa holder and not to their spouses. Language proficiency 
may increase a person’s capacity to act autonomously, access information and manage 
medication, and may be another point of difference between temporary visa holders, 
asylum seekers and refugees. Drummond and colleagues’ study (2008) on HIV/AIDS 
knowledge and attitudes among West African immigrant and Australian-born women 
in Western Australia showed that knowledge of HIV and HIV prevention was linked to 
education. Indeed health literacy, and particularly numeracy may be a major factor 
underpinning the successful medication adherence and persistence seen in the group 
of temporary visa holders; together with clinical protocols for adherence monitoring 
and counselling, although this finding has not been replicated universally (Paasche-
Orlow, et al., 2006). Only one of the participants expressed concern that generic drugs 
might not be effective since he was not experiencing side effects that he had when 
taking a patented combination. This is in contrast with a recent study by Bulsara and 
colleagues (2010) who found that Western Australians were suspicious of foreign 
generic manufacturers and sceptical about generic drug bioequivalence. 
The ethnographic research of Nguyen and colleagues cited earlier, is relevant to this 
study, first, because it underscores the value of such literacy, which if it increased 
adherence and persistence with treatment, has the capacity to shrink an epidemic at a 
population level by reducing population prevalence (Cohen, et al., 2011; Cohen & Gay, 
2010); and secondly because Nguyen alludes to evangelical movements in Africa and a 
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long history of Christian Missionary involvement in the region (Bornstein, 2001) which 
gives a cultural context to the current HIV epidemic.  
Religion  
There was a notable leaning towards an active expression of Christianity evident in the 
African participants’ dialogue and also in their positive expressions of coping, it 
behoves us to consider how the influence of this culture might impact on people with 
those backgrounds that are now residing in Australia—whether living with HIV 
infection or without it—since it may have relevance to how, for example, sex 
education is delivered. A migrant health worker interviewed for background to this 
study noted that the attitudes of the wider African community towards the delivery of 
sex education to teenagers was nuanced by religious-cultural attitudes which had 
shaped her practice within that community.  I acknowledge also that the Asian women 
cited their active association with Buddhism, which they commented offered them 
emotional support. A young Asian woman commented “I really think I did something 
really bad in a past life and this life I am paying for it.” One of the men living in a rural 
area was a practicing Christian and his experience of HIV was deeply connected with 
his sense of self with regard to his Christianity.  Whether in Australia’s secular society 
we pay sufficient attention to the role religion plays in people’s lives is a subject that 
should be examined, particularly in the light of Australia’s growing multi-faith 
community. It is, however, beyond the scope of this thesis to further explore the role 
of religion and coping. 
Classical barriers to adherence: depression and alcohol use 
The results of the West Australian arm of PROQOL-HIV, presented in Chapter Three, 
show that the Australian group reported depression and alcohol usage more 
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commonly than other countries (Duracinsky et al., 2012). This was not altogether 
surprising since a contemporaneous study in our unit (Herrmann et al., 2012), the 
manuscript can be found in the appendix,  showed a high and sustained use of alcohol 
(and nicotine) which we noted was in excess of a comparable Swiss cohort (Conen et 
al., 2009). Among our recommendations were that clinic-based interventions uncover 
harmful patterns of alcohol use and address their causes. However, interventions need 
to be resourced and researched as well as accepted by clinic personnel and integrated 
into care.   
Integrating interventions into this setting is important because it is evident that people 
with HIV in Western Australia are, in general, not accessing primary care through their 
GPs who might be expected to manage depression and substance use issues, such as 
heavy drinking and smoking. And it is particularly true of the temporary visa holders 
who appear to have reasons related to their concerns about visa continuations and 
applications for residency. These concerns—which are increasing their stress levels—
appear to limit their involvement with the Australian health care system to the  
minimum required. In the studies presented here, past drug use, including intravenous 
drugs, was queried as well as current alcohol use and smoking status. Data from the 
recent interviews showed that only one person was a current smoker and, while three 
reported using intravenous drugs and 10 recreational (mainly marijuana), in the past, 
none reported current use.   However, 38% of men were using alcohol in quantities 
beyond that recommended by NHMRC guidelines (NHMRC, 2009) (and so were two 
women), and four of these men were FIFO workers. It is possible that this mode of 
working increases the likelihood of heavy drinking. A recent study by the WA 
Department of Health, which surveyed FIFO workers, found a significantly higher rate 
of smoking, risky drinking and obesity than in other shift workers associated with 
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sociodemographic status (Joyce, et al., 2012) Intoxication is a risky state in the context 
of HIV, and appears more common in the phase of early infection. Since people may 
not be on treatment at this time, there is a heightened risk of HIV transmission (Conen 
et al., 2009; Herrmann et al., 2012; Koblin et al., 2006; Woolf & Maisto, 2009). 
 However, for the participants in Chapters Four and Five, neither alcohol nor any of the 
other classical risk factors, were cited barriers to medication adherence, except by one 
woman, and one man who said he drank heavily after learning he was HIV positive. In 
fact, the primary obstacles to medication adherence and persistence were around the 
complexity of uninterrupted access to antiretroviral drugs for the people who were not 
eligible for Medicare; and the potentially fragile arrangement (for people in rural 
areas) around the process of dispatching ARVs to rural centres. This arrangement 
seems to rely on close communication and requires both motivation and organisation 
on the part of the patient; and efficiency and good record keeping on the part of the 
nurse, to ensure that drugs are ordered and delivered without a treatment gap 
between scripts.  
Acceptance, support and engagement with HIV Care 
Despite limited access to ARVs posed by non-citizen status and/or distance from 
dispensing pharmacies, participants overcame potential barriers posed by access. This 
was largely because of motivation to accept treatment and support from key health 
care professionals, which resulted in high levels of adherence and firm engagement 
with care underscoring the importance of patient-provider communication. This 
engagement was reinforced by health care workers who recognised that establishing 
and maintaining trusting relationships with clients was critical to the long term 
engagement (Figure 19) necessary to support, in particular, medication persistence; 
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and monitor immune status and virological control. It is the case that lack of 
engagement with HIV care is of increasing concern in the US where less than half of 
persons from 13 sites surveyed had evidence of ongoing HIV care (Hall et al., 2012). 
Health providers who contributed to data in this study also focused on ensuring access 
to care was facilitated by devising means to enhance their availability to clients; and by 
taking steps to reduce organisational impediments to accessing ARVs and support 
uninterrupted treatment, as recommended in recent published guidelines (Melanie A. 
Thompson et al., 2012). 
 
Figure 19: Continuum of HIV care, adapted from Eldred and Malitz (2007) and Gardner et al. (2011)  
Access to medication and ATRAS (AHOD Temporary Residents Access Study) 
However, at the end of 2011, things changed for a number of people on temporary 
visas—at least for a four year period until the end of 2015. A joint initiative between 
the National Association of People living with HIV AIDS (NAPWA), The Kirby Institute 
and seven pharmaceutical companies, began a programme to provide antiretroviral 
drugs, at no cost, to 180 people who are in Australia, legally, but ineligible for 
Medicare benefits. The study is expected to run for 48 months. The Kirby Institute 
manages the Australian HIV Observational Database (AHOD) in which a repository of 
data from the enrollees is collated, including information such as: reasons for 
ineligibility (e.g. visa status and type); and the length of time taken for each enrolee to 
become eligible for Medicare. It is anticipated that other information to assist the 
ongoing advocacy work conducted by NAPWA and other affiliated organisations, such 
as AFAO and state-based AIDS councils, will also be collected. This study, while not 
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providing a long term solution to the issues of ART access, provides a compassionate 
short term solution that offers significant support to 180 people across Australia. In 
WA the entire Medicare-ineligible cohort followed up at RPH no longer have to 
purchase generic ARVs from internet providers and the study is now fully enrolled. 
Although the impacts of this study on the participants and the health setting will not 
be further discussed in this thesis, it is relevant to note that community advocacy 
consistent with the activism throughout the HIV/AIDS epidemic was largely responsible 
for this initiative (http://napwa.org.au/trials/atras, website accessed August 2012). 
Changing conditions in WA affecting access to treatment  
A further change which is expected to reduce obstacles to accessing ARVs for people in 
WA not eligible for Medicare came in March 2012 when the Health Department issued 
an Operational Directive (OD 0364/12) to address the provision of treatment of 
Medicare ineligible patients in WA public hospitals. The Directive recognises that it may 
not be ‘reasonable’ for long term visitors to return to their home countries to access 
non-urgent treatment and therefore the Health Department “seeks to assist health 
services in having proper processes in place to identify and support such patients and to 
recover associated treatment costs” (2012). In effect the Health Department cites the 
Health Act of 1911 (WA) to indicate that hospitals in WA should provide assessment 
and treatment free for all notifiable sexually transmitted infections, including HIV, 
regardless of Medicare eligibility.  However, where treatment is expected to be 
required longer than two months and annual costs exceed $10,000 per annum, final 
authorisation must be sought from the Director General of Health. In addition “Health 
Services must have in place, processes for appeal should HIV treatment be refused on 
compassionate grounds” (Operational Directive OD 0364/12, March 2012, p.3). In 
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addition to these opportunities, people applying for Permanent Residency are now 
eligible for interim Medicare access, and therefore access to medicines subsidised on 
the PBS, including ARVs. 
Methodological considerations in the assessment of health-related quality of 
life 
The analysis of the Australian PROQOL-HIV data presented in Chapter Three, revealed 
that just over half of the variation in quality of life was explained by the new 
instrument. This begs the question: what about the other 45% of the variance? In the 
subsequent discussion I observed that the finding concurred with Wilson’s conceptual 
model (I. B. Wilson & Cleary, 1995), perhaps suggesting that total HRQL is substantially 
impacted by some hard-to-measure factors relating to personality, which may 
contribute to resilience and coping in difficult circumstances. But other researchers 
(Cummins et al., 2004) have argued that Health-Related Quality of Life Measurement is 
a confounded construct, limited in its capability and potentially insensitive to change.  
They argue for the ‘operationalising’ of the subjective component of quality of life—
subjective well-being—which rests in the idea of the Theory of Subjective Wellbeing 
Homeostasis. Cummins cites his own work and that of others to describe the theory 
which asserts that “...subjective QOL is actively controlled and maintained by a set of 
psychological devices that function under the influence of personality.” (2003, p. 414). 
Later, Hutton and colleagues used the Personal Wellbeing Index (PWI-A), an 
instrument based on the ‘Theory of Subjective Wellbeing Homeostasis; and the HIV 
version of the unsupportive social interactions inventory (USII) to study perceptions of 
‘felt’  stigma, in 128 PLWH in Australia and 146 in the US (Hutton, et al., 2012). 
Unsupportive social interactions were those that participants found unhelpful or 
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upsetting, for example, coldness of manner. The results showed that participants 
scored below the normative range of subjective wellbeing seen in Western 
populations. This score was negatively correlated with unsupportive social interactions 
which outweighed any supportive interactions in their net effect on subjective 
wellbeing. It is possible the findings of this contemporaneous study conducted in an 
Australian population, have the capacity to amplify the observations made in PROQOL-
HIV. Future studies might co-administer the two instruments since while the PROQOL-
HIV has been shown to be sensitive to the impact of specific treatment as well as 
aspects of stigma; the PWI-A appears to accommodate aspects of personality 
important in the assessment of subjective well-being, such as resilience.  
The pattern that has emerged from these studies is one of lives both shaped and 
limited by HIV/AIDS through, not only adverse physical impacts, but primarily through 
the psychosocial effects of HIV. How people cope with the emotional impairment that 
HIV stigma provokes through its various manifestations may depend, not only on 
factors such as social support but internal resources such as psychological resilience. I 
suggest it would be of particular value to consider the aspects of clinical care that are 
most important in providing support, particularly around the time of diagnosis since 
this event provokes a vivid and formative memory as was seen in the participants of 
this study.  
Summary  
The primary objective of this work was to understand the experience of HIV in the 
West Australian context and how it came to determine health outcomes; framed by 
issues such as access, adherence and citizen status; and referenced to health-related 
quality of life. In the first part of this chapter, I have discussed the issues within that 
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framework. However, over the period of my candidature, as the work progressed and 
the data was analysed I discovered that I had become, within the interviews, as Ezzy 
suggests, “a facilitator who enables the interviewee to re-experience and reflect on 
events” (Brown et al., 2003; Ezzy, 2010). This was particularly true, for example, with 
regard to the diagnosis event. As I describe in the methods, I usually began the 
recorded part of interview with a question about the participants’ responses when 
informed of their HIV diagnosis of HIV. It was clear that this event was a formative 
memory for participants. Formative memories have a particular impact on identity and 
adaptation and three types have been described by Cohen-Mansfield and colleagues 
(2010) as: first memories, pivotal memories and traumatic memories. The enormity 
that the diagnosis event posed for almost all participants led me to question the very 
nature of the threat posed by HIV. What follows is an exploration of the stigma 
construct in an effort to understand how the participants are confined within it.  
The Construction of Stigma  
The seminal contributor to the topic of stigma was Irving Goffmann (1963, p.9) and he 
remains widely cited. He conceptualised the stigma construct as: “the situation of the 
individual who is disqualified from full social acceptance”, by embodying a significantly 
discrediting attribute. Historically, this attribute has been represented by a physical 
manifestation, known as stigmata and disqualification arose from a violation or 
perceived violation of socio-cultural norms and, in particular, was associated with sex, 
death and race. Figure 20 illustrates that stigma is constructed within individuals; and 
collectively within society by way of sociocultural norms. As such, the person applying 
the behaviour and the person receiving the behaviour can be one and the same. This 
theory accounts for how people internalise stigma and why educational interventions 
 275 
to reduce stigma in ‘stigmatisers’, by increasing their knowledge and understanding of 
the ‘condition’, have purportedly limited effectiveness (Brown, Macintyre & Trujillo, 
2003; Parker & Aggleton, 2003; Weiss, et al., 2006). Societal, including governmental 
structures, that operate to exclude individuals also operate on this level but justify 
actions against individuals based on the need to protect those that ‘belong’ e.g. 
citizens against those who do not, non-citizens.  
The Construction of Stigma in HIV/AIDS 
HIV infection is subject to the public health strategy of cordon sanitaire or quarantine.  
David Armstrong (2011) asserts that this practice, adopted before the mid-nineteenth 
century is one of a number of distinct periods of public health practice which began by 
marking areas of prohibition between geographical spaces (an early example might be 
the plague villages in England in the 14th and 17th Centuries) but progressed to drawing 
lines of exclusion around the human body (Douglas, 1984). These lines of exclusion are 
enshrined in the legislation of many countries. Humans greatly fear exclusion and 
rejection, especially from their social groups, and Baumeister and Tice (1990) suggest 
that this fear is innate. Leclerc-Madala (2011) comments that there are contexts where 
fear of social death by HIV, is greater than physical death. People with HIV adjust their 
lives in order to protect themselves and others from real or imagined emotional, social 
or physical injury. Although scientists have developed potent treatments for HIV, and 
work is progressing towards a cure, interventions to treat the social manifestations of 
HIV; subtle, insidious and often invisible, yet so powerful in their effects on peoples’ 
lives, are lagging behind.  
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The third epidemic – understanding stigma in HIV 
Early concerns about AIDS-related stigma were raised somewhat prophetically, by the 
Founding Director of the World Health Organisations former Global Programme on 
AIDS, Jonathan Mann, when he addressed the United Nations General Assembly in 
1987. He described three phases of the AIDS epidemic. In phase one, he asserted, the 
epidemic of HIV would spread silently and to an extent imperceptibly; subsequently 
the natural course of the untreated infection would lead to an epidemic of AIDS which 
would represent phase two; and phase three would culminate in a social, political, 
economic and cultural epidemic characterised by stigma, discrimination and denial 
(Parker & Aggleton, 2003). Since then there has been a sharp increase in stigma 
related research (Weiss, et al., 2006); and increased effort to reconceptualise and 
reframe historical constructs in a way that will lead to greater understanding of the 
modes of stigma and how they can be alleviated .  
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MANIFESTATIONS 
STIGMA 
ATTRIBUTES 
 
Perceived/Anticipated 
Actual/Enacted 
Internalised 
OUTCOMES  
 
Societies are alert to a violation of 
acceptable socio-cultural norms 
deeply internalised by individuals 
Reinforced by social structural & 
institutional factors 
 
 National &International legal and 
regulatory sanctions  
 Emphasis on contagion/criminality 
 Emphasis on economic detriments 
 Public health campaigns 
 Actions of HCP’s (may be well 
intentioned) 
 
Feelings of 
 
 Sadness,  
 Anxiety, depression 
 Low self esteem, decreased self 
worth 
 
Fear consequences of disclosure for self 
and/or family 
 Being publicly shamed within 
community 
 Being ostracized (shunned, banned), 
personally and/or family 
 Experiencing 
discrimination/workplace  
 
Fear consequences of transmitting infection 
 Causing harm to another, or loved 
ones (partner/children) 
 Punitive actions of society 
 
 
 
 
 
 
 
Social and health impacts  
 
 Influences decision-making processes around 
health seeking and risk behaviours e.g. 
disclosure and adherence to medication 
 Influences interaction with health services with 
regard to testing and engagement with care    
 Limits personal/intimate relationships 
 Complicates decisions around pregnancy  
 Complicates parenting 
 Limits employment, economic, travel, migration 
opportunities 
 
Figure 20: Model of HIV-related stigma, theory, manifestations and 
outcomes  
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Stigma and discrimination  
In the field of HIV/AIDS, Parker and Aggleton (2003) asserted that there was a 
collective inability to confront Mann’s third epidemic because of the limited theoretical 
and methodological tools. They argued that current research emphasis is centred on 
the individual, that is, the view that stigma occurs as a consequence of mistaken 
beliefs about the condition or the race of the person affected, rather than the social 
and economic exclusion that results from social structural conditions, and is 
perpetuated by policy. This first view tends to lead to educative interventions 
operating on the ‘stigmatisers’ that will result in more ‘tolerance’ of the ‘stigmatisee’. 
However, informed by Michel Foucault, a contemporary of Goffman’s, Parker and 
Aggleton (2003, p.17) assert that: “Stigma arises and stigmatisation takes shape in 
specific contexts of culture and power”, and that “Stigma always has a history which 
influences when it appears and the form it takes.” In effect it is Foucault’s powerful 
‘regimes of knowledge’ that assert social control by defining normal and deviant 
properties. Once defined, these properties can then be applied to categories of people 
in order to place them within systems or structures of power. By reframing stigma in 
this way, the authors assert that the theory then leads to the possibility of 
understanding stigma and stigmatisation as central to the constitution of social order. 
This is, in effect, how stigma functions as a social construct within wider societies 
which are based on fundamental structures of hierarchy and inequality. Link and 
Phelan (2001), in particular, offer insights that speak to the multidimensionality of the 
construct. Most importantly in the study of HIV disease, this interpretation may help 
us to understand why people with HIV are stigmatised across cultures, and how this 
impacts on their well-being to a greater or lesser extent. The contextualised 
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characteristics of stigma and how they are made manifest were vividly described in 
vignettes presented at the recent World AIDS Conference held in Washington in July 
2012. 
Attributes of HIV/AIDS stigma  
The treatment or the symptoms—no problem, medications—take care of all 
that, but I think it’s the psychological factor that’s the toughest.  
(Man with HIV living in a rural area of WA). 
Stigma can be experienced through a perception of others’ views based on an 
assumption of shared sociocultural norms; this is stigma as it is perceived, anticipated 
or ‘felt’. Stigma is also experienced as enacted in that social exclusion occurs as the 
consequence of action taken against an individual or group by an individual/s or group. 
This is commonly known as discrimination. Perceived and enacted stigma has 
interpersonal and intrapersonal dimensions. However, and particularly in the context 
of infectious disease, there is also an intrapersonal dimension when acceptance 
(internalisation) of society’s views leads to a form of ‘self’ discrimination where one 
feels deserving of society’s disapprobation. Herek (2002) and Deacon (2006) 
respectively, give rich insights into the psychological and social dimensions of stigma. 
Earnshaw and Chaudoir (2009) argue that the three stigma attributes should be 
assessed separately since they may be related to psychological, behavioural and health 
outcomes in different ways. These authors also point out that internalised stigma 
appears predictive of significant outcomes for PLWH. Kalichman and colleagues (2009) 
found that internalised stigma was associated with depression in populations in South 
Africa and the USA and inversely associated with social support. Furthermore, Deacon 
(2006) argues for a model of health-related stigma not wholly defined in terms of 
discrimination. 
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Stigma: telling people and ‘giving it to someone else’  
The new PROQOL-HIV instrument demonstrated that the intensity of disclosure fear 
was proportional to the fear of infecting others. This phenomenon may reflect a 
personal sense of contagion as one participant commented: “Worst fear I have is 
giving it to someone else and the second most fear I have is people finding out.” This 
participant had unknowingly infected a partner; and had been in a situation where a 
health care worker had a percutaneous exposure to her blood during a routine medical 
procedure. The resultant distress fuelled the sense of being contagious although the 
incident did not result in transmission of HIV to the health worker. The participant 
explained to me:  
The thought of it terrifies me….and I don’t know why because if someone got 
infected they could live 20 or 30 years like me, relatively fine, but again it’s the 
stigma you know yeah I, it would be the worst thing in the world to do to 
someone. 
 The participant had a history of depression and identified herself as socially isolated. 
This example and others presented in the results, illustrate the exaggerated perception 
of risk around the fear of ‘catching’ HIV and transmitting it once one is infected. But it 
also demonstrates how people fear harming others, a sentiment that crosses cultures. 
For example, the Asian and African women did not want to disclose their status to 
their families for fear of distressing them and this was true of the men as well wanting 
protect their parents, especially, from the pain of worrying. Nonetheless, it is also 
possible that people, especially in collective cultures, fear that potentially punitive 
consequences for themselves and their families might ensue as a result of transmitting 
the infection.  
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In my research, the women’s concerns about casual transmission to their own or 
others children were evident, for example: “I try my best to keep everything nice and 
clean and disinfected, but I still have this feeling that I will give it to [the child] 
somehow.  That is my biggest scare.”  
This sentiment was expressed by women across cultures. Furthermore, HIV 
complicates plans for having children and not just because of the fear of transmission, 
which in a successfully managed pregnancy in a developed country is quite unlikely. 
For example, one of the young women in the PROQOL study who had chosen a partner 
on the basis of believing her choices would be limited by her HIV status, observed this 
about the prospect of having children: “What if I did have a baby and it was perfectly 
healthy, then the poor little kid’s got to face all the like the stigma attached to it, of 
having a mum that’s positive.” 
These examples from my research exemplify Goffmann’s (1963) seminal descriptions 
of stigma as associated with sex, death and race. More contemporaneously, O’Connor 
and Earnest (2011) provide a rich description of women’s experiences of stigma and 
marginalisation living with HIV in India, as does Jane Bruning in her Master’s thesis as 
mentioned previously in this work. A more thorough examination of the stigma 
construct, including the position of gender, is warranted.   
The role of health care workers in perpetuating stigma 
Public health sector communication campaigns can have unintended consequences 
and convey messages of culpability and responsibility (Guttman & Salmon, 2004); and 
within the health system the fear of casual transmission can be reinforced by well 
meaning health care workers. For example, the rigorous efforts of health care workers 
to prevent inadvertent disclosure of a patient’s HIV serostatus and advise the patient 
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to consider carefully, to whom they disclose, may send a message which implies that 
people have something of which they should be ashamed. One family man was advised 
to rent a house with two bathrooms so that there was no danger of him infecting his 
children by sharing a single facility. Education about HIV transmission can result in a 
person with HIV feeling that they should isolate themselves. A man described his post-
test discussion experience:  
I think what she did most was just scare and scare, sort of scare me and scare 
me even more and it was, we were really scared and we didn’t know where to 
go or what to do. 
An extensive review of the literature pertaining to stigma and discrimination around 
HIV and HCV in health care settings was commissioned by the New South Wales (NSW) 
Ministry of Health and produced by ASHM in partnership with the National Centre in 
HIV Social Research (NCHSR) (2012). Interviews were conducted with people who were 
identified as stakeholders: healthcare workers, academics and service providers 
working in the area of HIV and/or hepatitis C (HCV), some of whom identified as 
infected with blood borne viruses. This report identified a number of ways in which the 
providers perceived that people with blood borne viruses (BBVs) were discriminated 
that would resonate with the participants of this research; including those related to 
body language, modifying duties or procedures e.g. double gloving; and lack of 
understanding of legislative and requirements when providing services to people with 
BBVs.  Interestingly, many of those interviewed had observed that stigma was more 
likely to be enacted in a primary health care setting rather than a tertiary setting, and 
that finding non-judgemental care was difficult in rural areas and led to doctor 
‘shopping’. This echoes the observation of the ‘patient’ participants in my studies. 
However, one participant interviewed in the ‘stigma report’ observed that for 
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Aboriginal people the reverse appeared to be true. Therefore, the treatment 
‘appropriateness’ may vary according to the care required and the cultural group that 
requires it. However, the study was confined to NSW and may therefore be less 
relevant for the WA context. One interviewee in the NCHSR report made the following 
observation about structural stigma, that which restricts the opportunities of 
stigmatised groups (Corrigan et al., 2004) by way of laws and policies, saying that the 
community is ‘hardly aware’ of this form of stigma. It is notable that the participants of 
my studies largely cited supportive health care workers in the tertiary setting. 
Therefore, focusing scarce resources beyond ensuring an understanding of current 
legislation on reducing stigma in health care settings may be less appropriate in the 
current Western Australia context. 
National and international legislation, and human rights: structural stigma  
In Chapter Two I outlined the national and international restrictions faced by people 
with PLWH. By limiting the movement of people across borders on the basis of HIV 
serostatus, the laws serve to reinforce stigma and discrimination against people with 
HIV which, in my research, was clearly exemplified by the participants on temporary 
visas. It is not too strong a word to say that a couple of participants were terrified and 
most remained anxious. Furthermore, the Health Requirement (Department of 
Immigration and Citizenship, 2010a) (Walensky et al., 2012) is contributing, at a 
societal level, to discrimination against people with HIV, and is obfuscated by issues of 
access to antiretroviral drugs further complicated by TRIPS agreements. There are a 
number of issues that arise. First, people are afraid of being deported or discriminated 
against, which prevents them from accessing testing, secondly it appears that there 
may be some self imposed delay (with some tacit physician involvement) in beginning 
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ART since people think as long as they do not need medication they are less of a 
burden on the Australian community. Thirdly, there is not the opportunity for people 
to ‘level the playing field’ by declaring their intention to continue access and import 
generic drugs after successful PR application to remove the barrier (to successful PR) 
proposed by the Health Requirement. There are no generic antiretroviral drugs in 
Australia available for prescription for citizens or non-citizens. A recent, sophisticated 
presentation at the World AIDS Conference in Washington showed data demonstrating 
that switching to generic-based regimens could result in annual cost savings of $1.01B 
(USD) (Walensky et al., 2012). Removing barriers to accessing ARVs may result in a 
significant diminution of institutional sources of stigma and flow on ‘test and treat’ 
benefits.  
Stigma, work and rural environments 
The interviews revealed the extra challenges of living in rural areas and working in 
small groups as the fly in fly out workers do. I found that there was perception of 
increased stigma in rural areas and small communities, so that the fear of people 
finding out was heightened because the odds of inadvertent disclosure were perceived 
to be higher and the consequences more severe. This was true in Australia and other 
countries, for example, this man in reference to his country in Oceania “back in the 
traditional villages, people talk bad things about you.” Researchers have sought to 
understand the social structures that may lead to increased stigma or perception of it, 
(Yebei et al., 2008) and the size of the community may matter. An example is the ‘off 
shore’ worker in a male dominated environment, who kept his same sex orientation 
and HIV serostatus a secret from his employers and his workmates. But people living 
with HIV may live also live with family members who care for them, (Knodel et al., 
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2011) and this may increase their resilience if family members are emotionally 
supportive (Frain, et al., 2008). The health care workers in the North West and 
Kalgoorlie-Boulder regions commented on this in relation to their Aboriginal clients 
who were fearful of family gossip and disapprobation. This observation was supported 
by an Aboriginal man in the larger study. My field diary noted his comment that, being 
in an Aboriginal family everybody talks to everyone else and knows each others’ 
business, his fear also extended to being afraid of being labelled a ‘faggot’. This man 
could be said to be part of two small communities: the FIFO community and the 
Aboriginal community which for many families is dispersed across the state. My 
research showed that the participants perceived less tolerance in their communities 
both in the regions, and within the male dominated fly in fly out community of 
workers.  
Heightened concern about confidentiality in small (geographic) communities resulted 
in many people avoiding health care providers in the town in which they lived and 
many travelled to Perth to access care where they were less likely to run into people 
they knew. But they also cited access to a greater variety of services than is available in 
the country areas.  There was one exception to this rule, and this man trusted the 
goodwill of rural residents:          
So I like to think that even in a small town ... they’re not going to go up to the 
quilters club and *say+ you know, Jack he’s got AIDS you know? 
However, Preston et al. (2004) reported higher rates of unprotected sex in gay men 
living in rural areas of the US and attributed this to the influence of stigma on sexual 
risk in regions where homosexuality and HIV/AIDS were disapproved, noting that 
people in rural areas were more likely to be conservative. Significantly, they were able 
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to point towards low self esteem and self worth mediated by stigma as being 
associated with unprotected sex.  
All of the health care workers interviewed reported the high level of stigma in 
Aboriginal communities leading to considerable efforts by them to maintain 
confidentiality, and this is supported by the literature (Newman et al., 2007b). This 
Western Australian Curtin University study by Newman and colleagues used qualitative 
methods to look at barriers to the uptake of and adherence to antiretroviral therapy in 
Western Australian Aboriginal people and found that fear of discrimination was a 
major impediment while pregnancy was a primary motivator for acceptance and 
adherence. This data and related research (Bonar et al., 2004; Newman et al., 2007a; 
Newman et al., 2007b; S. C. Thompson et al., 2009) gathered nearly ten years ago in 
2003, evokes the broad-based interdisciplinary service that exists in the North-West 
today. The study identified that participants prioritised families and community over 
individual health and recommended that: 
Treatment regimens must be tailored to fit the logistical, social and cultural 
context of everyday life, and be delivered within the context of broad-based 
health services, in order to be feasible and sustainable. 
The interviews with the health care providers, presented in Chapter Four illustrate 
their efforts to offer the type of service that meets their clients’ needs with regard to 
support for HIV treatment, even if that includes social welfare support. According to 
the North West Public Health Physician this has largely been successful. However, the 
impact of stigma continues to complicate clinical management and distress their 
clients as evidenced by the difficulties of establishing trusting relationships when there 
are staff disruptions as well as with local hospital staff. In this instance clients can 
disengage from services altogether.   
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Recommendations 
There are a number of recommendations that can be made on the basis of the findings 
in these studies. I have categorised these as: clinical practice and policy direction, and 
areas for future research. The recommendations are summarised below: 
Clinical practice  
 Uncover emotional impacts of HIV and intervene to treat underlying stressors; 
including those related to stigma and consider the role of the wider 
multidisciplinary team in improving psychosocial outcomes for patients.  
 Ensure staff members are adequately trained in issues that are relevant to the 
current population of people living with HIV/AIDS presenting for treatment in 
the hospital outpatient clinic  
 Improve treatment literacy and include key information in adherence support 
protocols that will promote autonomy and independence; and embed 
evaluation of patient education into these protocols 
 Utilise internet and web-based educational resources according to patient 
preference  
 Ensure a focused, educative approach to mobile individuals that will enable and 
empower them to seek treatment continuation across national and 
international health care settings  
 Ensure staff are resourced and educated to provide and evaluate this education 
 Ensure staff familiarisation with protocols, including short term clinical staff 
and evaluate compliance with protocols  
 Ensure staff familiarity with their legal responsibilities around discrimination  
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Policy Direction 
 Efforts could be made to encourage the import of generic ARVs to Australia in 
order to reduce overall costs and make more funds available for prevention, 
identification and treatment of infections.  
 All people working in Australia regardless of residency or visa status should 
have unfettered access to life-saving antiretroviral drugs.  
 Continue to advocate for changes in laws that discriminate against people with 
HIV at a national and international level with regard to free movement 
between countries. 
 Governments and HIV representative groups could work with employers to 
facilitate confidential screening for HIV after ensuring that workers will have 
free access to treatment and that they will be protected from discriminatory 
action by their employers or co-workers.   
 Develop international networks that support programs that facilitate access to 
HIV care and treatment for all categories of mobile populations, including guest 
workers and visiting workers like sailors.   
Areas for Future Research  
Medication adherence 
 Explore the impact and relevance of the emergent FIFO lifestyle on medication 
adherence and clinic attendance 
 Explore the impact of mobility on medication persistence and linkage with care. 
 Explore how families manage and what would help them to manage 
medication issues, especially those with children who or may not have the 
infection and develop interventions to support good treatment outcomes. 
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Stigma-related  
 Further reveal how stigma operates as a construct within society and make it 
visible so as to design effective interventions.  
 The questions are: (1) Who is being affected by HIV/AIDS stigma? (2) How does 
HIV impact on individuals? (3) What are the outcomes of HIV/AIDS stigma? 
(Earnshaw & Chaudoir, 2009) 
More specifically the following research questions could be asked:  
 What is the relationship between fear of disclosing HIV serostatus and the fear 
of transmitting the infection?  
 What interventions will be effective to reduce perceived stigma, anxiety and 
self imposed limitations in affected individuals and their families?  
 What would help individuals & families manage disclosure issues, particularly 
those with children who may or may not have the infection? 
 What issues, nuanced by gender or other potentially devalued identities, need 
addressing?  
 How does HIV serostatus discordancy impact on relationships and within the 
broader family structure and what can be done about it? 
Health and treatment literacy  
 Research is needed into health literacy and treatment literacy, in particular, 
taking into consideration knowledge from other disciplines, e.g. education and 
anthropology. The research should include aspects of gender and culture that 
may interact to influence what education will be accepted and how it should 
delivered, and by whom, to the people who will benefit. This also has a broader 
relevance than HIV, especially for mobile and vulnerable populations.  
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Rural populations 
 More research is needed to understand and meet the needs of people with HIV 
who are designated ‘hard to reach’; and the issue of why they are ‘hard to 
reach’ needs to be explicated.  
Health sector  
 Research into the health of non-citizens such as temporary visa holders, 
refugees and migrants is required to ensure their human rights needs are met 
and they can continue to make a contribution to Australian society  
 Research into models of care that will support the populations above will be 
required in the near future particularly since the numbers of temporary visas is 
set to increase and swell the numbers of mining and construction, and health 
sector workers 
 Support and recognition for research is needed from clinicians, particularly in 
circumstances where patients limit their contact with the health system thus 
making conventional methods of offering participation in research studies less 
effective 
 Researchers could be better integrated into clinical practice settings in order to 
be aligned with immediate and pressing clinical questions, including evaluating 
systems of care that may be under threat.  
Policy  
 Potential barriers around the manufacture and importation of generic drugs in 
Australia, including those concerns related to quality of medicines and drug 
bioequivalence need to be identified. 
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 A local bureau where visa holders with HIV/AIDS can access free and 
confidential legal advice around visa and immigration issues could be 
established. This might be largely pro bono like the model for Legal Aid or 
perhaps funded from philanthropic sources. 
Limitations 
This study has a number of limitations, the first and primary limitation was the lack of 
representation of women in the study. Further, I sensed that while the women in the 
study had some things in common, for example, around concerns of how their HIV 
serostatus would impact on childbearing and rearing, there were other issues that 
were not explored, although they may have been beyond the scope of this study. For 
example, the Thai women who presented with their Australian-born husbands 
potentially lacked an independent voice, and their lack of proficiency in English may 
have made it more difficult for them to express themselves as fluently as they might in 
their first language. The interpersonal issues that arise from living in an HIV serostatus 
discordant relationship were not explored nor were the influences of culture within 
that dynamic. However, these and other unexplored aspects of the studies leave some 
area for future research. Further, the PROQOL-HIV studies revealed limitations with 
regard to intimate relationships which I discuss. But in the latter interviews I did not 
seek to ‘probe’ issues of sexuality because I believed this would be disrespectful, 
intrusive and, potentially, culturally inappropriate with the populations that would be 
included in this part of the work. It was also the case, outlined in the methods, that I 
used an interviewing technique which allowed participants to lead the conversation 
towards the subjects most relevant for them and those that they felt most comfortable 
talking about. This approach led to diversity and heterogeneity of content and is more 
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consistent with the view of Howard Becker (1998) with regard to understanding the 
range of certain phenomenon. Ezzy (2010) argues that a good interview is a merging of 
the agendas of the interviewer and interviewee resulting in ‘communion’ of 
understanding. This may lead to some items on the interviewer’s agenda being 
unaddressed. I also tried to ensure that by the end of the interview the participants 
were not left with feelings of sadness, and given the limited time available, this may 
have led to some themes left only superficially addressed or unexplored.   
With regard to the rural arm of the study, I was able to recruit three participants only 
who attended the Public Health Physician in Kalgoorlie-Boulder, and they were all 
permanent residents. Given the social diversity within that cohort I sense that I have 
not tapped into the experience of living with HIV in that context, and further themes 
may have emerged had I been able to do so. All of the other patients in the rural group 
travelled from country regions to the city and were seen by the Tertiary Hospital Team. 
That I was not able to recruit patients at Fremantle Hospital also impacted on the 
usefulness of the study in that the opportunity to capture some diversity may have 
been lost. 
Conclusion 
The research presented in this thesis exposes the paradox of HIV/AIDS showing that, 
given favourable conditions outlined by Friedland et al. (2006) (Figure 7), one can 
survive HIV/AIDS but die a ‘social death’ because of lack of intervention into the social 
effects of the infection. These interventions are lacking, despite best efforts, either 
because of the technical focus of science, or because as a society we have not fully 
exposed discrimination nor understood the complex stigma construct, or a 
combination of these factors. The late Jonathan Mann spoke in 1987, of the AIDS 
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epidemic culminating in a social, political and cultural phase characterised by stigma 
and discrimination. This has come to pass. Since the AIDS epidemic has been 
characterised by the intense involvement of activists partnering with scientists, policy 
makers and legislators, the work is not yet done — and the invisible must be made 
visible.  
I suppose for two thirds of my life, because ... I have been living with HIV for a 
third of my life, I lived a quality of life where I didn’t have to think about 
everything, I just did what I wanted to do basically within ones responsibilities 
and obligations. Now, through HIV, my quality of life has changed in that now 
everything I do has to be considered. 
Man (45 years) living with HIV 
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